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ABSTRACTS OF THE EIGHTH EDCTP FORUM,
6–9 NOVEMBER 2016
Defeating poverty-related and neglected
diseases in Africa: harnessing research for
evidence-informed policies
Michael Makanga, Pauline Beattie, Gabrielle Breugelmans, Thomas Nyirenda,
Moses Bockarie. European & Developing Countries Clinical Trials Partnership,
The Netherlands
10.1136/bmjgh-2016-000260.1
The Eighth Forum of the European & Developing Countries
Clinical Trials Partnership took place in Lusaka, Zambia from 6
to 9 November 2016. The biennial Forum has grown in size
and recognition to become one of the largest international con-
ferences for the presentation and discussion of frontier clinical
research on poverty-related infectious diseases, as well as cap-
acity development including ethics, regulatory and training
initiatives in sub-Saharan Africa. With the support of the
European Union, EDCTP member countries and other spon-
sors, the conference offers scholarships to many early and mid-
career researchers especially from sub-Saharan Africa to present
results of their studies and meet colleagues from Africa, Europe
and beyond. Moreover, the conference provided opportunities
for new collaborations with other actors in the field of global
health, such as research institutes, international private and
public funders, development agencies, product development
partnerships and pharmaceutical and biomedical companies.
The conference was attended by 434 participants from 48 coun-
tries, with scholarships for 120 early career scientists.
The theme of the Eighth Forum was: ‘Defeating
poverty-related and neglected diseases in Africa: harnessing
research for evidence-informed policies’ This reflects two spe-
cific aspects of the second EDCTP programme (EDCTP2,
2104–2024). The reference to neglected infectious diseases
points to the broadening of the scope of the programme. In
addition to HIV, tuberculosis and malaria, the scope of EDCTP
includes now most neglected infectious diseases, diarrhoeal dis-
eases, lower respiratory tract infections, and emerging or
re-emerging infectious diseases of relevance to sub-Saharan
Africa. Secondly, the theme refers to the importance of making
sure that new scientific results find their way into health care
policies and practice.
The Forum offered a comprehensive scientific programme
with keynote addresses by prominent speakers from the North
and South, oral presentations in plenary and parallel sessions,
panel discussions, a collaborative session, scientific symposia,
educational workshops, meet-the-expert sessions and poster pre-
sentations. In this Supplement to BMJ Global Health, the
abstracts of the plenary presentations, the oral presentations in
the various parallel sessions, and poster presentations are pub-
lished. The abstracts give a work-in-progress impression of the
scope and objectives of the EDCTP programme.
This Forum was officially opened by His Excellency Mr.
Edgar Chagwa Lungu, the President of the Republic of Zambia,
who is a true advocate for health research capacity development
in Africa. Several high-ranking government policy makers
including ministers, directors from ministries of health, higher
education and science & technology from Zambia and other
African countries participated. This was a clear demonstration
of the growing interest among African governments to
strengthen their collaboration with EDCTP. The EDCTP pro-
gramme has an added value for all countries in sub-Saharan
Africa through its funding strategies and plans.
This general theme of partnership between North and South,
between Europe and Africa was taken up again by the new High
Representative for the North, Professor Marcel Tanner, in his
keynote address to the conference. He reflected on the nature of
partnership which should go beyond cooperating on individual
projects to programme portfolio level and partnering at a stra-
tegic level. ‘Mutual learning for change’ is a feature of a true
partnership in which North and South can learn much from
each other.
Partnership was also demonstrated by many stakeholders who
enriched the programme by organising workshops, a collabora-
tive meeting and satellite meetings. Moreover, nine symposia
were organised as part of the scientific programme by
BioVentures for Global Health, Cochrane Centre South Africa,
Deutsche Stiftung Weltbevölkerung, European Vaccine Initiative,
Medicines for Malaria Ventures with the West African Network
for Clinical Trials for Antimalarial Drugs, NWO-WOTRO
Science for Global Development, the Pan-African Consortium
for the Evaluation of Antituberculosis Antibiotics (PanACEA)
consortium, and the University of Tübingen. The Ministry of
Health of Zambia organised a symposium on Clinical research
in Zambia for effective control programmes and showed further
support by co-hosting the Forum.
The Forum, which showcases the tangible results of collabora-
tive research and partnership, was the appropriate setting for the
award of four EDCTP 2016 Prizes. EDCTP recognised outstand-
ing individuals and research teams from Africa and Europe who
have made significant contributions in their field of research. In
addition to their scientific excellence, the awardees made major
contributions to the EDCTP objectives of clinical research cap-
acity development in Africa and establishing research networks
between North and South as well as within sub-Saharan Africa.
The Award for Outstanding Research Team was given to the
University of Zambia – University College London Medical
School (UNZA-UCLMS) Research & Training Program.
Professor Marleen Temmerman (Aga Khan University, Kenya)
received the Award for Outstanding Female Scientist. Professor
Shabir A. Mahdi ( University of the Witwatersrand, South Africa)
was given the Award for Scientific Leadership, while Professor
Fred Newton Binka (Ghana; currently coordinator of WHO’s
Emergency Response to Artemisinin Resistance in Phnom Penh,
Cambodia) was honoured with the Dr Pascoal Mocumbi Prize in
recognition of his outstanding achievements in advancing health
research and capacity development in Africa.
We would like to express our sincere thanks to the EDCTP
member states and all our sponsors for their generous support. In
particular, we extend a special thanks to the Ministry of Health
of the Republic of Zambia, an EDCTP member country, for
co-hosting the Eighth EDCTP Forum. In conclusion, we would
like to thank the EDCTP Organising committee, colleagues and
friends for their help, support and advice in planning and imple-
menting the Forum. The members of the Programme committee,
i.e. the members of the Scientific Advisory Committee and the
EDCTP Project Officers, earned our warm thanks for putting
together the Eighth EDCTP Forum Programme.
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ABSTRACTS OF PRESENTATIONS IN PLENARY
SESSIONS
PS-001 R&D TO TACKLE GLOBAL HEALTH CHALLENGES: ROLES
AND RESPONSIBILITIES FOR EDCTP
Marcel Tanner1,2,3,4. 1Swiss TPH, Switzerland; 2University of Basel, Switzerland;
3High Representative North, EDCTP; 4Swiss Academy of Sciences, Switzerland
10.1136/bmjgh-2016-000260.2
As well documented, the diseases of poverty and Neglected
Tropical Diseases (NTDs) cost the lives of millions of people
worldwide and threaten the health of millions more. More than
200 million health years of life are lost every single year due to
mortality, morbidity and disability. This not only represents an
unacceptable burden for the populations concerned, mainly the
most impoverished segments of a population, but also impairs
health development and all our efforts to reach the Sustainable
Development Goals. NTDs and diseases of poverty are clearly
part of the overall neglect of people and health and social
systems.
The high burden of diseases of poverty and NTDs calls for
new efforts in developing effective and efficient approaches to
control or even eliminate these diseases. This in turn implies
that we must aim at new discoveries and innovations and – at
the same time – make most effective use of existing tools as well
as of innovative partnerships between the public and the private
sectors and between different countries; clearly the niche and
responsibility of EDCTP.
The presentation will discuss needs and ongoing efforts in
diagnosis, drug and vaccine development against diseases of
poverty and NTDs and will also discuss (i) obstacles at the level
of health and social systems that prevent access of the popula-
tions to new and existing efficacious tools as well as (ii) new
approaches in R&D to overcome these obstacles and barriers.
While there are great hopes and also substantial advances in
drug, diagnostics and vaccine development, R&D does not and
should not alone focus on developing new tools, but rather on
combining existing and new tools for integrated approaches of
diseases control and elimination that are tailored to a given
endemic setting and are combined with effective capacity build-
ing. The outlook and discussion will emphasize the potential,
chances and responsibilities of EDCTP to strengthen effective
partnership, capacity building and national and global health
development.
PS-003 EVIDENCE-INFORMED POLICY MAKING: CHALLENGES
AND OPPORTUNITIES
Jimmy Volmink. Stellenbosch University, South Africa
10.1136/bmjgh-2016-000260.3
Evidence-informed health policy making depends on the avail-
ability of the results of studies that have assessed what works,
what does not work, and what may be harmful. However, even
where such evidence exists it will not always be embraced by
policy makers or other decision makers.
This presentation begins by discussing the environment in
which policy making takes place and identifying the role of
players involved, drawing attention to the complexity of the
policy making process. It shows how competing forces, such as
beliefs, vested interests, values, habits and financial considera-
tions can lead to important evidence being rejected or ignored
by national and international policy makers, sometimes with
serious consequences.
The talk also explores the role researchers can play in pro-
moting the flow of evidence from research to policy to imple-
mentation by focussing on 5 key issues: generating primary
research, conducting systematic reviews of evidence, improving
access to relevant evidence, enhancing the use of evidence in
policy making, and providing information on how best to scale
up programmes. Case studies from LMIC settings, relevant to
the EDCTP’s remit, will be employed to illustrate the various
concepts covered in the presentation.
PS-004 REVIEW OF HIV IN SUB-SAHARAN AFRICA: CURRENT
SITUATION, OPPORTUNITIES AND CHALLENGES
Catherine Hankins. Amsterdam Institute for Global Health and Development, The
Netherlands
10.1136/bmjgh-2016-000260.4
UNAIDS estimates that in 2015, 19 million (17.7–20.5 million)
and 6.5 million (5.3–7.8 million) people were living with HIV
in Eastern and Southern Africa (ESA) and Western and Central
Africa (WCA), respectively. Between 2010 and 2015, new HIV
infections declined by 14% in ESA and 8% in WCA, while
AIDS-related deaths fell by 38% and 10%, respectively. In ESA,
10.3 million people or 54% (50–58%) of all people living with
HIV were accessing antiretroviral therapy (ART), compared to
1.8 million people or 28% (23–34%) of all people living with
HIV in WCA. Since 2010, there has been a 66% decline in new
HIV infections among children in ESA compared to a 31%
decline in WCA.
These striking regional differences mask large discrepancies in
country progress, sex differences in ART uptake, and a diversity
of micro-epidemics across sub-Saharan Africa. The goal to end
AIDS as a public health threat by 2030, the UN-AIDS 90–90–90
treatment cascade goal for 2020, and the WHO recommendation
to offer ARTwhen HIV is diagnosed regardless of CD4 count are
galvanizing public health and community-based responses in
Africa. Despite improvements in ART and new prevention tools,
including voluntary medical male circumcision and oral pre-
exposure prophylaxis, the goals will not be achieved without
new tools, including an HIV vaccine and a cure.
EDCTP has funded high-impact HIV research that has resulted
in, among others, policy change; prequalification of new pro-
ducts; improved treatment strategies, including for children; and
strategies to prevent mother-to-child transmission, while building
research capacity and clinical trial infrastructures. Promoting
African country membership and increased financial contribu-
tions from African countries, EDCTP2 aims to leverage
co-funding from public/private sources for calls for proposals
that address important gaps in HIV prevention and treatment
science that can be answered through phase I-IV clinical trials in
sub-Saharan Africa.
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PS-005 POLICY-DRIVEN INTERVENTIONS: TUBERCULOSIS
Gerhard Walzl,1 Novel Chegou,1 Stephanus Malherbe,1 Mark Hatherill,2 Thomas
J. Scriba,3 Daniel E. Zak,4 Clifton E. Barry III,5 Stefan H.E. Kaufmann6.
1DST/NRF Centre of Excellence for Biomedical TB Research and MRC Centre for TB
Research, Division of Molecular Biology and Human Genetics, Stellenbosch
University, Tygerberg, South Africa; 2South African Tuberculosis Vaccine Initiative,
Institute of Infectious Disease and Molecular Medicine & Department of Paediatrics
and Child Health, University of Cape Town, Cape Town, South Africa; 3South African
Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine
& Department of Paediatrics and Child Health, University of Cape Town, Cape Town,
South Africa; 4The Center for Infectious Disease Research, Seattle (WA) USA;
5Tuberculosis Research Section, Laboratory of Clinical Infectious Diseases, Division of
Intramural Research, National Institute of Allergy and Infectious Diseases, National
Institutes of Health, Bethesda (MD) USA; 6Department of Immunology, Max Planck
Institute for Infection Biology, Berlin, Germany.
10.1136/bmjgh-2016-000260.5
Annual tuberculosis (Tb) rates decline by 1.7%, which is inad-
equate to reach WHO targets. We describe three host-biomarker
developments that are entering clinical testing and that could
accelerate progress against TB.
Blood mRNA signatures with promising predictive ability for
incident TB were recently described in African cohorts.
Correlate of risk (COR) positive participants have 7 to 18 times
increased risk for progression. A clinical trial is underway in
South Africa under leadership of the South African Tuberculosis
Vaccine Initiative to evaluate targeted chemoprophylaxis in
COR positive people in an area with a very high prevalence of
latent TB infection, where untargeted preventative treatment is
not practical.
Historical data suggests that 85% of patients are cured after 4
months of TB treatment but attempts to shorten treatment
without an unacceptable relapse rate have failed. Treatment
shortening criteria based on PET/CT imaging and microbio-
logical criteria were developed. An EDCTP/Bill & Melinda
Gates Foundation/NIH co-funded study, led by the Tuberculosis
Research Section of the NIH, will start in South Africa and in
China in 2017 to evaluate biomarker-driven treatment shorten-
ing to 4 months.
To address diagnostic bottlenecks, a blood-based 7-host
marker diagnostic signature was recently found with promising
screening potential for active TB. An EDCTP-funded project
with Africa and EU partners aims to develop a point-of-care,
finger stick blood test that can simultaneously measure all 7
markers and rule out 75% of people with symptoms compatible
of active TB in whom the diagnosis is subsequently ruled out.
Such screening tests could speed up diagnostic work-up and
save significant costs. Taken together, biomarker-driven interven-
tions are now being actively tested and hold promise to provide
important tools towards the eventual eradication of the TB
scourge.
PS-006 MALARIA
Abdisalan Noor. WHO, Switzerland
10.1136/bmjgh-2016-000260.6
At the beginning of the Roll Back Malaria (RBM) initiative
around 2000, sub-Saharan Africa was going through a major
malaria epidemic, compounded by the failure of chloroquine
and emerging resistance to sulphadoxine-pyremithamine, as the
first-line treatments for uncomplicated malaria. The initial call
for increased funding through the 2000 Abuja Declaration only
began to materialise in 2002 when the Global Fund to Fight
AIDS, Tuberculosis and Malaria was established. The scale-up of
malaria interventions, especially for vector control, began in
earnest in 2004 in sub-Saharan Africa but by 2007 only less
than 20% of children in Africa had slept under an insecticide-
treated net. In addition, it is only from 2006 that the wide-
spread use of artemesinin combination therapy (ACT) started to
occur on a wide scale. By 2015, however, substantial coverage
with both vector and treatment interventions had been achieved.
Consequently, the malaria burden has decreased across
sub-Saharan Africa. Here I review the current malaria situation
in sub-Saharan Africa and discuss opportunities and challenges.
I discuss some of the analytical work, including mapping that
contributed to our understanding of the epidemiology of
malaria and progress during the RBM era. I present examples of
how this research has led to changes in policy and practice glo-
bally and in sub-Saharan Africa. I discuss the current major
research needs and policy gaps in the malaria elimination
agenda and how these may be applicable to other diseases in the
EDCTP remit. I conclude with suggestions on the potential role
of EDCTP in supporting clinical trials and capacity strengthen-
ing towards malaria elimination.
PS-007 NEGLECTED INFECTIOUS DISEASES
Nathalie Strub-Wourgaft. DNDi, Switlzernad
10.1136/bmjgh-2016-000260.7
Achievement of the UN’s Sustainable Development Goals
(SDGs) will only be possible if the burden of neglected tropical
diseases (NTDs) is significantly reduced. NTDs have an impact
on population health, and are a drain on community resources,
hindering economic development. The burden is particularly
high in Africa, and urgent action is required on NTDs to enable
the attainment of the SDGs.
The World Health Organization has listed 17 NTDs that
impact one billion people worldwide and produced overwhelm-
ing evidence to show that their impact may be effectively con-
trolled and, in many cases, eliminated or eradicated. The WHO
Strategic and Technical Advisory Group for NTDs and partners
adopted a roadmap for control, elimination and eradication
which set targets for 2012–2020.
In its systematic assessment of the drug and vaccine landscape
for neglected diseases up to 2011, DNDi found a persistent
insufficiency in drug and vaccine development, and that new
therapeutic products urgently need to be developed and deliv-
ered to improve control and potentially achieve elimination. It is
significant that the second EDCTP programme includes
neglected infectious diseases and more trial phases. DNDis
focusses on the needs of neglected patients, and is developing
treatments for sleeping sickness, leishmaniasis, Chagas disease,
filariasis, HCV, paediatric HIV, and Mycetoma. In Africa there is
an acute need for treatments for visceral leishmaniasis (VL),
HIV-VL coinfection, post kalaazar dermal leishmaniasis, and
cutaneous leishmaniasis. Mycetoma was recognized as an NTD
by the WHA in 2016; this devastating disease affects remote
populations; is poorly understood and lacks effective treatment.
In Africa, 115 million people are at risk of onchocerciasis and
410 million people require preventive chemotherapy for lymph-
atic filariasis; mass administration programs are hampered by
drugs that only kill the juvenile form of the worms, leaving only
temporarily sterilized adults, requiring repeated administration
over a period of decades.
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PS-008 INNOVATIVE CLINICAL TRIAL DESIGNS
Patrick Phillips. MRC Clinical Trials Unit, UCL, United Kingdom
10.1136/bmjgh-2016-000260.8
Since the middle of the 20th century, randomised controlled
trials have provided the strongest level of evidence to inform
the treatment of all diseases. In particular, trials in the 1970s
and 1980s in Africa led to a highly efficacious 6-month regimen
for the treatment of TB; these were followed by trials in the
1990s and 2000s which resulted in today’s HAART regimens
that are recommended for all patients living with HIV.
These diseases, however, still cause 1.3 million deaths every
year in Africa, and further trials are needed to improve treat-
ment and develop control strategies that will ultimately end the
epidemics. Furthermore, there are many neglected diseases
where few if any trials have been conducted and therefore the
evidence base for treatment is extremely weak.
The randomised clinical trial is an indispensable tool for
defeating poverty-related and neglected diseases in Africa, but it
should not be seen as a static instrument that has remained
unchanged since its first introduction in the 1940s. Innovations
in clinical trial design can overcome many barriers, facilitating
more efficient trials where alternatives are prohibitively long or
resource-intensive. For example, adding multiple intervention
arms or sequential randomisations allows for more questions
being answered in a single trial, and adaptive designs permit
modifications to ongoing trials in light of internal or external
data, thereby making better use of limited resources.
This presentation covers the opportunities for innovation in
clinical trial design in poverty-related and neglected diseases.
Recent developments relate to multi-arm multi-stage and other
adaptive trial designs, interpretation of non-inferiority trials,
choice of comparator arms, the role of pragmatic trials, and
treatment strategy trials. Specific examples will be presented,
including recent TB, HIV and Ebola trials, in addition to other
areas for possible progress, all with the ultimate goal of faster
patient benefit.
PS-009 IMPROVING MATERNAL AND CHILD HEALTH THROUGH
COMMUNITY ENGAGEMENT IN CLINICAL TRIALS
Khátia Munguambe. Universidade Eduardo Mondlane and CISM, Mozambique
10.1136/bmjgh-2016-000260.9
Clinical trials contribute to the improvement of health through
testing potentially efficacious interventions (e.g. vaccines, drugs,
devices, and even behavioural strategies) among selected popula-
tion segments to provide evidence to support health policy and
practice. There are indisputable health benefits, not only to the
communities directly involved in the trials but also to the wider
population affected by the health problems in question. On the
other hand, regardless of the results of the trials, it is assumed
that there are immediate benefits disseminated to the whole
population of reference resulting from training, resources, ser-
vices quality, and improvement and local knowledge.
Particularly for low-income countries, this assumption is often
taken for granted, as the implementation of clinical trials is
usually accompanied by infrastructure development, institutional
capacity building, and improved standards of care. The actual
direct benefit to health and health care delivery, its sustainability,
and more importantly, the communities’ perceptions of those
benefits are seldom measured, because clinical trials often miss
the opportunity to evaluate communities’ acceptability of the
potential intervention, and the extent to which their needs and
priorities are met through the trials. Formative research, which
must be conducted in advance and during trial implementation,
is a valuable approach to address such questions and to recom-
mend appropriate ways of conducting the trials so as to gain
optimal synergies with communities’ expectations while balan-
cing those with the intended improvement of health. The
Manhiça Health research centre takes such approach when
implementing complex interventions involving large segments
of the population and health services catchment areas, such as
entire districts and provinces. This talk focuses on lessons learnt
from engaging the community in three different interventions,
namely the Malaria Elimination Program in Magude District,
the Community Level Interventions for Pre-eclampsia in
Maputo and Gaza Provinces, and the Cause of Death
Determination using Minimally Invasive Autopsies in Manhiça
District, all in Southern Mozambique.
ABSTRACTS OF ORAL PRESENTATIONS
OA-001 THE ADDED VALUE OF A MULTICOUNTRY NETWORK
FOR PROMOTING ETHICAL AND REGULATORY
STANDARDS IN CLINICAL TRIALS IN LOW- AND
MIDDLE-INCOME COUNTRIES: THE EXPERIENCE OF THE
‘SWITCHING THE POLES NETWORK’
Raffaella Ravinetto,1 Halidou Tinto,2 Ermias Diro,3 Yodi Mahendrahata,4
Joseph Okebe,5 Suman Rijal,6 Coralith Garcia,7 Shyam Sundar,8 Gilles Ndayisaba,9
Thai Sopheak,10 Thang Ngoduc,11 Harry Van Loen,1 Jan Jacobs,1
Umberto D’Alessandro,5 Marleen Boelaert,1 Anne Buvé1. 1ITM Antwerp, Belgium;
2Clinical Research Unit Nanoro, Burkina Faso; 3University of Gondar, Ethiopia;
4Gadah Madja University, Indonesia; 5MRC, The Gambia; 6BPKI-HS, Nepal;
7IMTAvH, Peru; 8Baranas University, India; 9Rinda Ubuzima, Rwanda; 10SHCH,
Cambodia; 11NIMPE, Vietnam
10.1136/bmjgh-2016-000260.10
Background In 2008, we created the ‘Switching The Poles’
Clinical Research Network, by joining the forces of non-
commercial clinical research groups in Benin, Burkina Faso,
Cambodia, Cuba, the Democratic Republic of Congo, Ethiopia,
India, Indonesia, Nepal, Peru, Rwanda, The Gambia and
Vietnam. Our aim was to strengthen capacity to conduct non-
commercial clinical trials that comply with ethical/regulatory
standards.
Methods Our capacity building initiatives were designed to dir-
ectly benefit the implementation of clinical trials, including
various EDCTP-sponsored projects, e.g. 4ABC (7 countries),
PREGACT (4), Microbicide Safety Biomarkers (3) and Ring Plus
(1). Our training, coaching and networking activities targeted
young researchers from the South as well as research profes-
sionals who are traditionally ‘neglected’ in trainings, such as
data managers and laboratory staff. There were several thematic
packages: Good Clinical Practice (GCP), Good Clinical
Laboratory Practice, data management (DM), monitoring, and
informed consent.
Results We developed a theoretical and practice-based GCP
training that was adopted by WANETAM Plus in 2013, and a
set of standardised DM procedures. Data managers used to
working on their own, now benefit from an e-platform (admit-
network.org) for collaboration and peer advice. We started
coaching clinical monitors, for facilitating reciprocal monitoring
schemes. We publicly spoke out about ethical issues, e.g. ethical
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review of externally-sponsored trials, voluntariness in informed
consent in vulnerable populations, and provided recommenda-
tions to the International Conference of Harmonization in its
revision of GCP Guidelines. The inclusion of partners from so
many diverse countries and settings resulted in cross-fertilisation
and mutual learning. The Networks’ small size facilitated inter-
personal collaboration.
Conclusions Our experience shows that a relatively small, but
focused international network provides an excellent platform
for supporting young researchers across different professional
disciplines and helps to strengthen capacity for clinical research.
This approach has enabled partners in low- and middle-income
countries to successfully conduct harmonised GCP-compliant
clinical trials.
OA-002 TRANSLATING ETHICS GUIDELINES ON COMPENSATION
FOR RESEARCH-RELATED INJURIES INTO POLICY IN
LOW-INCOME COUNTRIES: LESSONS LEARNT FROM
MALAWI
Patrick Kamalo,1 Lucinda Manda-Taylor,1 Stuart Rennie2. 1University of Malawi,
Malawi; 2University of North Carolina, United States of America
10.1136/bmjgh-2016-000260.11
Background Injury to human participants in biomedical
research is a known problem and despite a number of ethical
guidelines advocating compensation for research-related injuries
(RRIs), African countries do not have a unified approach for
compensation. In 2012, Malawi introduced a policy mandating
no-fault insurance coverage for RRIs. We conducted this study
to explore the challenges associated with the implementation of
this policy and what lessons can be learnt from Malawi.
Methods We conducted a qualitative case study through nine
in-depth interviews with purposively sampled key stakeholders
in research in Malawi: policy-makers, researchers, ethics com-
mittee members and insurers. Interviews were conducted by one
researcher, recorded using a voice-recorder and later transcribed
and verified for consistency. Manual data analysis was done
using a word-table and pattern-matching. The study was
approved by two ethics committees: in Malawi and South
Africa.
Results Participants were in favour of compensation for RRIs
through the insurance mechanism of no-fault type, although
there was discordance in the understanding of the ‘no-fault’
principle. Some researchers felt this policy was instituted to
punish them and stifle clinical research. In addition, we found
that the local insurance industry was not in a position to cover
clinical research. This deficiency in local capacity to provide
insurance left some researchers feeling that Malawi would lose
out by externalising hard-earned resources.
Conclusions All stakeholders in research in Malawi view the
policy mandating no-fault insurance cover for RRIs as a positive
step in research governance. However, certain challenges need
to be addressed, such as the understanding of the concept of
no-fault and local capacity to handle clinical trial insurance.
Compensation for RRIs through no-fault insurance needs to be
tried in other African countries and be adopted by the African
Union in order to standardise and enforce compensation in
Africa, where it is ethically acceptable based on the African ethic
of Ubuntu.
OA-003 IMPROVING THE EFFICIENCY OF AFRICAN RESEARCH
ETHICS COMMITTEES AND STANDARDISING ETHICS
REVIEW PROCESSES THROUGH AN AUTOMATED
REVIEW PLATFORM
Boitumelo Mokgatla,1 Prince Bahati,2 Carel Ijsselmuiden3. 1IAVI, South Africa; 2IAVI,
Kenya; 3COHRED, Switzerland
10.1136/bmjgh-2016-000260.12
Background The sheer amount of research being conducted in
Africa, the under-resourced research ethics committees (RECs),
and the lack of modern review technologies has resulted in
unprecedented review timelines – with an estimated 1.5 years to
get ethical clearance in many African countries. The Research
for Health Innovation Organiser (RHInnO), a cloud-based
ethics review platform, has ushered a new frontier of digital
ethics review in Africa. It facilitates and manages the entire
ethics review process. RHInnO ethics integration is estimated to
reduce the review time by 12 months. In 2015, RHInnO ethics
was used by 25 RECs in 8 African countries. We evaluated its
impact on efficiency, data security and cost.
Methods Qualitative and quantitative data was collected using
an online questionnaire administered to REC administrators/
chairpersons in user countries.
Results Responses were received from 60% of RECs using
RHInnO ethics. Reported areas of high impact (81%-100% of
respondents) included: improved protocol submission and distri-
bution process, improved quality of communication between
RECs and researchers, improved standardisation of review
process and improved data security. Reported areas of medium
impact (60%-80% of respondents) included reduced REC
administrator’s workload and reduced RECs’ administrative
costs. Improved reviews of multicentre trials were reported as a
low impact area by over 60% of respondents. Respondents
(20%) who used RHInnO ethics for more than 2 years reported
57% reduction in review time while those who used RHInnO
ethics for less than a year, (80%) reported it is too early to see
the impact on reduction of review timelines.
Conclusions RHInnO ethics had high impact on data security,
submission process, communication, standardisation and cost
reduction. However, a long-term evaluation approach is needed
to determine impact on review timelines. Integration of new
monitoring and evaluation (M&E) indicators on efficiency into
the platform would improve RECs capacity to conduct long-
term impact analysis.
OA-004 DEVELOPMENT AND EVALUATION OF A MULTIMEDIA
TOOL FOR OBTAINING INFORMED CONSENT IN THE
GAMBIA: A MIXED METHOD STUDY
Muhammed Afolabi,1 Nuala Mcgrath,2 Umberto D’Alessandro,1 Beate Kampmann,1
Egeruan Imoukhuede,3 Raffaella Ravinetto,4 Neal Alexander,5 Heidi Larson,5
Daniel Chandramohan,5 Kalifa Bojang1. 1MRC, The Gambia; 2University of
Southampton, United Kingdom; 3University of Oxford ( Jenner), United Kingdom;
4ITM Antwerp, Belgium; 5LSHTM, United Kingdom
10.1136/bmjgh-2016-000260.13
Background Communicating crucial research information to
low-literacy research participants in Africa is highly challenging
in the context of several factors which make the participants
vulnerable to poor comprehension of consent information. We
A6 BMJ Glob Health 2017;2(Suppl 2):A1–A67
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previously developed and validated a digitised audio compre-
hension questionnaire. Here, we report the development and
evaluation of a multimedia consent tool amongst low-literacy
participants in The Gambia.
Methods Adults eligible for inclusion in a malaria treatment
trial (n=311) were randomised to receive information needed
for informed consent using either a multimedia tool (interven-
tion arm) or a standard procedure (control arm).
A computerised audio questionnaire was used to assess parti-
cipants’ comprehension of informed consent. This was done
immediately after consent had been obtained (at day 0) and at
subsequent follow-up visits (days 7, 14, 21 and 28). The accept-
ability and ease of use of the multimedia tool were assessed in
focus groups.
Results On day 0, the median comprehension score in the
intervention arm was 64% compared with 40% in the control
arm (p=0.042). The difference remained significant at all
follow-up visits. Poorer comprehension was independently asso-
ciated with female sex (odds ratio, OR: 0.29; 95% CI: 0.12 –
0.70) and residing in Jahaly rather than Basse province (OR:
0.33; 95% CI: 0.13–0.82). There was no significant independ-
ent association with educational level. The risk that a partici-
pant’s comprehension score would drop to half of the initial
value was lower in the intervention arm (hazard ratio 0.22, 95%
CI: 0.16–0.31). Overall, 70% (42/60) of focus group partici-
pants from the intervention arm found the multimedia tool
clear and easy to understand.
Conclusions A customised multimedia tool significantly
improved comprehension and retention of consent information
by research participants with low levels of literacy in The
Gambia. Further evaluation of the tool is warranted in similar
settings.
OA-005 PERFORMANCE OF XPERT MTB/RIF AND DETERMINE
LAM IN HIV-INFECTED ADULTS IN PERI-URBAN SITES
IN ZAMBIA (CDC OP-X STUDY)
Margaret Phiri Kasaro,1 Brenda Muluka,1 Kaunda Kaunda,1 Jill Morse,1
Andrew Westfall,2 Nathan Kapata,3 Annika Kruuner,2 German Henostroza,2
Stewart Reid2. 1CIDRZ, Zambia; 2UAB, United States of America; 3Ministry of
Health, Zambia
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Background Tuberculosis (TB) mortality in HIV-infected
patients remains high in sub-Saharan Africa. Inadequate diagnos-
tic tools delay time to TB treatment.
Methods A two-phase TB diagnostic study was conducted
among HIV-infected adult patients from 2014–2016. Patients
underwent history/physical exam, chest x-ray, urine for lipoara-
binomannan (LAM), sputum smear and culture. We evaluated
sensitivity, specificity and time to appropriate treatment within
14 and 28 days of screening for culture-positive patients, com-
paring Xpert MTB/RIF assay (GXP), and LAM to
standard-of-care (SOC) in 3 peri-urban clinics. chi-square and
Wilcoxon Rank-Sum tests were used to test for differences
between SOC and GXP for categorical variables and continuous
variables, respectively.
Results 1353 patients were enrolled; 755 in the SOC arm and
598 in the GXP arm. Median age was 34.3 and 65.1% were
male. TB was diagnosed by any method (smear, clinical, GXP,
LAM, culture) in 237 (17.5%) and with positive MTB culture
in 152 (11.2%); 84 and 68 in the SOC and GXP arms, respect-
ively. The overall sensitivity and specificity (culture as reference
standard) of SOC was 91.7% and 92.9% respectively while
GXP was 50.8% and 99.2%, respectively. LAM, when used
with SOC, did not improve sensitivity or specificity in any CD4
strata, however when used with GXP increased sensitivity from
20% to 50% at CD4<50. There was a marginally significant
difference (p=0.08) at 14-day TB treatment initiation between
the GXP and SOC phases but no difference at 28-days. Among
those initiating therapy, the median time to TB treatment initi-
ation was shorter for the GXP arm (4 vs15 days).
Conclusions GXP did not significantly increase the number or
accuracy of TB diagnoses compared to SOC but reduced
median number of days to TB treatment by 11 days. GXP and
LAM when used together have the potential to rapidly identify
TB in patients with advanced HIV disease.
OA-006 COMPARATIVE EVALUATION OF GENOTYPE
MTBDRPLUS VERSION 2 AND GENE XPERT MTB/RIF
ASSAYS TO DETECT MYCOBACTERIUM TUBERCULOSIS
AND RESISTANCE GENE PATTERNS IN GABON
Abraham Alabi,1 Francis Foguim,1 Jeyaraj Sankarganesh,2 Ellen Bruske,2
Arnault Mfoumbi,1 Chester Mevyann,1 Ayola Adegnika,1 Bertrand Lell,1
Katharina Kranzer,3 Peter Kremsner,2 Martin Grobusch4. 1CERMEL, Gabon; 2ITM
Tübingen, Germany, Germany; 3NRC for Mycobacteria, Germany; 4AMC, The
Netherlands
10.1136/bmjgh-2016-000260.15
Background Tuberculosis (TB) remains a major cause of mor-
bidity and mortality in Africa. A major challenge of TB diagno-
sis is slow growth of its causative agent, Mycobacterium
tuberculosis complex (MTBC). WHO has endorsed the applica-
tion of molecular methods to rapidly diagnose TB and detect
drug resistance mutations in MDR-TB. We hereby evaluate the
efficacy of the GenXpert MTB/RIF and the GenoType
MTBDRplus, using culture as gold standard.
Methods We applied the GeneXpert MTB/RIF (Cepheid) and
the Genotype MTBDRplus (Hain Life Sciences, Germany) to
compare between molecular and standard traditional methods
(smear microscopy and culture). In total, 246 consecutive sputa
samples from suspected TB cases (individuals) in Lambarene
and surrounding villages were analysed. The molecular methods
confirm MTBC and detect resistant mutations in the rpoB, katG
and inh genes corresponding to rifampicin (RIF) and isoniazid
(INH), respectively.
Results Of the 193 samples available for analysis, 51 were posi-
tive and 142 were negative by culture. The overall sensitivity of
GeneXpert compared to culture was 86.3% and the specificity
was 93.7%. The sensitivity and specificity of Genotype
MTBDRplus compared to culture were 82.5% and 95.8%.
Rifampicin-resistant strains determined by standard drug suscep-
tibility testing (DST) were 100% identified by GeneXpert and
83.3% by Genotype MTBDRplus. All the rifampicin-resistant
strains were also exhibiting the high level resistance against high-
level isoniazid corresponding to katG genes. Genotype
MTBDRplus identified two isolates carrying only mutations to
low-level isoniazid resistance.
Conclusions This comparative study has established a strong
correlation between the GeneXpert and the MTBDRplus assays
for the rapid diagnosis of multi-drug resistant TB (MDR-TB); as
well as with drug susceptibility testing by standard culture
method. Our findings further strengthen the WHO recommen-
dation for the universal implementation of molecular tests in
order to enhance the rapid diagnosis of TB and early initiation
of treatment in confirmed cases.
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OA-007 MOLECULAR BACTERIAL LOAD ASSAY: A FAST AND
ACCURATE MEANS FOR MONITORING TUBERCULOSIS
TREATMENT RESPONSE
Wilber Sabiiti,1 Nyanda Ntinginya,2 Davis Kuchaka,3 Khalide Azam,4
Elizabeth Kampira,5 Bariki Mtafya,2 Ruth Bowness,1 Nilesh Bhatt,4 Gerry Davies,5
Gibson Kibiki,6 Stephen Gillespie1. 1University of St. Andrews, United Kingdom;
2NIMR- MMRC, Tanzania; 3KCRI, Tanzania; 4INS, Mozambique; 5University of
Malawi, Malawi; 6EAHRC, Burundi
10.1136/bmjgh-2016-000260.16
Background Tuberculosis is a difficult disease to treat. We
report a multi-centre performance evaluation of the molecular
bacterial load assay (MBLA) that monitors change in patient
bacterial load (BL) as they respond to TB therapy.
Methods Smear or Xpert MTB/RIF-positive patients were pro-
spectively monitored for treatment response using MBLA and
culture at four sites in Southeast Africa. Treatment response was
defined as decline in BL and or rise in time to culture positivity
(TTP) or conversion to negative culture status. Positive culture
at 5 or 6 months confirmed treatment failure. MBLA-MGIT cor-
relation and association with treatment outcome were deter-
mined by Spearman’s ρ and logistic regression, respectively.
Results A total of 1764 serial samples from 178 patients were
assessed for treatment response of which 91% were treatment
success. Of those who failed treatment (n=17), MBLA detected
TB in 82% at 2 months of treatment compared to MGIT 24%
and LJ 6%. Mean BL at baseline was 6±1.3log10 CFU/ml
falling to zero in 59% of the patients by 3 months of treatment.
A corresponding rise in MGIT TTP, 5±3 to 22±11 was
observed, r=–0.5, p<0.0001. The rate of sputum clearance
(SLOPE) was high among high-burden patients – 1.0log10C-FU/
ml than low-burden patients, –0.7log10CFU/ml in the first 2
weeks of treatment. Despite higher rates of clearance, high-
burden patients were more likely to be TB-positive at 2 months
of treatment, p=0.01(OR 2.5). Response was generally slower
among the MDR than susceptible TB patients. Time to result
was 4h with MBLA and 5–22 days for MGIT. Contamination
was 25% in MGITand 4% on solid culture.
Inter-site testing revealed that MBLA was reproducible,
ANOVA p >0.05.
Conclusions MBLA is a contamination-insensitive, reproducible
method capable of giving results in real-time. Direct quantifica-
tion of bacterial load from uncultured sputum demonstrates
considerable potential for application in resource-limited set-
tings where TB culture facilities are scarce.
OA-009 DIAGNOSTIC TOOLS FOR HUMAN AFRICAN
TRYPANOSOMIASIS ELIMINATION AND CLINICAL
TRIALS: THE DITECT-HAT PROJECT
Veerle Lejon,1 Hamidou Ilboudo,2 Dieudonné Mumba,3 Mamady Camara,4
Dramane Kaba,5 Crispin Lumbala,6 Eric Fèvre,7 Vincent Jamonneau,8
Bruno Bucheton,9 Philippe Büscher10. 1IRD Paris, France; 2CIRDES, Burkina Faso;
3INRB, Republic of Congo; 4PNLTHA, Guinea; 5Institut Pierre Richet, Côte d’Ivoire;
6PNLTHA, Republic of Congo; 7University of Liverpool, United Kingdom; 8IRD, Côte
d’Ivoire; 9IRD, Guinea; 10ITM Antwerp, Belgium
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Background Trypanosoma brucei gambiense (Tbg) causes
human African trypanosomiasis (HAT), one of the neglected
tropical diseases targeted for elimination. Integration of diagno-
sis and case management into the general health system,
sustainable monitoring of eliminated foci and development of
safe and efficacious drugs, remain important challenges.
Methods The DiTECT-HAT project tackles these challenges.
For passive case detection, we will determine the diagnostic per-
formance and cost of rapid diagnostic tests (RDTs) performed
on clinical suspects in peripheral health centres, whether or not
combined with serological and/or molecular tests on filter paper
done at regional reference centres. Cost-effective diagnostic
algorithms with high positive predictive values might allow
test-and-treat scenarios without the need for complicated para-
sitological confirmations. Secondly, health workers performing
house to house visits in foci with very low HAT prevalence can
easily collect blood on filter paper and send it to regional HAT
reference centres for analysis. The feasibility and cost of diag-
nostic algorithms with RDTs, serological and molecular high-
throughput tests for post-elimination monitoring will be deter-
mined. An appropriate threshold will be established to trigger
active case finding to avoid re-emergence of HAT, without
unnecessarily raising the alarm. Finally, the accuracy of neop-
terin and RNA detection as early test-of-cure will be determined
in therapeutic trials.
Earlier treatment outcome assessment will speed up the devel-
opment of new drugs for HAT, and improve management of
relapses in routine care.
Results An update of ongoing and planned activities is given.
The passive case detection sub-project is being set up in DR
Congo, Côte d’Ivoire and Guinea. The inclusions for the early
test-of-cure sub-project are ongoing in DR Congo.
Conclusions The proposed research will provide evidence to
support policies for improved HAT diagnosis and patient man-
agement within a context of disease elimination, and will con-
tribute to successful and sustainable HATelimination.
OA-010 PREVALENCE AND CLINICAL SIGNIFICANCE OF
SCHISTOSOMIASIS-CHRONIC HEPATITIS B VIRUS
CO-INFECTION IN ZAMBIA
Caroline Chisenga,1 Edford Sinkala,2 Roma Chilengi,1 Hellen Chitundu,2
Zude Zyambo,1 Gilles Wandeler,3 Michael Vinikoor1. 1CIDRZ, Zambia; 2UTH,
Lusaka, Zambia; 3University of Bern, Switzerland
10.1136/bmjgh-2016-000260.18
Background Hepatosplenic schistosomiasis (HSS) and hepatitis
B virus (HBV) are both endemic in sub-Saharan Africa but the
clinical epidemiology of co-infection is not well-characterised.
Within a current HIV cohort study, we assessed the prevalence
of HSS and its impact on markers of liver fibrosis in HIV-HBV
co-infected individuals.
Methods At two urban HIV care facilities in Zambia’s capital
Lusaka, we screened for HBV co-infection using a hepatitis B
surface antigen (HBsAg) test and for lifetime infection with
Schistosoma mansoni using an IgG enzyme-linked immunoassay
(Abcam, Cambridge, UK). Among HIV-HBV patients, we also
performed abdominal ultrasonography. We defined HSS as evi-
dence of periportal hepatic fibrosis on ultrasound regardless of
IgG result. Patient characteristics, including liver fibrosis
markers (ALT and transient elastography) were measured and
stratified by HSS. We used Wilcoxon rank sum test for continu-
ous and chi-square test for categorical comparisons between
groups.
Results Among 895 HIV-infected adults, lifetime exposure to S.
mansoni was observed in 23.3%. Within the cohort 92
HBsAg-positives underwent assessment for HSS. Median age
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among these was 34.7 years (interquartile range [IQR], 28.9–
39.9), 48% were men, CD4 count was 247 cells/mm3 (IQR,
145–335), HBV viral load was 2.87 (IQR, 1.00–5.18) log10 IU/
mL, and liver stiffness was 5.5 kilopascals (IQR, 4.7–6.9).
On ultrasound, 1 patient had cirrhosis and 36 (39.1%) had evi-
dence of HSS. HBV-HSS patients had a non-significant trend
toward higher portal vein diameter (8.5 versus 10.2; p=0.15) com-
pared to those without HSS but ALT (18.5 vs 20 U/L), and liver stiff-
ness (5.3 vs 5.0 kPa) were similar between groups (both p >0.05).
Conclusions Lifetime S. mansoni exposure and current HSS were
common among HIV-infected patients with HBV co-infection in
Zambia. Mild HSS did not appear to alter non-invasive markers of
liver fibrosis. Further research on the impact of more advanced HSS
on HBV co-infection is needed.
OA-011 THE IMMUNE TRYPANOLYSIS TEST: AN ACCURATE
SEROLOGICAL MARKER TO MANAGE ELIMINATION OF
T.B. GAMBIENSE HUMAN AFRICAN TRYPANOSOMIASIS
Dama Emilie,1,2 Oumou Camara,3 Koffi Mathurin,4 Dayo Guiguigbaza-Kossigan,2
Büscher Philippe,5 Fikru Regassa,6 Sakande Hassane,2 Somda Martin Bienvenu,1,2
Hamidou Ilboudo,2 Courtin Fabrice,7 Elie Ouédraogo,8 Lingue Kouakou,9
Dramane Kaba,10 Mamady Camara,4 Bruno Bucheton,7 Veerle Lejon,7
Vincent Jamonneau7. 1UPB, Bobo-Dioulasso, Burkina Faso; 2CIRDES, Burkina Faso;
3PNLTHA, Guinea; 4UJILOG (LIHME), Côte d’Ivoire; 5ITM, Antwerp, Belgium; 6CVMA
(Addis Ababa University), Ethiopia; 7IRD (UMR177 IRD-CIRAD, TA A-17/G), France;
8DLM, Burkina Faso; 9PNETHA, Côte d’Ivoire; 10Institut Pierre Richet, Côte d’Ivoire
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Background Continued post-elimination monitoring is required
to ensure sustainability of zero transmission of human African
trypanosomosis (HAT) and to avoid re-emergence caused by
potential remaining Trypanosoma brucei gambiense reservoirs
(animal and/or human). Until now, no tool is able to attest or
validate elimination. Increasingly, the serological immune trypa-
nolysis test is being implemented in the decision algorithms to
characterise parasitological unconfirmed CATTor RDT seroposi-
tive subjects. Therefore, we wanted to assess further the high
specificity of immune trypanolysis.
Methods We first tested samples from domestic animals from a
tsetse-infested area in Ethiopia, a country where no
T. b. gambiense exists, but where bovine trypanosomosis is
prevalent. Then, we tested cattle and human samples from the
south-west of Burkina Faso, a historical focus of gambiense
HAT that still shelters tsetse flies populations and animal trypa-
nosomosis. Lastly, we were interested in testing human samples
from active foci in Côte d’Ivoire and Guinea.
Results Our results showed zero trypanolysis-positive animals
from Ethiopia while in the historical HAT foci in Burkina Faso,
4.89% (14/286) of cattle were trypanolysis-positive. In humans,
zero samples over 729 were trypanolysis-positive in Burkina
Faso, while the percentage of positives was 3.77% (44/1166) in
Guinea, including 7 new cases diagnosed during the sampling
and 1.3% in Côte d’Ivoire (8/598).
Conclusions Considering results from this study, we think that
trypanolysis test, confirmed to be a very specific test in human,
can be a tool able to certify HAT elimination in a given area. It
also suggests that the risk of the reintroduction of
T. b. gambiense in Burkina Faso is real, especially in the south-
west which shelters a high density of tsetse populations, in add-
ition to the possible presence of T. b. gambiense in domestic
animals. However, further studies on the specificity of the trypa-
nolysis test regarding T. b. gambiense in animals should be
conducted.
OA-012 PREVALENCE AND RISK FACTORS OF VIROLOGICAL
FAILURE AMONG CHILDREN ON ANTIRETROVIRAL
THERAPY
Michael Owusu,1 Eric Mensah,2 Anthony Enimil,2 Mohamed Mutocheluh2. 1KCCR,
Ghana; 2KNUST, Ghana
10.1136/bmjgh-2016-000260.20
Background An unprecedented global effort at scaling up uni-
versal access to antiretroviral therapy has decreased the progres-
sion of HIV. However, due to challenges with supplies and
adherence to intermittent antiretroviral therapy (ART) for
mothers, infants continue to be infected, some with resistant
viruses. Exposure to these resistant strains leads to non-
responsiveness to therapy resulting in virological failure.
Children are more vulnerable to HIV drug resistance because of
their life long treatment, the possible selection of resistant
strains as a result of prophylaxis for mothers with HIV enrolled
in PMTCT. The objective of the study was to determine the
prevalence and risk factors of virological resistance among
HIV-1-positive children on antiretroviral therapy.
Methods This was a longitudinal study that was performed at
the HIV paediatric clinic of the Komfo Anokye Teaching
Hospital, Kumasi, Ghana. Blood samples of children below the
age of 18 years who had been on therapy for at least 3 months
were analysed for virological load using real-time COBAS
AmpliPrep/COBAS Taqman PCR. The samples were analysed at
two consecutive time points when they came for their ART
refill. Socio-demographic and clinical information was collected
from their folders and also from the mother.
Results A total of 188 subjects were enrolled into the study
from September 2015 to June 2016. The average duration on
ART was 36 months (IQR=12–72 months). Of all subjects
recruited, 134 (71.3%) were found to be on regular drug ART.
Of these, 21 (15.7%) had virological failure and 102 (76.1%)
had virological suppression. A regression analysis showed that
subjects whose parents were unemployed had 5.4 (1.4–20.9)
chances of virological failure compared to those with parents
employed.
Conclusions The risk of virological failure among HIV-positive
children is still high. Efforts must be made to further identify
the potential causes of virological failure among these children.
OA-013 VIROLOGICAL RESPONSE TO EARLY COMBINED
ANTIRETROVIRAL THERAPY IN HIV-INFECTED INFANTS:
EVALUATION AFTER TWO YEARS OF TREATMENT IN
THE PEDIACAM STUDY
Francis Ateba Ndongo,1 Mathurin Cyrille Tejiokem,2 Gaetan Texier,3 Calixte Penda,4
Suzie Ndiang,5 Jean-Audrey Ndongo,1 Georgette Guemkam,1 Casimir
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Josiane Warszawski8. 1Chantal Biya Foundation, Cameroon; 2Centre Pasteur du
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Background Little is known about virological responses to
early combined antiretroviral therapy (cART) in HIV-infected
infants in limited-resource settings. We estimated the probability
of achieving viral suppression within two years of cART initi-
ation, and investigated the factors associated with success.
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Methods We analysed all 190 infants from the Cameroon
PediaCAM study who began free cART before the age of 12
months. The main outcome measure was viral suppression
(<1000 cp/mL) on at least one occasion. The other outcome
measures considered were viral suppression (<400 copies/ mL)
on at least one occasion and confirmed viral suppression (both
thresholds) on two consecutive occasions. We used
competing-risks regression for a time-to-event analysis to esti-
mate the cumulative incidence of outcomes, and univariate and
multivariate models to identify risk factors.
Results During the first 24 months of cART, 20.0% (38) of the
infants died, giving a mortality rate of 11.9 deaths per 100
infant-years [95% CI: 8.1–15.7]. The probability of achieving a
viral load below 1000 or 400 copies/mL was 80.0% [69.0–81.0]
and 78.0% [66.0–79.0], respectively. The probability of viro-
logical suppression (with these two thresholds) on two consecu-
tive occasions was 67.0% [56.0–70.0] and 60.0% [49.0–64.0],
respectively. Virological success was associated with not having
missed any doses of treatment before the visit, but not with
socioeconomic and living conditions.
Conclusions The long-term daily administration of drugs to
babies seems to be difficult. Mortality remained high despite
early cART initiation. Future studies should focus on longer-
term treatment outcomes in children still alive after two years of
treatment.
OA-014 HIV INFECTION AND CARDIOVASCULAR RISK PROFILE
IN A RURAL SOUTH AFRICAN POPULATION: THE
NDLOVU COHORT STUDY
Alinda Vos,1 Walter Devillé,2 Roos Barth,3 Kerstin Klipstein-Grobusch,1
Hugo Tempelman,2 François Venter,4 Roel Coutinho,1 Diederick Grobbee1.
1UMC Utrecht ( Julius Center), The Netherlands; 2Ndlovu Research Consortium,
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Background Life expectancy increased in HIV-infected popula-
tions due to antiretroviral treatment (ART). Whether
HIV-infection and/or ART increase cardiovascular risk against a
background of increasing prevalence of obesity, hypertension
and diabetes in low- and middle-income countries is not yet
clear. To answer this question in a rural South-African popula-
tion, the Ndlovu Cohort Study was designed. We describe the
baseline distribution of cardiovascular risk factors in relation to
HIV and ART.
Methods The Ndlovu Cohort Study is a prospective cohort
study of 1000 HIV-positive and 1000 HIV-negative adults from
the Moutse area, Limpopo, South Africa with an intended
follow-up duration of ten years. Information is collected on
demographics, anthropometrics, life-style, kidney and liver func-
tion, CRP, glucose and proteinuria. Carotid intima-media thick-
ness (CIMT) and pulse wave velocity (PWV) measurements are
used to assess subclinical atherosclerosis, respectively arterial
stiffness. Cardiovascular risk factors were compared between
HIV-negative and HIV – positive participants, whether or not
on ART. Data were adjusted for gender and age.
Results By December 2015, 1053 participants were included,
66% women; 345 (32.8%) women were HIV-positive of whom
235 (68.1%) received ART. HIV-infected participants were sig-
nificantly older (40.0 versus 37.3 years), and mainly women
(73%). HIV was associated with a lower body mass index, lower
total – and LDL cholesterol and a lower prevalence of hyperten-
sion and diabetes. ARTwas associated with increased HDL and
triglyceride levels. Current smoking did not differ between
groups (23.6%), HIV and ARTwere associated with higher CRP
values. Framingham risk scores (FRS) did not differ between
HIV+/HIV- and/or ARTuse.
Conclusions HIV infection is accompanied by a lower preva-
lence of cardiovascular risk factors, although the level of inflam-
mation is increased. So far, we found no evidence that the
10-year cardiovascular disease risk according to FRS is influ-
enced by HIV infection or HIV treatment.
OA-015 PHYLOGENETIC AND DEMOGRAPHIC
CHARACTERISATION OF HIV-1 TRANSMISSION
NETWORKS IN A GENERAL POPULATION COHORT IN
UGANDA
Deogratius Ssemwanga,1 Frederick Lyagoba,1 Brian Magambo,1 Anne Kapaata,1
Joseph Kirangwa,1 Maria Nannyonjo,1 Faridah Nassolo,1 Rebecca Nsubuga,1
Gonzalo Yebra,2 Andrew Brown,2 Pontiano Kaleebu1. 1MRC-UVRI AIDS, Uganda;
2University of Edinburgh (IEB), United Kingdom
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Background The General Population Cohort (GPC) in
Southwestern Uganda is a low-risk population with low HIV
incidence rates (<1%). Despite several interventions for close to
30 years, new cases of HIV continue to emerge. We set out to
use phylogenetics and patients’ demographic data to understand
the HIV transmission dynamics in this population to inform
prevention.
Methods A total of 2049 pol sequences of participants diag-
nosed from 2003–2015 were included in this analysis; pol
sequences were from GPC (n=1049), Central Uganda (n=800)
and Eastern Uganda (n=200). Phylogenetic analysis was used to
identify transmission networks. The demographic and clinical
characteristics of the transmission clusters were analysed.
Results The overall subtype distribution was: A (45%), C (3%),
D (40%) and others (12%). The subtype distribution by region
was for GPC: A (41%), C (2%), D (45%) and others (12%).
For Central: A (49%), C (4%), D (35%) and others (12%).
Eastern: A (60%), C (3%), D (24%) and others (13%). We iden-
tified 233 transmission clusters (cluster size variation 2–10) that
comprised of 559 (27%) of the 2049 participants.
The majority of clusters comprised transmission pairs
(n=186) and triplets (n=30). The majority (∼60%) of the 233
clusters was from the GPC and all 13 large clusters (≥5) were
also from the GPC. A significant number of clusters (n=25,
11%) was formed between individuals from different geo-
graphic locations. Participants in transmission networks were
associated with high-risk sexual behaviour: low condom use,
high alcohol use, and partner change even with known
HIV-positives.
Conclusions The transmission networks identified among indi-
viduals from the GPC and other populations or geographic
regions may imply HIV introductions from outside communi-
ties. This suggests that HIV introductions into communities are
common and account for a substantial number of new infections
in the GPC. HIV prevention efforts should therefore target the
broader communities beyond the GPC.
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OA-016 PREVALENCE AND RISK FACTORS FOR
EFAVIRENZ-BASED ANTIRETROVIRAL
TREATMENT-ASSOCIATED SEVERE VITAMIN D
DEFICIENCY: A PROSPECTIVE COHORT STUDY
Hanna Nylén,1 Abiy Habtewold,2 Eyasu Makonnen,2 Getnet Yimer,2
Jürgen Burhenne,3 Ulf Diczfalusy,1 Eleni Aklillu1. 1KI, Sweden; 2Addis Ababa
University, Ethiopia; 3University of Heidelberg, Germany
10.1136/bmjgh-2016-000260.24
Background Initiation of efavirenz-based combination anti-
retroviral therapy (cART) is associated with Vitamin D defi-
ciency, but the risk factors for cART-induced severe vitamin D
deficiency (SVDD) and the impact of anti-tuberculosis (TB)
co-treatment is not explored well.
Methods Treatment-naïve HIV patients with (n=102) or
without (n=89) tuberculosis co-infection were enrolled pro-
spectively and received efavirenz-based cART. In TB-HIV
co-infected patients, rifampicin-based TB treatment was
initiated. Plasma 25-hydroxyvitamin D (25(OH)D), cholesterol
and 4-beta hydroxycholesterol concentrations were measured at
baseline, and weeks 4, 16 and 48 of cART. Plasma efavirenz
concentrations were determined at week 4 and 16 of cART.
Genotyping for CYP2B6, CYP3A5, ABCB1, SLCO1B1, and
UGT2B7 were done.
Results TB-HIV patients had significantly lower plasma 25
(OH)D3 levels than HIV-only patients at baseline. TB
co-infection, low Karnofsky score, high viral load and high
CYP3A activity as measured by plasma 4-beta hydroxycholes-
terol/ cholesterol ratios were significant predictors of low 25
(OH) D3 levels at baseline. In HIV-only patients, initiation of
efavirenz-based cART increased the prevalence of SVVD from
27% at baseline to 76%, 79% and 43% at weeks 4, 16 and 48
of cART, respectively. The median 25(OH)D3 levels declined
from baseline by –40%, –50% and –14% at weeks 4, 16 and 48
of cART, respectively. In TB-HIV patients, prior TB therapy had
no influence on 25(OH)D3 levels, but the initiation of
efavirenz-based cART increased the prevalence of SVDD from
57% at baseline to 70% and 72% at weeks 4 and 16 of cART,
respectively. Whereas the median plasma 25(OH)D3 declined
from baseline by –17% and –21% at week 4 and 16 of cART,
respectively. None of the genotypes were significantly associated
with SVDD.
Conclusions Low plasma cholesterol, high CYP3A activity, and
high plasma efavirenz concentrations are significant predictors
of early efavirenz-based cART-induced SVDD. Low plasma 25
(OH)D3 level at baseline is associated with TB co-infection and
HIV diseases progression.
OA-018 THE BURDEN AND FUTURE SCOPE FOR IMPORTANT
VIRAL ENTERIC PATHOGENS IN AFRICA
Duncan Steele. Bill & Melinda Gates Foundation, United States of America
10.1136/bmjgh-2016-000260.25
Background The burden of viral enteric infections in Africa is
enormous, although poorly described. Some, such as rotavirus,
are well recognized, whereas others including norovirus or
enteric adenovirus (EAd), show high burden which is only now
being described. Hepatitis E virus (HEV) is a neglected enteric
viral infection although is on WHO’s radar screen as an import-
ant pathogen which needs further evaluation in Africa and Asia.
This presentation will focus on these four enteric viral
pathogens describing our current understanding of disease
burden and the potential for vaccines as potential interventions.
Many countries in Africa have documented the high burden of
rotavirus. Almost 30 countries have introduced rotavirus vac-
cines with or without Gavi support, and recent studies docu-
ment dramatic reductions in diarrhoeal hospitalizations and
diarrhoeal deaths post introduction.
Norovirus is a ubiquitous virus causing diarrhoeal disease in all
age ranges, although the incidence is highest in young children.
Although a common cause of diarrhoea, norovirus is often asso-
ciated with asymptomatic shedding making it difficult to ascer-
tain the true burden of the disease. Nevertheless, advances
towards understanding the epidemiology and diversity of noro-
virus in Africa are important to inform future vaccine efforts.
EAds have recently been described as one of the top 5 patho-
gens associated with acute severe diarrhoea in young children
<5 years in Africa and Asia. Coupled with the high prevalence
of EAds in HIV-infected children requires more focused
research, although there is very limited vaccine development
currently.
HEV is associated with water-borne and zoonotic infections,
and is reported in large outbreaks. It has high mortality in preg-
nant women and is associated with high rates of stillbirths.
Little is known of the extent of HEV infection in Africa. A
Chinese vaccine against HEV has been licensed and WHO has
identified gaps in research that are required for future immun-
ization opportunities.
OA-019 NEW POSSIBILITIES FOR THE DEVELOPMENT OF A
COMBINED VACCINE AGAINST ETEC AND SHIGELLA
Richard Walker. PATH, United States of America
10.1136/bmjgh-2016-000260.26
Background Together, enterotoxigenic Escherichia coli (ETEC)
and Shigella contribute greatly to the mortality and the morbid-
ity due to diarrhoeal diseases, including a number of negative
lifetime health impacts. Vaccines represent a reasonable option
to reduce this burden.
Vaccine candidates PATH has reviewed the landscape of
vaccine candidates for these diseases and identified two candi-
dates to be moved towards licensure in the near-term as a com-
bined ETEC and Shigella vaccine for use on an Expanded
Programme on Immunisation (EPI) schedule.
ETVAX One candidate is a formalin-inactivated ETEC vaccine
(ETVAX) consisting of four E. coli preparations, each engi-
neered to hyper-produce the CFA/1, CS3, CS5, and CS6 anti-
gens of ETEC. In addition, the vaccine contains a cholera B
subunit modified to be more cross-reactive with the B subunit of
ETEC. ETVAX is co-administered with a double-mutant of the
ETEC heat-labile toxin (dmLT), which serves as a potent
mucosal adjuvant.
TSWC The other candidate includes formalin-killed S. flexneri
2a and 3a and S. sonnei prepared as a trivalent vaccine, called
TSWC. A prototype of TSWC, S. flexneri 2a, was administered
to North American volunteers and found to be safe and
immunogenic; it is now currently in a challenge trial.
Looking ahead Early 2017 in a phase I trial, we will test TSWC
given alone and co-administered with ETVAX. ETVAX given
alone exceeded expectations for immunogenicity in Swedish
volunteers and is projected to be evaluated for safety and early
efficacy in Finnish travellers to Benin in early 2017. ETVAX is
also currently being tested in a descending-age trial in
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Bangladesh to determine the optimum safe dose of vaccine and
adjuvant to be given to infants as young as 6 to 10 weeks of
age. We also hope that the dmLTwill have a dose-sparing effect
on the vaccine given to this target population.
OA-020 IMPACT OF TARGETED INTERVENTIONS AGAINST
DIARRHOEA IN ZAMBIA
Roma Chilengi,1 Michelo Simuyandi,1 Laura Beres,1,2 Samuel Bosomprah1. 1CIDRZ,
Zambia; 2Johns Hopkins Bloomberg School of Public Health, Baltimore (MD), USA
10.1136/bmjgh-2016-000260.27
Background Diarrhoea is a leading cause of morbidity and
mortality with the brunt of diarrhoea felt most in developing
countries like Zambia where 13% of all deaths of children
between 1–59 months are attributable to the disease. The
Ministry of Health, in partnership with the Centre for
Infectious Disease Research in Zambia (CIDRZ) and other sta-
keholders, implemented the Programme for the Awareness and
Elimination of Diarrhoea (PAED) in 2012 to reduce all-cause
under-five mortality by 15% in Lusaka Province.
Methods Baseline data were collected in 2012 and endline data
were collected 3 years following PAED implementation. The
primary outcome of interest was all-cause under-five mortality
rate. Additionally, a case-control study to estimate rotavirus
vaccine effectiveness (VE) was undertaken.
Results The percentage of children under age 5 who had diar-
rhoea in the last 2 weeks preceding the survey declined from
15.8% (95% CI: 15.2–16.4%) in 2012 to 12.7% (95% CI:
12.3–13.%) in 2015. Post-neonatal mortality declined by 34%,
from an estimated rate of 29 (95% CI: 26–32) to 19 (95% CI:
16–21) deaths per 1000 live births. The adjusted 2-dose VE was
26% (95% CI: 30%–58%) among children ≥6 months of age.
VE against hospitalised children ≥6 months of age was 56%
(95% CI, – 34%–86%).
Conclusions Well-packaged preventive and treatment interven-
tions against diarrhoea could reduce probability of death among
children aged 1–59 months. VE results from Zambia were con-
sistent with others in the region, and while we observed a
higher point estimate for VE against increased severity of illness
compared with milder disease, the study was not powered to
detect a low level of VE against milder disease.
OA-021 POINT-OF-NEED DIAGNOSTICS: BIOSURVEILLANCE
WITH A DEVICE2CLOUD CAPABILITY IN SIERRA LEONE
Rashid Ansumana,1 C. Taitt,2 J.M. Lamin,1 K.H. Jacobsen,3 S.P. Mulvaney,2
T. Leski,2 U. Bangura,1 D. Stenger2. 1MHRL, Njala University, Sierra Leone; 2Naval
Research Laboratory, United States of America; 3George Mason University, United
States of America
10.1136/bmjgh-2016-000260.28
Background Infectious diseases contribute to a high burden of
diseases globally. Surveillance using low-cost technology, com-
bined with cutting edge platforms offers a path for understand-
ing the disease ecology of locations of interest in resource-poor
countries. Our goal was to pilot a bio surveillance system com-
prising of rapid lateral flow immunoassays, rapid PCR and a
cloud database.
Methods The study was carried out in Bo, Sierra Leone at the
Mercy Hospital. We recruited 1570 subjects over a period of
two years. Inclusion criteria for the study were being febrile,
being at least five years of age, living within the city of Bo or its
neighbouring villages and agreeing to participate in the study.
The assays used included a DPP multiplex lateral flow assay for
dengue, Burkholderia pseudomallei, Yersinia pestis, malaria Pf/
Pan, a Film Array PCR platform with multiplex Biothreat and
SASFI panels that together detect over 30 pathogen targets. We
used a Deki Reader to upload lateral flow images to the cloud
database. The Deki reader quantitates test results, such that
scores at ≥1.75 are considered positive. A special computer
program was designed to upload pdf images of PCR results to
the cloud database. The cloud database was designed for auto-
mated quality assessment and remote monitoring.
Results Preliminary results show that out of 1570 samples pro-
cessed by DPP, 30(1.9%) were positive for Burkholderia, 41
(2.6%) were positive for Dengue NS1 antigen, 22(1.4%) were
positive for Yesinia pestis fraction 1 antigen, and 340(21.7%)
were positive for malaria. When a cross-section of results
obtained by eye was compared with results automatically
detected by the D2C platform, there was 95.2% concordance
between results obtained by eye and those obtained automatic-
ally by the Deki reader to the cloud database.
Conclusions Active disease surveillance and the ability to
remotely monitor activities in peripheral health units are critical
needs in many poor countries. Our results provide additional
perspectives on the twin problem of surveillance and remote
quality assessment.
OA-022 SAFETY AND IMMUNOGENICITY OF CO-ADMINISTERED
HOOKWORM VACCINE CANDIDATES NA-GST-1 AND
NA-APR-1 WITH ALHYDROGEL® AND
GLUCOPYRANOSYL-LIPID A IN GABONESE ADULTS:
INTERIM RESULTS
Ayola Adegnika,1 Sophie De Vries,2 Frejus Jeannot Zinsou,1 J Honkpehedji,1 Jean
Claude Dejon,1 Marguerite Massinga Loembe,1 Bache Bache,1 Nadine Pakker,3
Remko Van Leeuwen,3 Aurore Bouyoukou Hounkpatin,1 Peter Kremsner,4
Maria Yazdanbakhsh,5 Bertrand Lell,1 Jeffrey Bethony,6 Peter Hotez,7
David Diemert,6 Martin Grobusch2. 1CERMEL, Gabon; 2AMC, The Netherlands;
3AIGHD, The Netherlands; 4ITM Tübingen, Germany; 5LUMC (LIPG), The
Netherlands; 6George Washington University (MITM), United States of America;
7Sabin Vaccine Institute; 8BCM (School of Tropical Medicine), United States of
America
10.1136/bmjgh-2016-000260.29
Background Hookworm disease is one of the most prevalent of
the neglected tropical diseases. To date, the control of hook-
worm infection has been limited to mass-administration of
anthelminthic drugs. Despite this, the global hookworm preva-
lence does not decrease, thus there is a need for a vaccine. We
evaluated the Na-GST-1 and Na-APR-1 hookworm vaccine can-
didates simultaneously in a hookworm endemic Gabonese
population.
Methods Eligible healthy Gabonese adults aged 18–50 years
were enrolled in a randomised, double blind, controlled phase I
trial. The first cohort received 30 mg Na-GST-1 co-administered
with 30 mg Na-APR-1. The second cohort received 100 mg
Na-GST-1 and 100 mg Na-APR-1. All doses were administered
after mixing with 5 mg of an aqueous formulation of glucopyra-
nosyl Lipid A (GLA-AF), a Toll-like Receptor-4 agonist.
Hepatitis B vaccination (HBV) was administered as a compara-
tor. Study subjects were vaccinated on days 0, 28 and 180 by
intramuscular injection. IgG antibody levels were measured by
qualified ELISA. This study evaluated the safety, reactogenicity,
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and immunogenicity of Na-GST-1/Alhydrogel® co-administered
with Na-APR-1/Alhydrogel®.
Results Thirty-two study participants were enrolled. No serious
adverse events or significant changes in haematological, renal or
liver function parameters were observed. Mild-to-moderate
injection-site pain, headache and fever were common adverse
events. Elevated Na-GST-1 and Na-APR-1 IgG antibody levels
were detected on day 194. Significant differences in mean anti-
body levels were observed between dose groups for Na-APR-1
[30 mg: 18 (50–86.9) vs 100 mg: 197 (131– 264); p< 0.0001]
but not for Na-GST-1 [30 mg: 338 (213–463) vs 100 mg:
402.54 (283.65–521); p=0.5].
Conclusions Co-administration of the hookworm vaccine can-
didates (Na-GST-1 and Na-APR-1) was safe and well tolerated.
In order to achieve optimal antibody levels, a series of three
high doses needs to be administered. Additional investigations
are necessary to consider this combination as a potential
bivalent vaccine candidate.
OA-023 ONE-YEAR SAFETY OF THE RVSVΔG-ZEBOV-GP
VACCINE IN ADOLESCENTS AND CHILDREN IN
LAMBARENE, GABON
Bache Emmanuel Bache,1 José F. Fernandes,1,2 Régis M Obiang Mba,1 Anita
L. Kabwende,1 Martin P. Grobusch,1,2,3 Sanjeev Krishna,1,2,4 Peter G. Kremsner,1,2
Agnandji Selidji Todagbe1,2. 1Centre de Recherches Médicales de Lambaréné
(CERMEL), Lambaréné, Gabon; 2Institut für Tropenmedizin, Universitätsklinikum
Tübingen, Germany; 3Centre of Tropical Medicine and Travel Medicine, Department
of Infectious Diseases, Division of Internal Medicine, Academic Medical Centre,
Amsterdam, The Netherlands; 4Institute for Infection and Immunity, St. George’s,
University of London, UK
10.1136/bmjgh-2016-000260.30
Background The rVSVΔG-ZEBOV-GP vaccine was safe and
immunogenic in American, European and African adults. Few
cases of transient, self-limiting arthritis have been reported in
some adult participants in Geneva. We describe one-year safety
of a single dose (2×107 plaque forming unit (PFU)) of the
vaccine administered to adolescents and children living in
Lambaréné.
Methods A phase I, open label randomized trial conducted in
Lambaréné, Gabon, to assess the clinical safety (adverse events
(local/systemic symptoms, and laboratory anomalies)) for 365
days’ post injection. The primary objective was to assess the
nature, frequency, and severity of adverse events (AEs) and/or
serious adverse events (SAEs) associated with the administration
of the vaccine.
Results From 08-May 2015 to 07-Jul-2015, a total of 20 ado-
lescents and 20 children aged 13–17 and 6–12 years respect-
ively, were vaccinated with a single intramuscular dose of
2×107 PFU rVSVΔG-ZEBOV-GP vaccine. Two serious adverse
events (SAE) were reported over one year of follow-up. Two
adolescents were hospitalized for Plasmodium falciparium
malaria and pneumonia infection. Up to 12 months’ (6 months
of extended follow-up) of both active and passive reporting, the
most frequently reported symptoms by vaccinees are classified
under the following system organ classes (SOC):
Gastrointestinal disorders 30%(6/20) and 40%(8/20),
respiratory-thoracic and mediasternal disorders 5%(1/20) and
45%(9/20), and infections/infestations 20%(4/20) and 20%(4/
20) for adolescents and children respectively. No case of arth-
ritis was observed, few cases 13%(5/40) of mild to moderate
arthralgia, unrelated to the vaccine were reported. No delayed
reactogenicity symptoms were reported beyond the already mild
to moderate intensity symptoms reported during the first 28
days’ post injection. No severe (grade 3) adverse event was
reported. Median haematology and biochemistry values were
within site normal ranges at month 12.
Conclusion The vaccine dose of 2×107 PFU showed an accept-
able safety and tolerability profile in our volunteers’ age 6–17
years, living in a setting endemic for Ebola virus transmission.
This acceptable safety profile seen in adolescents and children is
similar to that previously reported in adults.
OA-024 THE ROLE OF CLINICAL TRIALS FOR ELIMINATION OF
NEGLECTED INFECTIOUS DISEASES AMENABLE TO
MASS DRUG ADMINISTRATION
Moses Bockarie. EDCTP, South Africa
10.1136/bmjgh-2016-000260.31
Background In 2012, WHO published a roadmap, for
‘Accelerating Work to Overcome the Global Impact of
Neglected Tropical Diseases (NTD)’, which set out control and
elimination targets for five NTDs that were considered tools-
ready. Lymphatic filariasis, onchocerciasis, schistosomiasis, trach-
oma and soil-transmitted helminthiasis are amenable to the pre-
ventive chemotherapy (PC) strategy and manageable through
the implementation of available diagnostic products, and safe
and effective medicines. The optimism for achieving the WHO
2020 targets for control and elimination for these PC NTDs
was crystallised by the London Declaration of 2012 – a pledge
by leaders of several major global health and development orga-
nizations, together with industry partners to unite efforts to
achieve the targets by 2020. Clinical research involving human
subjects is driven primarily by the need for novel products,
devices or interventions. The question remains whether clinical
trials have a role in the fight against NTDs that are tools-ready.
Can an investment case be made for vaccines or new drugs for
the five PC NTDs? Four of the five PC NTDs are vector-borne
diseases, but clinical trials are not normally designed to measure
vector outcomes and there is little information available for the
conduct of clinical trials involving entomological tools and pro-
ducts. Moreover, human and laboratory capabilities for conduct-
ing clinical trials in the countries most affected by NTDs in
sub-Saharan Africa are limited. Nonetheless, alternative inter-
vention strategies based on new drugs, vaccines and novel
devices have been proposed as additional tools that could fast-
track the fight against the PC NTDs. The role of clinical trials in
defining these new strategies will be discussed.
OA-025 ARTEMISININ-BASED COMBINATION TREATMENTS IN
PREGNANT WOMEN IN ZAMBIA: EFFICACY, SAFETY
AND RISK OF RECURRENT MALARIA
Michael Nambozi,1 Jean-Bertin Kabuya,1 Sebastian Hachizovu,1
David Mwakazanga,1 Webster Kasongo,1 Jozefien Buyze,2 Modest Mulenga,1
Jean-Pierre Geertruyden,3 Umberto D’Alessandro4. 1TDRC, Zambia; 2ITM Antwerp,
Belgium; 3University of Antwerp, Belgium; 4MRC, The Gambia
10.1136/bmjgh-2016-000260.32
Background In Zambia, malaria is one of the leading causes of
morbidity and mortality, especially among under five children
and pregnant women. For the latter, WHO recommends the use
of Artemisinin-based Combinations Treatments (ACTs) in the
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second and third trimester of pregnancy. In a context of limited
information on ACTs, the safety and efficacy of three ACTs,
namely artemether-lumefantrine (AL), mefloquine-artesunate
(MQAS) and dihydroartemisinin-piperaquine (DHAPQ) were
assessed in malaria-infected pregnant women.
Methods Trial was carried out between July 2010 and August
2013 in Nchelenge district, Luapula Province, an area of high
transmission, as part of multi-centre trial. Women in second or
third trimester of pregnancy and with malaria were recruited
and randomized to one of three study arms. Women were
actively followed up for 63 days, and then at delivery and one
year post-delivery.
Results Nine hundred pregnant women were included, 300 per
arm. PCR-adjusted treatment failure was 4.7% (12/258) (95%
CI:2.7–8.0) for AL, 1.3% (3/235) (95%CI:0.4–3.7) for MQAS
and 0.8% (2/236) (95%CI:0.2–3.0) for DHAPQ, with signifi-
cant risk difference between AL and DHAPQ (p=0.01) and
between AL and MQAS (p=0.03) treatments. New infections
during follow up were more frequent in AL (Hazard Ratio
(HR):4.70; 95%CI:3.18–6.94; p<0.01) and MQAS (HR:1.59;
95%CI:1.02–2.46; p=0.04) arms compared to DHAPQ arm.
PCR-adjusted treatment failure was significantly associated with
women under 20 years [HR5.35 (95%CI:1.07–26.73; p=0.04)]
and higher malaria parasite density [3.23 (95%CI:1.03–10.10;
p=0.04)], and still women under 20 years [1.78, (95%CI:1.26–
2.52; p<0.01)] had a significantly higher risk of new infections.
Unadjusted for treatment, low treatment dosage per kg body
weight was significantly associated with the risk of new infec-
tions (HR:1.72; 95%CI:1.29–2.28; p<0.01). The three treat-
ments were generally well tolerated. Dizziness, nausea,
vomiting, headache and asthenia as Adverse Events (AEs) were
more common in MQAS than in AL or DHAPQ (p<0.001).
Birth outcomes were not significantly different between treat-
ment arms.
OA-027 MASS DRUG ADMINISTRATION (MDA) INTEGRATED
MALARIA ELIMINATION IN A HYPO-ENDEMIC ISLAND
IN LAKE VICTORIA, KENYA
Jesse Gitaka,1 Chim Chan,2 James Kongere,3 Wataru Kagaya,4
Akira Kaneko5. 1MKU, Kenya; 2KI, Sweden; 3NUITM, Kenya; 4TMDU, Japan; 5Osaka
City University, Japan
10.1136/bmjgh-2016-000260.33
Background Mass drug administration (MDA) for malaria elim-
ination has been proposed as a feasible weapon especially for
low endemicity settings. Nonetheless, the concept has not been
tried for hypo-endemic areas of inland Africa. We conducted
MDA using artemisinin-piperaquine and low dose primaquine
with insecticide-treated bed nets (ITN) in Ngodhe Island, Lake
Victoria, Kenya, aiming to reduce prevalence to below 1% in 6
months post MDA.
Methods We conducted 2 rounds of MDA on days 0, 1, 35 and
36. We employed strong community linkages to ensure robust
engagement with the community using workshops, feedback
sessions and involvement of community health volunteers previ-
ously set up by the Ministry of Health and community fieldwor-
kers. The MDA was administered (directly observed) and
participants followed up for possible side effects. Participants
were not tested for glucose-6-phosphate dehydrogenase
deficiency. Malaria infection was determined by microscopy and
polymerase chain reaction (PCR).
Results MDA coverage was 90% for round 1 and 89% for
round 2, with no major drug side effects or haemolytic emer-
gencies. The mean haemoglobin decrease after MDA was not
significant. Prevalence by microscopy decreased from 3.1% on
day 0 to 0% on day 8. Prevalence was 1.1% on day 35, and
0.21% on day 120. Importation of malaria was noted to pose a
challenge in maintaining malaria freedom.
Conclusions MDA led to a rapid reduction in malaria preva-
lence in a hypo-endemic setting in Western Kenya demonstrat-
ing feasibility when combined with strong community
engagement. Primaquine was well tolerated with no haemolytic
emergencies. Nonetheless, strategies to mitigate imported
malaria need to be developed for long-term sustainability.
OA-028 RANDOMIZED TRIAL TO ASSESS EFFECT OF REPEATED
TREATMENT OF DHA-PQ AND AL ON QTC INTERVAL IN
PATIENTS PRESENTING WITH UNCOMPLICATED
MALARIA IN BOBO-DIOULASSO, BURKINA FASO
Naomie Kabore,1 Nouhoun Barry,1 Zachari Kabre,1 Karidia Werme,1
Aminata Fofana,1 Daniel Compaore,1 Frederic Nikiema,1 Fabrice Some,1
Abdoulaye Djimde,2 Issaka Zongo,1 Bosco Ouedraogo1. 1IRSS-DRO, Burkina Faso;
2MRTC, University of Bamako, Mali
10.1136/bmjgh-2016-000260.34
Background Artemisinin combination therapies (ACTs) are
widely used for the management of malaria and even tested for
chemoprevention. In single episode efficacy studies, these drugs
were clinically well tolerated but cardiac effects over repeated
treatment are less investigated.
Methods We conducted a prospective randomised controlled
trial in Bobo-Dioulasso from August to October 2013 where
patients aged 6 months and over were randomly allocated to
receive either dihydroartemisinin-piperaquine (DHAPQ) or
artemether-lumefantrine (AL) on first and subsequent episodes.
Each participant was screened against inclusion criteria includ-
ing the ECG which was repeated again 2 hours after the last
dose. We considered that a QTc interval more than 30 ms com-
pared to the baseline value is abnormal, but a prolonged QTc
interval over 450 ms was reported as adverse event. QTc values
were categorised into less or greater or equal to 450 ms. Drug
tolerance was compared using Chi-square test, and p-value of
less than 0.5 is significant.
Results Patients were randomised to receive DHAPQ (n=224)
or AL (n=236). During the 2 years follow-up we observed a
total of 130 (in 1173 electrocardiogram performed on day 2
monitoring) prolonged QTc more than 450 ms (96/548 for
DHAPQ and 34/625 for AL, p< 0.001). Irrespective of the
drug, these proportions of prolonged QTc decreased over the
subsequent episodes (50 QTc =450 in episode 1 to 0 in episode
8 up to episode 10).
Conclusions The proportion of prolonged QTc was higher in
DHAPQ group compared to the AL group but decreased along
with the number of retreatments. Otherwise, DHAPQ and AL
were well tolerated despite repeated treatment of malaria, which
seemed to improve over consecutive episodes.
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OA-029 PATTERNS OF MOLECULAR MARKERS OF RESISTANCE
IN ‘REAL LIFE’ REPETITIVE
DIHYDROARTEMISININ-PIPERAQUINE MALARIA
TREATMENT: A MOLECULAR ANALYSIS OF THE
WANECAM CLINICAL TRIAL PLATFORM OUTPUT
Aminatou Kone,1 Issaka Sagara,1 Anders Björkman,2 Abdoulaye Djimde,1 Jose
Pedro Gil2. 1MRTC, University of Bamako, Mali; 2KI, Sweden
10.1136/bmjgh-2016-000260.35
Background The pharmacologic characteristic of piperaquine
(PPQ), namely its very long half-life, raises concerns on the pos-
sibility of relatively rapid rise of resistance. Recent unequivocal
reports from SE Asia support this worry. Due to its long half-
life, conventional follow-up of up to 63 days in efficacy trials
misses the low concentrations of PPQ, prone to select less sensi-
tive parasite sub-populations. The WANECAM clinical trials
included a follow-up of two years of the same patients, allowing
for the first time the analysis of both, the patterns of selection
upon an expected large range of PPQ concentrations and the
potential effect of residual levels upon repetitive treatments.
Methods We have successfully determined a random sample of
E1 (D0) 151 and 405 (E2-E10) pfcrt K76T genotypes, as well
as 151 E1 (D0) and 389 (E2-E10) genotypes for the pfmdr1
E2-E10 episodes. Pfmdr1 N86Y analysis was limited by a large
(>90%) prevalence of the 86N allele. Established PCR-RFLP
methods were applied, with high precision band analysis being
performed through image analysis software (GelEval®). Qui
Square and Kruskal Wallis tests were used as applicable.
Results The present data analysis was limited to episodes with
an intervening period of<180 days. Preliminary conclusions
point to recurrences of pfmdr1 carrying 184Y parasites to
emerge earlier as compared with 184F (D78 vs D89, Kruskal
Wallis test, p< 0.01), corresponding to an expected difference
of ca. 20 to 10 nM on PPQ blood levels. No significant differ-
ences were detected concerning pfcrt K76T.
Conclusions Long-term analysis of molecular markers through-
out repetitive treatments is expected to unveil informative pat-
terns concerning early steps of PPQ resistance development.
The complete set of data will be presented and analysed in the
context of the recent findings of PPQ resistance in SE Asia. Its
relevance for the East African settings will be discussed.
OA-030 IMMUNOGENS DESIGNED FOR TARGETING
NEUTRALIZING EPITOPES OF HIV-1 ENVELOPE
GLYCOPROTEIN
Godwin Nchinda,1 Alain Bopda,2 Nadesh Nji,1 Georgia Ambada,1 Loveline Ngu,1
Jules Tchadji,3 Carol Sake,3 Suzanne Magagoum,3 Ghislain D. Njambe,3
Abel Lisom,3 Chae Gyu Park4. 1CIRCB, Cameroon; 2Alabama State University,
United States of America; 3University of Yaoundé I, Cameroon; 4YUCM (SBSI), Korea
10.1136/bmjgh-2016-000260.36
Background Due to its unique challenge of establishing lifelong
reservoirs a successful HIV-1 vaccine must elicit protective anti-
bodies responses at the portals of entry. Broadly neutralising
antibodies (bnAb) have been demonstrated not only to be thera-
peutic through suppressing viraemia in HIV-1 infected people
but also preventive in blocking HIV-1 infection in animal
models. This implies that a desirable HIV-1 vaccine candidate
should be able to induce HIV-1 specific bnAb with an extensive
ability to neutralise a broad range of HIV-1 isolates. Although
several bnAb are known to target conserved regions in the
HIV-1 envelope glycoprotein, no vaccination strategy has suc-
cessfully produced such antibodies. Thus, the ability to optimise
and deliver HIV envelope immunogens that can induce bnAb
has remained a formidable challenge.
Methods To optimise immunogens for inducing bnAb, our
group has pursued two main directions. In the first instance we
developed B cell immunogens mimicking the native HIV-1
enveloped gp120 glycoprotein. Supernatants of stably trans-
fected mutant lec1 CHO cells using a flag tag. We next assess
antibodies isotypes specific to this immunogen in plasma
obtained from antiretroviral naive participants. Secondly,
through surface engineering of the evolutionary phage Qbeta
we built in several epitopes of bnAbs for effective delivery to
the immune system. We next assess in plasma from 648 sero-
positive participants the abundance of antibody isotypes specific
to these B cell immunogens.
Results The results obtained showed that all IgG isotypes were
detected for both the manosylated and CHO wild-type
expressed gp120. Although all IgG antibody isotypes including
IgG1, IgG2, IgG3 and IgG4 were dictated, there was no signifi-
cant difference between antibody titres directed to manosylated
gp120 and wild-type gp120. Well over 87% of seropositive par-
ticipants showed specific antibody responses to conserved B cell
epitopes displayed on the surface of Qbeta phage.
Conclusions These novel immunogens can be used as vaccine
candidates.
OA-031 PROGRESS IN THE DEVELOPMENT OF SAFE AND
EFFECTIVE TUBERCULOSIS VACCINES
Dereck Tait. Aeras, South Africa
10.1136/bmjgh-2016-000260.37
Background Tuberculosis (TB) is the largest cause of mortality
due to a single infectious agent. There were ∼9.6 million cases
of TB and ∼1.5 million TB deaths in 2014, of which over 80%
occurred in low- and middle income countries. In 1993, TB was
declared a public health emergency by the World Health
Organisation. Multidrug- and extensively drug-resistant TB is
becoming increasingly common and adding significantly to the
burden of disease. We will not meet the target of the WHO End
TB Strategy of TB elimination by 2035 unless new interven-
tions, drugs, diagnostics, and vaccines, become available.
Modelling has demonstrated that elimination of TB is most
likely to be achieved with new and effective TB vaccines.
Effective and safe TB vaccines will also address the global crisis
of drug resistant TB. The development of safe and effective TB
vaccines is achievable as the human immune response does
control TB in some circumstances – the highest risk of TB
disease is within two years of skin test conversion, 90% of
people with latent TB infection never develop TB disease, and
BCG vaccine does provide partial protection. The probability of
success is improved by significant progress in the field and the
availability of new tools such as the robust use of improved
animal models, increased diversity of mechanisms of action,
combination vaccines, use of alternative routes of administration
and stringent stage gates to concentrate resources of those vac-
cines most likely to succeed. New tools such as a controlled
human infection model are in development, and novel clinical
trial designs and use of special populations allow more stream-
lined studies and potentially earlier proof of concept. Globally,
there are currently 13 TB vaccines in various stages of clinical
development and efficacy data will be available from some of
these candidates within one to three years.
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OA-032 COMMUNITY ENGAGEMENT IN TB VACCINE RESEARCH
AND DEVELOPMENT IN ZAMBIA
Hlatjwako Sibusiso,1 Olga Manda,2 Kristin Croucher,1 Anja Van Der Westhuizen,1
Isaac Mshanga2. 1Aeras, South Africa; 2ZAMBART, Zambia
10.1136/bmjgh-2016-000260.38
Background Community engagement (CE) is an essential com-
ponent of clinical research. In 2000, the National Institute of
General Medical Sciences recommended that researchers obtain
community input into all phases of research, respect communi-
ties as partners, and establish appropriate community review
procedures.
Method: Aeras incorporated CE activities into all its studies
and continues to seek input from communities into
Aeras-conducted clinical trials.
Results In Zambia, Aeras conducts TB vaccine clinical trials in
collaboration with Zambia AIDS Related Tuberculosis
(ZAMBART) Project and the Centre for Infectious Disease
Research in Zambia (CIDRZ). Through an established CE
program communities have received information on, and pro-
vided input to, the design and conduct of clinical trials. CE has
provided a very useful avenue for communication between
communities where clinical trials are being conducted and
researchers.
Conclusions The presentation will highlight CE activities
related to TB vaccine clinical trials and their impact, and will
promote discussion on the utility of CE activities in Zambia
and elsewhere. The impact of funding shortfalls for CE will be
discussed. As CE is an essential component of clinical trials
continuous evaluation, it is important to ensure it remains
effective and addresses changing knowledge and beliefs.
OA-033 THE RESULTS OF THE EV06 DNA-PROTEIN
COMBINATION TRIAL AND PLANS FOR GREAT, AN
EDCTP2-FUNDED CONSERVED-MOSAIC EPITOPE HIV
VACCINE TRIAL
Pontiano Kaleebu,1 Jonathan Levin,1 Annet Nanvubya,2 Freddie Kibengo,1
Walter Jaoko,3 Pietro Pala,1 Matthieu Perreau,4 Annemarie Namuniina,2
Paul Kitandwe,2 Gonzalo Tapia,4 Jennifer Serwanga,1 Nicole Yates,5 Pat Fast,6
Bryan Mayer,7 David Montefiori,5 Georgia Tomaras,5 Merlin Robb,8 Carter Lee,9
Ralf Wagner,10 Edward Sanders,11 William Kilembe,12 Noah Kiwanuka,2
Jill Gilmour,6,13 Hester Kuipers,6 Dani Vooij,6 Kundai Chinyenze,6 Frances Priddy,6
Song Ding,14 Tom Hanke,15 Giuseppe Pantaleo,4,16 EV06 study team GREAT study
team1. 1MRC-UVRI AIDS, Uganda; 2UVRI-IAVI HIV Vaccine Program, Uganda;
3University of Nairobi, Kenya; 4CHUV, Switzerland; 5Duke University, United States of
America; 6IAVI, United States; 7Fred Hutchinson Cancer Research Center, United
States of America; 8MHRP, United States; 9GSID, United States of America;
10Universität Regensburg, Germany; 11KEMRI, Kenya; 12ZEHRP, Zambia; 13Imperial
College London, United Kingdom; 14EuroVacc Foundation, Switzerland; 15University
of Oxford, United Kingdom; 16SVRI, Switzerland
10.1136/bmjgh-2016-000260.39
Background These two trials under Europe-Africa collabora-
tions aim at addressing two factors relevant for Africa i.e hel-
minth infections and HIV-1 diversity. EV06 used a novel
combination of DNA expressing clade C Env, Gag and Pol-nef
co-administered with AIDSVAX®B/E Env protein to study the
effect of S. mansoni on vaccine responses. GREAT is a recently
awarded trial using a 2nd generation improved conserved
tHIVConsvX T-cell vaccine candidate combined with bivalent
mosaic design to increase breadth and protective epitopes.
Methods EV06 enrolled 72 males and females aged 18–45,
half infected with S. mansoni (SM+). In each arm 30 received
vaccine and 6 placebo at week 0, 4 and 24. Responses were
evaluated at week 0, 6, 26 and 36. Humoral responses were
measured as binding IgG against a panel of HIV-1 envelope gly-
coproteins and as neutralizing antibodies (Nabs), using TZM/ bl
cells and tier 1 pseudoviruses. Cellular responses were measured
as HIV-specific CD4+ and CD8+ T-cell by IFN-γ ELIS-pot and
multi-cytokine intracellular staining flow cytometry. GREATwill
be a phase IIa trial and preparation for efficacy trials in Kenya,
Uganda and Zambia testing ChAdOx1.tHIVconsv5 and
ChAdOx1.tHIVconsv6 followed by MVA.tHIVconsv3 and
MVA.tHIVconsv4 on week 2 (Arm 1) or week 8 (Arm 2).
Progress Differences in binding IgG response rates were
observed in vaccinated participants against the vaccine matched
clade C V1V2 (gp70–96ZM651.02 V1V2) at week 6: 56%
among SM+ versus 86% among SM – (p=0.039). At week 36,
response magnitudes were statistically lower in the SM+ against
gp120 and gp140 proteins (p=0.04 for both). SM+ also had
lower Nabs and ELISpot responses at various time points. Still
blinded data on the first 20 volunteers show 80% responders
for CD4 T cell at w26 and 70% CD8 responders at w36. These
trials will provide more data on challenges facing HIV vaccine
development in Africa.
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PA-001 OCCURRENCE OF DAY 3 SUBMICROSCOPIC
PLASMODIUM FALCIPARUM PARASITAEMIA BEFORE
AND AFTER IMPLEMENTATION OF
ARTEMETHER-LUMEFANTRINE TREATMENT POLICY IN
TANZANIA
Billy Ngasala,1 Irina Jovel,2 Maja Malmberg,3 Bruno Mmbando,4 Anders Björkman,2
Zul Premji,5 Andreas Mårtensson,6 Richard Mwaiswelo1. 1MUHAS, Tanzania; 2KI,
Sweden; 3SLU, Sweden; 4NIMR, Tanzania; 5Aga Khan University Hospital, Kenya;
6Uppsala University, Sweden
10.1136/bmjgh-2016-000260.40
Background Emergence of Plasmodium falciparum resistance
against artemisinin in Southeast Asia raises a serious concern
about the long-term efficacy of artemisinin-based combination
therapy (ACT) globally. In Africa, ACT has remained highly
efficacious with a microscopy determined asexual parasites clear-
ance occurring within 48 hours post-treatment in most patients.
However, submicroscopic parasitaemia has been reported on
Day 3 after ACT treatment. We assessed the prevalence of
patients with submicroscopic parasitaemia on Day 3 and its asso-
ciated factors following treatment with artemether-lumefantrine
(AL) from 2006 to 2014 in Bagamoyo district, Tanzania.
Methods Cytochrome b-nested polymerase chain reaction
(PCR) was used for screening of submicroscopic parasitaemia
from blood samples collected on filter paper on Day 3 post-AL
treatment for acute uncomplicated P. falciparum malaria.
Primary outcome was proportion of patients with submicro-
scopic parasitaemia on Day 3 from 2006 to 2014. Secondary
outcomes included proportional difference in submicroscopic
parasitaemia across years, association of pre-treatment character-
istics with submicroscopic parasitaemia, and association of sub-
microscopic parasitaemia with recurrent infection.
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Results Only 2/584 (0.34%) of the screened patients had
microscopy determined parasitaemia on Day 3, whereas, 256/
584 (43.8%) had submicroscopic parasitaemia. Submicroscopic
parasitaemia prevalence increased from 28% (14/50) in 2006 to
74.2% (132/178) in 2007–8, and thereafter declined to 36%
(50/139) in 2012–13 and 27.6% (60/217) in 2014, with the
likelihood of being positive for submicroscopic parasitaemia
decreasing by 14.7% (95% CI: 9.5–19.7%, p<0.001) for an
increase in year by one. Pre-treatment parasitaemia >100,000/
mL, haemoglobin <10 g/dL, fever, being aged <5 years and
year of study 2007–8 and 2012–13 were associated with the
presence of submicroscopic parasitaemia. There was no associ-
ation between submicroscopic parasitaemia and recurrent
infection.
Conclusions Day 3 submicroscopic parasitaemia was common
in patients treated with AL before and after implementation of
the policy, and changed considerably across years from 2006 to
2014, however, its presence was associated with pre-treatment
characteristics.
PA-002 EVIDENCE OF PLASMODIUM FALCIPARUM RESISTANCE
TO SULPHADOXINE-PYRIMETHAMINE (SP) IN
PREGNANT WOMEN ALONG THE SLOPE OF MOUNT
CAMEROON
Lenshina Agbor, Tobias Apinjoh. University of Buea, Cameroon
10.1136/bmjgh-2016-000260.41
Background Malaria in pregnancy (MiP) has debilitating effects
for both mother and neonate, with intermittent preventive treat-
ment in pregnancy (IPTp) central to successful malaria control
and management in this vulnerable group. However, the effect-
iveness of IPTp with sulphadoxinepy-rimethamine (SP) is threa-
tened by the emergence of drug resistant Plasmodium
falciparum parasites vastly documented in some settings but not
in south-western Cameroon. This study sought to ascertain the
level of resistance of natural parasite populations to SP in this
area.
Methods A total of 358 parturients were enrolled through a
cross-sectional survey from May to October 2015. Malaria para-
sitaemia was determined by light microscopy using
Giemsa-stained thick and thin smears of the peripheral blood,
while DNA was extracted from dried blood spots of P.
falciparum-positive samples by the Chelex-PBS method. SNPs in
pfdhps and pfdhfr were then genotyped by nested polymerase
chain reaction followed by allele-specific restriction analysis
(ASRA).
Results A total of 47 women (13.1%) had MiP, with a geomet-
ric mean parasitaemia density of 1064 parasites/ml of blood.
The weight (p=0.038), gestational age (p=0.001), IPTp-SP
usage (p< 0.001) and IPTp-SP dosage (p=0.001) of parturients
were identified as risk factors of malaria parasitaemia. Overall,
76.5% (274/358) and 60.3% (216/358) of the women took
IPTp-SP and two or more SP doses, respectively. Participants
who had taken IPTp-SP (p=0.009) and two or more SP doses
(p<0.001) had lower parasite loads compared to non-IPTp-SP
users and those who had taken one dose or less, respectively.
The Pfdhps K540E substitution was absent in the area, the
prevalence of Pfdhfr S108N and Pfdhps A581G was 97.6% and
51.1%, respectively.
Conclusions These results show the value of IPTp-SP usage
and dosage in malaria parasitaemia control, in spite of the high
prevalence of P. falciparum resistance to SP in the area, with
implications for the control of malaria in this vulnerable group.
PA-003 CHLOROQUINE-SENSITIVE PLASMODIUM FALCIPARUM
IN A HIGH-BURDEN MALARIA AREA AFTER OVER A
DECADE OF ITS WITHDRAWAL AS FIRST-LINE
ANTIMALARIAL MEDICINE: CASE OF NCHELENGE
DISTRICT
Sydney Mwanza,1 Michael Nambozi,1 Justin Chileshe,1 Sudhaunshu Joshi,2
Phidelis Malunga,1 Jean-Bertin Kabuya,1 Sebastian Hachizovu,1
Christine Manyando,1 Miriam Laufer,2 Modest Mulenga1. 1TDRC, Zambia;
2University of Maryland, United States of America
10.1136/bmjgh-2016-000260.42
Background Plasmodium falciparum (Pf ) resistance to anti-
malarial drugs remains a major hindrance to malaria control and
elimination. Pf has developed resistance to nearly all antimalarial
drugs including chloroquine, the first most frequently used first-
line treatment for uncomplicated malaria. In Zambia, chloro-
quine was used as treatment for uncomplicated malaria for a
long time until Pf-developed resistance and rose to as high as
60% in some parts of the country. This prompted the Ministry
of Health to effect a drug policy change in 2003. Recent
reports have indicated recovery of chloroquine susceptibility in
neighbouring like Malawi, Mozambique and Tanzania. To
update the information on chloroquine sensitivity in Zambia we
conducted a study that assessed the prevalence of mutant Pf in
Nchelenge district 10 years post chloroquine withdrawal.
Methods Dried blood spots for this study were collected from
finger-prick blood of consenting pregnant women.
Deoxyribonucleic acid (DNA) was extracted and genotyped for
Pfcrt-76 resistance marker using specific primers in a nested
polymerase chain reaction (PCR). The PCR products obtained
were then pyrosequenced and read using PyroMarkTM
Q96MD software. The wild-type 3D7 and Dd2 were used as
wild-type and mutated controls.
Results No chloroquine resistance mutation, Pfcrt 76T was
detected in any of the 302 samples that were successfully ampli-
fied. This represents a 100% prevalence of Pf that are sensitive
to chloroquine in the study population.
Conclusions This study demonstrates a total return of
chloroquine-sensitive Pf in Nchelenge after over a decade of
withdrawal of chloroquine. In combination with another drug,
chloroquine could be a good substitute for the currently used
artemether lumefantrine, and intermittent preventive treatment
in pregnancy (IPTp) and children.
PA-004 EFFECT OF ARTESUNATE MONOTHERAPY ON
PLASMODIUM FALCIPARUM IN VIVO GENOMIC
EXPRESSION
Aminatou Kone,1 Antoine Dara,1 Amadou Niangaly,1 Indranil Sinha,2 David Brodin,2
Bakary Fofana,1 Souleymane Dama,1 Demba Dembele,1 Bakary Sidibe,1
Nouhoum Diallo,1 Mahamadou Thera,1 Issaka Sagara,1 Karin Wright,2
Anders Björkman,2 Jose Gil,2 Ogobara Doumbo,1
Abdoulaye Djimde1. 1MRTC, University of Bamako, Mali; 2KI, Sweden
10.1136/bmjgh-2016-000260.43
Background Artemisinin-based combination therapies (ACTs)
are the main treatment for malaria in endemic countries.
Plasmodium falciparum resistance to artemisinins is described as
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delayed parasite clearance, which is associated with mutations
on the parasite K13 propeller gene. Both the mechanisms of
action and mechanisms of resistance to artemisinins are poorly
understood. Transcriptomic studies can help in improving our
understanding of these processes. Here we explore P. falciparum
in vivo RNA expression profile after a curative dose of artesu-
nate monotherapy.
Methods During a prospective study of the efficacy of artesu-
nate in monotherapy in children aged 1–10 years and presenting
uncomplicated P. falciparum malaria in Bougoula-Hameau,
Mali, venous blood was collected on PAXgen blood RNA tubes
before treatment (H0) and one (H1), two (H2) and three hours
(H3) after treatment. RNA was extracted from these respective
blood samples and used for microarray experiments with
Plasmodium/Anopheles GeneChips and the Affymetrix® plat-
form.
Results A total of 23 samples from 6 patients were included in
the final analysis after quality control using Affimetrix® and
Qlucore® softwares. With a 2-groups comparison of H0/H after
treatment, 236 genes were identified as differentially expressed.
Overall 42 genes were up-regulated including a knob-associated
histidine-rich protein, rifins (pf.12.409.0, pf.13_399.0), stevors
(pf.3.184.0), RESA-like proteins with DNAJ domain and thiore-
doxins. Heat shock protein (Pf.5.258.0), a number of AP2
domain-containing genes (Pf.6.27.0, Pf.11.99.0), an ABC trans-
porter (Pf.12.250.0), genes involved in cell cycle regulation and
many exported protein genes with unknown function and mem-
brane proteins genes were among the 194 down-regulated
genes.
Conclusions Our data support a role for these genes in the in
vivo response of P. falciparum to artesunate administration.
PA-005 LIMITED IMPACT OF TREATMENT AND RE-TREATMENT
WITH ARTEMETHER-LUMEFANTRINE AND
ARTESUNATE-AMODIAQUINE ON THE SELECTION OF
PLASMODIUM FALCIPARUM MULTIDRUG RESISTANCE-1
ALLELES
Vito Baraka,1 Carolyn Nabasumba,1 Filbert Francis,2 Pascal Lutumba,3
Hypolite Mavoko,3 Michael Alifrangis,4 Jean-Pierre Van Geertruyden1. 1GHI,
University of Antwerp, Belgium; 2NIMR, Tanzania; 3University of Kinshasa,
Democratic Republic of Congo; 4CMP, University of Copenhagen, Denmark
10.1136/bmjgh-2016-000260.44
Background The emergence of resistance against artemisinin
combination treatment (ACTs) is a major concern for malaria
control. ACTs are recommended as rescue treatment; however,
there is limited evidence on the impact of treatment and
re-treatment with ACTs on selection for drug-resistant parasites.
We aimed to investigate the impact of treatment and
re-treatment using artesunate-amodiaquine (ASAQ) and
artemether-lumefantrine (AL) on the selection of Plasmodium
falciparum multidrug resistance-1 (Pfmdr1) alleles.
Methods A total of 776 isolates were collected in 28-days
follow-up involving children aged 0–59 months in a clinical trial
in the Democratic Republic of Congo and Uganda. Nested PCR
and RPFL was used to detect Pfmdr1 single-nucleotide poly-
morphisms at codons N86Y, F184Y, and D1246Y. The analysis
compared Pfmdr1 alleles in the pre-randomisation (pre-RCT),
randomisation (RCT) and post-randomisation (post-RCT)
phases of the trial.
Results The pre-treatment prevalence of Pfmdr1 (N86 and
D1246Y) in the RCT phase varied significantly between the
sites. Pfmdr1 NYD haplotype was significantly higher in Uganda
while haplotype YYD was higher in the Democratic Republic of
Congo, (p<0.001). Comparison between pre-treatment and
post-treatment adequate clinical and parasitological response
(ACPR) or PCR-adjusted treatment failure did not indicate
increased selection of Pfmdr1 N86, D1246 and Y184 in either
AL or ASAQ arm in the pre-RCT, RCT and post-RCT phases.
The relative risk (RR) of treatment failure (TF) in patients har-
bouring Pfmdr1 N86 did not significantly increase in patients
treated with AL (RR=0.2, 95% CI: 0.11–1.05, p=0.061) or
ASAQ (RR=1.03, 95% CI: 0.47–2.26, p=0.94).
Conclusions Our findings suggest the limited impact of treat-
ment and re-treatment with AL or ASAQ on selection for Pfmdr1
variants and haplotypes associated with resistance to partner
drugs. These findings support the recent WHO recommendation
to use ACTs as alternative rescue therapy for P. falciparum
malaria. However, enhanced resistance monitoring is warranted
to maintain the drug’s effectiveness in endemic settings.
PA-006 PF3D7_1343700 KELCH PROPELLER (K13-PROPELLER)
POLYMORPHISMS AND ARTESUNATE MONOTHERAPY
EFFICACY IN UNCOMPLICATED MALARIA TREATMENT
IN MALI
Sekou Sissoko, Aminatou Kone, Bakary Fofana, Cheick Sangaré, Demba Dembele,
Sekou Toure, Kassim Sanogo, Hamadoun Diakite, Siaka Toure, Diagassan Doumbia,
Kadiatou Haidara, Ogobara Doumbo, Abdoulaye Djimde. MRTC, University of
Bamako, Mali
10.1136/bmjgh-2016-000260.45
Background Several mutations in the PF3D7_1343700 kelch
propeller (K13-propeller) were recently described as associated
with artemisinin resistance in vivo and in vitro in Southeast
Asia. In Mali, a preliminary study on artesunate efficacy in 2011
found no delay in parasite clearance. A larger study including
two sites in Mali is conducted here in the context of regular
monitoring of artemisinin resistance.
Methods From October 2015 to March 2016, we conducted a
prospective study on artesunate monotherapy in
Bougoula-Hameau and Faladje on uncomplicated malaria
patients aged more than 6 months. Patients were treated for 7
days and followed up for 28 days. Blood smear was performed
for parasite evaluation every 8 hours until three consecutive
slides were negatives. MSP2, Ca1 and TA99 polymorphisms
were used to distinguish new infections from recurrent parasites.
The PfK13 mutations were genotyped using direct sequencing
of PCR amplicons from dried blood spots of pre and post-
treatment falciparum parasites. The results were compared with
the studies conducted in a same area on 2011.
Results A total of 100 and 120 patients were enrolled in
Bougoula-Hameau and Faladje, respectively. The uncorrected
adequate clinical and parasitological responses (ACPR) were
92.0% in Bougoula-Hameau and 78.3% in Faladje. After
molecular correction, we obtained 100% cACPR in both sites.
The prevalence of the non-synonymous single nucleotide poly-
morphisms (SNPs) K13 was 2% in Bougoula (found only at
enrolment) but null in Faladje. However SNPs were 3% and 7%
in Bougoula-Hameau and Faladje, respectively.
Conclusions Artesunate monotherapy remains effective on P.
falciparum in Mali and there are only low levels of PfK13
mutations.
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PA-007 VARIABILITY IN CLINICAL RESEARCH DATA
MANAGEMENT PRACTICES: LESSONS FROM THE
MALARIA COMMUNITY
Amélie Julé,1 Hazel Ashurst,2 Laura Merson,2 Piero Olliaro,3 Vicki Marsh,1
Trudie Lang,4 Philippe Guérin2. 1Nuffield – University of Oxford, United Kingdom;
2WWARN, United Kingdom; 3UNICEF-UNDP-World Bank-WHO-TDR, Switzerland;
4TGHN, University of Oxford, United Kingdom
10.1136/bmjgh-2016-000260.46
Background Appropriate data management (DM) is critical to
produce valuable research data, especially with growing pro-
spects for long-term archiving, sharing and individual patient
data meta-analysis. The experience of the WorldWide
Antimalarial Resistance Network (WWARN) in handling data
from clinical studies is that DM practices vary greatly, which
affects curation and optimal use of shared data. Our work
explores how clinical trial data are usually managed and why
this varies. We aim to understand the needs in DM systems
(DMS) for resource-limited research settings within low- and
middle-income countries (LMICs).
Methods Using published literature and discussions with key
informants, we developed a semi-quantitative instrument to
assess the robustness of the initial DMS and the resulting
‘re-usability’ of clinical research data. We also defined study cov-
ariates which could account for the observed variability (e.g.
type of sponsor/funding, partners involved, trial phase). The
strength of correlations between indicators of good DM prac-
tices, resulting data quality and study context will be tested
through statistical modelling.
Results The instrument covers the following dimensions of data
robustness: meta-data availability, comprehensiveness and
exhaustiveness; dataset completeness; and data accuracy. It is cur-
rently being piloted on a subset of 20 studies (about 5% of the
total WWARN database), to test its applicability in highlighting
DM practices’ variations and in capturing other relevant study
characteristics. After finalisation of the instrument, the analysis
will be rolled out to 150 studies. We will present the patterns and
correlations between specific indicators and study covariates we
observe within this randomly selected sample, and discuss their
implications in terms of DM capacity-strengthening.
Conclusions The significance of quantitative findings will be
challenged using qualitative interviews and visits at institutions
for in-depth case studies of DM practices. Results of the overall
mixed-methods work could inform strategies for clinical research
DM capacity-strengthening in LMICs, including initiatives rele-
vant to the European & Developing Countries Clinical Trials
Partnership (EDCTP).
PA-008 THE QUEST FOR BUILDING LABORATORY CAPACITY TO
SUPPORT CONTROLLED HUMAN MALARIA INFECTION
(CHMI) STUDIES IN SUB-SAHARAN AFRICA:
EXPERIENCE WITH FIVE SITES
Kennedy Awuondo,1 Daniel Njenga,2 Elizabeth Nyakarungu,3 Pauline Titus,2
Awalludin Sutamihardja,4 Brett Lowe,1 Bernhards Ogutu,2
Peter Billingsley5. 1KEMRI-Wellcome Trust, Kenya; 2KEMRI (Coast), Kenya; 3IHI,
Tanzania; 4Walter Reed, Indonesia; 5Sanaria Inc., United States of America
10.1136/bmjgh-2016-000260.47
Background Conducting Controlled Human Malaria Infection
(CHMI) studies in sub-Saharan Africa presents unique chal-
lenges yet it provides enormous opportunities for fast-tracking
malaria vaccine and drug development. Sanaria Inc. USA, has
devised methods of producing, characterising and shipping
aseptic, purified, cryopreserved Plasmodium falciparum sporo-
zoites (PfSPZ). Unlike in the past, the sporozoites can be
shipped to any field site including malaria-endemic countries in
sub-Saharan Africa. CHMI studies need cutting-edge laboratory
capacity to allow screening of potential study participants for
their eligibility, perform safety tests, efficacy testing of the inves-
tigation product, and determine immune markers, responses
and parasite kinetics.
Methods The sites were identified within sub-Saharan Africa,
based on local population, malaria epidemiology status and clin-
ical research capacity. The laboratory assays, equipment and
consumables were identified. The methods and procedures were
optimised, standardised and documented. The laboratory tech-
nical team were selected and trained. EDCTP provided financial
support whilst Sanaria Inc. provided technical support.
Results The capacity strengthening successfully supported
CHMI studies in five sites in Africa namely; IHI, Bagamoyo,
Tanzania; KEMRI CRC, Nairobi, Kenya; EGMVI, Malabo
Equatorial Guinea; CERMEL, Lambarane, Gabon;
KEMRI-CDC, Siaya-Kenya and KEMRI-WT, Kilifi Kenya.
Capacity strengthening was aimed at clinical and immunology
laboratory systems required for CHMI studies.
Conclusions As more CHMI studies are anticipated, vigorous
capacity strengthening will be required for laboratory facilities
in Africa to accelerate the evaluation of malaria vaccines, anti-
malaria drugs, diagnostic assays and assessment of host immune
response to malaria infection.
PA-009 EFFICACY AND TOLERABILITY OF REPEATED
ADMINISTRATION OF ACTS OVER A PERIOD OF TWO
YEARS IN CHILDREN AND ADULT PATIENTS WITH
ACUTE UNCOMPLICATED MALARIA IN BURKINA FASO
Issiaka Soulama, Moïse Kaboré, Aboubacar Coulibaly, Maurice Ouattara,
Souleymane Sanon, Amidou Diarra, Edith Bougouma, Alphonse Ouedraogo,
Benjamin Sombie, Amidou Ouedraogo, Désiré Kargougou, Daouda Ouattara,
Nebie Issa, Alfred Tiono, Sodiomon Sirima. CNRFP, Burkina Faso
10.1136/bmjgh-2016-000260.48
Background According to the guidelines of the Burkina Faso
National Malaria Control Programme, artesunate-amodiaquine
(ASAQ) and artemether-lumefantrine (AL) are the first-line drugs
for uncomplicated malaria treatments. However, in some contexts
where individuals will experience more than 1 episode of clinical
malaria per year, it is unknown to what extent giving any of these
ACTs repeatedly is safe. In the framework of the activities of the
West African Network for Antimalarial Drugs (WANECAM)
network, we have compared the efficacy and tolerability of repeated
use of dihydroartemisinin-piperaquine (DHA-PQ) or artesunate-
pyronaridine (PYR) with artesunate-amodiaquine (ASAQ).
Methods A randomised open-label parallel 3 arms trial was con-
ducted to compare the efficacy of a three-day regimen of DHA-PQ
and PYR with ASAQ. The trial involved children and adults with
uncomplicated falciparum malaria. Participants were randomly
assigned to one of the three treatment arms at the first clinical
episode. During the subsequent clinical episodes, the same drug
was administered. Follow-up duration was 42 days for each
episode. Study duration was two years for each participant. Primary
endpoints were the incidence rate of uncomplicated malaria over a
period of 2 years and PCR corrected/uncorrected ACPR at day 28
and day 42. Safety parameters were also assessed.
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Results Of the 763 patients enrolled, the incidence rate of clinical
malaria was 1.4, 1.2, and 1.5 episodes / person-year at risk in the
ASAQ, DHA-PQ and PYRAMAX arms, respectively. The
PCR-uncorrected efficacy at day 28 versus day 42 was: ASAQ
93.4% vs 79.5%; PYR 98.1% vs 74.8%; and DHA-PQ 99.5% vs
95.2%. Bronchitis, rhinitis, abdominal pain, cough, QTc prolonga-
tion, headache, and vomiting were registered as the main adverse
events in each of the three groups.
Conclusions The findings from our study support the current
recommendations for using artemisinin-based combinations in the
treatment of uncomplicated malaria in areas of high malaria trans-
mission such as Burkina Faso.
PA-010 EFFICACY AND SAFETY OF ARTEMISININ-BASED
COMBINATION THERAPIES IN PEOPLE WITH
PLASMODIUM FALCIPARUM MALARIA RECEIVING
ANTIRETROVIRAL THERAPY IN ZAMBIA
Mike Chaponda. TDRC, Zambia
10.1136/bmjgh-2016-000260.49
Background The coverage of Artemisinin-based Combination
Therapies (ACTs) for treatment of malaria and antiretroviral
therapy (ART) is increasing rapidly in Sub-Saharan Africa.
Because of the geographical overlap in areas of high malaria and
HIV prevalence, HIV-infected people receiving ART may
become malaria-infected and will need ACTs.
However, few studies have assessed the safety and efficacy of
administering ACTs in people taking ART. The interactions
might lead to high ACT drug levels which might cause toxicity
or low drug levels which might adversely affect malaria parasite
clearance, thereby fuelling resistance.
Methods We conducted a phase IIIb single arm (non-
comparative), open label clinical trial. We enrolled and followed up
155 patients at St. Paul’s Hospital in Nchelenge district of Zambia.
The patients were enrolled in the study after they consented to par-
ticipate and met strict inclusion and exclusion criteria.
Results Patient enrolment was completed in September 2015. The
results of this study are currently being analysed.
Conclusions Data on the safety and efficacy of ACTs in people
taking different types of ARTare lacking since previous regulatory
trials have systematically excluded HIV-positive people, including
those receiving ART. Thus, the results of our study will assist in the
following ways: determine whether HIV-infected individuals
receiving specific types of ART require a specific type of ACTs,
inform clinical practitioners about what sort of adverse events they
should expect and monitor in people taking different combinations
of ACTs and ARTs, and provide evidence-based recommendations
to the WHO and National Malaria Control Programmes on safe
and effective ACTs that can be used in patients’ EFV-based
regimen. This study was part of a multicentre trial including
centres in Malawi and Mozambique.




Edgard Dabira. MRC, The Gambia
10.1136/bmjgh-2016-000260.50
Background With the decrease of malaria burden, additional
interventions capable of interrupting transmission from human
to mosquitoes are required to achieve malaria elimination.
Primaquine (PQ) is the only antimalarial drug recommended
against mature gametocytes; however, its use has been limited
because it causes a dose-dependent haemolytic anaemia. A clin-
ical trial was conducted in The Gambia to evaluate the impact
of dihydroartemisinin-piperaquine (DP) with and without PQ
on gametocyte carriage and infectiousness to mosquitoes. As an
ancillary study, we compared the efficacy of the four different
treatments in asymptomatic Plasmodium falciparum-infected
individuals.
Methods The main study was a four-arm, open label,
randomised-controlled trial comparing the effect of three differ-
ent single doses of PQ (0.75 mg/kg, 0.4 mg/kg, and 0.2 mg/ kg)
on gametocyte carriage in malaria-infected, asymptomatic indi-
viduals with normal glucose-6-phosphate dehydrogenase status.
All treatment arms received DP with the fourth arm acting as
control. Our ancillary study aimed to determine the duration of
gametocyte carriage in the PQ groups compared to the control
group and to assess the adequate and clinical response of treat-
ment (ACPR) at day 42 of follow-up.
Results A total of 694 individuals were enrolled; 175 were ran-
domised to the control, 172 to the 0.75PQ, 175 to the 0.4PQ,
and 172 to the 0.2PQ arms. The hazard ratio (HR) of gameto-
cytes carriage was significantly longer in the control group com-
pared to each of the PQ arms; 1.8 (1.2–2.6 p=0.002) in
0.75PQ, 1.5 (1.0–2.1 p=0.03) in 0.4PQ and 1.5 (1.0–2.1
p=0.04) in 0.2PQ. At day 42, ACPR was 97.04%; 95.48%;
92.45%; 99.37% in DP group; 0.75PQ; 0.4PQ and 0.2 PQ,
respectively.
Conclusions Adding PQ to DP shortens the duration of gam-
etocyte carriage and the adequate and clinical response of treat-
ment (ACPR) is high.
PA-013 COMPARISON OF AUTOMATIC AND MANUAL
MEASUREMENT OF QT AND QTC INTERVALS DURING A
CLINICAL PHASE III-B/ IV IN KOLLE, MALI
François Dao, Nianwalou Dara, Bouran Sidibe, Moctar Coulibaly, Allaye Tolo,
Hamma Maiga, Nouhoum Ouologuem, Hamidou Niangaly, Issaka Sagara,
Abdoulaye Djimde. MRTC, University of Bamako, Mali
10.1136/bmjgh-2016-000260.51
Background The detailed assessment of the QT and corrected
QT (QTc) intervals prolongation is recommended when testing
new drugs. The electrocardiograph automatically displays gener-
ally reliable values of the QT interval and corrected QT but
morphological variations of the T wave may cause reading
errors, hence the use of the manual measurement as an alterna-
tive method. Our objective was to evaluate the correlation
between the automatic and manual measurement of QT values.
Methods In Kolle from March 2012 to December 2015, an
open randomised, phase III-b/IV study comparing
dihydroartemisinine-piperaquine, pyronaridine-artesunate and
artemether-lumefantrine was conducted. An electrocardiograph
cartridge 12 electrodes coupled to a computer with the Tele
Touch software was used for the electrocardiogram on Day 0
before the study drugs administration and on Day 2, 2–4 hours
after the administration of the last dose of the antimalarial. The
manual measurement of QT and QTc was made using the Bazett
method [QTcB_m=(Number leaded×0.04×QTcF) / QTcB]. For
prolonged QTc cases on Day 2, another measurement was done
during the next scheduled visit (Days 7, 14, 21, 28, 35 and 42)
until the QTc normalisation.
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Results A total of 764 ECG was recorded with 398 participants.
Different automatic and manual values of QT and QTc are scat-
tered around different medium. Comparisons of different values
of QT (p=0.1245) and QTc (p<0.001) showed a statistically sig-
nificant differences and the concordance between automatic and
manual tests was QT: Rho_c=0.77 and QTc: Rho_c=0.46.
Conclusions Our results indicate no perfect match between
automatic and manual methods for QTand QTc. Manual reading
remains important to correct any machine errors during clinical
studies.
PA-014 CXCL10 GENE PROMOTER POLYMORPHISM – 1447A>G
IS ASSOCIATED WITH MALARIA IN GHANAIAN
CHILDREN
Felix Botchway, Nana Wilson, Carmen M Dickinson-Copeland, Andrew A. Adjei,
Michael Wilson, Jonathan K. Stiles. Korlebu Teaching Hospital, University of Ghana
Medical School, Ghana
10.1136/bmjgh-2016-000260.52
Background Recent studies indicate that interferon gamma indu-
cible chemokine, CXCL10, is a strong predictor of both human
and experimental cerebral malaria. We hypothesised malaria infec-
tion is associated with variation in CXCL10 expression. We deter-
mined whether polymorphisms in the CXCL10 gene promoter
region played a role in the clinical status of malaria patients and
addressed the genetic basis of CXCL10 expression during malaria
infection.
Methods Basic demographics that may impact our assessments
including age, gender, full blood count, sickle cell status and
CXCL10 polymorphism were assessed. We assessed a single
nucleotide polymorphism in the CXCL10 promoter (–1447A>G
[rs4508917]) among 382 malaria and 117 non-malaria subjects
using PCR-restriction fragment length polymorphism assay.
Adjusted Odds Ratio (AOR) was used to find out if there was any
association between CXC10 promoter polymorphism –1447
A>G and susceptibility to malaria.
Results The median age for malaria patients was 4 years and that
for non-malaria was14 years. There was significant difference with
regards to haemoglobin levels and White cell counts between
malaria patients and non-malaria subjects ( p<0.0001).
Individuals with the 21447(A/G) genotype were susceptible to
malaria (adjusted odds ratio [AOR]=2.60, 95% CI: 1.51–5.85,
p=0.021). Additionally, individuals with the 21447(A/G) geno-
type had significantly higher plasma CXCL10 levels than indivi-
duals with the 21447(A/A) genotype. Stratifying patients
according to gender, the observed association of malaria with over
expression of CXCL10 were more pronounced in females than in
male patients (AOR=5.47, 95% CI: 1.34–22.29, p=0.018).
Conclusions Polymorphisms in the CXCL10 gene promoter
sequence were associated with increased CXCL10 production,
which is linked to severity of malaria. These results suggest that
the 21447A>G polymorphism in CXCL10 gene promoter could
be partly responsible for the reported variation underlying severity
of malaria outcomes particularly in females.
PA-015 GENE VARIATION AND SUSPECTED PLASMODIUM
FALCIPARUM HISTIDINE-RICH PROTEIN 2 GENE
DELETION AND ITS IMPACT ON SENSITIVITY OF
MALARIA RAPID DIAGNOSTIC TESTS IN SUDAN
Muzamil Abdel Hamid,1 Mona Awad-Elgeid,1 Awad Nasr2. 1IEND, University of
Khartoum, Sudan; 2University of Khartoum, Sudan
10.1136/bmjgh-2016-000260.53
Background Malaria rapid diagnostic tests (RDTs) play a signifi-
cant role in malaria case management and case investigations.
Variability or absence of antigens targeted by PfHRP2-based
RDTs have been reported worldwide. However, little data is
available concerning genetic variability within Sudanese
Plasmodium falciparum isolates while variable sensitivity of
PfHRP2 based RDTs has been observed. The objective was to
find out the possible effect of PfHRP2 gene variation and sus-
pected deletion on the performance of PfHRP2-based RDTs.
Methods Seventy-seven P. falciparum isolates were selected
from three geographical regions of Sudan. Malaria HRP2-RDTs
and Giemsa-stained blood films data were included for analysis.
The pfhrp2 exon 2 fragments were amplified to study genetic
variation and suspected deletion. Chi-square test was used for
testing significance of results.
Results Forty percent (31/77) of P. falciparum isolates showed
amplification for PfHRP2 (which revealed five alleles of differ-
ent sizes), whereas 60% of isolates were PfHRP2 PCR-negative.
There is a concordance of positive and negative rates on
PfHRP2 RDT and gene amplification results of (35%) and
(33%) respectively. Eighty-seven percent (78%) of RDTs positive
isolates were PfHRP2 negative (p-value=0.001), while 4 out of
31 pfhrp2 positive isolates gave false negative results in RDT
detection. Twenty out of 47 RDTs positive isolates were
PfHRP2 negative (p-value=0.001). Plasmodium falciparum
HRP2-RDTs showed higher sensitivity than microscopy in
malaria detection (p-value=0.007).
Conclusions The study provided baseline data on genetic vari-
ation and suspected deletion in PfHRP2 and its potential effect
on RDT performance.
PA-016 RE-EVALUATION OF MALARIA DIAGNOSIS BY
MOLECULAR METHODS REVEALS MUTATIONS IN HRP-2
AND DRUG RESISTANCE MARKERS IN CAMEROON
Palmer Netongo,1 Séverin Kamdem,1 Thirumalaisamy Velavan,2
Peter Kremsner2. 1University of Yaoundé I, Cameroon; 2ITM Tübingen, Germany
10.1136/bmjgh-2016-000260.54
Background As the decline in malaria cases becomes obvious in
most sub-Saharan African countries, a new major concern is
accurate diagnosis of low parasitaemia which can cause sub-
patent infections and false-negative Rapid Diagnostic Test
(RDT) results. We assessed the accuracy malaria diagnosis by
RDT and microscopy are currently been conducted in
Cameroon, by re-evaluating some samples from patients who
sought medical care at three health centres in Yaounde. The
study would provide information which can help the national
malaria control program to reorient interventions strategies to
enhance accurate diagnosis within the country.
Methods We undertook a research project within a period of
six months to re-evaluate malaria confirmed cases by micros-
copy and RDT test (HRP2: SD BIOLINE Malaria Ag P.f/Pan:
Optimal screening test for P. falciparum and other Plasmodium
species). We used molecular methods such as nested PCR,
in-house tailored loop amplified isothermal amplification
(LAMP) and GenoType MalariaDR molecular assay to revalidate
these samples. DNA was directly extracted from the RDT cas-
settes using qiagen spin columns.
Results Results showed discrepancies in malaria diagnosis by
microscopy, RDT, PCR, LAMP and GenoType MalariaDR. Most
false negatives results (RDT negative but positive by microscopy
and molecular methods) are linked to low parasite density
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usually<150 asexual parasites/μl. However, there were some
cases where higher parasite density >5,00/μl could lead to false
negative results (linked to a deletion of about 870 bp in the
HRP-2 gene). GenoType MalariaDR revealed the presence of
mutations on Pfmdr1 and Pfcrt associated with resistance to
ART.
Conclusions The study provided factual information on the
detected P. falciparum isolates, HRP-2 mutations and the per-
formance of RDTs and Pfmdr1, Pfcrt and ART resistance
markers present in the population. The first-line of ACT in
Cameroon is artesunate+amodiaquine, yet possible resistance
isolates of amodiaquine and artesunate could be circulating in
the country.
PA-018 SEASONAL MALARIA CHEMOPREVENTION WITH
SULPHADOXINE-PYRIMETHAMINE AND AMODIAQUINE
SELECTS DHFR-DHPS QUINTUPLE MUTANT GENOTYPE
IN MALI
Hamma Maiga,1 Estrella Lasry,2 Modibo Diarra,1 Issaka Sagara,1 Amadou Bamadio,1
Aliou Traore,1 Samba Coumare,1 Bahonan Soma,2 Yeyia Dicko,1 Nouhoum Diallo,1
Boubou Sangare,1 Aly Tembely,1 Djibril Traore,1 Hamidou Niangaly,1 François Dao,1
Aboubecrin Haidara,1 Alassane Dicko,1 Ogobara Doumbo,1
Abdoulaye Djimde1. 1MRTC, University of Bamako, Mali; 2Médecins Sans Frontières,
United States of America
10.1136/bmjgh-2016-000260.55
Background Seasonal malaria chemoprevention (SMC) with
sulfadoxine-pyrimethamine (SP)+amodiaquine (AQ) is being
scaled up in countries of the Sahel in West Africa. However, the
potential development of Plasmodium falciparum resistance to
the respective component drugs is a major concern.
Methods Two cross-sectional surveys were conducted before
(August 2012) and after ( June 2014) a pilot implementation of
SMC in Koutiala, Mali. Children aged 3–59 months received 7
rounds of curative doses of SP+AQ over two malaria seasons.
Genotypes of P. falciparum dhfr codons 51, 59 and 108; dhps
codons 437 and 540, pfcrt codon 76 and pfmdr1codon 86
were analysed by PCR on DNA from samples collected before
and after SMC, and in non-SMC controls.
Results In the SMC population 191/662 (28.9%) and 85/670
(13.7%) of children were P. falciparum-positive by microscopy
and were included in the molecular analysis before (2012) and
after SMC implementation (2014), respectively. In the control
population 220/310 (71%) were successfully PCR analysed. In
the SMC children the prevalence of all molecular markers of SP
resistance increased significantly after SMC including the
dhfr-dhps quintuple mutant genotype, which was 1.6% before
but 7.1% after SMC (p=0.02). The prevalence of Pfmdr1–86Y
significantly decreased from 26.7% to 15.3% (p=0.04) while
no significant change was seen for pfcrt K76T. In 2014, preva-
lence of all molecular markers of SP resistance were significantly
higher among SMC children compared to the non-SMC control
population (p<0.01). No dhfr – 164 mutation was found
neither at baseline nor post SMC.
Conclusions SMC increased the prevalence of molecular
markers of P. falciparum resistance to SP in the treated children.
However, there was no significant flow of these resistance genes
into the general parasite population after 2 years and 7 rounds
of SMC.
PA-019 IMPACT OF TREATMENT OF UNCOMPLICATED MALARIA
BY AMODIAQUINE−ARTESUNATE (AS-AQ) ON PFCRT
76T AND PFMDR1 86Y MUTATIONS SELECTION IN
PLASMODIUM FALCIPARUM ISOLATES, REPUBLIC OF
GUINEA
Elisabeth Diawara,1 Abdoul Beavogui,1 Daouda Camara,1 Malick Sylla,1
Mohamed Yattara,1 Amadou Sow,1 Gnèpou Camara Camara,1 Saliou Diallo,1
Ogobara Doumbo,2 Abdoulaye Djimde2. 1CNFRSR, Guinea; 2MRTC, University of
Bamako, Mali
10.1136/bmjgh-2016-000260.56
Background The use of Amodiaquine monotherapy is asso-
ciated with the selection of resistance markers (Pfcrt and
Pfmdr1). The decrease in sensitivity and the emergence of
Plasmodium falciparum-resistant strains have been reported.
It is therefore important to know the impact of treatment of
uncomplicated malaria with amodiaquine−artesunate (AQ−AS)
on Pfcrt76Tand Pfmdr1 86Y mutations strains of P. falciparum.
Methods We applied the standard protocol of 28 days of
WHO 2003, to determine the in vivo efficacy of the combin-
ation AQ−AS. In total 170 subjects were included in the study.
Molecular analysis focused on 168 dried blood spots. The aims
were to determine the frequency of Pfcrt76T and Pfmdr1 86Y
mutations, to determine the rates of reinfection using poly-
morphism markers MSP1, MSP2, and microsatellite CA1, Ta87,
TA99. Nested PCR followed in some cases by a restriction
enzyme.
Results The level of P. falciparum clinical response was 92.85%
(156/168) of ACPR before molecular correction and 7% (12/
170) LPF. The ACPR after molecular was 97.01% (163/168).
The frequency of mutation point Pfcrt 76T was 76.19% (128/
168) before treatment and 100% (7/7) after treatment, p=0.14.
For Pfmdr1 mutation the frequency was 27.97% (47/168)
before treatment and 60% (6/10) after treatment, p=0.03. Rate
of Pfcrt76T +Pmdr1 86Y was 22.02% (37/168) before and
50% (6/12) after treatment p=0.003.
Conclusions Despite the combination of AQ with AS, the treat-
ment selected Pfcrt76Tand Pfmdr1 86Y mutations in Guinea.
PA-020 FOSMIDOMYCIN-PIPERAQUINE AS
NON-ARTEMISININ-BASED COMBINATION FOR ACUTE
UNCOMPLICATED PLASMODIUM FALCIPARUM
MALARIA
Ghyslain Mombo-Ngoma,1 Jonathan Remppis,1 Moritz Sievers,1 Rella
Zoleko Manego,1 Lilian Endamne,1 Bertrand Lell,1 David Hutchinson,2
Peter Kremsner3. 1CERMEL, Gabon; 2Jomaa Pharma GmbH, Germany; 3ITM
Tübingen, Germany
10.1136/bmjgh-2016-000260.57
Background As investment in research related to artemisinin
resistance is a key objective of the Global Plan for Artemisinin
Resistance Containment (GPARC), fosmidomycin and pipera-
quine are being developed to address the delay in parasite clear-
ance following treatment with Artemisinin-based Combination
Therapy (ACT). Though artemisinin resistance occurs princi-
pally in the Greater Mekong Region, there are concerns that it
will emerge in sub-Saharan Africa.
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Methods A proof-of-concept study has been conducted in
Gabon to determine the efficacy, tolerance and safety of fosmi-
domycin and piperaquine when administered orally for three
days. A total of 100 subjects, including 10 adults, 40 children
aged 5–14 years and 50 children aged 1–5 years fulfilling the
inclusion criteria of mono-infection with Plasmodium falcip-
arum and initial parasite counts between 1,000 and 150,000/mL
were enrolled and followed up for 63 days. The primary efficacy
endpoint was per protocol, the PCR-corrected cure rate on Day
28. Safety endpoints included the incidence, severity,
drug-relatedness and seriousness of adverse events and labora-
tory abnormalities. ClinicalTrials.gov Identifier: NCT02198807
Results The PCR-corrected 28-day cure rate in the older chil-
dren was 100% (n=31). It was also 100% (n=38) in the
younger children, a group deemed to be more therapeutically
challenging on account of their lower immune status. Tolerance
was excellent and there were no drug-related safety issues. Full
results will be presented.
Conclusions Fulfilling the WHO criteria for combination
therapy, fosmidomycin as a rapidly acting blood schizonticide
and piperaquine with its prolonged post-treatment prophylactic
effect have been shown to be highly efficacious for the treatment
of acute uncomplicated falciparum malaria in an area of intense
malaria transmission. Dose optimisation studies with the dual
aim of achieving a reduction in the dose of fosmidomycin
within a therapeutic regimen of once daily dosing are planned.
PA-021 SAFETY AND EFFICACY OF SAR97276A FOR TREATING
MALARIA: TWO OPEN-LABEL MULTICENTER PHASE II
CLINICAL STUDIES IN AFRICAN CHILDREN AND ADULTS
Jana Held,1,2,3 Christian Supan,1,2 Carmen L. Ospina Salazar,1,2 Halidou Tinto,4 Léa
Nadège Bonkian,4 Alain Nahum,5 Ali Sié,6 Salim Abdulla,7 Cathy Cantalloube,8
Elhadj Djeriou,8 Marielle Bouyou-Akotet,9 Bernhards Ogutu,10
Benjamin Mordmüller,1,2,3 Mohamadou Siribie,11 Sodiomon B. Sirima,11,12 Peter
G. Kremsner1,2,3. 1Institut für Tropenmedizin, Universitätsklinikum Tübingen,
Tübingen, Germany; 2Centre de Recherches Médicales de Lambaréné, Lambaréné,
Gabon; 3German Centre for Infection Research, partner site Tübingen, Germany;
4Centre Muraz – IRSS, Bobo-Dioulasso, Burkina Faso; 5Centre de Recherche
Entomologique de Cotonou, Benin ; 6Centre de Recherche en Santé de Nouna,
Burkina Faso ; 7Ifkara Health Research Center, Bagamoyo, Tanzania; 8Sanofi
Research and Development, France; 9Département de Parasitologie, Mycologie,
Médecine Tropicale, Université des Sciences de la Santé, Libreville, Gabon ; 10KEMRI
Walter Reed Project, Kisumu, Kenya; 11Groupe de Recherche Action en Santé,
Burkina Faso; 12Centre National de Recherche et de Formation sur le Paludisme,
Burkina Faso
10.1136/bmjgh-2016-000260.58
Background SAR97276A, is a choline analogue inhibiting the
phospholipid biosynthesis of Plasmodium falciparum. Treatment
options for severe malaria are limited and SAR97276A repre-
sents a drug candidate for this indication.
Methods This is a report on two consecutive trials evaluating
safety and efficacy of parenterally administered SAR97276A for
the treatment of malaria.
The first study was a phase 2, multicenter, open-label study at
six African hospitals (NCT00739206). At first adults with
uncomplicated malaria were included receiving a single dose
SAR97296A (IM: 0.18 mg/kg or IV: 0.14 mg/kg) followed by
repeated dosing with daily administration of the IM dose for
three days in case of lack of efficacy of the single-dose regimen
before age de-escalation.
The second study was a phase 2, multicenter, randomized,
controlled open label study at five African hospitals assessing
safety and efficacy of a higher dose of SAR97276A IM once
(0.5 mg/kg) or twice (0.25 mg/kg) daily for 3-days compared to
artemether-lumefantrine in children 12–17 years before age
de-escalation to younger children (NCT01445938).
Results In the first study 113 patients received SAR97276A: 30
adults single-dose IV, 34 adults single-dose IM, 30 adults 3-day
dose IM and 19 children 3-day dose IM. SAR97276A given as a
single-dose to adult patients showed insufficient efficacy by IM
route (20 cured of 34; and IV route (23/30 cured). The 3-day
treatment showed a sufficient level of efficacy when given IM to
adults (27/30 cured) but not when given to children 7–17 years
(13/19 cured).
In the second study 20 patients were recruited and randomly
assigned (2:2:1 ratio) to receive once-daily SAR97276A, twice-
daily SAR97276A or artemether-lumefantrine. All patients
receiving SAR97276A once-daily and 5/8 patients receiving
SAR97276A twice-daily required rescue therapy. All patients in
the control group were cured.
Conclusion Both studies were stopped due to lack of efficacy.
SAR97276A given as monotherapy up to three days is not effi-
caciously curing malaria.
The studies were funded by Sanofi.
PA-022 COMPARATIVE PROTECTIVE EFFECT OF REPEATED
ADMINISTRATION OVER A TWO YEAR PERIOD OF 3
ACTS ON THE EMERGENCE OF HYPERPARASITEMIA IN
MALARIA PATIENTS
San Maurice Ouattara, Issiaka Soulama, Sam Coulibaly, Jean Moïse Kabore,
Alphonse Ouedraogo, Edith Bougouma, Souleymane Sanon, Diarra Amidou,
Benjamin Sombie, Amidou Ouedraogo, Désiré Kargougou, Daouda Ouattara,
Nebie Issa, Alfred Tiono, Sodiomon Sirima. CNRFP, Burkina Faso
10.1136/bmjgh-2016-000260.59
Background Hyperparasitaemia in malaria infection represents
a worsening circumstance of the patient’s condition; however, it
still remains a concept with a controversial definition and seems
likely to be understudied. The present study in the framework
of the WANECAM activities aimed to assess the protective
effect of 3ACTs on the emergence of the hyper-parasitaemia
when repeatedly administrated over a period of two years to
patients with uncomplicated malaria.
Methods A two-year prospective longitudinal study (763 adults
and children) was conducted in a malaria endemic area of
Burkina Faso. Passive detection of malaria cases with parasit-
aemia ≥200000 trophozoites/ml was done. Malaria smear was
performed for hyperparasitaemia confirmation; a clinical exam-
ination and demographic data were recorded. Each patient was
repeatedly treated with one of the three anti-malarials,
pyronaridine-artesunate, dihydroartemisinin-piperaquine or
artesunate-amodiaquine, at any uncomplicated malaria episode.
Results A total of 107 cases of malaria with hyperparasitaemia
were diagnosed; 63.55% occurred in under-five years children.
The geometric mean of parasite density was 283366 tropho-
zoites/ml (CI 95%: 264644–302087). The 46 cases recorded in
the pyronaridine-artesunate treatment arm (224 patients) was
higher compared to the 39 cases in the artesunate-amodiaquine
arm (315 patients), (p=0.0024) and to the 22 cases in the
dihydroartemisinin-piperaquine arm (224 patients),
(p=0.0022). The difference between dihydroartemisinin-
piperaquine and artesunate-amodiaquine treatment arms was
not statistically significant (p=0.40).
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Conclusions From this study, children under five year of age
were mostly at risk of hyperparasitaemia. Dihydroartemisinin-
piperaquine and artesunate-amodiaquine seem the most protect-
ive antimalarial against the occurrence of hyperparasitaemia.
PA-023 ASSESSMENT OF SAFETY PARAMETERS FOLLOWING
REPEATED ARTEMISIN-BASED TREATMENTS OF
MALARIA-INFECTED PATIENT LIVING IN ENDEMIC
AREA OF BURKINA FASO
Sam Coulibaly, Issiaka Soulama, Jean Moïse Kabore, San Maurice Ouattara,
Edith Bougouma, Alphonse Ouedraogo, Souleymane Sanon, Diarra Amidou,
Benjamin Sombie, Amidou Ouedraogo, Désiré Kargougou, Daouda Ouattara,
Nebie Issa, Alfred Tiono, Sodiomon Sirima. CNRFP, Burkina Faso
10.1136/bmjgh-2016-000260.60
Background Artemisinin-based combination therapies (ACTs)
constitute the worldwide recommended antimalarial drug as first-
line treatment of uncomplicated malaria. However, the safety of
repeated administration of a given ACT is poorly documented.
The aim of this study was to evaluate the safety of repeated admin-
istration of ACTs in malaria patients over a period of 2 years.
Methods A randomised, open-label phase IIIb/IV comparative
three arms trial comparing pyronaridine tetraphosphate/artesunate
(PA), dihydroartemisinine-pipéraquine (DHA-PQP) and
artesunate-amodiaquine (ASAQ) was carried out in Burkina Faso
site as part of the WANECAM (West African Network for Clinical
Trials of Antimalarial Drugs) global study. The study involved
patients from 6 months of age presenting with uncomplicated
malaria (fever/history of fever and Plasmodium spp. density
<200,000). The patients were treated repeatedly with the same
ACT they were assigned to at enrolment. Safety assessments con-
sisted with electrocardiographic and laboratory evaluations.
Results A total of 763 participants with uncomplicated micro-
scopically confirmed Plasmodium spp. malaria were included. The
proportion in ASAQ treated patients with creatinin abnormal
value did not differ significantly between episode 1 and repeated
malaria episodes (16.14% versus 13.98%, p=0.31). The propor-
tion of patients with abnormal value of ALAT decreased signifi-
cantly from baseline (25/234 versus 16/787, p< 0.01), but there is
no difference in haemoglobin mean between the different episode
(p>0.05) within each treatment arms. No evidence was found in
the risk of QTc interval prolongation during repeated treatment in
any arm.
Conclusions The findings showed that safety was similar on first
malaria treatment versus retreatment of subsequent episodes. The
safety parameters were also comparable between the 3 treatment
arms. These results support the repeated use of the three ACTs in
uncomplicated malaria patients in Burkina Faso.
PA-024 LUMEFANTRINE DISPOSITION AFTER REPETITIVE
TREATMENT OF UNCOMPLICATED MALARIA PATIENTS
WITH ARTEMETHER-LUMEFANTRINE IN MALI
Mamadou Tekete,1 Juergen Burhenne,2 Bakary Fofana,1 Sekou Toure,1
Souleymane Dama,1 Nianwalou Dara,1 Oumar Traore,1 Bouran Sidibe,1
Abdoulaye Djimde,1 Walter Haefeli,2 Steffen Borrmann3. 1MRTC, University of
Bamako, Mali; 2Heidelberg University, Germany; 3ITM Tübingen, Germany
10.1136/bmjgh-2016-000260.61
Background Since 2006 the national malaria control program
in Mali recommended artemether-lumefantrine (AL) as the first-
line treatment of uncomplicated malaria. The role of lumefan-
trine in this combination is to eliminate remaining parasites
after the action of artemether and to protect the patient against
a new blood infection. Some studies showed a correlation
between lumefantrine’s day 7 concentration and the efficacy of
AL after treatment of a single episode of malaria. The objective
of this work is to validate this observation after repetitive treat-
ment of uncomplicated malaria patients with AL.
Methods During a phase IIIb/IV comparative, randomised, mul-
ticentre, clinical study of artemisinin-based combination therap-
ies, we collected plasma on Day 7 from patients treated with
standard dose of AL in Sotuba, Bougoula Hameau, and Kolle
(Mali). The age of the patients enrolled in this study was from 6
months old. The plasma samples were kept at – 80°C until
lumefantrine analysis using high performance liquid chromatog-
raphy was performed.
Results We included 1076 subjects, of which 595 were females
and a mean age of 12 years old in this analysis.
The median concentration was 66% higher (p<0.0001) in
patients without recurrent parasite on day 28 compared to
patients with recurrent parasitaemia: 509.1 ng/ml (inter quartile
range: 329.6–723.2; n=919) vs 372.5 (255.7–538.4; n=157).
Day 7 concentrations increased with age; the difference between
age group was statistically significant: 305.9 (207.3–491.5,
n=140), 447 (290.7–622.9, n=399), 544.7 (383.9–738.5,
n=254) and 571.1 (378.8–850.9), n=283) in patients under 5
years old, 5–9 years old, 10–14 years old and 15 years old and
older, respectively. Girls under 5 years old had a lower lumefan-
trine concentration at day 7 compared to other age groups of
223.3 ng/ml (159.7–425.6, n=37).
Conclusions We found a lower concentration of lumefantrine
in patients with recurrent parasitaemia at day 28.
PA-025 TO VALUE THE EFFICIENCY OF
PYRONARIDINE-ARTESUNATE AND
ARTEMETHER-LUMEFANTRINE IN THE TREATMENT OF
UNCOMPLICATED MALARIA OF PLASMODIUM SPP. IN
BURKINA FASO
Nouhoun Barry,1 Naomie Kaboré,1 Zachari Kabré,1 Aminata Fofana,1
Fréderic Nikèma,1 Daniel Compaoré,1 Fabrice Somé,1 Issaka Zongo,1
Abdoulaye Djimdé,2 Jean Ouédraogo1. 1IRSS-DRO, Burkina Faso; 2MRTC, University
of Bamako, Mali
10.1136/bmjgh-2016-000260.62
Background No safe and highly effective malaria vaccine is
available today. The treatment drugs currently in use remain
insufficient. Moreover, resistance to these drugs makes malaria
control difficult. The development of new therapeutic drugs is
required. This abstract is part of a survey from the WANECAM
study entitled ‘Randomised trial to assess the effect of repeated
treatment of pyronaridine-artesunate (PA), dihydroartemisinin-
piperaquine (DHA-PQ) and artemether-lumefantrine (AL) in
patients presenting uncomplicated malaria in Bobo-Dioulasso,
Burkina Faso’. We present here the analysis of the first episodes
on the therapeutic efficiency of PA compared to AL, which is
the first-line antimarial used in Burkina Faso.
Methods A total of 448 subjects were randomised to receive
treatment (224 subjects in each arm). Malaria diagnosis was
assessed by microscopy. Subjects were follow-up during 42 days.
Treatment response was measured according to standard of care
as per WHO guidelines of 2003. The correction of the cases of
treatment failure by molecular biology techniques is under ana-
lysis.
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Results On Day 28, the therapeutic failures were 3.35% in the
PA group as against 18,10% for the AL group. On Day 42, a
significant increase of the treatment failures in every group is
observed with a higher rate in the AL group (31.43%), against
17.22% in the PA group.
Conclusions This survey shows that less cases of treatment
failure occurred in the patients’ group treated with PA compared
to the group treated with AL. These findings contributed to evi-
dence base for a change in malaria treatment policy guidelines
for uncomplicated malaria in Burkina Faso.
PA-027 ADVERSE EVENT (AE) REPORTING FROM MALARIA
MASS DRUG ADMINISTRATION (MDA) ROUNDS
CONDUCTED IN SOUTHERN ZAMBIA
Victor Chalwe, John Miller. Ministry of Health, Zambia
10.1136/bmjgh-2016-000260.63
Background The National Malaria Control Centre (NMCC) of
the Ministry of Health in Zambia is conducting a large-scale mass
drug administration (MDA) community randomised-controlled
trial to evaluate the effectiveness of different MDA distribution
strategies on reducing malaria parasitaemia. The trial involved two
MDA strategies: MDA, where all eligible individuals were treated
with dihydroartemisinin and piperaquine (DHAp), and focal
MDA (fMDA), where all eligible individuals residing in a house-
hold with at least one positive member (rapid diagnostic test) were
treated with DHAp. This provides an opportunity to document
the extent to which potential safety issues are reported or adverse
events occur given the level of exposure to treatments.
Methods Field teams comprised of community health workers,
enumerators and adherence monitors, and supervised by facility-
based staff, received standardised training on the treatment cam-
paign procedures, use of DHAp for eligible participants, adverse
event monitoring, grading of events, and emergency and event
handling procedures by grade. Adverse events were recorded on
standard forms and in line with the national pharmacovigilance
network recommendations. The principle aim of this data collec-
tion activity was to document and follow up on all adverse events
(AEs) and serious adverse events (SAEs) occurring during the
course of the MDA trial for individuals taking DHAp.
Results Four rounds of MDA were conducted over 2 years.
During the first two intervention rounds, 280,638 participants
were tested, 159,696 were treated with dihydroartemisinin-
piperaquine (DHAp) in 40 health catchment areas. During the
second two intervention rounds, 261,814 participants took part.
A total of 687 AEs (0.13% of participants and 0.24% of treat-
ments) were reported; four were recorded as serious adverse
events (SAEs). The most common AE reported were gastrointes-
tinal disturbances (diarrhoea, abdominal pain and nausea)
31.20%; dizziness 19.8%; vomiting 17.35%; headache 16.03%;
and general body weakness at 11.37%.
Conclusions During this large MDA trial, the use of DHAp for
malaria treatment was generally safe and well tolerated.
PA-028 TIME TO SECOND AND THIRD EPISODES OF MALARIA
OF DIHYDROARTEMISININ−PIPERAQUINE VS
ARTESUNATE−AMODIAQUINE AND ARTESUNATE
−PYRONARIDINE VS ARTEMETER−LUMEFANTRINE IN
BOUGOULA HAMEAU, MALI
Bakary Fofana, Abdoulaye Djimde, Hamadoun Diakité, Issaka Sagara,
Ogobara Doumbo, Sekou Toure, Kassim Sanogo. MRTC, University of Bamako, Mali
10.1136/bmjgh-2016-000260.64
Background Currently, five artemisinin combination therapies
(ACTs) are recommended by WHO for treatment of uncompli-
cated malaria in Africa. While artemisinin derivatives have a
short half-life, the partner drugs give rise to differing durations
of post-treatment prophylaxis. The pharmacokinetic and phar-
macodynamic properties of drug regimens have implications for
the public health benefit of the drugs. The development of new
antimalarials is ongoing. The objective of this work is to evalu-
ate the prophylactic effect of artesunate−pyronaridine
(Pyramax) and dihydroartemisinin−piperaquine (Eurartesim) vs
artemether−lumefantrine (AR_L) and artesunate-amodiaquine
(ASAQ), respectively in Bougoula Hameau.
Methods Through the phase IIIb/IV clinical trial of the West
African Network of clinical trial of antimalarial drugs
(WANECAM) in Bougoula hameau (Mali) from January 2012
to December 2013, we evaluated the median time of occurrence
for the second and third episodes of malaria on patients aged
from 6 months to above. After the first randomisation, any
other subsequent episodes of malaria as treated by the same
ACT initially taken. Treatment failure before day 28 was treated
by quinine.
Results Whilst 448 patients were randomised to receive DHA
(224) vs ASAQ (224), 428 received PA (214) vs AR_L (214).
The median time to second and third episodes of malaria were
116 days and 60.5 with PA versus 82.5 and 56.0 for AR_L,
respectively. Otherwise, we found 118 and 98 vs 82.5 and 60
days as median time to second and third episode for DHA-PQP
vs AS/AQ, respectively. DHA-PQP highly prolonged the median
time to second and third episode as compared to ASAQ
(p=0.003 and p<0.001, respectively).
Conclusions The ACTs artesunate−pyronaridine and dihydroar-
temisinine−piperaquine significantly prolonged the median time
to second and third episode of malaria as compared to
artemether-lumefantrine and artesunate−amodiaquine,
respectively.
PA-029 ONE MERCK FOR MALARIA PROGRAM: AN
INTEGRATED R&D APPROACH TO FIGHT AGAINST
MALARIA
Beatrice Greco,1 Thomas Spangenberg,1 Elly Kourany-Lefoll,1 Claude Oeuvray,1
Jim Mulry,2 Kamala Tyagarajan,3 Bettina Magsaam4. 1Merck KGaA (Ares Trading S.
A.), Switzerland; 2Merck KGaA (EMD Serono Inc.), Switzerland; 3Merck KGaA (EMD
Millipore Corporation), United States of America; 4Merck KGaA, Darmstadt, Germany
10.1136/bmjgh-2016-000260.65
Background Integrated health care approaches are the most
effective ways to tackle infectious diseases such as malaria.
Within its Global Health activities focusing on health issues of
vulnerable populations within developing environments, Merck
has launched a program named ‘One Merck for Malaria’ inte-
grating development of new antimalarials with new sensitive
diagnostic approaches together with improving access to per-
sonal protection.
Methods The first pillar of the program is based on drug dis-
covery and development of new antimalarials. The second pillar
focuses on development of diagnostics addressing the need for
highly sensitive methods to identify low parasitaemia levels. The
third pillar is to improve access to personal protection against
malaria vectors.
Results Merck is carrying out screens and early drug discovery
with its partners, Medicines for Malaria Venture (MMV,
Switzerland) and H3D (University of Cape Town, South Africa),
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to identify new compounds to address current gaps in existing
antimalarials. Furthermore Merck is conducting regulatory pre-
clinical activities to reach clinical phase 1 of a compound origi-
nated by Dundee University (UK). Based on its excellent efficacy
and pharmaceutical profile shown in pre-clinical models, it is
intended to be developed as a long-lasting single oral combin-
ation treatment for uncomplicated P. falciparum and P. vivax.
Other research activities focusing on target identification are
conducted. The portable MUSE® cytofluorometer system is
launched in African countries to measure the number and % of
CD4 cells. An additional set of P. falciparum and P. vivax detec-
tion kits are in development to detect type and parasitaemia
levels in low blood quantities. Merck IR3535 is a widely used
insect repellent being retested to assess the degree of its efficacy
against various Anopheles carrying P. falciparum in Africa.
Conclusions Besides the drug and technology developments,
the program covers also aspects of e-health, education, and local
capacity building to complement the integrated approach being
applied at Merck.
PA-030 THE IMPACT PROJECT: IMPROVING THE IMPACT OF
EXISTING MALARIA PRODUCTS – ACTS
Karen Barnes,1 Philippe Guérin,2 Eva Maria Hodel,3 Georgina Humphreys,2
Cheryl Pace,3 C.G Banda,4 Paulo Denti,1 Elizabeth Allen,1 David Lalloo,3
Victor Mwapasa,5 Anja Terlouw3. 1University of Cape Town, South Africa;
2WWARM, United Kingdom; 3LSTM, United Kingdom; 4MLW, Malawi; 5University of
Malawi-College of Medicine, Malawi
10.1136/bmjgh-2016-000260.66
Background The antimalarial dihydroartemisinin-piperaquine
(DHA-PPQ) is one of the recommended drugs to treat uncom-
plicated Plasmodium falciparum malaria. However, DHA-PPQ
has a relatively narrow, poorly defined therapeutic dose range
and it is unclear whether PPQ concentration-dependent cardio-
toxicity (QTc prolongation) poses a clinical risk for specific sub-
groups. Uncertainty about the exact safe upper PPQ concentra-
tion threshold and recognition of the vulnerability of children
has led WHO to consider a complex weight-based dosing
regimen. These complex dosing schemes may challenge
DHA-PPQ introduction into national control programmes. It
also highlights the urgent need to standardise the dose optimisa-
tion process.
Methods The IMPACT project aims to determine the frequency
and severity of DHA-PPQ cardio-toxicity, and its correlation
with dose and drug concentration through WWARN-pooled
patient-level pharmacokinetic-pharmaco-dynamic safety analysis,
and antiretroviral drug interactions using all available data.
Using the established WWARN platform, an open study group
has been established to allow data sharing and joint analyses by
data contributors and other key stakeholders.
Results We will present a progress update of the IMPACT
project and associated WWARN DHA-PPQ safety group.
Findings will inform an up-to-date safety profile and upper PPQ
dose thresholds across key risk groups and identify remaining
research priorities. DHA-PPQ dosing challenges, lessons learnt,
and opportunities to address these through a more standardised
process for antimalarial dose optimisation will be reviewed, and
awareness of dose optimisation research priorities will be raised
among researchers, funders and control programmes.
Conclusions This work will help inform policy decisions on
DHA-PPQ dosing regimens and help demonstrate the import-
ance of identifying global research priorities for targeted
antimalarial safety studies and of integrating pooled individual
level safety analyses into WWARN’s global efficacy data plat-
form, as a powerful standardised process for dose optimisation.
PA-031 SPATIAL-TEMPORAL DYNAMICS IN HETEROGENEITY OF
MALARIA INFECTION IN A SETTING WITH SEASONAL
TRANSMISSION: A LONGITUDINAL STUDY IN THE
GAMBIA
Julia Mwesigwa,1 Jane Achan,1 Musa Jawara,1 Gian Ditanna,2 Archibald Worwui,1
Muna Affara,1 Jean-Pierre Geertruyden,3 Umberto D’Alessandro4. 1MRC, The
Gambia; 2QMUL, United Kingdom; 3University of Antwerp, Belgium; 4LSHTM, United
Kingdom
10.1136/bmjgh-2016-000260.67
Background The reduction in the malaria burden previously
reported in The Gambia is largely due to the successful scaling
up of control interventions. Understanding the current dynamics
of malaria transmission in a context of high coverage of control
interventions is critical to inform pre-elimination efforts.
Methods A cohort study was conducted in 12 villages across
the country during the 2013 transmission season. Enrolled resi-
dents aged over 6 months old had a blood sample collected
monthly for molecular analysis (PCR) and microscopy. Clinical
malaria cases were captured by passive detection. Mosquito
abundance and species distribution were determined by collec-
tions with CDC light traps, human landing catches.
Results A cohort of 4235 participants with a median age of 13
years (IQR 5, 28) was followed up. Long Lasting Insecticidal
Nets coverage was 71.6% (2774/3876). The incidence rate of
Plasmodium falciparum parasitaemia infection was 1.1 episodes
per person-year (95% CI: 0.8–1.2). P. falciparum transmission
was heterogeneous with low rates in the western region 0.47
episodes p-pyear (0.41–0.56) and highest in the eastern region
2.8 episodes per person-year (95% CI: 2.6–3.1). The peak mos-
quito densities were in September preceding peak P. falciparum
incidence in December. Anopheles (An.) Gambiae S form and
An. arabiensis were the predominant species in all the regions
except the central and lower river regions where An. gambiae M
form and An. melas were the predominant species. The risk of
clinical malaria during the season was higher among individuals
living with asymptomatic malaria at the start of the season;
(Western region HR=3.9, 95% CI: 2.1–7.5) and eastern region
(HR=1.5, 95% CI: 1.1–2.1).
Conclusions In The Gambia, malaria transmission is seasonal
and heterogeneous across the country, with clustering of infec-
tion and disease at household level, suggesting the need for tar-
geted interventions.
PA-032 GENETIC POLYMORPHISM OF MEROZOITE SURFACE
PROTEIN-2 IN PLASMODIUM FALCIPARUM ISOLATES
FROM DELIVERING WOMEN IN SOUTHERN
BRAZZAVILLE, REPUBLIC OF CONGO
Félix Koukouikila-Koussounda, Michael Kombo, Christevy Vouvoungui,
Francine Ntoumi. FCRM, Republic of Congo
10.1136/bmjgh-2016-000260.68
Background In the Republic of Congo, the genetic diversity of
Plasmodium falciparum has been extensively studied in isolates
from children. However, limited data are available for isolates
collected from delivering women. This study was conducted to
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determine the genetic polymorphism of merozoite surface
protein-2 (msp-2) gene in Plasmodium falciparum isolates from
asymptomatic delivering women in Brazzaville.
Methods We used a total of 114 peripheral whole blood
samples from delivering women collected from April 2014 to
April 2015 at Madibou health centre in Southern Brazzaville
and previously characterised as P. falciparum-positive by PCR
technique targeting the SSUrRNA gene. After extraction of DNA
using QIAamp DNA Blood Mini kit (Qiagen), the samples
underwent nested PCR of the msp-2 (block 3) and the allelic
families, namely 3D7 and FC27, were determined.
Results All the isolates were successfully genotyped. A total of
33 msp-2 alleles were detected, of which 17 belonged to the
allelic family 3D7 and 16 to FC27 family. The 3D7 allelic
family showed higher frequency (63.4%) compared to FC27
(36.6%) and 62 isolates (54.36%) harboured only 3D7 allele,
while 22 (19%) harboured FC27 allele only and 30 (26%)
showed both of these alleles. The mean multiplicity of infection
(MOI) was 1.4 (95% CI: 1.33–4.01) and 35% of isolates had
multiple genotypes. The MOI was lower in isolates from
women who had not received any IPTp-SP (1.3) compared to
those from women who had 3 doses of IPTp-SP (1.5) or in iso-
lates from primiparous (1.3) compared to that of multiparous
(1.5); however, the difference was not statistically significant (p
>0.05).
Conclusions This is the first report on genetic diversity of fal-
ciparum isolates from delivering women in the Republic of
Congo. A noteworthy diversity was observed; the multiplicity of
infection was neither influenced by IPTp-SP or parity.
PA-033 PLASMODIUM FALCIPARUM INFECTION IN FEBRILE
CONGOLESE CHILDREN: PREVALENCE OF CLINICAL
MALARIA TEN YEARS AFTER INTRODUCTION OF
ARTEMISININ-COMBINATION THERAPIES
Mandingha Kosso Etoka-Beka,1 Francine Ntoumi,1 Michael Kombo,1 Julia Deibert,2
Pierre Poulain,1 Christevy Vouvoungui,1 Simon Kobawila,3
Félix Koukouikila-Koussounda1. 1FCRM, Republic of Congo; 2ITM Tübingen,
Germany; 3Université Marien Ngouabi, Republic of Congo
10.1136/bmjgh-2016-000260.69
Background The detailed assessment of the QT and corrected
QT interval prolongation is recommended when testing new
drugs. Generally the electrocardiograph automatically displays
reliable values of the QT interval and corrected QT but mor-
phological variations of the T wave may cause reading errors;
hence the use of manual measurement as an alternative method.
Our objective was to evaluate the correlation between the auto-
matic and manual measurement of QT values.
Methods In Kolle from March 2012 to December 2015, an open
randomised, phase III-b/IV study comparing dihydroartemisinine-
piperaquine and pyronaridine-artesunate artemether-lumefantrine
was conducted. An electrocardiograph cartridge with 12 electro-
des coupled to a computer with the Tele Touch software was
used for the electrocardiogram on Day 0 before the study drugs
administration and on Day 2, two to four hours after the admin-
istration of the last dose of the antimalarial. The manual
measurement of QT and QTc was made using the Bazett method
[QTcB_m=(Number leaded×0.04×QTcF) / QTcB]. For pro-
longed QTc cases on Day 2, another measurement was done
during the next scheduled visit (day 7, 14, 21, 28, 35 and 42)
until the QTc normalised.
Results A total of 764 ECG were recorded with 398 partici-
pants. Different automatic and manual values of QTand QTc are
scattered around different medium. Comparisons of different
values of QT: p=0.1245 and QTc: p< 0.001 showed statistically
significant differences and the concordance between automatic
and manual tests was (QT: Rho_c=0.77 and QTc: Rho_c=0.46).
Conclusions Our results indicate no perfect match between
automatic and manual methods for QTand QTc. Manual reading
remains important to correct any machine errors during clinical
studies.
PA-034 PLASMODIUM FALCIPARUM MEROZOITE SURFACE
PROTEIN-1 GENETIC DIVERSITY AND MULTIPLICITY OF
INFECTION IN ISOLATES FROM CONGOLESE CHILDREN
CONSULTING IN A PAEDIATRIC HOSPITAL IN
BRAZZAVILLE
Nerly Gampio Gueye,1 Christevy Vouvoungui,1 Felix Koukouikila-Koussounda,1
Simon Kobawila,2 Francine Ntoumi1. 1FCRM, Republic of Congo; 2University Marien
Ngouabi, Republic of Congo
10.1136/bmjgh-2016-000260.70
Background As in many countries in sub-Saharan Africa, the
burden of malaria has been reduced in the Republic of Congo
as a result of massive deployment of insecticide-treated nets and
availability of artemisinin combination therapies.
However, limited data are available on the impact of these
interventions on parasite populations. In this study, we investi-
gated the P. falciparum genetic diversity and multiplicity of
infection in isolates from Congolese young patients and we
compared the results to previous studies conducted before the
introduction of ACTs.
Methods A total of 229 children were enrolled at the paediatric
hospital located in Northern part of Brazzaville. Inclusion criter-
ion was fever (T°>=37.5°C); then thick and thin blood smears
were done to detect malaria parasites and determine parasite
density as well as plasmodial species. In order to identify sub-
microscopic infection, P. falciparum msp1 gene was used as
molecular marker. The genetic diversity and the multiplicity of
infection (MOI) were determined.
Results We found 22 children with positive blood smear, there-
fore diagnosed with uncomplicated malaria (UM, 9.6%).
Among the 216 microscopy-negative children, using msp1
marker, 57 were shown to harbour submicroscopic malaria
infection (27,5%). In the age group 1–5 years, MOI was 1.4
and 2.4 in submicroscopic and UM children, respectively while
in the age group>= 5 years, MOI was 1.7 and 3 in submicro-
scopic and UM children, respectively. The number of msp1
alleles in isolates was 15 and 18 in SM and UM group, respect-
ively. We observed that new alleles were detected only in isolates
from UM children. Data are further analysed to investigate any
association with age, living area, haemoglobin type carriage, and
haemoglobin rate.
Conclusions This study shows no change either in P. falciparum
genetic diversity or in MOI 10 years after the introduction of
ACTs.
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PA-035 FEASIBILITY OF IMPLEMENTING A CONTINUOUS
HOUSEHOLD MALARIA INDICATOR SURVEY IN
RARIEDA SUB-COUNTY, SIAYA COUNTY, WESTERN
KENYA
Brian Seda,1 Titus Kwambai,1 Phelix Jangu,1 Aaron Samuels,2 Feike ter Kuile,3
Simon Kariuki1. 1KEMRI-CGHR, Kenya; 2CDC, United States of America; 3LSTM,
United Kingdom
10.1136/bmjgh-2016-000260.71
Background Malaria transmission in Siaya County is high and
perennial with peak transmission in May-July and
October-November. The Kenya Medical Research Institute
(KEMRI) and Centers for Disease Control and Prevention
(CDC) have historically conducted malaria surveillance in
western Kenya during peak malaria transmission season through
annual population-based cross-sectional surveys. However, it
may be important to characterise the seasonal spatial variation
in malaria transmission for surveillance purposes, to monitor
malaria interventions, and to inform decisions for changing and
targeting malaria control strategies. We describe the feasibility of
implementing a continuous malaria indicator survey (cMIS) for
malaria surveillance in Rarieda sub-County, Kenya.
Methods All households in the study area were GPS-mapped
and household members enumerated. Community interviewers
were trained and assessed in collecting blood for malaria rapid
diagnostic tests (RDT), preparation of dried blood spots on
Whatman 903 filter paper, preparing blood smears, and per-
forming HemoCue® tests for haemoglobin determination.
Community interviewers were also trained to provide appropri-
ate treatment with antimalarials and haematinics based on test
results. They visited a random subset of 5 houses in the study
area each week and collected and transmitted data in real-time
throughout the year.
Results Four trained community interviewers visited a total of
1041 compounds, and consented and tested a total of 4714 par-
ticipants for malaria by RDT in year one. Approximately 27%
were positive for malaria by RDTand were offered treatment.
Conclusions A large number of compounds were visited by few
staff in year one. This suggests that cMIS may be a viable way to
perform year-round surveillance, and to offer malaria testing
and treatment in the community with minimal staff. Further
analysis of results from cMIS and comparisons to existing sur-
veillance platforms are warranted to determine if cMIS can
provide accurate estimates of malaria case burdens throughout
the year.
PA-036 ASSESSING THE COMMITMENT, MATURATION AND
INFECTIVITY OF SEXUAL STAGES OF MALARIA
PARASITES IN SCHOOLCHILDREN LIVING IN A HIGH
MALARIA TRANSMISSION AREA OF BURKINA FASO
Aissata Barry, Alfred Tiono, Sodiomon Sirima, Teun Bousema. CNRFP, Burkina Faso
10.1136/bmjgh-2016-000260.72
Background With the move towards malaria elimination, it
becomes essential to understand the contribution of asymptom-
atic parasite carriers to disease transmission. However, the
dynamics of infection and gametocyte development are poorly
understood in asymptomatic versus symptomatic malaria infec-
tions. This was addressed in a longitudinal study of school chil-
dren in Balonghin, district of Saponé, Burkina Faso.
Methods The study involved healthy schoolchildren (with no
malaria parasite at microscopy) age 5–10 years. For the first
year survey, children were cleared for subpatent infections using
standard malaria therapy. No clearance will occur for the
second year survey. Children are followed up for 6 months
during which repeated finger prick blood samples for the detec-
tion and characterisation of infections are collected. Also at
three occasions a venous blood sample is collected for direct
membrane feeding assay (DMFA) to assess infectiousness to
mosquitoes.
Results The first year survey was completed. Fifty (50) children
were recruited and followed up. Almost all the children develop
infection and symptomatic malaria during the follow-up period
post clearance of initial infection. None of the children has
infected mosquitoes during the DMFA assays. The second year
survey is in process. The full results will be presented during the
forum.
Conclusions These data will be pivotal in understanding
human infectious reservoir. This will help designing interven-
tions to tackle the spread of malaria from symptomatic and
asymptomatic malaria individuals towards global in eliminating
malaria.
PA-037 ANTIBODY RESPONSE TO SEVERAL MALARIA
ANTIGENS IS ASSOCIATED WITH PROTECTION FROM
SEVERE MALARIA IN UGANDAN CHILDREN
Brenda Okech,1 Thomas Egwang,2 Patrick Corran,3 Eleanor Riley3. 1Makerere
University, Uganda; 2Med Biotech Laboratories, Uganda; 3LSHTM, United Kingdom
10.1136/bmjgh-2016-000260.73
Background Malaria is one of the leading causes of morbidity.
Both natural infection and irradiated sporozoites have yielded
partial and sterile immunity and contain multiple antigens so a
malaria vaccine with multiple antigens may be protective. Our
hypothesis is that responses to several malaria antigens may
protect against severe malaria. Currently various candidate vac-
cines are being tested and are in various stages. This study is
from a case control study conducted in Apac district in
Northern Uganda.
Methods Children with severe and complicated malaria were
compared with those having uncomplicated malaria in a
matched case-control study. Antibody titers in serum samples of
children were assessed by ELISA and parasitaemia was quanti-
fied by microscopy.
Results When all children who had antibodies to at least 4 of
the antigens tested were compared to children who responded
to less than 4 of the antigens, multiple responders were signifi-
cantly more prevalent in the mild malaria group. For all the
antibodies studied, there was a tendency for the children with
mild malaria to have higher OD levels than the children with
severe malaria. Children who were responders to AMA1, P. fal-
ciparum lysate, SE36, MSP1 42, GPI, MSP2–2FC or MSP2–
3D7 were significantly more likely to be in the mild malaria
group.
Conclusions There were significant differences between chil-
dren with severe and mild malaria for antibodies. Higher levels
of these antibodies were associated with protection from severe
malaria disease and from high parasitaemia. Our data suggest a
role for multiple blood stage antigen vaccines and denatured
toxin vaccine supports the development of multiple component
vaccines.
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PA-038 COST-BENEFIT ANALYSIS OF MALARIA RAPID
DIAGNOSTIC TEST IN ENUGU METROPOLIS, NIGERIA:
THE PERSPECTIVE OF THE COMMUNITY PHARMACY
PRACTITIONER
Ifeoma Ezennia, Obinna Ekwunife. Nnamdi Azikiwe University, Nigeria
10.1136/bmjgh-2016-000260.74
Background Malaria is a great health burden in Nigeria. Since
2010, the World Health Organization issued guidelines that call
for a shift from presumptive to test-based treatment. However,
test-based treatment is still unpopular in community pharmacies
in Nigeria. This could be due to unwillingness of customers to
spend more for a rapid diagnostic test (RDT). It could also
result from lack of interest from community pharmacy practi-
tioners since they may perceive that there is no financial gain
attached to the service. This study assessed the costs and benefits
of test-based malaria treatment for the community pharmacy
practitioner.
Methods The study was a community pharmacy-based cross
sectional survey. Potential benefit of RDT test to the practitioner
was determined using customers’ willingness-to-pay (WTP) for
this service. Average WTP was estimated using contingent valu-
ation. Binary logistic regression was used to assess correlates of
WTP. Costs associated with provision of RDT test were esti-
mated. Costing was based on the provider’s perspective.
Probabilistic sensitivity analysis through Monte Carlo simulation
was used to capture parameter uncertainty. The Benefit-cost
ratio was calculated to determine study objective.
Results Average WTP was $1.23 (95% CI: $1.03–$1.44).
Educated customers were 1.8 more likely to prefer RDT test
before taking malaria treatment. Customers that understood
RDT as described in the fact sheet were 18.3 times more likely
to prefer RDT test before malaria treatment. The predictive cap-
acity of the model was 18.1%. Average cost [min – max] of the
RDT test kit and the pharmacist’s time spent for the test was
0.15 [0.13–0.17] and 0.41 [0.18–0.52], respectively. The
benefit-cost ration of test-based malaria treatment was 6.7 (95%
CI: 6.4–7.0).
Conclusions Test-based malaria treatment is cost-beneficial for
pharmacy practitioners. Return on invested time was approxi-
mately 7 times. This finding should be capitalised upon to
increase community pharmacy practitioners’ interest and uptake
of test-based malaria treatment.
PA-040 SEASONAL ABUNDANCE AND SPOROZOITE RATES IN
MALARIA VECTORS IN NCHELENGE INCLUDING
ISLANDS OF LAKE MWERU AN AREA WITH A HIGH
BURDEN OF MALARIA IN NORTHERN ZAMBIA
Mbanga Muleba,1 Jennifer Stevenson,2 Keith Mbata,3 Modest Mulenga,1
Maureen Coetzee,4 Douglas Norris5. 1TDRC, Zambia; 2Macha Research Trust,
Zambia; 3University of Zambia, Zambia; 4Wits University, South Africa; 5JHSPH,
United States of America
10.1136/bmjgh-2016-000260.75
Background Nchelenge district is a holoendemic malaria trans-
mission zone in northern Zambia. The district occurs in a
region characterised by a mix of water, marshes, islands and
lagoons presenting a uniquely suitable ecology for mosquitoes.
Annual indoor residual spraying (IRS) campaigns are carried out
between September and December synchronised with other
regions in the country with different environmental conditions.
Targeted vector control interventions have been applied since
2008 without appreciable impact on disease burden. The timing
and targeting of vector control measures are not guided by an
informed entomological baseline. This study was aimed at pro-
viding entomological information on the seasonal abundance,
spatial distribution and Plasmodium falciparum sporozoite
infections in the local malaria vector species in order to guide
implementation of vector control in the district.
Methods Entomological studies were conducted intermittently
spanning the rainy, cold-dry, and hot-dry seasons from 2015–
2016. Mosquitoes were collected by CDC light traps, identified
to species both morphologically and by PCR techniques.
Circumsporozoite ELISA assay was used to detect P. falciparum
in mosquito salivary glands.
Results A total of 5437 female Anopheles funestus and An.
gambiae and over 6000 culicines, mostly Mansonia mosquitoes
were collected. The peak number of the An. funestus from all
sites occurred in July. Overall P. falciparum infection rates in An.
funestus were Kilwa island 2.7% (4/146), Mainland 2.5%
(3/122), Chisenga island 0.4% (1/220), Isokwe 5.9% (2/34) and
in An. leesoni from Kilwa 33% (1/3). The highest number of
An. gambiae was collected from Kilwa and none was found
infected with P. falciparum regardless of collection site.
Conclusions The annual IRS conducted between September
and December may be ineffective in controlling malaria as this
misses the vector peak abundance and peak transmission season.
Two rounds of IRS covering more areas would be needed to
control the two vector species with different population peak
seasons and malaria transmission.
PA-042 EFFECT OF COMMUNITY-BASED SCHEDULED
SCREENING AND TREATMENT (CSST) OF MALARIA IN
PREGNANCY ON INFANT MALARIA INFECTION IN A
SEASONAL MALARIA TRANSMISSION SETTING
Ngozi Moneke-Anyanwoke, Julia Mwesigwa, Muna Affara, Jasseh Momodou,
Ed Clarke, Umberto D’Alessandro, Susana Scott. MRC, The Gambia
10.1136/bmjgh-2016-000260.76
Background Children born to mothers who had malaria in
pregnancy have an increased risk of malaria infection in the first
24 months of life and they also experience earlier episodes of
malaria compared to their counterparts. This study compared
the pre- and post-seasonal prevalence of P. falciparum infection
and anti-malarial antibodies among children whose mothers
received either intermittent preventive treatment in pregnancy
using sulphadoxine-pyrimethamine (IPTp-SP) plus community-
based scheduled screening and treatment (CSST) of malaria in
pregnancy or standard IPTp-SP.
Methods In 2015, two cross-sectional surveys were conducted
before and after the malaria transmission season among children
aged 0–24 months, born to women who participated in a 2-arm
cluster-randomised trial to compare CSST plus IPTp-SP vs
IPTp-SP alone in the Upper River Region of The Gambia. For
each survey, finger prick samples were collected for slide micros-
copy and indirect ELISA to compare prevalence of malaria para-
sitaemia and IgG antibodies to 19-kDa merozoite surface
protein 1.
Results Of 905 children recruited in the pre malaria transmis-
sion survey, the prevalence of malaria in the overall population,
IPTp-SP alone and CSST plus IPTp-SP arms were 1.07%,
2.30% and 0%, respectively. Nearly 70% of children with para-
sitaemia were aged 1–5 months old. The seroprevalence in
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children whose mothers received CSST plus IPTp-SP compared
to IPTp-SP alone was 10.54% vs 11.85%. Seroprevalence ana-
lysis and reading of slide microscopy for 1172 children
recruited in the second survey as well as final statistical analysis
are currently on-going. Final results will be available by
November 2016.
Conclusions Infants whose mothers received CSST plus
1PTp-SP appear to be less likely to have malaria infection com-
pared to those whose mothers received IPTp-SP only.
Community scheduled screening and treatment of malaria in
pregnancy may also be protective against malaria in children.
PA-043 MALARIA PREVENTION PRACTICES AMONG PREGNANT
MOTHERS IN OSOGBO, NIGERIA
Adelani Tijani. Bayero University Kano, Nigeria
10.1136/bmjgh-2016-000260.77
Background Pregnant women are susceptible to symptomatic
malaria due to invasion of the placenta by Plasmodium. The
study aimed to find out the preventive measures put in place by
pregnant mothers against malaria.
Methods It is a descriptive cross-sectional survey comprising
294 pregnant women selected randomly in three hospitals in
Osogbo. The instrument used for data collection was a self-
developed, structured questionnaire with reliability of 0.802
using Cronbach’s alpha coefficient.
Results The results show that 87.8% of the respondents had
adequate knowledge about malaria in pregnancy and 75.5% of
them were knowledgeable about various available measures in
malaria prevention. However, only 34.4% used the insecticide
treated nets (ITNs) and 21.4% used intermittent preventive
therapy (IPTp). Findings also revealed that the respondents
practiced other preventive measures such as clearing of sur-
rounding bushes (12.8%), maintenance of drainages and netting
of windows and doors (15.4%). The results of the study
revealed that various barriers to the use of ITNs were deficient
knowhow (45.9%), spousal disapproval (36.7%), socio-cultural
misconceptions about sleeping under ITNs (18.8%) and unaf-
fordability of ITNs (45.5%). The hypotheses were tested using
Pearson’s chi-square method at 0.05 level of significance. There
is no significant relationship between the pregnant mothers’
knowledge and their practice of malaria prevention. However,
there are respective significant relationships between the age,
parity and educational status and practice of malaria prevention.
Conclusions It was concluded that the practice of malaria pre-
vention was generally low among the respondents. It was there-
fore recommended that concerted effort be put in place by the
nurses, more especially public health nurses to address the bar-
riers to utilisation of the universally accepted effective methods
of malaria prevention. This could be done through mass health
education to market women at regular interval.
PA-044 WEIGHT STATUS ROLE ON ANTIMALARIAL DRUG
EFFICACY AND SAFETY IN SUBURBAN CHILD
POPULATION IN MALI
Moussa Djimde,1 Michel Vaillant,2 Hanen Samouda,2 Issaka Sagara,1
Abdoulaye Djimde,1 Ogobara Doumbo1. 1MRTC, University of Bamako, Mali;
2Luxembourg Institute of Health, Luxembourg
10.1136/bmjgh-2016-000260.78
Background Malnutrition and Plasmodium falciparum malaria
are two major public health problems in sub-Saharan Africa. In
this study, we described as our primary outcome the proportion
of presence of P. falciparum during follow-up and explore the
relationships between malaria drug safety and nutritional inad-
equacies.
Methods This was a secondary analysis of an in vivo prospect-
ive randomised control trial conducted in Bougoula-Hameau,
Mali. Our analysis concerned 749 children followed during 28
days. We determined the BMI status of each child according to
the cut-offs defined by WHO in 2007. R-software was used for
statistical analysis.
Results The median of parasite density was higher in thin and
severely thin children (17800). The median of haemoglobin
levels at enrolment was lower in children who were thin and
severely thin (9.85) compared to the children with normal
weight, overweight and obesity. At 21 days, there was no para-
site in thin and severely thin children. At the same point of
follow-up, 7.5% of children with normal weight had parasites
versus 8.4% of overweight and obese children. Between the
three groups the difference was significant (p=0.03). On day 7
the highest ASAT level was observed in children with normal
weight (p=0.03). We didn’t observed differences between
weight status groups regarding the level of creatinine. The
p-value was respectively 0.99, 0.41 and 0.07 at enrolment, day
7 and day 14.
Conclusions This study showed that children with BMI defi-
ciency had a higher parasite density and lowest haemoglobin
level at enrolment. However, we did not observe a relationship
between weight deficiency and the safety of antimalarial drugs
used in our study.
PA-045 IMMUNOGENICITY OF MALARIA-VECTORED VACCINES
IS NOT AFFECTED BY CO-ADMINISTRATION WITH
ROUTINE EPI VACCINES IN A RANDOMISED
CONTROLLED TRIAL IN GAMBIAN INFANTS AND
NEONATES
Muhammed Afolabi,1 Victorine Mensah,2 Sophie Roetynck,1 Ebrima Kanteh,1
Georgina Bowyer,3 Amy Ndaw,2 Francis Oko,1 Carly Bliss,3 Ya Jankey Jagne,1
Riccardo Cortese,4 Alfredo Nicosia,4 Rachel Roberts,3 Flavia D’Alessio,5 Odile Leroy,5
Babacar Faye,2 Beate Kampmann,1 Badara Cisse,2 Kalifa Bojang,1 Stephen Gerry,6
Nicola Viebig,5 Alison Lawrie,3 Ed Clarke,1 Katie Ewer,3 Egeruan Imoukhuede,3
Adrian Hill3. 1MRC, The Gambia; 2Universite Cheikh Anta Diop, Senegal; 3University
of Oxford ( Jenner), United Kingdom; 4ReiThera, Italy; 5EVI, Germany; 6NDORMS,
University of Oxford, United Kingdom
10.1136/bmjgh-2016-000260.79
Background Recent global estimates show that P. falciparum
malaria still constitutes an enormous public health concern.
Chief amongst desirable interventions is an effective vaccine
that could complement existing control measures. Heterologous
prime-boost vaccinations involving chimpanzee adenovirus 63
(ChAd63) and modified vaccinia Ankara (MVA) encoding
ME-TRAP have consistently shown acceptable safety, excellent
immunogenicity and substantial efficacy in African adult and
paediatric populations. When licensed, malaria vaccines would
preferably be given to infants receiving routine childhood
immunisations. Nevertheless, no studies have evaluated the
interference of ChAd63/MVA ME-TRAP when co-administered
with routine Expanded Programme Immunisation (EPI) vac-
cines.
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Methods We enrolled 65 Gambian infants and neonates in an
age de-escalating fashion, priming at 4 months, 8 weeks or 1
week of age, and randomised them to vaccine or control (EPI
vaccines only) arm. Safety was assessed by the description of
vaccine-related adverse events ascertained through clinical
assessments, biochemical and haematological tests.
Immunogenicity was evaluated by IgG ELISA, interferon-gamma
ELISPOT, intra-cellular cytokine staining and flow cytometry.
Antibody testing was performed to assess any interference of
the EPI vaccines with responses to ChAd63/MVA ME-TRAP.
Results Overall, the vaccination regimes were well tolerated in
all age groups with no vaccine-related serious adverse events.
High level IgG and antigen-specific T cell responses were gener-
ated after boosting with MVA, with T cell responses highest in
the infants 8 week old at priming dose. EPI vaccines retained
unchanged antibody levels in all age groups.
Conclusions Potent humoral and cellular immunity induced by
heterologous prime-boost immunisation with ChAd63 and MVA
ME-TRAP did not interfere with the immunogenicity of
co-administered routine EPI vaccines in infants and neonates.
Potent T cell induction was again observed with the vectored
malaria vaccines despite co-administration with EPI vaccines.
PA-046 A MALARIA VACCINE SITE CHARACTERISATION:
PREVALENCE AND SPECIES DISTRIBUTION OF
PLASMODIUM MALARIA IN A MALARIA ENDEMIC
SETTING OF BURKINA FASO (WEST AFRICA)
Amidou Diarra, Issa Nebie, Alfred B Tiono, Guillaume Sanou, Alphonse Ouedraogo,
Amadou T Konate, Baptiste J Yaro, Issiaka Soulama, Sirima Sodiomon. CNRFP,
Burkina Faso
10.1136/bmjgh-2016-000260.80
Background Any development of a vaccine strategy or its
implementation is based on a good knowledge of the biology of
the pathogen and its temporal and spatial distribution. In the
case of malaria, the main four species responsible for the disease
though having a similar biological structure are not equally
represented spatially due to factors such as environment and
susceptibility of human to species.
Methods In order to characterise a site for a future malaria
vaccine implementation in terms of malaria prevalence and its
species distribution, two cross sectional studies were conducted
in October and March corresponding to the high and low
malaria transmission season, respectively, in the Banfora Health
District. A total of 1203 volunteers aged from 0.5 to 45 years
consented to participate in the study. During each survey, after a
brief physical examination, blood was taken from each volunteer
by finger prick to perform thick and thin blood film examin-
ation. Blood smears collected were air dry and the thin film
fixed with methanol. Dry smears were then stained with con-
trolled PH Giemsa buffer solution and checked for malaria
parasite using light microscope.
Results Malaria prevalence was markedly high during high
malaria transmission: 54.26% compared to low malaria trans-
mission season 39, 40%. Plasmodium index was 46.8% with a
gametocyte index of 11%. Main species present in the study
area were P. falciparum, P. malariae and P. ovale. Species distri-
bution was almost the same across the two seasons with
P. falciparum being more prevalent compared to other species
with respectively 97.8% and 98.7%.
Conclusions P. falciparum, P. malariae and P. ovale are the
three main species in the study area with almost the same distri-
bution across the two seasons.
PA-048 PLASMODIUM FALCIPARUM PARASITE DYNAMICS
DETERMINED BY QPCR AFTER CONTROLLED HUMAN
MALARIA INFECTION IN SEMI-IMMUNES FROM GABON
Yabo Honkpehedji,1 Jean Claude Dejon Agobe,1 Frejus Zinsou,1 Juliana Mengue,2
Ayola Adegnika,1 Thomas Richie,3 Benjamin Mordmüller,2 Peter Kremsner,2
Stephen Hoffman,3 Bertrand Lell1. 1CERMEL, Gabon; 2ITM Tübingen, Germany;
3Sanaria Inc., Rockville, MD, United States of America
10.1136/bmjgh-2016-000260.81
Background Characterising the effect of natural acquired
immunity and sickle cell anaemia on the pattern of Plasmodium
falciparum parasitaemia may be useful to understand the patho-
physiological mechanisms of protection against malaria.
Controlled human malaria infection (CHMI) by direct venous
inoculation of aseptic, purified, cryopreserved sporozoites
(Pf-SPZ challenge) is a new tool which can be used to investi-
gate the pathophysiology of malaria.
Methods The study was performed in Lambarene, Gabon, one
of seven African partners in the EDCTP-funded CHMI plat-
form. Adults aged 18–35 from three groups NI: 5 non-immune
(NI), 11 semi-immunes with haemoglobin AA (IA), and 9 semi-
immunes with haemoglobin AS (IS) received 3,200 sporozoites
after a curative treatment course with clindamycin. Capillary
blood samples were taken daily up to Day 28 to determine para-
sitaemia by real-time quantitative polymerase chain reaction
(RT-qPCR). Treatment was administered for a malaria episode
or at Day 28, whichever came first.
Results Parasitaemia was detected in 5 (100%) subjects in the
NI group, 9 (82%) in the IA group and 7 (78%) in the IS
group. All volunteers in the NI group showed similar patterns
with parasitaemia starting around Day 8 and rising quickly.
Patterns for parasitaemia in the immune groups (IA and IS) were
highly heterogeneous. Although time points of initial parasit-
aemia and duration of parasitaemia varied, all semi-immunes
managed to control parasitaemia for at least several days. There
were no discernible differences in patterns between the IS and
IA group, including the area under curve of parasitaemia over
time.
Conclusions No parasitaemia was detected in 20% of the semi-
immunes, likely due to liver stage immunity. The highly variable
patterns of parasitaemia did not allow us to discern immune
mechanisms against blood stages. Haemoglobin AS had no
visible effect on parasite dynamics at the low parasitaemia
encountered.
PA-049 SOLUBLE HLA-G LEVEL EFFECT ON GMZ2 SPECIFIC IgG
PRODUCTION AFTER IMMUNISATION
Odilon Nouatin,1 Ulysse Ateba Ngoa,1 Jean Claude Dejon,1 Jean R Edoa,1
Andreas Homoet,2 Julie Englhon Engelhon,2 Marguerite Massinga-Louembe,1
Meral Esen,2 Michael Theisen,3 Kim Lee Sim,4 Thomas Richie,4 Adrian Jf Luty,5
Kabirou Moutairou,6 Stephen Hoffman,7 Peter Kremsner,2 Bertrand Lell,1
Benjamin Mordmüller,2 Ayola Adegnika1. 1CERMEL, Gabon; 2ITM Tübingen,
Germany; 3Statens Serum Institut, Denmark; 4Sanaria Inc., United States of America;
5IRD, Benin; 6National University of Benin, Benin; 7Sanaria Inc., United States of
America
10.1136/bmjgh-2016-000260.82
Background Malaria is a major public health problem particu-
larly in Africa. Despite the relatively good immunogenicity
profile of the vaccine candidates in naive population, most of
them are poorly immunogenic in malaria endemic population.
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This could be due to an induction of various immune regulatory
mechanisms. It has recently been shown that high levels of an
immune regulatory molecule sHLA-G in infants increased the
risk of malaria, and question may arise as to whether it can
equally impair vaccine induced immune response. In this study
we have assessed the correlation between sHLA-G and the
immune response induced by GMZ2 a blood stage malaria
vaccine candidate.
Methods It was an observational study nested within a phase Ib
trial aiming to assess the safety, immunogenicity and efficacy of
GMZ2 adjuvanted with CAF01, on fifty Gabonese adults life-
long exposed to Plasmodium spp. Three doses of either the
vaccine candidate or Rabies vaccine were injected at Day 0, Day
28, Day 56. Peripheral blood sample was collected at Day 0 and
Day 7 after the first vaccine administration as well as 28 days
after the third vaccine administration (Day 84). sHLA-G level
was measured by ELISA on Day 0 and Day 7, and the anti
GMZ2, anti MSP3, Glurp IgG concentrations were determined
by ELISA on Day 0, 7 and 84. Vaccine efficacy was assessed
using PfSPZ Challenge.
Results sHLA-G level was significantly increased from Day 0 to
Day 7 (p=0.004) and correlated with a significant decrease of
anti-GMZ2 total IgG (r=–0.35, p=0.04). No correlation was
found between sHLAG and anti MSP3, Glurp IgG production.
Interestingly, individuals who did not develop malaria after the
challenge had a lower level of sHLA-G at baseline (p=0.03).
Conclusions Vaccination with GMZ2 induces an increase of
sHLA-G level resulting in a decrease of vaccine immunogenicity.
This could have an implication for the design of malaria vaccine
candidates in semi-immune individuals.
PA-050 ANTIBODY RESPONSES TO SURFACE ANTIGENS OF
PLASMODIUM FALCIPARUM GAMETOCYTE-INFECTED
ERYTHROCYTES AND THEIR RELATION TO
GAMETOCYTAEMIA
Bismarck Dinko,1 Elizabeth King,2 Geoffrey Targett,2 Colin Sutherland2. 1UHAS,
Ghana; 2LSHTM, United Kingdom
10.1136/bmjgh-2016-000260.83
Background An essential element for continuing transmission
of Plasmodium falciparum is the availability of mature gameto-
cytes in human peripheral circulation for uptake by mosquitoes.
Natural immune responses to circulating gametocytes may play
a role in reducing transmission from humans to mosquitoes.
Methods Here, antibody recognition of the surface of mature
intra-erythrocytic gametocytes produced either by a
laboratory-adapted parasite, 3D7, or by a recent clinical isolate
of Kenyan origin (HL1204), was evaluated longitudinally in a
cohort of Ghanaian school children by flow cytometry.
Results This showed that a proportion of children exhibited
antibody responses that recognised gametocyte surface antigens
on one or both parasite lines. A subset of the children maintained
detectable anti-gametocyte surface antigen (GSA) antibody levels
during the five week study period. There was indicative evidence
that children with anti-GSA antibodies present at enrolment were
less likely to have patent gametocytaemia at subsequent visits
(OR=0.29, 95% CI: 0.06–1.05; p=0.034).
Conclusions Our data support the existence of antigens on the
surface of gametocyte – infected erythrocytes, but further studies
are needed to confirm whether antibodies against them reduce
gametocyte carriage. The identification of GSAwould allow their
evaluation as potential anti-gametocyte vaccine candidates and/
or biomarkers for gametocyte carriage.
PA-051 MYCOBACTERIUM TUBERCULOSIS RESISTANCE TO
ISONIAZID AND RIFAMPICIN IN A HIV-1 ENDEMIC
POPULATION IN WESTERN KENYA IN 2014
Clement Likhovole,1 Collins Ouma,2 John Vulule,3 Susan Musau,3
Jeremiah Khayumbi,3 Albert Okumu,3 Wilfred Murithi3. 1Maseno University, Kenya;
2AFIDEP, Kenya; 3KEMRI, Kenya
10.1136/bmjgh-2016-000260.84
Background The spread of mono-resistant and multi-drug
resistant tuberculosis (MDR-TB) has been enhanced by delays in
the identification of resistant strains. However, resistance gene
patterns and the extent and distribution of mono-resistant TB
and MDR-TB is unknown, particularly for western Kenya where
Human Immunodeficiency Virus (HIV) is common. As such, the
overall objective of the current study was to identify cases of
mono-resistant TB and MDR-TB among enrolled patients in
health facilities in western Kenya.
Methods Patients with a suspected TB history were referred by
clinicians to the health facilities for TB and HIV diagnosis. HIV
testing was done using the Unigold and Abbott Determine kits.
Early morning sputum samples were collected and cultured on
Mycobacteria growth indicator tubes (MGIT) and incubated at
37°C. Drug susceptibility testing (DST) using the SIRE® kit was
done on ZN smear positive MGIT tubes and line probe assay
(LPA) performed to identify specific mutations on the rpo B, kat
G and inh A genes. Mutations on discordant samples were con-
firmed by the BigDye® Terminator v3.1 Cycle Sequencing Kit.
Results The proportion of MDR-TB, RIF mono-resistant
(RMR) TB and INH mono-resistant TB as estimated by LPA
and DST, was as follows: MDR-TB: 1.38% / 1.26%; RMR-TB:
1.2% / 0.72%; INH mono-resistant TB: 2.1% / 2.4%, respect-
ively. Our study showed that the H526Y rpo B and S315T1 kat
G mutations were common in HIV-positive patients (8% and
18% respectively) and that the S3I5T1 and S531L was the most
common mutation in MDR-TB strains in both HIV-positive and
HIV-negative patients (5% and 8% respectively). Binary logistic
regression, indicated that RMR-TB significantly predicted HIV
status (p=0.025).
Conclusions Our findings show that RIF mono-resistant TB
predicts HIV infection.
PA-052 MULTIDRUG-RESISTANT TUBERCULOSIS (MDR-TB): AN
EMERGING PROBLEM IN WEST AFRICA
Jacob Otu,1 Florian Gehre,1,2 Dezemon Zingue,3 Samuel Kudzawu,4 Audrey Forson,4
Morto Mane,5 Paulo Rabna,5 Bassirou Diarra,6 Salako Kayede,7 Emmanuel Adebiyi,7
Aderemi Kehinde,7 Nneka Onyejepu,8 Catherine Onubogu,8 Emmanuel Idigbe,8
Awa Ba,9 Aissatou Diallo,9 Souleymane Mboup,9 Kodjo Disse,10 Gerard Kadanga,10
Yaotse Dagnra,10 Ignatius Baldeh,11 Tumani Corrah,1 Bouke De Jong,2
Martin Antonio1. 1MRC, The Gambia; 2ITM Antwerp, Belgium; 3Centre Muraz
Research Institute, Burkina Faso; 4Korle-Bu Teaching Hospital, Ghana; 5Laboratório
Nacional de Saúde Pública, Guinea-Bissau; 6SEREFO (HIV/TB RESEARCH and
Training Centre) Bamako, Mali; 7Zonal TB Reference Laboratory, UCH, Nigeria;
8NIMR, Nigeria; 9University Hospital Centre Le Dantec, Senegal; 10Sylvanus Olympio
Teaching Hospital, Lomé, Togo; 11National Public Health Laboratories, Ministry of
Health, The Gambia
10.1136/bmjgh-2016-000260.85
Background Multidrug-resistant tuberculosis (MDR-TB)
remains a clear threat to TB control. There is a paucity of data
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on DR-TB for many countries especially in sub-Saharan Africa.
The study was undertaken to measure the prevalence of DR-TB,
including MDR-TB, from West Africa.
Methods Mycobacterial isolates were obtained from consecu-
tive new and previously treated TB patients from Burkina Faso,
Ghana, Guinea-Bissau, Mali, Nigeria, Senegal, The Gambia and
Togo from December 2012 to December 2014. Phenotypic
drug susceptibility testing to first- and second-line anti-TB drugs
was performed using BACTEC MGIT 960 system.
Results Viable isolates from a total of 44% (416/950) new and
56% (534/950) previously treated TB patients were included.
HIV results were available for 599 (63%) with estimated
HIV-TB co-infection of 21% (95% CI: 18.2−24.9%). Pooled
estimate of any DR-TB prevalence among new TB patients was
20% (95% CI: 16.4−24.4%) while for MDR-TB this was 6%
(95% CI: 4.1−9.0%). Among previously treated TB patients,
these were 53% (95% CI: 48.3−56.9%) and 34% (95% CI:
30.1−38.3%), respectively. Significant factor for the develop-
ment of MDR-TB was the history of previous anti-TB treatment
(Crude OR=0.13; 95% CI: 0.08−0.20; p=<0.001).
Mono-resistance was detected in 12% (95% CI: 10.2
−14.5%) with the highest resistance to streptomycin 6% (95%
CI: 4.8−7.9%). Pooled estimate of pre-XDR-TB prevalence rate
among MDR-TB patients was 21% (95% CI: 15.2−26.9%).
Estimated resistance to ofloxacin, kanamycin, capreomycin and
kanamycin and capreomycin were 7% (95% CI: 3.5−10.9%),
2% (95% CI: 0.6−5.1%), 9% (95% CI: 5.8−14.5%), and 3%
(95% CI: 0.8−5.8%), respectively.
Conclusions The reported prevalence of MDR-TB and
pre-XDR-TB are high compared to WHO estimates. Resistance
to streptomycin may indicate a high risk of failure for the WHO
standard regimen. MDR-TB patients with resistance to either
the fluoroquinolone or injectables may have suboptimal
response; thus the need for continuous surveillance of TB
resistance.
PA-053 ROAD TO BUILDING AND SUSTAINING NOVEL CLINICAL
RESEARCH CAPACITY IN RESOURCE-LIMITED SETTINGS:
LESSONS LEARNT SO FAR FROM RWANDA
Clarisse Musanabaganwa, Jean Pierre Musabyimana, Etienne Karita, Blondin Diop,
Abidan Nambajimana, Valentine Dushimiyimana, Prosper Karame, Jim Russell,
Jules Ndoli, Prince Bahati, Theobald Hategekimana, Augustin Sendegeya,
Jeannine Condo, Agnes Binagwaho. RBC-MRC, Rwanda
10.1136/bmjgh-2016-000260.86
Background Harnessing research for enhancing capacity for
evidence-informed policies is key for sustainability in countries
that are still facing poverty-related diseases. During current cus-
tomised medicine and drug-resistance era, priority has shifted to
clinical research making clinical trials a powerful tool in availing
tailored and affordable drugs and medical interventions. There
is need to address disparities in clinical research capabilities
worldwide, particularly sub-Saharan Africa, where disease
burden is rampant. We share our achievements and lessons
learnt so far from establishing three new clinical research sites
among the eleven targeted for in Rwanda.
Methods Referral, provincial and specialty hospitals have been
selected by the Ministry of Health as potential clinical research
sites. Based on the International Conference on Harmonization
in Good Clinical Practice (ICH-GCP), a baseline assessment was
conducted. Three best-scoring hospitals were developed to
become clinical research sites by: alignment with the national
priorities; acceleration of current laboratory accreditation pro-
cesses, improvement of data management, clinical infrastructure,
financial management systems; careful recruitment, continuous
training and a retention plan of critical research staff; collabora-
tions with private clinical research organisations; marketing of
research sites to funders; strengthening institutional review
boards; creation of local ownership; and diversification of the
research portfolio.
Results Clinical research sites established are Centre Hospitalier
Universitaire de Kigali (CHUK) in Kigali city, Centre Hospitalier
Universitaire de Butare (CHUB) in Southern province, and
Butaro Hospital in Northern province with 26, 26 and 11 dedi-
cated staff, respectively. Sites have minimally a clinical research
laboratory under accreditation process, 5 private medical/exam-
ination room, a counselling rooms, a data management unit, a
waiting area, a pharmacy with restriction-area, administrative
area, tele-conference/training room.
Conclusions Development of novel clinical research capacity in
resource-limited settings is feasible, with considerable time and
resources. Political initiative is a key element for sustainability.
Staff retention is the main challenge. For minimising the risk,
partnerships between experienced clinical organisations and
sponsors are vital for financial stability and knowledge transfer.
PA-054 CORRELATION OF HIV-1 P24 ASSAY WITH CD4 T-CELL
COUNT, HIV, HBV AND HCV CO-INFECTIONS AND ITS
IMPLICATION FOR ART MONITORING IN VASTLY
HIV-INFECTED POPULATION OF NIGERIA
Iheanyi Okonko,1 Phillip Okerentugba,1 Oluyinka Opaleye,2 Ezinwanne Awujo,1
Nnenna Frank-Peterside1. 1University of Port Harcourt, Nigeria; 2LAUTECH, Nigeria
10.1136/bmjgh-2016-000260.87
Background Reports indicate that extensive genetic diversity of
HIV-1 impacts almost every aspect of HIV-1 epidemiology,
including laboratory detection, ART/resistance, monitoring of
ART and vaccine development. Therefore, in order to support
the scale-up of access to HAART to mitigate the HIV-1 scourge,
prompt, accurate and cost-effective diagnosis and monitoring of
ART is crucial in Nigeria (a resource-limited country).
Methods Plasma of 200 confirmed HIV-1 patients on a speci-
fied and uniform ART regimen was monitored with P24 antigen
assay and CD4 T-cell count as virologic and immunologic assess-
ments of response to ART. The results of the assays (P24 and
CD4 count) were compared to assess sensitivity, turn-around
time and financial advantages of P24 over the CD4 count.
Serological analysis of HBV and HCV were performed accord-
ing to the manufacturer’s instructions. Enumeration of CD4+
levels was done with a Partec flow cytometer.
Results Of these patients, 77.5% had HIV only, 14.5% had
HIV−HBV and 11.5% had HIV-HCV. Evaluation of levels of
P24 antigen revealed that lower limits for P24 antigen 0.577–
2.308 were detected in the subjects with CD4 cell count >500.
However, higher limits for P24 antigen 2.308–2.885 were
detected in subjects with CD4 cell count within the range of
200–499. Correlation analysis showed an inverse relationship
between CD4 count and level of P24 antigen (CD4 count of
200–499 cells/ml versus 2.308–2.885 of P24, r=–0.319, CD4
count≥500 cells/ml versus 0.577–2.307 of P24, r=–0.088).
Conclusions This study suggests that p24 could serve as one of
such diagnostic and monitoring facilities that could be used in a
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resource-limited area like Nigeria. This will in turn lead to selec-
tion of more specific ARV options that best suppress viraemia
during initiation of ART, as well as for monitoring HIV-1
patients in Nigeria, knowing that the virus subtype impacts
effectiveness of ART.
PA-055 LOW FALSE RECENT RATE OF LIMITING ANTIGEN
AVIDITY ASSAY COMBINED WITH HIV-1 RNA DATA IN
BOTSWANA
Sikhulile Moyo,1 Kenanao Kotokwe,1 Terence Mohammed,1 Coretah Boleo,1
Lucy Mupfumi,1 Samuel Chishala,1 Simani Gaseitsiwe,1 Lesedi Tsalaile,1
Herman Bussmann,1 Joseph Makhema,2 Marianna Baum,3 Richard Marlink,2
Susan Engelbretch,4 Max Essex,2 Vladimir Novitsky2. 1BHP, Botswana; 2Harvard T.H.
Chan School of Public Health, United States of America; 3FIU-CHUA, United States
of America; 4Stellenbosch University, South Africa
10.1136/bmjgh-2016-000260.88
Background Cross-sectional tests for recency of HIV infection
are increasing in utility for estimating HIV incidence and evalu-
ating impact of interventions. However, they have been shown
to misclassify individuals with long standing infection as recent.
Local performance characteristics are essential for their applica-
tion. We estimated the false recency rate (FRR) among long
term HIV-1 infected individuals from Botswana.
Methods A total of 1036 specimens from treatment naïve indi-
viduals known to be HIV-infected 1.5 to 2 years from baseline
were tested using the limiting antigen-avidity assay (LAg) using a
cut-off of 1.5 normalised optical density units (OD-n). Study
participants were enrolled in HIV disease progression and did
not qualify for treatment according to national guidelines at the
time of enrolment. Baseline HIV status was determined using
double ELISA. Viral and CD4 measures were done every 3
months.
Results Most participants were females (74.8%) and median
age was 35 years (IQR 30–42). The median CD4 cell count and
viral load were 394 cells/mL (IQR 303–524) and 4.25 copies/
mL (IQR 3.51–4.87), respectively. Overall the FRR was 0.97%
(10/1036; 95% CI: 0.46–1.77). Four samples had viral loads
>1000 copies/mL, giving an adjusted FRR of 0.39% (4/1036;
95% CI 0.11–0.99).
Conclusions LAg had a very low FRR in this Botswana popula-
tion using the algorithm involving viral load. We found viral
load to be a complementary marker for improving the specifi-
city of the LAg-avidity assay. To our knowledge, this is the first
report of LAg-avidity FRR for the Botswana population, which
is much lower than the 2% recommended by the WHO
Incidence Assays Working Group.
PA-056 NEED FOR REANALYSIS OF CURRENT TESTING OF
HIV-EXPOSED INFANTS
Emmanuel Saka,1 Zex Kalipalire,1 Ravikiran Bhairavabhotla,2 Dalitso Midiani,3
Judith Sherman1. 1UNICEF, Malawi; 2UNICEF, United States of America; 3HIV &
AIDS Department, Ministry of Health, Malawi
10.1136/bmjgh-2016-000260.89
Background In 2015, 12% of HIV-exposed infants in Malawi
received an early infant diagnostic test (EID) in the first two
months of life. Provider-initiated testing and counselling (PITC)
is recommended as a standard component of comprehensive
clinical management for inpatients and outpatients in entry
points, including at mother-infant pair (MIP) clinics, nutrition
rehabilitation units (NRU) and paediatric wards.
Methods An analysis of the 2015 databases of Community
Management of Acute Malnutrition (CMAM), Laboratory
Information Management System (LMIS) and EID at
point-of-care (EID POC) was conducted to identify optimal
entry points for identifying HIV-infected children. A chi-square
test was used to determine differences between groups.
Results A total of 7629 children below 5 years of age were
admitted in NRUs; 60% were tested for HIV and 17% were
HIV-infected. The EID POC database showed that most (50%)
of the children identified from the inpatient paediatric ward
were HIV-infected as compared to 2.5% in MIP clinics and
11% in outpatient paediatric wards. A chi-square test of signifi-
cance shows that the HIV positivity varies between entry points
(chi-square value=182.34, with 2 degrees of freedom and
p-value <0.001). The LMIS database showed that 45% of chil-
dren identified in the paediatric ward were HIV-infected com-
pared to 30% of children identified via NRUs and 4% in MIP
clinics. A chi-square test of significance shows that HIV positiv-
ity varies between entry points (chi-square value=597.83, with
6 degrees of freedom and p-value <0.001).
Conclusions High yield of HIV positivity in children was
found in the paediatric wards and NRUs as opposed to MIP and
outpatient wards. Targeting EID POC testing to these settings
can reduce infant mortality and morbidity as HIV-infected chil-
dren will be identified and initiated on treatment more quickly.
PA-057 ENHANCING TUBERCULOSIS DETECTION BY TRAINED
RATS AND TRACKING OF MISSED PATIENTS THROUGH
COMMUNITY-BASED STRATEGY IN TB HIGH-BURDEN
COUNTRIES
Georgies Mgode,1 Christophe Cox,2 Dickens Bwana,3 Leah Mtui,4 Daniel Magesa,4
Amos Kahwa,5 Godfrey Mfinanga,6 Christiaan Mulder7. 1Sokoine University of
Agriculture, Tanzania; 2APOPO project, Tanzania; 3MUKIKUTE, Tanzania; 4PASADA,
Tanzania; 5NIMR Muhimbili, Tanzania; 6NIMR, Tanzania; 7APOPO project, The
Netherlands
10.1136/bmjgh-2016-000260.90
Background Tuberculosis (TB) diagnosis in most sub-Saharan
African countries with high TB burden is by direct smear
microscopy that has low sensitivity. More sensitive tests like
GeneXpert are expensive and not yet available in most African
settings. Therefore, a need for cheap and rapid tests is inevit-
able. Trained rats (Cricetomys spp.) detect TB by targeting the
Mycobacterium tuberculosis specific volatile compounds.
Accredited rats evaluated 150 sputa in 20 minutes. We report
on intervention involving TB detection by rats and additional
patient tracking by community healthcare workers from
MUKIKUTE and PASADA for treatment.
Methods Sputum was collected in hospitals in Dar es Salaam,
Coast and Morogoro, Tanzania after microscopy. Sputa were heat
inactivated at 100oC×30 minutes to kill pathogens and thereafter
presented to rats in random computer generated positions for
evaluation. Samples indicated as TB-positive by rats were con-
firmed by concentrated smear microscopy whether they contained
TB bacilli. Confirmed TB cases were reported to community
healthcare workers and hospitals for tracking and treatment.
Healthcare workers recorded contact details of presumptive TB
patients for subsequent tracking when detected by rats.
Results From 2011 to 2015 detection rats evaluated 306,346
sputum samples from 152,118 presumptive TB patients, which
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were also tested by microscopy in hospitals. DOTS smear-positive
TB patients were 21,911 and rats detected an additional 7961
patients missed in hospitals. Community healthcare workers track-
ing the additional patients brought 2715 additional TB patients to
treatment whereas treatment initiation increased from 56% (1020/
1812) in 2013 to 73% (870/1,198) in 2015. This prevented TB
transmission to 27,150 to 40,725 people since one untreated TB
patient can spread the disease to 10–15 persons annually.
Conclusions TB detection using rats and involvement of commu-
nity healthcare workers to track the additional TB patients for
treatment can increase TB detection and treatment initiation rate
of missed TB cases.
PA-058 A RAPID SEROLOGICAL TRIAGE TEST FOR DETECTING
ACTIVE TUBERCULOSIS
Nick Borain,1 Lizette Petersen,2 Julianne Du Plessis,1 Grant Theron,3
Carol Holm-Hansen2. 1Lateral Flow Laboratories, South Africa; 2NIPH, Norway;
3Stellenbosch University, South Africa
10.1136/bmjgh-2016-000260.91
Background A rapid screening test for active tuberculosis (TB)
will reduce diagnostic delay and expedite referral for confirma-
tory testing and treatment. Antigen detection tests, which may
utilise a rapid lateral flow (LF) platform suited to point-of-care
use, offer a promising alternative to conventional methods for
TB diagnosis. To date, the lack of accurate biomarkers has pre-
cluded the development of a serological assay.
Methods Sera and saliva were obtained by our consortium part-
ners from culture-positive TB cases and healthy asymptomatic
controls in high-burden settings. Mycobacterium tuberculosis
(Mtb) antigens with diagnostic potential were expressed in
eukaryotic and prokaryotic systems, and antigen combinations
evaluated for sensitivity/specificity on multiplex, ELISA and LF
platforms.
Results Based on a comparison of proteins recognised by anti-
bodies from patients and controls, we have identified a combin-
ation of secreted and membrane-associated antigens involved in
cell wall/cell processes and lipid metabolism that differentiate
between active disease and latent infection. Sensitivities of 84–
94% among TB cases and specificities of 97–100% among
healthy endemic controls were obtained by screening over 300
samples against combinations of eukaryotic-expressed antigens
on different platforms. Results indicating active TB were also
observed among samples from symptomatic smear/culture-
negative TB suspects. Antibody reactivity was not Mtb strain-
specific. Sera from Norwegian latent TB controls yielded nega-
tive results. Our LF assay detects TB in the context of HIV
co-infection, and is currently being optimised using sera from
well-characterised TB suspects in Cape Town.
Conclusions Screening our sample sets against a selected com-
bination of Mtb antigens by multiplex and LF prototype assays
yielded sensitivities and specificities superior to that obtained by
sputum smear microscopy. Our LF prototype conforms to the
WHO target product profile criteria for a community-based
triage test. Modification of the lateral flow platform for finger-
stick blood and/or saliva samples will further increase assay suit-
ability for use at the health post level.
PA-059 MOLECULAR TYPING AND DRUG RESISTANCE IN
MYCOBACTERIUM TUBERCULOSIS COMPLEX ISOLATES
FROM JAMOT AND MBALMAYO DISTRICT HOSPITALS,
CAMEROON
Emmanuel Mouafo Tekwu,1 Larissa Kamgue Sidze,1 Jean Paul Assam Assam,2
Sarah Eyangoh,3 Stefan Niemann,4 Francine Ntoumi,5 Veronique Penlap Beng,1
Matthias Frank6. 1BTC, University of Yaoundé I, Cameroon; 2University of Douala,
Cameroon; 3CPC, Cameroon; 4Research Centre Borstel, Germany; 5FCRM, Republic
of Congo; 6ITM Tübingen, Germany
10.1136/bmjgh-2016-000260.92
Background Cameroon is a country where tuberculosis still
remains a major public health problem. The aim of the present
research was to evaluate the potential of molecular markers in
predicting first-line drug resistance and to investigate the pre-
dominant genotypes representative of Mycobacterium tubercu-
losis strains in the Centre region of Cameroon.
Methods A total of 169 strains of M. tuberculosis isolate from
the Centre Region of Cameroon were screened for mutations
associated with first-line drug resistance by DNA sequence ana-
lysis. Spoligotyping and MIRU-VNTR (24 loci; mycobacterial
interspersed repetitive units typing – variable number tandem
repeat) were combined to identify clustered isolates.
Results Rifampicin-resistant strains had the rpoB mutations
D516V, H526D or S531L; isoniazid-resistant strains had the
mutations katG S315T or inhA promoter C15T; streptomycin-
resistant strains had the mutations rpsL K43R, gidB V36G,
H48N, P75S, L79W, or A138P; ethambutol-resistant strains had
the mutation embB M306V. Among those M. tuberculosis iso-
lates, 52.5% isolates were Cameroon genotypes followed by
Haarlem genotype (22.1%). The frequencies of isoniazid, rifam-
pin, streptomycin and multidrug-resistant isolates were equally
distributed in Cameroon genotype strains and non-Cameroon
strains. Furthermore, the analysis also shows the very low fre-
quency of M. africanum since only 2.6% of isolates belong to
this species.
Conclusions Mutations of common genes known to be
involved in resistance had high specificities in detecting resist-
ance. This study reveals the highly diverse M. tuberculosis popu-
lation structure, It confirms a predominance of the Cameroon
lineage in the Centre Region of Cameroon and the disappear-
ance of M. africanum in Cameroon.
PA-060 EMERGENCE OF NONTUBERCULOUS MYCOBACTERIUM
PULMONARY INFECTIONS, ANALYSIS OF ISOLATES
FROM PREVIOUSLY TREATED TB CASES
Samuel Kudzawu,1 Samuel Atiadeve,1 Doris Hilmann2. 1Korle-Bu Teaching Hospital,
Ghana; 2Tuberculosis Reference Laboratory, Germany
10.1136/bmjgh-2016-000260.93
Background The main objective of this study was to character-
ise supposed non-tuberculous mycobacteria (NTM) found in
previously treated tuberculosis (TB) cases to inform policy on
inclusion of NTM diagnosis and management as a differential
in TB care. In addition, the objective was to test the sensitivity
or otherwise of the identification algorithm used in Ghana to
declare an isolate an NTM.
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Methods Thirty-one supposed NTM isolates from previously
treated TB patients were collected. The NTM identification was
based on culture positivity by BD MGIT 960TM, smear positiv-
ity for acid fast bacilli and finally by BD MGIT TB-cIDTM test
kit. DNA was extracted using the Hain Lifescience GMBH
GenolyseTM kit. The specimens were further subjected to
sequencing.
Results Five (16%) of the previously treated cases were
Mycobacterium tuberculosis complex (MTBC); two (6.5%) were
M. abscesus/cholenae; 1 case (3.2%) for M. fortuitum and
M. gordonae each. One (3.2%) was an unknown mycobacterium
and 4 (12.9%) were other bacteria. Streptomyces and
Brevibacteria were 8 (25.8%) and 6 (19.4%), respectively. There
were three incidences of mixture with other bacteria; 2 MTBCs
(6.5%) and 1 NTM (3.2%).
Conclusions There is some evidence to suggest the prevalence
of NTM colonisation and disease in previously treated TB
patients. There is the possibility of some smear positive new
cases being NTM lung diseases but may be put on TB treatment.
Emphasis on differentiation of AFB positive smears before treat-
ment especially for retreatment cases must be made. The rapid
deployment of new molecular methods has the potential of
bridging the gap. There is the need for a definite diagnostic
algorithm that can detect both NTMs and MTBCs. Further
studies are encouraged to determinate whether the other organ-
isms identified are relevant possible pathogens or contaminants.
PA-061 COMBINED SPECIFIC IGG – AND IGA-BASED
DIAGNOSIS OF TUBERCULOSIS IN AFRICAN PRIMARY
HEALTHCARE CLINIC ATTENDEES WITH SIGNS AND
SYMPTOMS SUGGESTIVE OF TUBERCULOSIS
Dolapo Awoniyi,1 Ralf Baumann,2 Novel Chegou,1 Belinda Kriel,1 Ruschca Jacobs,1
Martin Kidd,1 Andre Loxton,1 Susanne Kaempfer,3 Mahavir Singh,3
Gerhard Walzl1. 1Stellenbosch University, South Africa; 2IOSM, RWTH Aachen
University, Germany; 3Lionex GmbH, Germany
10.1136/bmjgh-2016-000260.94
Background IgG-based tests for the diagnosis of active tubercu-
losis disease (TB) often show a lack of specificity in TB endemic
regions, which is mainly due to a high background prevalence
of latent TB infection (LTBI). Here, we investigate the combined
performance of the responses of different Ig classes to selected
mycobacterial antigens in primary healthcare clinic attendees
with signs and symptoms suggestive of TB.
Methods We evaluated the sensitivity and specificity of sero-
logic IgA, IgG and/or IgM to LAM, 7 mycobacterial protein
antigens (ESAT-6, Tpx, PstS1, AlaDH, MPT64, 16 kDa and 19
kDa) and 2 antigen combinations (TUB, TB-LTBI) in the plasma
of 42 individuals with other respiratory diseases (separated into
21 LTBI controls and 21 uninfected healthy controls), and 21
active TB patients at baseline, of whom 19 were followed up at
month 6 at the end of TB treatment.
Results The leading single serodiagnostic markers were anti-16
kDa IgA, anti-MPT64 IgA, anti-LAM IgG and anti-TB-LTBI
IgG. IgA responses to MPT64 and 16 kDa had the highest sensi-
tivity/specificity of 95%/95% and 95%/90% in differentiating
active TB from other respiratory diseases and active TB from
LTBI controls, respectively. The combined use of 3 or 4 anti-
bodies further improved this performance to accuracies above
95%. After successful completion of anti-TB treatment at month
6, only particularly anti-TUB IgG showed distinctively decreased
levels.
Conclusions These results show the potential of combining IgG
and IgA responses against selected protein and non-protein anti-
gens in differentiating active TB from other respiratory diseases
in TB endemic settings, and may provide a benchmark for
vaccines.
PA-062 DISCORDANT RESULTS BETWEEN GENOTYPIC ASSAYS
(XPERT MTB/RIF AND HAIN MTBDRPLUS) AND BACTEC
MGIT 960 SYSTEM FOR DETECTION OF
RIFAMPICIN-RESISTANT MYCOBACTERIUM
TUBERCULOSIS ISOLATES IN ZAMBIA
Winnie Mwanza,1 Deborah Milimo,2 Maureen Moyo,2 Nkatya Kasese,2
Maina Cheeba-Lengwe,2 Stembiso Munkondya,2 Helen Ayles,2 Petra De Haas,3
Monde Muyoyeta1. 1CIDRZ, Zambia; 2ZAMBART, Zambia; 3KNCV Tuberculosis
Foundation, The Netherlands
10.1136/bmjgh-2016-000260.95
Background Combination of genotypic assays (Xpert MTB/
RIF and MTBDRplus (LiPA) would be a powerful tool to
shorten the time for diagnosis of MDR tuberculosis (TB).
However, the algorithm used for these assays in Zambia has not
yet been implemented and the most widely used drug suscepti-
bility testing (DST) method remains MGIT DST. Missed rifam-
picin resistance on the MGIT 960 system has been reported by
several studies due to silent rpoB gene mutations. We report
comparative observations made on the performance of Xpert,
LiPA and MGIT DST methods for detection of rifampicin resist-
ance (RR) at the ZAMBART Central Laboratory (ZCL).
Methods Specimens were collected from consecutive patients
with Xpert rifampicin resistance positive (RR+) or rifampicin
resistance indeterminate (RRI) results at peripheral site labora-
tories for further testing at the ZCL. Each sample was tested
using Xpert, LiPA and MGIT culture/DST.
Results 30 patient samples were received and 17 were RR+, 8
were rifampicin-sensitive (RR-) and 5 were TB-negative by
Xpert. All 17 RR+ on Xpert were RR+ on LiPA and all 8
Xpert RR – were sensitive on LiPA giving a 100% concordance
for diagnosis of RR. Three isolates that were rifampicin sensitive
by the MGIT system (Gold standard) were RR+ by both geno-
typic tests. Genotypic tests showed evidence of mutation in the
codon 526 region of the rpoB gene for all the three isolates
with discordant RR MGIT DST results. Xpert positive predict-
ive value for Multidrug Resistance (MDR) TB was 62.5% and
81.2% compared to MGIT DSTand LiPA, respectively.
Conclusions There is need for Zambia to perform a full classifi-
cation of rpoB mutations to determine the prevalence of silent
mutations. This will optimise national guidelines for diagnosis
of RR – and MDR-TB.
PA-063 ANALYSING THE TREND OF BIOMARKERS WITH TB
TREATMENT IN TUBERCULOSIS DISEASE SUSPECTS
Anna Ritah Namuganga,1 Harriet Mayanja Kizza2. 1JCRC Kampala, Uganda;
2Makerere University, Uganda
10.1136/bmjgh-2016-000260.96
Background The search for biomarkers of pulmonary tubercu-
losis (PTB) disease, infection, treatment progress among others
is especially due to lack of suitable tests for diagnosis or differ-
entiation of active PTB disease and mere latent TB infection.
The existing methods have, among others, poor sensitivity, long
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turnaround time, high cost and the need for skilled personnel
and infrastructure. Therefore, this study analysed 27 analytes
(previously identified as promising) in TB research for their
trend during TB treatment among PTB disease suspects in
Mulago Hospital in Kampala, Uganda.
Methods This study used plasma samples from 76 TB suspects
enrolled as part of a bigger longitudinal African-European TB
Consortium (AETBC) study funded by the EDCTP within
Kampala, Uganda. 71% were males, average age was 32±10,
14% were HIV-infected. PTB was confirmed by MGIT (myco-
bacteria growth indicator tube) and speciated for MTB complex.
Subjects were followed at month 2 and 6 of treatment. The 27
analytes: (IL-1b,1ra, 2, 4, 5, 6, 7, 8, 9, 10,12p70,13,15,17A,
eotaxin, Basic FGF,G-CSF, GM-CSF, IFNg,IP10, MCP-1,
MIP-1a,b, PDGF-BB, RANTES, TNF-a, VEGF) were analysed
using Luminex. Of the TB suspects, 38 had confirmed MTB by
MGIT. The 38 TB suspects, used as controls, had X-ray results
ranging from normal to consistent with TB.
Results Levels of 14 of the analytes most notably MIP-1a, b,
IP-10, RANTES, IL-8, IL-12p70, IL-17A and VEGF significantly
reduced throughout treatment. Notably, levels of IFNg,
IL-12p70, 4,6,IP10, and VEGF significantly reduced by month
of treatment. Combinations of IP10, RANTES, MIP-1b and
VEGF also showed promising abilities in identifying treatment
success with an interesting trend appearing in suspects with
non-TB chest infections and with HIV−TB co-infection.
Conclusions The above markers have promising abilities for
PTB diagnosis and identification of possible relapse or treatment
failures.
PA-064 IDENTIFICATION OF NOVEL PLASMA AND SALIVARY
BIOSIGNATURES FOR THE DIAGNOSIS OF TB DISEASE
AND MONITORING OF TREATMENT RESPONSE
Ruschca Jacobs, Novel Chegou, Gerhard Walzl. Stellenbosch University, South Africa
10.1136/bmjgh-2016-000260.97
Background New tools are urgently needed for the rapid diag-
nosis of TB disease, especially in resource-constrained settings.
We investigated the usefulness of host markers detected in
plasma and saliva as biomarkers for the diagnosis of TB disease
and monitoring of treatment response.
Methods We prospectively collected plasma and saliva samples
from 55 individuals that presented with signs and symptoms
suggestive of TB disease at a health centre in Cape Town, South
Africa, prior to the establishment of a clinical diagnosis. Patients
were later classified as having TB disease (n=22) or other
respiratory diseases (ORD) (n=33), using a combination of clin-
ical, radiological and laboratory findings. The concentrations of
74 host markers were evaluated in plasma and saliva samples
from all study participants using a multiplex cytokine platform.
Results Out of the 74 host markers evaluated, 18 markers
detected in plasma, and two detected in saliva, showed potential
as TB diagnostic candidates, with area under the ROC curve
≥0.70. A six-marker plasma biosignature comprising of NCAM,
SAP, IL-1ρ, sCD40L, IL-13 and Apo A-1 diagnosed TB disease
with a sensitivity of 100% (95% CI: 86.3−100%) and specifi-
city of 89.3%(95% CI, 67.6–97.3%), whereas a five-marker sal-
ivary biosignature comprising of IL-1ρ, IL-23, ECM-1, HCC1
and fibrinogen diagnosed TB disease with a sensitivity of 88.9%
(95% CI: 76.7−99.9%) and specificity of 89.7% (95% CI: 60.4
−96.6%), both regardless of HIV status. The plasma
concentrations of 11 of the host markers and 8 of the markers
detected in saliva changed during treatment, indicating that they
may be useful in monitoring of TB treatment response.
Conclusions We have identified novel plasma and salivary bio-
signatures which may be useful in the diagnosis of TB disease
and monitoring of the response to TB treatment. Our findings
have potential to be translated into point-of-care screening tests
after further validation.
PA-065 FACTORS AFFECTING TB TRANSMISSION FROM ADULT
TO CHILDREN WITHIN HOUSEHOLDS IN THE GAMBIA
Alieu Mendy, Leopold Tientcheu, Abigail Ayorinde, Edward Coker,
Uzochukwu Egere, Beate Kampmann. MRC, The Gambia
10.1136/bmjgh-2016-000260.98
Background Childhood tuberculosis (TB) has significant impact
on public health worldwide and it is believed that most children
acquire TB from an adult smear-positive index case within their
household. To further examine this hypothesis and to investigate
transmissibility of strains within the household setting, we com-
pared strain-types in adults and their child contacts. We also
examined the influence of bacillary burden and strain-type on
clinical outcome of contacts.
Methods Stored isolates from smear positive adult TB cases
(n=136) were selected according to clinical outcomes of their
household contacts (children<15 years old). Mycobacteria were
isolated from both adult and – where available – children samples
via culture, and typed using spoligotyping to enable strain classifica-
tion.
Results The AFB grade of adult index cases correlated with clinical
outcome of the children with microbiologically confirmed TB, clin-
ically diagnosed probable TB, asymptomatic but TST positive, and
asymptomatic, and TST negative children showed 60%, 35%, 34%
and 33% highest AFB grade (3+) levels, respectively. Strain-type
determination by spoligotyping showed that 93% of children had
acquired Euro-American lineages, while 7% had M. africanum
lineage. Combined results for adult index cases of children with
confirmed and probable TB showed 76% Mtb-Euro-American,
17% M. africanum and 7% Mtb-Indo-Oceanic. Index cases of TST
positive children showed 59%Mtb-Euro-American, 32%M. africa-
num, 8% Mtb-Indo-Oceanic and 2% Mtb-Beijing. Those of TST
negative children showed 63% Mtb-Euro-American, 26% M. afri-
canum, 9%Mtb-Indo-Oceanic and 2%Mtb-Beijing.
Conclusions The data so far support other published data, which
show that a higher bacillary burden in the index case increases the
likelihood of TB transmission to child contacts. Adult patients
appear to be more likely to transmit TB if they were carrying
Euro-American lineages rather thanWest African strains.
PA-066 VITAMIN D FOR TREATMENT AND PREVENTION OF
TB-HIV
Anna Coussens,1 Celeste Naude,2 George Chaplin,3 Mahdad Noursadeghi,4
Adrian Martineau,5 Nina Jablonski,3 Robert Wilkinson1. 1University of Cape Town,
South Africa; 2Stellenbosch University, South Africa; 3Pennsylvania State University,
United States of America; 4UCL, United Kingdom; 5QMUL, United Kingdom
10.1136/bmjgh-2016-000260.99
Background Susceptibility to reactivate tuberculosis infection is
influenced by immunosuppression. Amongst the greatest risk
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factors for active TB are HIV-1 infection and vitamin D defi-
ciency. These risks factors are not mutually exclusive and may
exacerbate each other. However, the phenotype of immunodefi-
ciency induced by each is different. Vitamin D deficiency not
only associates with TB risks, but it is greater in HIV-co-infected
patients. The effects of vitamin D on the immune system are
pleiotropic, being both anti-inflammatory and antimicrobial.
Evidence suggests that vitamin D may not only reduce risk of
TB by increasing anti-mycobacterial immunity and reducing
inflammation, but it may also reduce HIV replication and the
associated effects on innate and adaptive immunity; thus con-
comitantly reducing the associated risk of HIVon TB.
Methods We investigated in vitro and ex vivo the effect of
vitamin D supplementation on the response of monocyte-
derived macrophages (MDM) and peripheral blood mono-
nuclear cells (PBMC), respectively, to HIV-M. tuberculosis (Mtb)
co-infection. The effects of pathogen growth and susceptibility
to infection were correlated to cytokine, chemokine and anti-
microbial peptide production, by expression, secretion and flow
cytometry analysis.
Results MDM differentiated in the presence of vitamin D meta-
bolites, significantly restricted HIV-1 replication, alone and
during co-infection with Mtb. Type 2 MDM were considerably
more susceptible to HIV-1 infection than type 1. This correlated
with the level of CCL2 production, which was significantly
inhibited by vitamin D metabolites. PBMC isolated from
healthy individuals in summer and in winter after receiving
vitamin D, significantly restricted HIV-1 infection, compared to
PBMC collected in winter before supplementation. There was a
significant difference in circulating cell populations and serum
cytokines/chemokines in summer, compared to winter, and
these were investigated for correlations with HIV replication.
Conclusions Vitamin D may prove a cheap, effective, tool for
preventing TB-HIV disease progression and clinical trials are
warranted in at-risk populations.
PA-067 PHARMACOKINETICS OF RIFABUTIN IN COMBINATION
WITH LOPINAVIR-RITONAVIR IN ADULT PATIENTS WITH
HIV AND TUBERCULOSIS CO-INFECTION IN BURKINA
FASO
Henri Gautier Ouedraogo,1 Alberto Matteelli,2 Mario Regazzi,3 Grissoum Tarnagda,1
Paola Villani,3 Giorgia Sulis,2 Serge Diagbouga,1 Alberto Roggi,2
Francesco Giorgetti,4 Seni Kouanda1. 1IRSS, Burkina Faso; 2Institute of Infectious
and Tropical Diseases, Spedali Civili, Brescia, Italy; 3Fondazione IRCCS Policlinico
San Matteo, Italy; 4National TB Program, Burkina Faso
10.1136/bmjgh-2016-000260.100
Background This study aimed to assess the pharmacokinetic
profile of rifabutin (RBT) given at 150 mg or 300 mg every
other day (EOD) in tuberculosis (TB)-HIV co-infected adult
patients.
Methods This is a pharmacokinetic prospective, pilot, open,
randomised study of two doses of RBT in combination with
lopinavir/ritonavir among HIV−TB patients in Burkina. Sixteen
patients were randomised in two arms: TB treatment consisting
HZE standard doses in association with RBT150 mg EOD (arm
A, 8 patients) or RBT300 mg EOD (arm B, 8 patients) in com-
bination with lopinavir/ritonavir. RBT plasma concentrations
were evaluated after two weeks of combined HIV and TB treat-
ment. Samples were collected at pre-dosing and at 1, 2, 3, 4, 6,
8 and12 hours after drug ingestion to measure plasma drug con-
centration using HPLC–MS/MS assay.
Results The mean Cmax and AUC in the RBT 150 mg arm
(Cmax=0.35±0,18 mg/mL, AUC(0–24)=3.94±2,1 mg.h/mL)
were significantly lower (p=0.01) than those of the RBT 300
mg arm (Cmax=0.75±0.54 mg/mL AUC(0–24)=7.1±2.7 mg.h/
mL). There was no significant difference in Tmax (Tmax=3.44
±2.01 hours vs Tmax=3.86±2.04 hours) p=0.687. RBT
follows linear kinetics and no significant differences were appar-
ent in the mean oral clearance (CL/F) estimates (p=0.683),
which were dose independent and similar for the 2 assessment
doses. Five of 8 patients in RBT150 mg arm had a Cmax below
plasma therapeutic limit (<0.3 mg/ml). All patients in RBT 300
mg arm had a higher Cmax than this limit. Also, at 48 hours of
drug ingestion, all patients in the RBT 300 mg arm (8/8) had a
mycobacterial minimum inhibitory concentration (MIC) above
the limit (>0.06 mg/mL) compared with 4 of 8 patients in the
RBT150 mg arm. The means Cmax, AUC (0–24) and Tmax of
25-O-desacetyl rifabutin of the RBT 300 mg arm were increased
by 100% and 50% respectively compared to the RBT150 mg
arm.
Conclusions This study confirmed that the dose of rifabutin
150 mg three times a week in combination with lopinavir/ rito-
navir is inadequate and could lead to the selection of rifamycin-
resistant mycobacteria.
PA-068 CYTOLOGICAL PROFILE OF RED BLOOD CELLS IN
HIV-INFECTED PATIENTS: CASE OF THE DOUALA
GENERAL HOSPITAL (CAMEROON)
Amel Bidias,1 Dieudonné Ndjonka,1 Clémence Olemba,2
Arabo Souleymanou1. 1University of Ngaoundéré, Cameroon; 2General Hospital of
Douala, Cameroon
10.1136/bmjgh-2016-000260.101
Background Haematological abnormalities have been documen-
ted as strong independent predictors of morbidity and mortality
in HIV-infected individuals. Those infected with HIV without
antiretroviral treatment (ART) have a high prevalence of abnor-
mal blood cells. HIV-1 induced dyserythropoiesis in conjunction
with the effects of HIV-related inflammation and/or chronic
immune activation. The objective of the study is to identify and
characterise the different red cell morphological changes that
occur during the evolution of HIV infection in patients according
to clinical, biological and therapeutic variables.
Methods A total of 232 patients infected by HIV were included
in this cross-sectional and descriptive study conducted at the
Douala General Hospital (Cameroon) from June to December
2015. All the patients were screened for red blood cells abnor-
malities. Blood samples were taken in EDTA tubes for full blood
counts (FBC) and blood films. chi-square test was used to
compare the variables, and the statistical significance level
adopted was p-value under 0.05.
Results Three quarters of patients in our study had abnormal
quantitative or qualitative red blood cells, giving a prevalence of
77.5%. The mean value of haemoglobin was 11.9 g/dl with a
prevalence of anemia at 61.2% for all participants. The main red
blood cells abnormalities were the anisocytosis (43.1%), the aniso-
chromia (34.5%), the macrocytosis (24.1%), the microcytosis
(13.8%), the hypochromia (12.9%) and the poikilocytosis
(12.5%). These abnormalities are statistically significant and are
dependent on the severity of the anaemia the WHO clinical stage,
the ART duration and the medication regime with all p< 0.05.
Conclusions The frequency of cytological abnormalities of red
blood cells is high during HIV infection and proportional to the
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severity of the anemia, the duration of antiretroviral therapy diet
and its clinical evolution stage. We recommend that reading blood
films is systematic of FBC prescription in the monitoring of
HIV-infected patients.
PA-069 CYP2B6 GENOTYPE BASED EFAVIRENZ DOSE
RECOMMENDATIONS DURING RIFAMPICIN-BASED
ANTITUBERCULOSIS CO-TREATMENT FOR A
SUB-SAHARAN AFRICA POPULATION
Jackson Mukonzo,1 Ronald Kuteesa,1 Jasper Ogwal-Okeng,1 Lars L. Gustafsson,2
Joel Owen,3 Eleni Aklillu2. 1Makerere University, Uganda; 2KI, Sweden; 3Union
University, United States of America
10.1136/bmjgh-2016-000260.102
Background Pharmacogenetics is a major determinant of the
EFV–rifampicin interaction during HIV-TB co-treatment. We
assessed genetic factors that influence EFV PK, treatment out-
comes and provide genotype-based EFV dose recommendations
for adult TB-HIV-1 co-infected Ugandans receiving rifampicin
based anti-tuberculosis co-treatment.
Methods Steady state plasma EFV concentrations (n=1216)
from 158 HIV-TB co-infected patients (76 females) treated with
efavirenz/lamivudine/zidovidine and rifampicin-based TB treat-
ment were analysed. Patient genotypes for CYP2B6 (*6 & *11),
CYP3A5 (*3,*6 & *7) and ABCB1c.4046A>G, baseline bio-
chemistries and CD4 and viral load change from baseline were
determined. A one-compartment population PK model with first-
order absorption (NONMEMTM) was used to estimate geno-
type effects on EFV PK. Population genotype-frequency-based
PK simulations predicted AUCs and trough concentrations were
compared between the product label / known reference values
and different dose simulations.
Results Compared to CYP2B6*1/*1, EFV post-induction CL/F
was 2.5 and 1.7 times higher in CYP2B6*6/*6 and CYP2B6*1*/
6, respectively. A 23% increase in F1 was observed for the
variant ABCB1 c.4046A>G. EFV mean AUC was significantly
higher in CYP2B6*6/*6 genotypes compared to CYP2B6*1/*1
(p< 0.0001). Simulated AUCs for a 600 mg EFV dose were 1.2
and 2.4 times greater than the product label mean AUC for the
Ugandan population in general and CYP2B6*6/*6 genotypes,
respectively. EFV daily doses of 450 mg and 250 mg for the
general population and CYP2B6*6/*6 genotypes respectively
yielded simulated exposures that were comparable to the product
label. Overall, only 8.9% patients had HIV RNA >40 copies/mL
after 84 days of treatment.
Conclusions During rifampicin co-treatment, daily doses of
450 mg and 250 mg might meet the EFV dosing needs of
HIV-TB infected Ugandans in general and CYP2B6*6 homozy-
gous variants, respectively.
PA-070 PREVALENCE OF ADVERSE DRUG REACTIONS AMONG
HIV/AIDS PATIENTS ON HAART IN UNIVERSITY OF
MAIDUGURI TEACHING HOSPITAL (UMTH), NIGERIA:
A FOUR-YEAR RETROSPECTIVE STUDY
Peter Bassi,1 Wadzani Gashau,2 Klungel Olaf,3 Alexander Dodoo,4
Prosper Okonkwo,5 Phyllis Kanki6. 1CHS, University of Abuja, Nigeria; 2College of
Medical Sciences, UNIMAID, Nigeria; 3UIPS, University of Utrecht, The Netherlands;
4WHO Collaborating Centre for Advocacy and Training in Pharmacovigilance. Accra,
Ghana; 5APIN Ltd Program Office, Nigeria; 6Harvard School of Public Health, United
States of America
10.1136/bmjgh-2016-000260.103
Background Current evidence on highly active antiretroviral
therapy (HAART) indicates that each person will have to take
the drugs for life [1]. Since 2000, the prevalence of HIV in
Nigeria has shown a gradual consistent decline from 5.0% in
2003 to 4.1% in 2010 following the introduction of HAART.
While HAART improves the quality of life among HIV patients,
adverse drug reactions (ADRs) may compromise quality of life
in some patients.
Methods We performed a retrospective study at HIV/AIDs
clinic, UMTH Nigeria, among ART-naive adult patients
recruited from January 2006 to December 2010 and followed
up for 48 months from commencement of HAART. Database
and clinical charts of eligible patients were extracted for clinical
information, type of reported ADRs, and physician’s decision
on whether or not ADRs was serious according to ICH E2A
guidelines. Data was analysed using SPSS Ver. 21. Logistic
regression was used to calculate odds ratios and of ADR asso-
ciated with patient and treatment characteristics.
Results Patients initiated on HAART (n=7260) were reviewed
with a prevalence of serious ADRs (53.4%). Commonest ADRs
were peripheral neuropathy (11.0%), itching (9.5%), anaemia
(9.2%), dyspepsia (9.1%) skin rashes (9.1%), and various forms
of dermatitis (5.5%). Almost all (96%) the reported ADRs
occurred between 3–18 months of treatment. Patients initiating
on a zidovudine and efavirenz-based regimen (p=0.015 and
p=0.020 respectively), baseline CD4≤200/ mm3 (P=0.000),
unemployed patients (P=0.000), students (p=0.000) and petty
traders (p=0.000) were statistically significantly associated with
increase occurrence of an ADR.
Conclusions The study has identified the prevalence, types and
the determinants of ADRs among HIV/AIDs patients at UMTH,
Nigeria. These findings might be helpful in developing clinical
guidelines on ADRs profile as a major criterion for choosing
HAART drugs, hence promoting pharmacovigilance of ARVs in
Nigeria.
PA-072 GP41 DIVERSITY IN ANTIRETROVIRAL THERAPY NAïVE
AND EXPERIENCED HIV-1 SUBTYPE C-INFECTED
PATIENTS IN BOTSWANA: IMPLICATIONS FOR
ENFUVIRTIDE (T-20) USE
Dorcas Maruapula,1 Boitumelo Seraise,1 Kevin Einkauf,2 Amanda Reilly,2
Sikhulile Moyo,1 Terence Mohammed,1 Christopher Rowley,3 Rosemary Musonda,1
Joseph Makhema,1 Simani Gaseitsiwe1. 1BHP, Botswana; 2Harvard College, Harvard
University, United States of America; 3Harvard T.H. Chan School of Public Health,
United States of America
10.1136/bmjgh-2016-000260.104
Background With the expansion of HIV treatment programs in
sub-Saharan Africa, there are increased cases of HIV drug resist-
ance. In Botswana where the national HIV treatment program
has been in place since 2002, patients with HIV strains resistant
to the core antiretroviral classes are a reality. There is need to
investigate how some of the less frequently used antiretroviral
classes such as enfuvirtide (T-20) and its derivatives would fair
in this population.
Methods A total of 164 samples from 129 patients initiating
combination antiretroviral therapy (cART) and 35 patients
failing NRTI – and NNRTI-based cART in studies conducted in
Botswana were available for analysis. Viral RNA was isolated
from plasma and RT-PCR targeting HIV-1 gp41 was run and
the product sequenced. Sequences were edited using
Sequencher and alignments were made using Clustal-X. A
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search on the Los Alamos HIV database yielded 106 gp41
sequences from unique Botswana patients and these were
included in the analysis. The IAS-USA, 2015 Resistance
Mutations update report was used to define the T-20 drug resist-
ance mutations.
Results A total of 154 samples were successfully sequenced,
126 from treatment naïve patients and 28 from virologic failure
patients. Additionally, 106 gp41 sequences from previous
studies conducted in Botswana were included in the analysis.
No major T-20 was detected in any of the 260 sequences. The
N42S mutation which is associated with T-20 hypersensitivity
was found in (87.3%) and this is consistent with published data
from HIV-1C studies. The I69V mutation (95.6%) was the most
common detected HR1 polymorphism. The most common
HR2 polymorphism detected was I135L (98.4%) followed by
E151A (92.3%).
Conclusions These results provide invaluable data on gp41
diversity in Botswana and show that there is no background
resistance to T-20 or its derivatives. T-20 would be an alterna-
tive drug for patients failing cART in Botswana.
PA-073 BASELINE BACTERIAL LOAD AND RIFAMPICIN
EXPOSURE ARE ASSOCIATED TO CULTURE
CONVERSION IN A TWO-MONTH STUDY OF
TUBERCULOSIS
Nyanda Ntinginya,1 Anna Framhein,2 Stella Mpagama,3 Hadija Semvua,4
Gibson Kibiki,5 Leonard Maboko,1 Michael Hoelscher,2
Norbert Heinrich2. 1NIMR-MMRC, Tanzania; 2DITM, Medical Center, LMU,
Germany; 3KIDH, Tanzania; 4KCMC, Tanzania; 5East African Health and Research
Commission, Burundi
10.1136/bmjgh-2016-000260.105
Background Early bactericidal activity (EBA) during the first
two weeks of TB treatment is an important method for early
efficacy evaluation of new anti-tuberculosis agents.
Methods We performed an observational; two-site clinical
study in Tanzania in patients with newly diagnosed pulmonary
TB during the first eight weeks of standard HRZE treatment.
Baseline and treatment-related covariates including X-ray, base-
line bacterial load and rifampicin pharmacokinetics were ana-
lysed for their correlation to treatment success.
Results From Nov 2011 to July 2013 we enrolled 74 pulmon-
ary TB patients from Moshi (41) and Mbeya (33). Mbeya parti-
cipants had a higher baseline bacterial load measured by log
time to positivity (TTP) in the MGIT culture system (median
1.29; IQR 1.09–1.46 vs 1.58; IQR 1.44–1.87; p< 0.001)
Overall, 56/68 (80%) of patients achieved a negative solid
media culture, and 28/59 (47%) achieved a negative liquid
culture at 8 weeks. Median time to negative on LJ culture was
45.5 days (IQR 21–56), in liquid culture 56 days. The strongest
association with outcome for any covariate was found for base-
line bacterial load: patients with a positive week 8 LJ culture
had a median logTTP of 1.20 (IQR 0.94–1.35); patients with a
negative week 8 culture had 1.48 (1.29–1.73; p=0.006). In
exploratory analysis, rifampicin area under the concentration
curve (AUC) was associated with shorter time to LJ culture con-
version in patients who achieved negative culture, (hazard ratio
1.05, p=0.038), but not in the total population.
Conclusions This observation EBA study using standard HZRE
was successfully implemented with methodologies thus far
established for the first time at the two Tanzanian sites. Baseline
bacterial load was confirmed as an important predictive
parameter.
PA-074 HEPATITIS B VIRUS CO-INFECTION IS ASSOCIATED
WITH INCREASED ALL-CAUSE MORTALITY AMONG
HIV-INFECTED ADULTS ON
TENOFOVIR-DISOPROXIL-FUMARATE CONTAINING
ANTIRETROVIRAL THERAPY IN LUSAKA, ZAMBIA
Michael Vinikoor,1 Roma Chilengi,1 Lloyd Mulenga,2 Callistus Kaayunga,3
Zude Zyambo,1 Mary-Ann Davies,4 Matthias Egger,5 Gilles Wandeler5. 1CIDRZ,
Zambia; 2University of Zambia, Zambia; 3Ministry of Health, Zambia; 4University of
Cape Town, South Africa; 5University of Bern, Switzerland
10.1136/bmjgh-2016-000260.106
Methods We prospectively enrolled HIV-infected treatment
naïve adults in Lusaka, Zambia. At enrolment, we recorded
patient’s demographics, body mass index (BMI), WHO clinical
stage, CD4+ count, and hepatitis B surface antigen (HBsAg)
status. In HBsAg-positive patients we measured HBV viral loads
(VL; Roche, COBAS® AmpliPrep/COBAS® Taqman® Assay,
Pleasanton, California). We defined active HBV co-infection as
having an HBV VL 320 IU/ml. TDF-based ART was the pre-
ferred first-line regimen. Follow-up visits occurred per national
guidelines and we used phone and community tracing to opti-
mise retention. Deaths were ascertained by clinic, family
member, or community health worker report and losses to
follow-up (LFTU) were defined as absences from clinic for 6+
months. Using multivariable Cox regression, we assessed the
mortality risk among patients with HBV co-infection, adjusting
for age, sex, WHO stage, BMI, and CD4+ count.
Results During 2013–2014, 822 patients were enrolled and
analysed at 1 year after ART initiation. Among this group, 438
(53.1%) were women, median age was 34 years (interquartile
range, 29–40), 367 (44.8%) had WHO stage 3 or 4, 229
(28.2%) had BMI <18.5, and median baseline CD4+ 224 cells/
mm3. Of 126 HBsAg-positive individuals, 81 had active HBV
infection. During the first year on ART, 48 patients died, 19
transferred out or withdrew, and 52 were LTFU. Those with
HBV co-infection had twice the risk of death (adjusted hazard
ratio, 2.23, 95% CI: 1.07–4.65) after adjustment for covariates.
Conclusions In Southern Africa, HBV co-infection is a mortal-
ity risk factor and these patients should be diagnosed and those
with replicating virus may need closer monitoring. Further
investigation of the causes of death in HIV-HBV patients is
needed.
PA-075 RELATIONSHIP OF HIV-HBV CO-INFECTION WITH CD4
CELL COUNT AND ALANINE TRANSAMINASE LEVELS IN
ANTI-RETROVIRAL THERAPY-NAïVE PATIENTS
Kalo Musukuma,1 Roma Chilengi,1 Rosalia Dambe,2 Benjamin Usadi,1
Michael Vinikoor1. 1CIDRZ, Zambia; 2University of Zambia, Zambia
10.1136/bmjgh-2016-000260.107
Background In sub-Saharan Africa, the prevalence of hepatitis
B virus (HBV) is between 6–20%. In Zambia, prevalence of
HIV and HBV co-infection has been reported to be between
7.1% and 31.1%. Patients infected with HBV are at increased
risk of experiencing elevated alanine transaminase enzyme
(ALT) and HIV-HBV co-infection may lead to further reduced
CD4 cell count before initiating antiretroviral therapy (ART).
We investigated the relation of HBV with CD4 cell count and
ALT enzyme in HIV-positive antiretroviral therapy-naïve
patients.
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Methods This was a cross-sectional study conducted in 15 gov-
ernment clinics in Lusaka. There were 5436 adult patients who
initiated antiretroviral therapy between 2011 and 2013. Cases
were described as HIV-positive patients who tested
HBsAg-positive and controls as HIV-positive patients who
tested HBsAg-negative. HIV-HBV co-infection was defined as
the number of patients who tested HBsAg-positive divided by
the total tested (with 95% CI). Laboratory measures of CD4
and ALT were categorised in the analysis. Elevated ALT was
defined as ALT≥66 IU/ml. CD4 cell count was dichotomised
CD4 of >200 cells/ml.
Results The median age was 35 (29–41) years. The median
CD4 cell count was 202 (102–305) cells/ml with the median
ALT being 20 (14–30) IU/ml. HIV−HBV prevalence was 12.3%
(95% CI: 11.4−13.1). Elevated ALT was reported in 11.1%
cases and 4.7% in controls (p-value <0.001). The adjusted
odds ratio (OR) of experiencing elevated ALT before ART initi-
ation for HI-HBV patients was 2.4 (95% CI: 1.8−3.2) com-
pared to their HIV-mono-infected counterparts. Of the cases,
53.5% had a CD4<200 while only 48.9% of controls had CD4
<200 before ART initiation (p-value 0.026).
Conclusions Prevalence of HBV is high among HIV-infected
persons in Zambia. There is need to explore the interactions
of these co-infections and their impact on CD4 cell count
and ALT.
PA-076 CAN HIV TREATMENTS INFORM OTHER CONTEXTS? A
TRIAL OF AN ADDITIONAL INDICATION FOR
CO-TRIMOXAZOLE PROPHYLAXIS
Moses Ngari, Johnstone Thitiri, Laura Mwalekwa, Greg Fegan, James Berkley.
KEMRI-Wellcome Trust, Kenya
10.1136/bmjgh-2016-000260.108
Background Co-trimoxazole prophylaxis is part of HIV man-
agement of opportunistic infections. However, it is not known
if co-trimoxazole prophylaxis can prevent opportunistic infec-
tions among other vulnerable population such as people with
complicated severe acute malnutrition (SAM). It is unclear if
and how nutritional recovery may reduce susceptibility to infec-
tious diseases like pneumonia with co-trimoxazole prophylaxis.
We share secondary analysis results of multicentre, double-
blinded, randomised clinical trial (ClinicalTrials. gov, number
NCT00934492) of daily co-trimoxazole prophylaxis among
HIV non-infected children with SAM in Kenya.
Methods We recruited 1781 hospitalised SAM children and
randomised to either daily co-trimoxazole prophylaxis or
matching placebo for six months and followed up for 12
months. Our outcome of interest was risk of subsequent pneu-
monia after index admission discharge, defined using the WHO
guidelines. To determine changing susceptibility after discharge,
cox regression model with monthly weight-for-height and
height-for-age z-scores as time-varying covariates were used to
identify risk factors of developing pneumonia.
Results Overall, 257 children died, 122 (14%) among the
co-trimoxazole group and 135 (15%) of placebo group; Hazard
ratio (HR) 0.90 (95% CI: 0.71−1.16, p=0.43). There were
1257 episodes of pneumonia, 603 (21%) among co-trimoxazole
group and 654 (22%) among placebo; HR 0.93 (95% CI:0.79
−1.08, p=0.34) during 1556.6 child-years of observation (cyo).
The monthly incidence rate for pneumonia and severe pneumo-
nia declined over time (p=0.002 & p=0.001). Young age,
urban residence, index admission with clinical signs of rickets
and severe pneumonia, were associated with subsequent pneu-
monia. Index admission with diarrhoea and monthly
weight-for-length z-score had protective effect. Protective effect
of improving monthly anthropometric measures were evident
from month two onwards. Proportion of pneumonia progres-
sing to severe form declined with time (p=0.01) but there was
no evidence case fatality ratios changed over time (p=0.41).
Conclusions Improving nutritional status during recovery cor-
relates directly with reduced susceptibility, but not with case
fatality of pneumonia.
PA-077 PREVALENCE AND PREDISPOSING FACTORS TO
INTESTINAL PARASITIC INFECTIONS IN HIV/AIDS
PATIENTS IN FAKO DIVISION OF CAMEROON
Dickson Nsagha. University of Buea, Cameroon
10.1136/bmjgh-2016-000260.109
Background Understanding the epidemiology of intestinal para-
sitic infections is essential for the effective management of HIV
infection in areas where intestinal parasites are also endemic.
Data on the prevalence of intestinal parasitic infections in
people living with HIV/AIDS in Cameroon are scarce. This
study was designed to determine the prevalence of intestinal
parasitic infections, as well as assess the predisposing factors for
the infections in HIV/AIDS patients in Fako division of
Cameroon.
Methods Stool specimen was collected from consented partici-
pants and examined for ova, cysts, larvae or oocytes using the
Kato-Katz, Formalin-Ether Concentration, Modified
Ziehl-Neelsen and Modified field staining techniques. Statistical
analyses performed included the Chi-square test and logistic
regression.
Results At the end of the study, 300 participants were enrolled,
the majority being females 236 (78.6%). The participants were
between 21–70 years (mean±SD=40±10) of age. The overall
prevalence of intestinal parasites was 82.6% (95% CI: 78.4–
87.0). The prevalence of infection was associated with age,
being more prevalent in the age group 51–60 years (p=0.032).
Intestinal protozoa were more prevalent than intestinal hel-
minthes (74.3% vs 11.3%). The parasites isolated included:
Cryptosporidium parvum (44.0%), Blastocystis hominis
(25.0%), Microsporidium spp. (21.0%), Entamoeba histolytica
(7.3%), Ascaris lumbricoïdes (4.3%), Isospora belli (4.3%),
Trichuris trichiura (2.3%), hookworm (2.7%), Hymenolepis
nana (1.3%), Strongyloïdes stercoralis (0.7%), Cyclospora caye-
tatensis (3.7%) and Giardia lamblia (3.3%). The predisposing
factors for infection with intestinal parasites included poor edu-
cational background (OR=0.33, p=0.02), unskilled worker
(OR=0.27, p=0.04), a well as source of drinking water
(OR=2.6, p=0.03), and living with cats as pets (OR=3.06,
p=0.01).
Conclusions A very high prevalence of intestinal parasitic infec-
tions was observed in people living with HIV/AIDS. Routine
screening for intestinal parasites should be instituted as part of
HIV care in Fako division of Cameroon to improve the manage-
ment of HIV/AIDS.
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PA-078 IMPACT OF COMMUNITY TRACING ON HIV COHORT
OUTCOMES IN URBAN ZAMBIA
Virginia Munamunungu,1 Carolyn Bolton,1 Alice Siyunda,1 Jacinta Shilimi,1
Roma Chilengi,1 Gilles Wandeler,2 Michael Vinikoor1. 1CIDRZ, Zambia; 2University
of Bern, Switzerland
10.1136/bmjgh-2016-000260.110
Background We investigated the impact of community tracing
as recommended in national guidelines on outcomes within a
prospective HIV cohort in Zambia.
Methods HIV-positive, antiretroviral therapy-naïve adults were
enrolled at 2 Lusaka clinics. Per national guidelines we collected
detailed baseline patient locator information including patient
phone number, address, church, and a map from the clinic to
their home. Study visits were aligned with routine ART
program schedules and 3 telephonic attempts were made if
visits were missed. Per guidelines, a lay health worker conducted
a community home visit on lost to follow-up (LTFU) patients.
Transfers to other clinics and deaths were ascertained when
reported by the clinic staff, patients, or family members. At one
year, we measured the percentage retained, transferred out,
withdrawn (stopped ART), dead, and LTFU (>6 months
absent). A lay health worker went into the community to make
a home visit on LTFU patients. We recorded the change in mor-
tality after tracing. We also estimated the time and costs per
patient traced.
Results We enrolled 795 patients (median age 34 years; 53.7%
were female; median CD4 228 cell/mm3). Prior to tracing, we
recorded 45 deaths, 23 transfers, 1 withdrawal, and 83 LTFU
who could not be reached by phone. At 63 attempted home
visits, we learnt that 9 (14.3%) had died, 5 (7.9%) had trans-
ferred, and 2 had withdrawn. We could not locate 32 (50.8%)
but neighbours/family reported that 12 of these had relocated
(HIV care status unknown). After successful tracing, 15 (23.8%)
returned to clinic and HIV care. Community tracing increased
known mortality from 5.7% to 6.8% (95% CI: 5.1–8.8%) and
increased retention at 1-year from 80.9% to 82.8%. Tracing
required an average of 5 person-hours and K150.00 (∼15 USD)
in bus/taxi fares per patient.
Conclusions Community tracing was limited by patient mobil-
ity and had a modest impact on cohort mortality and retention.
PA-079 PREDICTORS OF RETENTION IN CARE OF HIV-INFECTED
ADULTS IN TIGRAY, ETHIOPIA: A PROSPECTIVE COHORT
STUDY
Raffaella Bucciardini,1 Vincenzo Fragola,1 Teshome Abegaz,2 Stefano Lucattini,1
Atakilt Halifom,3 Eskedar Tadesse,2 Micheal Berhe,2 Katherina Pugliese,1 Paola
De Castro,1 Roberta Terlizzi,1 Luca Fucili,1 Massimiliano Di Gregorio,1 Marco Mirra,1
Teame Zegeye,3 Andrea Binelli,1 Stefano Vella,1 Loko Abraham,2
Hagos Godefay3. 1ISS, Italy; 2Mekelle University, Ethiopia; 3Tigray Regional Health
Bureau, Ethiopia
10.1136/bmjgh-2016-000260.111
Background HIV/AIDS represents one of the major health chal-
lenges of Ethiopia, despite a proven record of universal access to
HIV care and treatment. Long-term antiretroviral therapy (ART)
retention is a key factor for personal and public health benefits.
Identification of determinants of attrition is needed to design
appropriate interventions.
Methods We used data from the CASA project, a prospective,
multisite study of a cohort of HIV-infected patients who started
ART in seven urban and rural health facilities located in the
Tigray. We analysed the retention in care and its associated deter-
minants in over 1000 patients followed for two years. The main
outcome measure was the retention in care rate, defined as the
proportion of patients alive and receiving ARTat the same health
facility as at ART initiation. Kaplan-Meier method was used to
estimate the probability of retention at different time points. Cox
Proportional Hazards model with robust sandwich estimates to
account for within health facility correlation was used to identify
factors associated with retention.
Results Kaplan–Meier estimates of retention in care were
83.9%, 80.6% and 77.6% at 12, 18 and 24 months of follow-up,
respectively. Attrition was mainly due to lost-to-follow-up and
transferred-out patients. Multivariate Cox proportional hazard
model showed that being male (HR 1.35, 95% CI: 1.04–1.75),
CD4 count<200 (HR 1.49, 95% CI: 1.13–1.96), haemoglobin
level <= 10 (HR 1.40, 95% CI: 1.11–1.76), the presence of
active TB co-infection at ART initiation (HR 1.47, 95% CI:
1.04–2.08) and the type of health facility were significantly asso-
ciated with attrition.
Conclusions According to our prospective data, combined inter-
ventions aimed to improve ARTretention shall include expansion
of HIV testing and earlier initiation of therapy, nutrition supple-
mentation, early detection and treatment of TB. Observed reten-
tion differences among health facilities and according to gender
suggest that innovative models of HIV care shall also be
explored.
PA-080 CRYPTOCOCCAL MENINGOENCEPHALITIS IN
HIV-INFECTED PATIENTS IN MADAGASCAR: HIGH
PREVALENCE AND LETHALITY AND THERAPEUTIC
CHALLENGES
Rivo Rakotoarivelo,1 Mihaja Raberahona,2 Njary Randriamampionona,3
Rabezanahary Andriamihaja,4 Tahinamandranto Rasamoelina,3 Muriel Cornet,5
Mamy Jean De Dieu Randria,2 Thomas Benet,6 Philippe Vanhems,6 Mala
Rakoto Andrianarivelo3. 1CHU Tambohobe Fianarantsoa, Madagascar; 2HUJR de
Befelatanana, Madagascar; 3CICM, Madagascar; 4CHU Analakininina, Madagascar;
5CHU de Grenoble, France; 6HEH, France
10.1136/bmjgh-2016-000260.112
Background In Madagascar the epidemiology of cryptococcosis
is poorly documented. The main objective of this study was to esti-
mate the prevalence of Cryptococcal meningoencephalitis (CM) in
Madagascar and to describe the presentation of the cases.
Methods This is an observational transverse study conducted in
the hospitals of Antananarivo and Toamasina cities. Between 3
November 2014 and 8 June 2016, HIV-infected adults presenting
CD4 cell count ≤200/mm3 were selected. The crytococcocal
antigen (CrAg) was screened in the blood using a lateral flow
immunoassay (IMMYCrAg® LFA). If the result was positive and
the patient symptomatic, CrAg was checked in the cerebrospinal
fluid (CSF) and examined with India ink, and culture was per-
formed. The isolated strains were subsequently analysed using
MALDI-TOF and an antifungal susceptibility test was performed
using the E-test method (BioMérieux).
Results Overall, 118 patients were included. The mean CD4 cell
count was 86.4/mm3 (SD±60.6) and 35.6% of the patients were
under ARV therapy at baseline. HIV-1 viral load of 88.5% of
patients was positive. We compared the clinical characteristics of
patients with cryptococcal infections to those of controls without
CM. Eleven cases of CMwere identified corresponding to a preva-
lence of 15.1% (95% CI: 7.8–25.4%). Cryptococcus neoformans
var. grubii (serotype A) was isolated. Fever, headache, neck pain
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and night sweats were the most common signs. In 7 cases, CrAg
titres in the CSF were very high (≥2560) and did not decrease
even 2 months post-treatment. The Case Fatality Rate was
unacceptably high (69%).
Conclusions Overall, prevalence of cryptococcal meningo-
encephalitis (CM) in Madagascar was very high (15.1%) com-
pared to that observed in some Sub-Saharan African countries.
The point-of-care LFA CrAg test was confirmed to be reliable and
cost-effective for the diagnosis. Challenges to facilitate access to
more effective molecules to treat patients with CM include heavy
administrative formalities linked to drug importation and low level
of priority in implementing the national control programme.
PA-081 FACTORS AFFECTING ANTIRETROVIRAL DRUG
ADHERENCE AMONG HIV ADULT PATIENTS ATTENDING
HIV CLINIC AT THE UNIVERSITY TEACHING HOSPITAL
IN LUSAKA
Uchizi Chirwa,1 Charles Michelo,1 Rosalia Dambe,1
Raymond Hamoonga2. 1University of Zambia, Zambia; 2Zambia Institute of Animal
Health, Zambia
10.1136/bmjgh-2016-000260.113
Background Effectiveness of anti-retroviral therapy (ART)
requires strict adherence. Adherence ≥95% achieves optimum
therapeutic levels and reduces drug resistance. We sought to
determine factors associated with ART adherence within the
context of patient demographics and factors, and explore care
treatment and support strategies used by patients and health
workers.
Methods A Mixed Method Sequential Explanatory Design
(MMSED) was employed to study adult patients receiving ART
from the University Teaching Hospital, Lusaka. Adherence was
measured by missed clinic appointments and pharmacy collec-
tions over the last six months. The quantitative method assessed
715 complete pharmacy records extracted from the dispensing
tool to ascertain demographic and patient factors. Bivariate and
multivariate logistic regression analysis was employed.
Qualitative research involved in-depth interviews with patients
and key informants.
Results Results showed 79.4% of the patients were adherent to
clinical appointments while 46.3% were adherent to pharmacy
refills. Multivariate analysis showed lower adherence amongst
the widowed on clinical appointments (OR=0.3; 95% CI: 0.1–
0.9). The stepwise regression analysis revealed significant factors
for adherence on clinical appointment and pharmacy refills for
widowed, co-habiting and no education, (p=0.008, p=0.044,
and p=0.018), respectively. About 80% of patients interviewed
were adherent to ART.
Conclusions The results show moderate ART adherence (80%).
However, in view of the identified factors affecting adherence,
concerted and collaborative efforts through effective and effi-
cient interventions are needed to improve the adherence levels
to at least ≥95%.
PA-082 IMPROVING TUBERCULOSIS SCREENING AND
DIAGNOSIS AMONG PEOPLE WITH HIV: UPDATES
FROM THE INTENSIFIED CASE FINDING STUDY IN
KISUMU COUNTY, KENYA
Steve Wandiga,1 Patience Oduor,1 Janet Agaya,1 Albert Okumu,1 Aditya Sharma,2
Sean Cavanaugh,2 Kevin Cain2. 1KEMRI, Kenya; 2CDC, United States of America
10.1136/bmjgh-2016-000260.114
Background Tuberculosis (TB) is the leading opportunistic
infection and cause of death among people living with HIV
(PLHIV). HIV predisposes latently TB-infected people to devel-
oping TB disease. Current TB screening algorithms lack sensitiv-
ity and specificity. We sought to determine the sensitivity and
specificity of conducting a two-step clinical screening and
testing for latent TB infection (LTBI).
Methods We enrolled 650 newly diagnosed HIV patients aged
>7 years from HIV clinics in Kisumu County, Kenya. Study par-
ticipants were screened for TB symptoms and sputum tested for
smear microscopy, liquid culture and GeneXpert MTB/RIF
(Xpert). Quantiferon (QFT) and tuberculin skin testing (TST)
for LTBI. Positive results from liquid culture or Xpert defined a
TB case. ‘Negative for TB’ was any participant with at least two
negative Xpert or culture results from different specimens.
Sensitivity, specificity, positive predictive value (PPV) and nega-
tive predictive value (NPV) were calculated and compared for
one – and two – stage screening and stratified by QFT results.
Results Females were 62% of participants. TST-positive were
88 of 592 (15%); 274 of 648 (42%) were QFT-positive. TB
prevalence was 15%. Screening results for one stage and second
stage: 75% and 97% sensitivity, 31% and 12%, specificity, 89%
and 96% NPV and 14% and 15% PPV, respectively. Screening
performance stratified by QFT for sensitivity, specificity, NPV
and PPV was 96%, 11%, 91% and 24% among QFT-positive.
Conclusions Two-step versus one-step screening increases sensi-
tivity but reduces specificity. Positive QFT result increases the
PPVof two-step screening.
PA-083 PREVALENCE AND FACTORS ASSOCIATED WITH
HYPOCHOLESTEROLAEMIA AMONG ADULTS WITH
PULMONARY TB AT DIAGNOSIS AND DURING TB
TREATMENT IN KAMPALA
John Mukisa, Ezekiel Mupere, William Worodria. Makerere University, Uganda
10.1136/bmjgh-2016-000260.115
Background Hypocholesterolaemia is associated with altered
immune function, possible delayed conversion at two months,
and increased risk of mortality. However, lipid profiles are not
done routinely for tuberculosis (TB) patients and there is
paucity of data regarding the prevalence of hypocholesterolae-
mia and its associated factors among adult bacteriologically-
confirmed pulmonary tuberculosis patients.
Methods This was a cross sectional study that consecutively
enrolled 323 participants at diagnosis, 2, 5, 6 and 8 months of
TB treatment, between February and April 2016. Physical exam-
ination and a structured questionnaire (administered by an inter-
viewer) were used for data collection. Lipid profiles were
determined from fasting blood samples from participants.
Descriptive statistics were used to describe the patterns of dysli-
pidaemias and prevalence of hypocholesterolaemia.
Log-binomial regression methods were used to determine the
independent factors associated with hypocholesterolaemia.
Results Hypocholesterolaemia was identified in 140/323
(43.3%, 37.9–48.8) of adults with pulmonary TB with a high
prevalence among those at diagnosis, 51/91 (56.0%, 45.8–66.3)
but a lower prevalence among those who were at completion of
treatment: 19/59 (32.2%, 20.9–44.3). On multivariate analysis,
male gender (PR 1.57, 95% CI: 1.16–2.06), diabetes (PR 1.37,
95% CI: 1.05–1.78) and duration of anti TB treatment (1.12,
1.07–1.20) were associated with hypocholesterolaemia. There
was no significant association between HIV infection status,
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presence of cavities on chest x-ray and hypocholesterolaemia at
diagnosis and during anti-TB treatment in this study.
Conclusions The overall prevalence of hypocholesterolaemia
among participants was high. Males with pulmonary tubercu-
losis are 60% more likely to develop hypocholesterolaemia.
There is a need for further research on dyslipidaemias in TB
patients and policy improvements regarding assessment of these
lipids and nutritional management.
PA-084 GENOTYPIC DIVERSITY AND DRUG SUSCEPTIBILITY
PATTERNS AMONG M. TUBERCULOSIS COMPLEX
ISOLATES RESPONSIBLE OF EXTRAPULMONARY
TUBERCULOSIS IN CAMEROON FROM 2006–2015
Justice Trésor Ngom,1 Francioli Koro,1 Celestin Godwe,1 Clemence Adande,1
Romaric Ateugieu,1 Tatiana Onana,1 Annie Ngono,1 Yannick Kamdem,2
Sara Ngo-Niobe,2 François-Xavier Etoa3. 1University of Douala, Cameroon; 2Centre
Pasteur, Yaoundé, Cameroon; 3University of Yaoundé I, Cameroon
10.1136/bmjgh-2016-000260.116
Background Extrapulmonary tuberculosis can cause major irre-
versible health complications if it is diagnosed late and not well
treated. In Cameroon, it remains neglected with very few data
concerning its different forms, causing species and their drug sus-
ceptibility, while these data may help to understand the global
epidemiology of tuberculosis in Cameroon.
Methods We have made a retrospective study on 215 clinical iso-
lates stored in Centre Pasteur of Cameroon. Isolates were geno-
typed using spoligotyping to identify lineages and families, and
the drug susceptibility patterns were determined through propor-
tion method.
Results The primary resistance rate of isolates was 12.5%,
among which 3.12% were mono-resistant to isoniazid, 1.56% to
rifampicin and 3.9% to streptomycin. No mono-resistance was
recorded for ethambutol. Multidrug-resistance rate to at least iso-
niazid and rifampicin was 3.12%. Spoligotyping revealed that
97.67% (210/215) and 2.32% (5/215) of extrapulmonary tuber-
culosis was caused by Mycobacterium tuberculosis and of M. afri-
canum, respectively. M. bovis was absent. Spoligotyping lineages
identified among the M. tuberculosis complex (MTC) showed a
dominance of Cameroon family (40.46%). The other families
were the ubiquitous T (36.27%), Haarlem (13.95%), U (6.04%)
and LAM (1.39%). Ten spoligotypes had no SIT numbers. Only
M. tuberculosis strains were associated to resistance. But there
was no significant difference for drug resistance between MTC
lineages.
Conclusions To the best of our knowledge, this study is the first
to give the population structure of MTC strains causing extrapul-
monary tuberculosis (ETB) and their drug susceptibilities. That
shows the predominance of M. tuberculosis species and the very
low contribution of M. africanum and M. bovis as the causative
agent of ETB. It also shows that the population structure of this
MTC is similar to that observed in pulmonary tuberculosis sug-
gesting the dissemination of the pulmonary tuberculosis.
PA-085 ETHICAL CONSIDERATIONS IN THE HANDLING OF A
COMPLAINT REPORT AGAINST A STUDY TEAM: CASE
OF A CLINICAL TRIAL (EARNEST) PARTICIPANT
Muchineripi Kanengoni, Sithembile Ruzario, Paul Ndebele, Melody Shana,
Fadzai Tarumbiswa, Rosemary Musesengwa, Rutendo Gutsire. MRCZ, Zimbabwe
10.1136/bmjgh-2016-000260.117
Background The major role of an ethics committee is to
protect participants from harm through participating in a health
research study. This includes investigating participant complaints
to ensure that their wellbeing is being upheld and queries
resolved satisfactorily. In this case, one clinical trial participant
passed away and a report implying that her death was caused by
trial medication received during participation was published by
WEMOS foundation. This necessitated the National Ethics
Committee (NEC) in Zimbabwe to investigate the case to under-
stand and come up with resolutions.
Methods A case study design was used to investigate the case.
Interviews with 5 conveniently selected study staff based on
their involvement and roles in the study were conducted.
Review of participant study records, the protocol, the WEMOS
report, Serious Adverse Event reports and Data Safety and
Monitoring Board reports were conducted. The investigation
was used to determine which ethical principles applied and
whether they were adhered to or not in the handling of the par-
ticipant by the research staff.
Results Results indicated that the research team adhered to the
necessary ethical principles enshrined in the major ethical codes
and local Zimbabwean research ethics regulations for the
conduct of clinical trials. Investigation showed that the report
was mainly based on incomplete information and contradicted
the actual events at the study site. There was also no record of
the participant’s complaint with NEC in the complaint register.
Appropriate standard of care was given to the participant.
Conclusions The NEC continues to protect the rights of clin-
ical trial participants by investigating complaints against study
teams as their wellbeing is of primary importance. Researchers
are being encouraged to adhere to best practises in conducting
human participant researches. The media should also be
engaged actively so that reporting is accurate to prevent incor-
rect information being relayed to the public.
PA-086 A REVIEW OF REGULATORY CAPACITY
STRENGTHENING IN AFRICA IN HIV RESEARCH: THE
NEED FOR A NEW PARADIGM
Kevin Fisher,1 Prince Bahati,2 Bargavi Thyagarajan3. 1AVAC, United States of
America; 2IAVI, Kenya; 3Global HIV Vaccine Enterprise, United States of America
10.1136/bmjgh-2016-000260.118
Background Recent African initiatives suggest the need for new
direction in capacity building and support for regulatory review
of HIV prevention research. The African Vaccine Regulatory
Forum recently harmonised practices to strengthen regulatory
oversight and helped create the African Medicines Agency
scheduled to be launched in 2018. The African Union, working
through the New Partnership for Africa’s Development, took a
major step in 2016 adopting the African Union Model Law on
Medical Product Regulation. These steps, as well as the work of
the African Medicines Regulatory Harmonisation Programme,
raise the question of how best to effect regulatory capacity
building in this new environment.
Methods This paper assesses the evolving role of support for
African regulatory systems using a desk review of various regula-
tory strengthening activities currently underway or planned,
with focus on Africa. This review was supplemented by inter-
views with key informants related to activities intended to
support regulatory capacity building in low- and middle-income
countries focused upon efforts that were of potential assistance
to HIV vaccine development. This analysis supplements findings
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from a Regulatory Capacity Building Workshop held in Rwanda
in 2015.
Results External capacity building efforts need to be responsive
to new and/or recent priorities and mechanisms by African
entities regarding the strengthening and coordination of regula-
tory systems. Current capacity building efforts will benefit from
coordination and information sharing geared toward new initia-
tives, as well as focus around ethics review.
Conclusions Remarkable progress is being made towards the
development of a safe and effective HIV prevention options,
and several HIV vaccine efficacy trials are planned over the next
few years. Recent ambitious African regulatory initiatives hold
the potential to expedite review. It is time for capacity building
efforts to consider how best to support the new coordinated
and regional regulatory systems being developed and launched
over the next few years.
PA-087 PREVALENCE OF HBV, HIV, AND HIV-HBV
CO-INFECTIONS AMONG HEALTHCARE WORKERS IN
IBADAN, NIGERIA
Oluyinka Opaleye, Olusola Akanbi, Michael Binuyo. LAUTECH, Nigeria
10.1136/bmjgh-2016-000260.119
Background HIV and HBV are endemic in Nigeria. HBV is glo-
bally the leading cause of death due to liver disease amongst
HIV-infected persons. The study was done to ascertain the
prevalence rate of HIV, HBV and HIV-HBV co-infections
amongst health care workers in Ibadan, Nigeria.
Methods A total of 217 healthcare workers working in large
hospitals in Ibadan, Nigeria were signed up for the study. The
socio-demographical data of the health care workers were col-
lected using a questionnaire. HIV antibodies were evaluated
using Stat Pak HIV test strips and HBV was evaluated using the
ABON HBsAg test strips.
Results There were 85 (39.2%) male and 132 (60.8%) female
health care workers. Most were 21–35 years of age (109/217,
50.2%). Of the 217 health care workers 103(47.5%) and 21
(9.7%) were positive for HBsAg and HIV, respectively, while 3
(1.4%) had HIV-HBV co-infections. The prevalence of HBV
infection was statistically significant (p<0.005) over HIV infec-
tion. Health care workers with ‘other’ level of education had
the most predominant HBV prevalence (58/83, 69.9%,
p=0.0267) while those with primary level of education had the
highest HIV prevalence (2/12, 16.7%, p=0.0267. Females had
the most predominant HBV (72/132, 54.5%) and HIV (17/132,
12.9%) (p=0.03). HIV was highest in age groups <20 years (2/
16, 12.5%). Only widows/widowers (33.3%) had the highest
HIV-HBV co-infection rates. Presence of tattoo in any part of
the body, hepatitis B vaccination was significantly associated
(p< 0.05) with HBV seropositivity among health care workers.
Conclusions This study reveals a high prevalence of HIV, HBV
and HIV-HBV co-infections among female health care workers.
From our finding, the high infection rates of HBV and HIV
noted amongst health care workers indicate the need to regu-
larly screen this group for these viruses to reduce the further
transmission of these viral infections.
PA-088 DO XPERT MTB/RIF CYCLE THRESHOLD VALUES
PROVIDE INFORMATION ABOUT PATIENT DELAYS FOR
TUBERCULOSIS DIAGNOSIS?
Willy Ssengooba,1 Durval Respeito,2,3 Edson Mambuque,2,3 Silvia Blanco,2
Inacio Mandomando,2,3 Bouke De Jong,4 Frank Cobelens,1
Alberto Garcia-Basteiro2,3. 1AIGHD, The Netherlands; 2ISGlobal Barcelona, Spain;
3CISM, Mozambique; 4ITM Antwerp, Belgium
10.1136/bmjgh-2016-000260.120
Background Early diagnosis and initiation to appropriate treat-
ment is vital for tuberculosis (TB) control. The Xpert MTB/RIF
(Xpert) assay offers rapid TB diagnosis and quantitative estima-
tion of bacterial burden through Cycle threshold (Ct) values.
We assessed whether the Xpert Ct value is associated with
delayed TB diagnosis as a potential monitoring tool for TB
control programme performance.
Methods This analysis was nested in a prospective study under
the routine TB surveillance procedures of the National TB
Control Program in Manhiça district, Maputo province,
Mozambique. Presumptive TB patients were tested using smear
microscopy and Xpert. We explored the association between
Xpert Ct values and self-reported delay of Xpert-positive TB
patients as recorded at the time of diagnosis enrolment. Patients
with >60 days of TB symptoms were considered to have long
delays.
Results Of 1483 TB presumptive cases, 580 were diagnosed as
TB of whom 505 (87.0%) were due to pulmonary TB and 302
(94.1%) were Xpert positive. Ct values (range, 9.7–46.4)
showed a multimodal distribution. The median (IQR) delay was
30 (30–45) days. Ct values showed no correlation with delay
(R2=0.001, p=0.621), nor any association with long delays:
adjusted odds ratios (AOR) (95% CI) comparing to >28 cycles
0.99 (0.50–1.96; p=0.987) for 23–28 cycles, 0.93 (0.50–1.74;
p=0.828) for 16–22 cycles; and 1.05 (0.47–2.36; p=0.897) for
<16 cycles. Being HIV-negative (AOR [95% CI]), 2.05 (1.19–
3.51, p=0.009) and rural residence 1.74 (1.08–2.81, p=0.023),
were independent predictors of long delays.
Conclusions Xpert Ct values were not associated with patient
delay for TB diagnosis and cannot be used as an indicator of TB
control program performance.
PA-089 CHILD PROTECTION AND DEVELOPMENT: ADDRESSING
THE PROBLEMS OF HIV/AIDS ORPHANS – A CASE
STUDY IN BAHIR DAR TOWN, ETHIOPIA
Ayele Tamene. Bahir Dar University, Ethiopia
10.1136/bmjgh-2016-000260.121
Background HIV/AIDS has continued to be a world social, eco-
nomic and political threat. Recent findings indicated that cur-
rently 34 million people are living with HIV/AIDS. Sub-Saharan
countries are particularly vulnerable to this pandemic.
Ethiopia’s HIV/AIDS epidemic pattern marked regional varia-
tions across urban and rural areas. Ethiopia which is one of the
largest populations in Africa has the highest number of orphans.
The proportion of orphan children due to AIDS is also alarm-
ingly increasing in this country. It increased from 26% to 43%
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in Ethiopia in 2001 to 2010. The situation of AIDS orphans
have become a serious problem in Ethiopia.
Methods A qualitative method of study, particularly a phenom-
enological approach, was used to guide the study. Data were col-
lected through interviews, focus group discussions and case
studies. In addition, a secondary review of documents such as
reports, annual and strategic plans was done.
Results The study indicated that there are variations in the
number of orphans across kebeles of the town. The Shinbit
kebele has the highest number of orphans, both male and
female. In Bahir Dar various forms of service are rendered to
orphans living with HIV/AIDS such as psycho-social support,
educational and medical support, economic strengthening
through guardians, home to home support, legal support, voca-
tional and skill development training.
Conclusions In Bahir Dar, various forms of service are ren-
dered to HIV/AIDS orphans such as psycho-social support, edu-
cational and medical support, economic strengthening through
the guardians, legal support, vocational and skill development
training. These methods of addressing HIV/ AIDS orphans form
a fragmented, only need-based approach, and are far from a
right-based approach as they lack institutional networking, sus-
tainability and community ownership. Therefore, in order to
meet one of the objectives of the Cross–Cutting Sectors
Development Plan of the Growth and Transformation Plan, it is
recommended to address the multifaceted problems of AIDS
orphans in an integrated and sustainable way.
PA-090 UNDERSTANDING PATIENT DECISIONS TO TRANSFER
OR DISENGAGE FROM HIV CARE AND TREATMENT IN
ZAMBIA
Stephanie Topp,1 Chanda Mwamba,2 Laura Beres,3 Nancy Padian,4
Izukanji Sikazwe,2 Elvin Geng,4 Charles Holmes3. 1James Cook University, Australia;
2CIDRZ, Zambia; 3Johns Hopkins University, United States of America; 4University of
California San Francisco, United States of America
10.1136/bmjgh-2016-000260.122
Background Despite widespread roll-out of free HIV care and
treatment (C&T), large numbers of HIV-positive Zambians are
disengaged from care. Nested within a 4-province study of HIV
C&T outcomes, we explored how interactions between system
hardware (tangible components) and system software (normative
& behavioural components) at the service-delivery level influ-
enced patients’ decision to transfer or disengage from care.
Methods In-depth interviews were conducted with a stratified
random sample of 75 HIV-infected adults from 4 provinces and
five patient categories: currently in-care, pregnant in-care, disen-
gaged, transferred (to another facility), friend/ family of
deceased patient. Sixteen focus group discussions were con-
vened with lay and professional healthcare workers (HCW) pro-
viders serving the same catchment areas. Audio transcripts were
translated, transcribed and subject to deductive and inductive
analysis guided by a modified social-ecological framework.
Results Health system ‘hardware’ factors influencing patient
decisions included distance and chronic understaffing that
resulted in long wait-times and administrative mistakes (e.g. loss
of patient records). Health system ‘software’ factors included
various aspects of clinic organisational culture. Examples are
limited consideration of HCWs of the way employment or
family circumstances affected patients’ ability to adhere to
protocol-driven treatment schedules and a harmful power
dynamic that compelled patients to ‘humble’ themselves and
‘obey’ HCWs to avoid being ‘punished’. Described by many as a
problem of HCWs ‘lacking heart’ or ‘having a bad attitude’,
these phenomena were often linked to experiences of disrespect
and/or abuse that influenced decisions to transfer or leave C&T.
Conclusions Findings demonstrate a dynamic and compound-
ing effect of health system ‘hardware’ and ‘software’ factors on
decisions to transfer/disengage. Data suggest a need for: i)
improvements in physical resourcing and structuring of HIV ser-
vices; ii) a move away from exclusively static clinic-based service
models and iii) revisions to policy enabling a re-orientation of
pre-service training, clinic leadership and workplace incentives
to encourage health-promoting, person-centred care.
PA-091 MEETING FIELD-BASED CHALLENGES: INNOVATIVE
APPROACHES TO COLLECTING DRY BLOOD SPOT
SAMPLES IN THE COMMUNITY
Kombatende Sikombe,1 Cardinal Hantuba,1 Nancy Czaicki,2 Elvin Geng,3
Charles Holmes,1 Kalo Musukuma,1 Sandra Simbeza,1 Paul Somwe,1
Izukanji Sikazwe1. 1CIDRZ, Zambia; 2University of California, Berkley, United States
of America; 3University of California, San Francisco, United States of America
10.1136/bmjgh-2016-000260.123
Background Community collection of dry blood spots (DBS) is
ideal to capture viral load results from HIV-positive, patients
lost to follow-up (LFTU) in order to monitor their health. We
sought to optimise protocols for high-quality community-based
DBS collection in resource-constrained settings such as Zambia.
Methods As part of a nested case-control study, we trained 23
non-medical interviewers who collected DBS from LTFU
patients in rural and urban Lusaka. We visited another Zambian
community-based DBS study improving upon their approach
through team-based problem solving methods. We evaluated our
innovation through field observations, bi-weekly meetings, inter-
viewer reports, and two debriefing meetings. The laboratory
assessed DBS quality for testing validity.
Results We transformed a first-aid box into a phlebotomy box
to keep DBS contamination free and in ambient temperature. A
styrofoam partition separated the DBS drying rack glued to one
side of the box from phlebotomy supplies and kept DBS cards
horizontal during transportation. Interviewers collected 229
DBS (60.6%) in participant homes or place of their choice with
149 refusals. DBS was air-dried in an area free of direct sun-
light, water, insects and dust for a few minutes so blood was not
flowing when placed on the rack. DBS was taken to the nearest
health facility for further drying using public transport, or study
motorbikes fitted with a custom made carrier to hold the box
horizontal. The laboratory did not report any blotted or double
spotted DBS cards. Barriers included privacy, visibility and
awkward box size.
Conclusions We optimised community-based DBS collection in
Zambia using non-medical staff and an innovative, low-cost
light-weight phlebotomy box to transport DBS without contam-
ination at ambient temperature. While we successfully collected
DBS from 60.6% of found LTFU patients, concerted efforts are
needed to re-engage LTFU patients who refuse HIV-related pro-
cedures even when made conveniently available.
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PA-092 CHANGES IN VAGINAL PRACTICES AFTER
CONTRACEPTIVE VAGINAL RING USE AMONG WOMEN
IN KIGALI, RWANDA
Michele Umulisa,1 Jennifer Ilo,2 Evelyne Kestelyn,3 Mireille Uwineza,1
Stephen Agaba,1 Therese Delvaux,4 Janneke Wijgert5. 1Rinda Ubuzima, Rwanda;
2Partners in Health, Rwanda; 3OUCRU, Vietnam; 4ITM Antwerp, Belgium;
5University of Liverpool, United Kingdom
10.1136/bmjgh-2016-000260.124
Background Recent developments in HIV prevention, includ-
ing the dapivirine vaginal ring, have shown promising results in
protecting women from HIV. Additionally, a healthy vagina is
protective against HIV/STIs but vaginal practices can disturb the
vaginal environment. The objective of this study was to explore
vaginal practices and assess the changes during contraceptive
vaginal ring (CVR) use among Rwandan women.
Methods Rinda Ubuzima, a research site in Kigali, Rwanda,
collected data on vaginal practices using mixed methods
(in-depth interviews, observations, focus group discussions,
surveys) during a safety and acceptability study of CVRs.
Education about safe vaginal practices was provided at study
visits after baseline. Descriptive and thematic analyses were con-
ducted.
Results At baseline, 57% of the 289 participants reported
washing inside and outside the vagina while 124 (43%) reported
washing outside only. 65% of those washing inside and outside
the vagina reported doing so once a day. Participants reported
washing inside the vagina while bathing (93%), after sex (63%),
and during menses (54%). A total of 157 (96%) participants
reported inserting water and/or soap with fingers into the
vagina. Qualitative data suggested that vaginal practices went
beyond those listed in the survey and included herbs, stones,
gels, and food in order to increase vaginal lubrication and tight-
ness, treat vaginal symptoms, and clean the vagina. Only 14 of
the 120 (12%) women reported a reduction/increase in their
vaginal practices following ring insertion. However, after
triangulation of data, over 25% of the participants
reported changes in their vaginal practices resulting from study
participation.
Conclusions Vaginal cleaning is frequent among the study
population and increased education from the research site about
vaginal practices encouraged some women to change their
behaviour during the short duration of the study. Additionally,
there are more vaginal practices that may need consideration for
ring development and rollout in Rwanda.
PA-094 AGREEMENT OF QUANTIFERON TEST AND TUBERCULIN
SKIN TEST IN DIAGNOSING LATENT TUBERCULOSIS
INFECTION AMONG HIV-INFECTED PEOPLE IN KISUMU
COUNTY, KENYA
Patience Oduor, Dickson Gethi, Lazarus Odeny, Janet Agaya, Steve Wandiga.
KEMRI, Kenya
10.1136/bmjgh-2016-000260.125
Background HIV-infected people are at greatest risk of progres-
sion from latent tuberculosis infection (LTBI) to development of
active tuberculosis (TB) disease. Accurate diagnosis and treat-
ment of LTBI in this group is an essential component of the
WHO TB control strategy. Interferon-gamma assays have
emerged as novel alternatives to the tuberculin skin test (TST)
for the diagnosis of LTBI. Comparable performance for these
two tests is not fully evaluated in regions with high incidence of
HIV and TB. We compared the performance of QuantiFERON
TB-Gold In-tube® assay (QFT) and TST tests for LTBI.
Methods Newly diagnosed HIV patients older than 7 years
were enrolled from HIV clinics. Blood was drawn for QFT
assay, thereafter TST was placed into the volar surface of the
forearm. The TSTwas read at 48–72 hours and deemed positive
at >or=5 mm. Statistical analyses were performed using SAS
9.2. Agreement evaluated using kappa (k) statistic.
Results Of the 650 HIV-infected participants, 62% were
females; median age (IQR) was 32 (26–39). Among 592 (91%)
who received TST, 88 (17%) were positive; QFT positives were
274 (42%). Indeterminate QFT results were 22 (3%). Overall
agreement between QFT and TSTwas 37% (95% CI: 30–45%).
Agreement was 56% (95% CI: 30–45%) and 15% (95% CI:
30–45%) for negative and positive QFTand TST results.
Conclusions Low prevalence of LTBI was found; however,
agreement between the 2 tests was moderate. This lack of agree-
ment calls for a search for a better diagnostic test for LTBI
among HIV-infected persons in TB endemic regions since TST
positivity is associated with better response to INH in LTBI
patients.
PA-095 A CROSS-SECTIONAL STUDY OF HEPATITIS B VIRUS
INFECTION IN HIV-INFECTED CHILDREN IN WINDHOEK,
NAMIBIA
Cynthia Tamandjou,1 Francina Kaindjee-Tjituka,2 Laura Brandt,3 Mark Cotton,3
Etienne Nel,1 Wolfgang Preiser,1 Monique Andersson1. 1Stellenbosch University,
South Africa; 2Ministry of Health and Social Services, Namibia; 3I-TECH, Namibia
10.1136/bmjgh-2016-000260.126
Background Hepatitis B virus (HBV) remains endemic in Africa
and an important co-morbidity in the HIV epidemic. The HIV
treatment guidelines of the World Health Organisation (WHO)
recommend tenofovir−lamivudine (or emtricitabine) as first-line
therapy for HIV−HBV co-infection management in children
≥10 years old. However, many children in sub-Saharan Africa
are not screened for HBVand may remain on lamivudine mono-
therapy for many years. This study aimed to characterise HBV
infection in HIV-infected children in Namibia.
Methods The study included HIV-infected/HBsAg-positive chil-
dren, exposed to lamivudine monotherapy, attending the
Katutura paediatric HIV clinic in Windhoek, Namibia. Dried
blood spots and serum samples were collected from participants.
Serological investigations were performed using Murex assays.
HBV DNA viral load was determined using the automated
AmpliPrep/COBAS TaqMan HBV test V2.0. Genotyping and
mutation analysis were performed through the NCBI HBV
Genotyping tool (www.ncbi.nlm.nih.gov/ projects/genotyping/
formpage.cgi) and Geno2Pheno (http:// hbv.geno2pheno.org/
index.php).
Results To date, 14 children have been enrolled; of whom 14
DBS and 11 serum samples were analysed. HBsAg was detected in
10 children (90%; 10/11); 7 were HBeAg-positive/
HBeAb-negative and 3 HBeAg-negative. Among HBeAg-negatives,
1 was HBeAb-negative and 2 were HBeAb-positive. One child was
non-reactive for all markers. Of the 14 children, 7(50%) tested
HBV DNA-positive. Lamivudine drug-associated resistance var-
iants, together with immune escape mutants in the overlapping
surface gene, were identified in these children. Resistance mutation
patterns included: rtV173L+rtL180M+rt-M204V (4/7; 57%),
rtL80I+rtV173L+rtL180M+rtM204I (1/7; 14%) and rtL180M
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+rtM204V (2/7; 29%); with the overlapping sE164D and/or
sI195M variants. HBV strains belonged to genotype E (6/7, 86%)
and genotype D3 (1/7, 14%).
Conclusions Half of the children included in this study had
detectable HBV DNA and showed lamivudine resistance.
Uncontrolled HBV infection is associated with an increased risk of
severe liver damage and hepatocellular carcinoma. HBsAg screen-
ing of HIV-infected children, using cost-effective point-of-care
methods, and treatment with tenofovir should be made more
widely available in resource-limited settings.
PA-096 INSTITUTIONAL BARRIERS TO IMPROVE ACCESS TO
DRY BLOOD SAMPLE COLLECTION IN NORTH-WESTERN
NIGERIA: A 12-MONTH RETROSPECTIVE DATA REVIEW
OF PARTNERSHIP WITH NIGERIA POSTAL SERVICE FOR
SAMPLE TRANSPORTATION
Abiola Adepoju, Musa Magana, Andrew Etsetowaghan. Management Science for
Health, Nigeria
10.1136/bmjgh-2016-000260.127
Background Institutional challenges still limit access of exposed
infants to dried blood spot (DBS) sampling at 6 weeks in Nigeria.
There is a paucity of data to evaluate the impact of multiple inter-
ventions in addressing these challenges. The objective of the
study was to review institutional barriers and issues regarding
access of exposed infants to DBS sampling in 6 general hospitals.
The study was supported by Management Science for Health
and funded by USAID in Kebbi State, Nigeria.
Methods Review of the partnership with Nigeria Postal Service
for DBS transportation (6 months after the take-off in October
2014) was conducted in April 2015. It revealed that 34% of
exposed infants had access to DBS sampling at 6 weeks. This led
to key informant interviews with 36 healthcare workers across 6
hospitals with identification of 5 major institutional challenges
limiting access to DBS collection. Targeted interventions
included: strengthening of Intra-facility referral; incorporation of
adherence and tracking into PMTCT/Early Infant Diagnosis
service, development of the capacity of hospital staff on the DBS
collection process and documentation in PMTCT service tools.
The outcome was then evaluated at 6 months.
Results By October 2015, the repeat evaluation showed that the
number of DBS samples collected increased from 42 to 138 and
results received increased from 31 to 112. The average turn-
around time improved from 70 days to 43 days, and DBS sam-
pling access increased from 32% to 86%, all within 6 months of
the interventions.
Conclusions Multiple structured interventions have the poten-
tial to improve access of exposed infants to DBS sampling for
early infant diagnosis. The study will inform implementers on
how best to improve early infant diagnosis in poor-resource set-
tings through interventions aimed at institutional barriers. Point-
of-care testing for DBS needs to be scaled up.
PA-097 FEASIBILITY OF USING THE LYNX POINT-OF-CARE TEST
FOR EARLY INFANT HIV DIAGNOSIS IN RURAL ZAMBIA
Mutinta Chilikwazi, Catherine Sutcliffe, Philip Thuma, Kathy Sinywimaanzi,
Hellen Matakala, Passwell Munachoonga, William Moss. Macha Research Trust, Zambia
10.1136/bmjgh-2016-000260.128
Background Early infant diagnosis of HIV is challenging in
sub-Saharan Africa, particularly in rural areas, leading to delays
in diagnosis and treatment. A point-of-care test would overcome
many challenges. This study was undertaken to evaluate the
feasibility of implementing a point-of-care p24 antigen detection
test (LYNX) in rural Zambia.
Methods A cross-sectional study of infants attending the Macha
Hospital HIV or primary care clinics for early infant diagnosis
was conducted in Choma district, Southern Province, Zambia
during 2014 and 2015. Two blood samples were collected from
each participant, one for immediate testing with the LYNX test
and a second for standard HIV DNA testing at a central labora-
tory. Counsellors were trained to perform the LYNX test and
observed for adherence to protocols.
Results A total of 210 LYNX tests were performed; 93% of
tests were run according to protocol with a result available with
a median time of 55 minutes (IQR:54, 57); 10% of tests were
run on battery power. The median turnaround time for the
availability of the HIV DNA test result was 2.5 months (IQR:
1.8, 5.0). The sensitivity and specificity of the LYNX test were
70% and 100%, respectively. Challenges to implementation
included the long duration of the LYNX test and multiple steps,
disruption of other daily activities, and managing variable
patient volumes.
Conclusions Point-of-care tests for early infant diagnosis are
urgently needed to increase access to testing. The LYNX test
was successfully performed by counsellors and had several
characteristics facilitating implementation in rural clinics. The
LYNX test could address many challenges to testing in rural
areas and allow for earlier diagnosis and treatment of
HIV-infected infants, therefore improving outcome.
PA-098 UPTAKE OF ANTIRETROVIRAL THERAPY AMONG
HIV-INFECTED PREGNANT WOMEN AND ITS IMPACT
ON HIV MOTHER-TO-CHILD TRANSMISSION IN MBEYA,
TANZANIA
Issa Sabi Masenza,1 Otto Geisenberger,2 Peter Agrea,1 Leonard Maboko,1
France Rwegoshora,3 Hellen Mahiga,1 Willyhelmina Olomi,1 Michael Hoelscher,2
Arne Kroidl2. 1NIMR-MMRC, Tanzania; 2DITM, Medical Center, LMU, Germany;
3Southern Highlands Zonal Hospital, Tanzania
10.1136/bmjgh-2016-000260.129
Background Maternal viral load (VL) and immunological status
are important risk factors for mother-to-child transmission of
HIV. In line with WHO recommendations (Option B+),
Tanzania introduced the initiation of life long antiretroviral
therapy (ART) in pregnant women in 2013. We present the
uptake of ARTand its impact on mother-to-child transmission.
Methods Between July 2015 and June 2016 data were obtained
from HIV-infected pregnant women participating in the
ongoing BABY Study (ClinicalTrials.gov Identifier:
NCT02545296), which evaluates point-of-care testing in HIV
Early Infant Diagnosis (HEID). Women were enrolled at the
time of delivery, and neonates were followed-up until 6 weeks
post-partum. Maternal HIV-RNA was assessed at delivery; neo-
natal HIV diagnosis was performed using the Cepheid Xpert
point-of-care test and confirmed by qualitative dry blood spot
HIV-DNA (Roche COBAS TaqMan).
Results In total 415 HIV-infected pregnant women were
enrolled (median age 29 years). Nearly all women had attended
antenatal care (96.4%); in 245 (59%) HIV was first diagnosed
during pregnancy, and in 63.8% ART was initiated within 1
week following diagnosis. At the time of delivery 368 (88.7%)
women were on ART, HIV-RNA >1000 copies/mL were
detected in 78 (18.9%) and a CD4 count <200 cells/mL in 63
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(15.2%). The overall mother-to-child HIV transmission rate was
2.4% (10/415) and 7/10 neonates were HIV diagnosed at the
time of birth correctly identified by point-of-care testing.
HIV-RNA >1000 copies/ml irrespectively of ART and low CD4
count <200 cells/μL were associated with higher risk of neo-
natal HIV transmission.
Conclusions Despite the implementation of life-long ART in all
pregnant women, reduction of HIV transmission from mother
to child is still sub-optimal. High HIV-RNA as the main risk
factor for HIV transmission irrespective of maternal ART points
to the need for maternal VL screening during the antenatal
period.
PA-099 VARIATION IN NEONATAL MORTALITY AND ITS
RELATION TO COUNTRY CHARACTERISTICS IN
SUB-SAHARAN AFRICA
Gbenga Kayode,1 Diederick Grobbee,2 Mary Amoakoh-Coleman,2 Evelyn Ansah,3
Olalekan Uthman,4 Kerstin Klipstein-Grobusch2. 1IHV, Nigeria; 2UMC Utrecht ( Julius
Center), The Netherlands; 3GHS, Ghana; 4WCAHRD, University of Warwick, United
Kingdom
10.1136/bmjgh-2016-000260.130
Background A substantial reduction in neonatal mortality is the
main priority to reduce under-five mortality. A clear understand-
ing of the variation in neonatal mortality and the underlying
causes is important for targeted intervention. We aimed to
explore variation in neonatal mortality and identify underlying
causes of variation in neonatal mortality in sub-Saharan Africa.
Methods This ecological study used publicly available data
from the World Health Organization, United States Agency for
International Development and World Bank. Variation in neo-
natal mortality across 49 sub-Saharan Africa countries was
examined using control chart and explanatory spatial data ana-
lysis. Associations between country-level characteristics and neo-
natal mortality were examined using linear regression analysis.
Results The control chart showed that 28 (57%) countries
exhibited special-cause variation, fourteen countries were below
and above the 99.8% control-limits. The remaining 21 (43%)
countries showed common-cause variation. No spatial clustering
was observed for neonatal mortality (Global Moran’s I statistic –
0.10; p=0.74). Linear regression analysis showed HIV/AIDS
prevalence among the population of reproductive age to be
positively associated with neonatal mortality (β 0.463; 95% CI
0.135 to 0.790; p-value <0.01). Declining socioeconomic
deprivation (β –0.234; 95% CI: –0.424–– 0.044; p-value
<0.05) and high quality of healthcare governance (β –1.327,
95% CI–2.073–– 0.580; p-value <0.01) were inversely asso-
ciated with neonatal mortality.
Conclusion This study shows a wide variation in neonatal mor-
tality in sub-Saharan Africa. A substantial part of this variation
can be explained by differences in the quality of healthcare gov-
ernance, prevalence of HIV and socioeconomic deprivation.
PA-100 IMPACT OF A HOLISTIC INTERVENTION ON PMTCT
UPTAKE WITHIN SUB-SAHARAN AFRICA: EVIDENCE
FROM ‘SAVE THE FAMILIES FOR AFRICA’ IN MALAWI
Joseph Fokam,1 Maria-Mercedes Santoro,1 Chrissie Musolo,2 Isabel Chimbiri,2
Gloria Chikwenga,2 Ruth Deula,2 Riccardo Massari,3 Agness Lungu,2
Carlo-Federico Perno1. 1University of Rome Tor Vergata, Italy; 2Likuni Mission
Hospital, Malawi; 3AVIRALIA Foundation, Italy
10.1136/bmjgh-2016-000260.131
Background Prevention of mother-to-child transmission
(PMTCT) option B+ makes effective the virtual elimination of
HIV (<5%) among African children effective. Some major chal-
lenges remain, such as accessibility to PMTCT-services and
male-partner involvement. To improve PMTCT-interventions/
expansion, we evaluated PMTCT-service uptakes within a
typical African context, using a holistic approach.
Methods As part of monitoring and evaluation of the ‘Save the
Families for Africa’, a comparative assessment of PMTCT-uptake
was conducted within the Likuni Mission Hospital catchment
area in Likuni, Malawi. Four performance indicators were mea-
sured before ( July-November 2015) and during (December
2015-May 2016) project-interventions: i) HIV-infected pregnant
women enrolled for antenatal care (ANC)/PMTCT-services; ii)
HIV-related deliveries at the hospital; iii) male-partner involve-
ment into PMTCT; iv) PMTCT community-outreach interven-
tions. Comparison was performed using Mann-Whitney test
(p< 0.05 considered significant).
Results During project-interventions, provision of free coupons
for ANC/PMTCT-related services (including CD4/
Haemoglobin point-of-care monitoring) and for nutritional sup-
plements, invitation notes and counselling intensification for
male-partners, as well as provision of a mobile unit (new ambu-
lance) for PMTCT-services expansion to remote/rural communi-
ties, were implemented. Overall, target performances appeared
to increase over time after interventions. Indeed, the total
number of women enrolled before intervention was 58, and
sharply increased thereafter (182). The median [interquartile]
number of HIV-infected pregnant women enrolled per month
for ANC/PMTCT-services was doubled (before vs during: 11
[10–13] vs 26[22–43], p=0.0043); HIV-related deliveries per
month increased 12 times [11–13] vs 17[11–22], p=0.3160);
male-partner involvement to PMTCT per month became effect-
ive [0% vs 23.1%[9.3–33.3%], p=0.0260); PMTCT
community-outreach per month increased by 12 fold (1[0–2] vs
12[6–14], p=0.0286). Maternal mortality and HIV-vertical
transmission were 0% throughout project-interventions.
Conclusions Our findings highlight that there is room for
improvement of PMTCT, starting from option B+, by imple-
menting a holistic interventional model. This can greatly con-
tribute to eliminating MTCT and in ameliorating the well-being
of the entire family (children, mother and father) living with
HIV/AIDS in sub-Saharan Africa.
PA-101 FUNCTIONAL AND PHENOTYPIC CHARACTERISATION
OF REGULATORY T (TREG) CELLS IN ANTIRETROVIRAL
NAïVE HIV-1 INFECTED PEOPLE
Georgia Ndzengue,1 Ngu Loveline,2 Carol Sake,2 Abel Lissom,2 Jules Tchadji,2
Tchouangueu Flaurent,2 Nadesh Nji,1 Samuel Sosso,1 Claudine Essomba,2
François-Xavier Etoa,2 Godwin Nchinda1. 1CIRCB, Cameroon; 2University of
Yaoundé I, Cameroon
10.1136/bmjgh-2016-000260.132
Background Regulatory T cells (Tregs) function in dampening
excessive immune activation in steady state. However during
HIV-1 infection there is sustained immune activation and it is
not known how Tregs function in this context. To optimise
immunotherapeutic strategies based on Tregs for HIV-1 infected
people we assessed the phenotypic and functional properties of
these cells from antiretroviral naïve HIV-1 infected adults in
Cameroon.
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Methods Tregs were purified by magnetic sorting from PBMCs
obtained from adults aged 21 to 65 years using microbeads
according to the manufacturer’s protocol (Miltenyi Biotec). The
phenotypic properties of the purified Tregs were then deter-
mined by multiparametric flow cytometry. Tregs functions were
assessed by measuring inflammatory cytokine formation by
monocytes following co-culture with autologous Tregs in the
presence of either polyICLC or CLO97. Samples were acquired
on BD Fortessa X5 cytometer using BDFACS Diva Software and
data analysed with FlowJo version 9.8.5. Graph Pad Prism 5
was used for statistical analysis.
Results Tregs were defined as CD4+CD25+CD127LoFoxP3+
cells. However, the strong correlation between Foxp3 with the
combination of CD25+CD127Lo (r=0,965; p< 0,001,
Pearson’s correlation) allowed us to use these surface markers as
previously reported for tracking Tregs in subsequent experi-
ments. With respect to surface expression there was a significant
elevation of HLA-DR /CD38 in Tregs from HIV-1-infected
people when compared to HIV-participants. When purified
Tregs were co-cultured with autologous monocytes in the pres-
ence polyICLC (a TLR 3 agonist) and CLO97 (TLR7/8 agonist)
they escalated the intracellular formation of both TNF-α and
IL-6 by monocytes. The escalation was significantly higher in
co-cultures of cells from antiretroviral naïve HIV-1-infected
people relative to seronegative participants.
Conclusions Dysregulation in Tregs function can exacerbate
inflammatory cytokine formation.
PA-103 DRUG RESISTANCE AND GENETIC PROFILE OF
BACTERIAL SPECIES ASSOCIATED WITH BURULI ULCER
WOUND INFECTIONS IN TWO DISTRICTS OF GHANA
Grace Kpeli,1 Isaac Otchere,1 Araceli Lamelas,2 Andrew Buultjens,3 Dieter Bulach,3
Sarah Baines,3 Torsten Seemann,3 Stefano Giulieri,3 Zuliehatu Nakobu,1
Samuel Aboagye,1 Evelyn Owusu-Mireku,1 Emelia Danso,1 Julia Hauser,4
Vladimira Hinic,5 Gerd Pluschke,4 Timothy Stinear,3
Dorothy Yeboah-Manu1. 1NMIMR, Ghana; 2Red de Estudios Moleculares
Avanzados, Instituto de Ecología A.C., Mexico; 3Doherty Institute, University of
Melbourne, Australia; 4Swiss TPH, Switzerland; 5University Hospital Basel,
Switzerland
10.1136/bmjgh-2016-000260.133
Background We identified secondary infection of Buruli ulcer
(BU) wounds as a cause of healing delay. In order to contribute
to the improvement of wound management and reduction of
healing delay, we initiated a study to gain understanding of the
possible routes of infection and also characterised the resistant
profiles of Gram negative bacteria isolated from the wounds of
patients attending two health facilities in Ghana.
Methods Staphylococcus aureus isolates were characterised by
the spa gene, mecA and the Pantone Valentine Leukocidin (PVL)
toxin followed by spa sequencing and whole genome sequencing
of a subset of isolates. Phenotypic antibiotic susceptibility
testing of Gram negative clinical isolates was performed and
multidrug-resistant Pseudomonas aeruginosa identified. The
Enterobacteriaceae were further investigated for ESBL and car-
bapenem production, and some resistance conferring genes
were analysed by PCR.
Results Twenty-four isolates were identified as methicillin-
resistant S. aureus (MRSA), and lukFS genes encoding PVL were
identified in 67 isolates. Typing and sequencing of the spa gene
from 91 isolates identified 29 different spa types with t355
(ST152), t186 (ST88), and t346 dominating. While many dis-
tinct strains were isolated from both health centres, genotype
clustering was identified within centres pointing to possible
health care-associated transmission. Phylogenomic analysis con-
firmed these clusters. Among the GNB, phenotype screening
showed widespread resistance to ampicillin, chloramphenicol,
ticarcillin-clavulanic acid, cefuroxime and sulphamethoxazole-
trimethoprim. ESBL production was confirmed in 15 isolates
phenotypically while 61.5% of screen-positive isolates har-
boured at least one ESBL-conferring gene. Carbapenem encod-
ing genes were detected in 41% of the isolates.
Conclusions Our findings indicate that the health-care environ-
ment likely contributes to superinfection of BU wounds and
calls for training in wound management and infection control
techniques. The observed frequency of ESBL and carbapenem
resistance indicates the need to set up surveillance networks and
strictly enforce policies which guide the rational use of
antibiotics.
PA-104 CURRENT PATTERNS AND PREDICTIVE TRENDS OF
MULTIDRUG-RESISTANT SALMONELLA TYPHI IN SUDAN
Ayman Elshayeb, Marmar El Siddig, Abdel Azim Ahmed, Adil El Hussien. University
of Khartoum, Sudan
10.1136/bmjgh-2016-000260.134
Background Enteric fever has a persistently great impact on
public health. It is caused by Salmonella enterica associated with
malaria during the rainy season; the bacterium is seldom
detected in wastewater of stabilisation stations due to treatment
processes. The aim of this study is to evaluate the recent state of
antibiotics susceptibility of Salmonella typhi with special atten-
tion to multidrug-resistant strains and predict the emergence of
new resistance patterns.
Methods S. typhi isolates were recovered from 128 wastewater
samples collected from ponds at Soba Stabilization Station and
Omdurman Hospital Stabilization Station. The isolates were
identified using standard Salmonella identification guidelines
and their susceptibility to seven antibiotics was determined.
Minimum inhibitory concentration (MIC) of ciprofloxacin and
minimum bactericidal concentrations (MBC) were also deter-
mined. Statistical predictions for the resistance emergence were
done using logistic regression and forecasting linear equations.
Results A total of 12 S. typhi isolated strains were recovered
from 128 samples of wastewater; they were resistant to anti-
biotics except Ciprofloxacin. Current patterns of ciprofloxa-
cin breakpoints interpretations were in susceptible ranges by
disc diffusion (S≥20 mm), minimum inhibitory concentration
was recorded as (I=16 mg/ml) and minimum bactericidal con-
centration=(R≥32 mg/ml). The probability of an isolate to
develop resistance was plotted for MBCs; the rate of resist-
ance solved by (y=0.0235×−0.0411). The predictive pat-
terns of resistance were spontaneously solved using
exponential trend (y=n ex) for each isolate at 16 mg/ml and
32 mg/ml of ciprofloxacin in certain period and the high
values of coefficient R2>0.5 indicate the incidence rates of
bacterial resistance.
Conclusions The current sensitivity patterns of S. typhi iso-
lates against ciprofloxacin were acceptable, but the probability
of emerging multidrug resistance to ciprofloxacin was
observed in sensitivity which had begun to decline according
to frequent consuming, drug policy and bacterial genetic
mutations.
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PA-105 AETIOLOGY, ANTIBIOTIC RESISTANCE AND RISK
FACTORS FOR NEONATAL SEPSIS IN A LARGE
REFERRAL CENTRE IN ZAMBIA
Mwila Kabwe,1 John Tembo,1 Lophina Chilukutu,1 Moses Chilufya,1
Francis Ngulube,2 Chileshe Lukwesa,2 Virve Enne,3 Hannah Wexner,4
Lawrence Mwananyanda,5 Davidson Hamer,5,6 Sylvester Sinyangwe,2 Yusuf Ahmed,7
Nigel Klein,8 Markus Maeurer,9 Ali Zumla,3 Matthew Bates1. 1UNZA-UCLMS
Research & Training Programme, Zambia; 2. UNZA, School of Medicine, Zambia;
3UCL (Division of Infection & Immunity), United Kingdom; 4Harvard Medical School,
United States of America; 5ZCAHRD, Zambia; 6CGHD, BU School of Public Health,
Zambia; 7University Teaching Hospital, Zambia; 8Institute of Child Health, UCL,
United Kingdom; 9KI, Sweden
10.1136/bmjgh-2016-000260.135
Background In sub-Saharan Africa there is scanty data on the
causes of neonatal sepsis and antimicrobial resistance among
common invasive pathogens, which might guide policy and
practice.
Methods This was a cross-sectional observational prevalence
and aetiology study of neonates with suspected sepsis admitted
to the neonatal intensive care unit, University Teaching
Hospital, Lusaka, Zambia, between October 2013 and May
2014. Data from blood cultures and phenotypic antibiotic sus-
ceptibility testing were compared with multivariate analysis of
risk factors for neonatal sepsis.
Results Of 313 neonates with suspected sepsis, 54% (170/313)
were male; 20% (62/313) were born to HIV-positive mothers;
33% (103/313) had positive blood cultures, of which 85% (88/
103) were early onset sepsis (EOS). Klebsiella species was the most
prevalent isolate, accounting for 75% (77/103) of cases, followed
by coagulase-negative staphylococci (6% (7/103)), Staphylococcus
aureus (6% (6/103)), Escherichia coli (5% (5/103) and Candida
species (5% (5/103). For Klebsiella species, antibiotic resistance
ranged from 96–99% for WHO-recommended first-line therapy
(gentamicin and ampicillin/penicillin) to 94–97% for third gener-
ation cephalosporins. The prevalence of culture-confirmed sepsis
increased from 0–39% from December 2013 to March 2014,
during which time mortality increased 29–47%. 93% (14/15) neo-
nates with late onset sepsis and 82% (37/45) with early-onset sepsis
aged 4–7 days were admitted >2 days prior to onset of symptoms.
Culture results for only 25% (26/103) of cases were available
before discharge or death. Maternal HIV infection was associated
with a reduced risk of neonatal sepsis (OR 0.46 [0.23–0.93],
p=0.029).
Conclusions Outbreaks of nosocomial multi-antibiotic-resistant
infections are an important cause of neonatal sepsis and associated
mortality. Reduced risk of neonatal sepsis associated with maternal
HIV infection is counterintuitive and requires further investigation.
PA-106 RESISTANCE OF ENTEROPATHOGENS MAINLY
ASSOCIATED WITH DIARRHOEA TO FREQUENTLY
PRESCRIBED ANTIBIOTICS IN KOUSSERI (FAR NORTH,
CAMEROON)
Landry Beyala, Guenou Etienne, Njimbia Anthony, Azike Benjamin,
Jerome Ateudjieu. BAHCARE, Cameroon
10.1136/bmjgh-2016-000260.136
Background The resistance of diarrhoea-causing enteropatho-
gens to antibiotics is a global concern.
Methods A cross-sectional descriptive study that had as object-
ive to test the sensitivity of these pathogens to antibiotics
frequently prescribed in the Logone and Chari Division was
carried out in Kousseri from 24 July to 23 October 2015.
Stool samples were collected from patients (children and
adults) presenting at the Kousseri Annex Regional Hospital, in
sterile containers and analysed as required by SOPs in the
cholera detection laboratory of the NGO ‘Better Access to
Health Care’ (BAHCARE) in Kousseri. Microbial isolation and
identification was done using Hektoen and EMB culture media
and API 20E pack (Biomerieux). Antibiotic susceptibility
testing was done using the Kirby Bauer method with Muller
Hinton medium.
Results A total of 150 stool samples were analysed, out of
which 45 enteropathogens were isolated (66% of isolated
microbes were Escherichia coli), identified and tested with anti-
biotic discs. The rate of resistance of Escherichia coli was
83.33% to cotrimoxazole and 43.33% to both ceftriaxone and
ciprofloxacin. Salmonella species had a resistance rate of
71.42%, 42.86%, and 28.57% to cotrimoxazole, ceftriaxone
and ciprofloxacine, respectively. Shigella spp were 100% resist-
ant to cotrimoxazole, ciprofloxacine and the combination of
amoxicillin with clavulanic acid.
Conclusions These results underscore the need to systematic-
ally assess the sensitivity of enteropathogens to antibiotics so as
to guide health workers on the prescription of antibiotics in
the Lake Chad area, Cameroon.
PA-107 ANTIBIOTIC RESISTANCE PATTERNS OF POTENTIAL
PATHOGENS ISOLATED FROM TWO MAJOR HOSPITALS
IN LUSAKA AND NDOLA
Bertha Chibwe,1 Michelo Simuyandi,1 David Ojok,1 Roma Chilengi,1
Annika Kruuner1,2. 1CIDRZ, Zambia; 2UAB, Zambia
10.1136/bmjgh-2016-000260.137
Background This study was conducted as part of an assessment
of the effectiveness of existing hygiene and sanitation practices
in two first-level hospitals in Lusaka and two central clinics in
Ndola to determine the drug resistance patterns of potential
pathogens in health care facilities in Zambia.
Methods In this cross-sectional study, the samples analysed
were collected from health care workers’ hands, touch surfaces,
disinfectant buckets in delivery rooms, post-natal and paediatric
wards, operation theatre, post-operation wards and outpatient
departments. The swabs in Cary-Blair transport media were
used for sample collection and inoculated to 3 (Blood-,
Chocolate- and MacConkey agar) primary plates. For species
identification and drug susceptibility testing BD Crystal ID
System and disk diffusion method with panel of 20 antibiotics
was used.
Results A total of 132 swabs were collected resulting in isola-
tion of 275 Gram negative and positive bacteria. 65 bacterial
isolates were successfully identified as the following species:
Acinetobacter, Enterobacter, Klebsiella, Pseudomonas,
Staphylococcus, Streptococcus spp. All identified bacteria were
tested for drug resistance. Among the Pseudomonas spp, the
highest level of resistance was detected to cephalosporins,
amoxicillin and carbenicillin and was up to 70%, 90% and
60%, respectively. Staphylococcus spp had high resistance to
penicillin, ampicillin, azithromycin and cephalosporins, up to
86%, 76%, 57% and 95%, respectively. Vancomycin resistance
among Staphylococcus spp was 19%.
Conclusions High drug-resistance levels among potential patho-
gens isolated in health care facilities reflect the long-term empiric
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use of antibiotics in Zambia. For better understanding of the
scale of this problem a more comprehensive study including all
central private and government health care facilities should be
conducted. A large number of isolated bacteria (35%) remained
unknown indicating that more than one identification method
should be used in order to capture the full spectrum of potential
pathogens colonising the health care facilities in Africa.
PA-108 LOCALLY DRIVEN RESEARCH IS BETTER FOR
INFECTIOUS DISEASES OUTBREAK PREPAREDNESS: AN
EDCTP CAPACITY-BUILDING PROJECT IN POST-EBOLA
LIBERIA
Christine Attia Tarr,1 Guillermo Martinez Perez,2 Senga Omeonga,1 Fanta Kibungu,1
Ana Meyer,3 Peter Lansana,1 Alfredo Mayor2. 1Saint Joseph Catholic Hospital,
Liberia; 2ISGlobal Barcelona, Spain; 3Fundación Juan Ciudad, Spain
10.1136/bmjgh-2016-000260.138
Background Liberia is recovering from an Ebola outbreak.
Liberia suffers from brain drain and a low gross enrolment ratio
in tertiary education alongside a dearth of institutions, skilled
investigators and funds for research. Liberia needs to rebuild its
capacity in epidemiological research. The Saint Joseph’s
Catholic Hospital (SJCH) in Monrovia –in collaboration with
ISGlobal and the Juan Ciudad Foundation, received an EDCTP
grant to strengthen its staff capacities to lead research in infec-
tious diseases.
Methods In March 2016, a participatory planning process
started. The hospital management team and medical department
staff were engaged. The process was guided by scientists from
ISGlobal. Thirty-two trainees were identified among staff of the
Ministry of Health and SJCH; community leaders were sought
to build a Community Advisory Board; and trainees’ suggestions
informed the design of a 6-months Moodle-based eLearning
program.
Results Two workshops on Good Clinical and Laboratory
Practices (GCLP) were conducted. In preparation for the SJCH
to conduct biomedical research and clinical trials, another work-
shop to design Standard Operating Procedures was done. All
trainees joined the eLearning program and received a certificate
of completion. Furthermore, the SJCH defined its own institu-
tional research program, submitted a research proposal to a
local ethics board, and is pooling resources to undertake further
research on infectious diseases in 2017.
Conclusions A collaborative multi-disciplinary framework that
promoted participation of the community was an approach that
fuelled the successful completion of all training activities of this
EDCTP-awarded project. The trainees capitalised on their
experiences during the Ebola epidemic to ensure all activities
were planned as per best quality standards. All trainees were
motivated to prevent that planning and implementation-related
errors they witnessed during the Ebola outbreak, were repeated
in new education and research initiatives. In addressing global
health challenges today, these motivational driving forces need a
responsible and prompt response from Northern countries.
PA-109 THE ROLE OF LOCAL CONTRACT RESEARCH
ORGANISATIONS IN BUILDING GCP-COMPLIANT
CLINICAL RESEARCH IN POVERTY-RELATED DISEASES
IN AFRICA: A CASE OF CLINWIN RESEARCH SERVICES
Peter Onyango. ClinWin Research Services, Kenya
10.1136/bmjgh-2016-000260.139
Background Africa carries the largest burden of the
poverty-related diseases in the world. Most of her popula-
tions live in resource-limited settings. These act as catalysts
for poverty-related diseases in those populations. There is
urgent need for affordable, safe and effective health technolo-
gies to reduce the economic burden of those diseases. Clinical
research provides an opportunity for access to new and
improved health technologies, which have undergone evalu-
ation in clinical trial settings, in compliance with Good
Clinical Practice (GCP) and local regulatory requirements.
The local Contract Research Organisations offer cost-effective
solutions, human resource capacity and experience in
poverty-related diseases research, regulatory affairs, culture
and politics.
Methods ClinWin provides clinical development services for
poverty-related diseases. It has partnered with industry,
not-for-profits and academic sponsors to provide a suite of trial
and site management, and sponsor oversight services to local
clinical research programs. These services include: training, trial
monitoring, quality assurance, ethical and regulatory expertise;
contract negotiation and trial coordination among others.
Leveraging its indigenous knowledge of the clinical trial land-
scape in the region, it has developed a database of potential and
current local investigators capable of conducting registration
trials. The lessons learnt in each project are documented and
shared with investigator staff at new sites.
Results We conducted 23 monitoring visits at an academic site
for a phase Ib HIV vaccine study and malaria phase IV drug
trial monitoring visits in Kenya and Tanzania. Academic epi-
demiological tuberculosis studies were also conducted and we
developed partnerships with professional development programs
in industry and academia.
Conclusions Africa is the next frontier for clinical research
enterprise, and the need for developing local human resource
capacity is critical. This will make the region attractive for
industry sponsored trials for poverty-related diseases and other
indications.
PA-111 HARNESSING THE DIGITAL SHARING REVOLUTION TO
DRIVE GLOBAL HEALTH RESEARCH: SHOWING
SIGNIFICANT IMPACT THAT SHOULD SUPPORT EDCTP
CAPACITY DEVELOPMENT
François Van Loggerenberg, Tamzin Furtado, Liam Boggs, Alexis Segrt,
Trudie Lang. TGHN, University of Oxford, United Kingdom
10.1136/bmjgh-2016-000260.140
Background The Global Health Network is a platform for
research capacity development and improving evidence gener-
ation and quality, especially in low- and middle-income coun-
tries. This is achieved by delivering training and career
development (through an on-line professional membership and
training scheme as well as face-to-face workshops). The plat-
form is also a mechanism for sharing research skills knowledge,
experience and tools.
Methods The Network has been consistently monitored using
web analytics data and targeted surveys which combine quanti-
tative and qualitative data, including 600 user interviews to
evaluate impact. The data have been compiled by four research-
ers working in collaboration; each researcher was responsible
for analysing specific datasets, which were later combined for
the overall evaluation to ensure a fully comprehensive and
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in-depth assessment.
Results The Global Health Network is made up of over 30
interconnected research communities, with over 770,000 visits,
over 73,000 individual site memberships and more than 30,000
tools or document downloads. It is clear that this is a much
needed, trusted and well-used resource. In all, 89.5% of users
indicated the quality of information provided on the Network is
of high quality. Importantly, over 130,000 online eLearning
modules have been taken. Ninety-six percent of users indicated
they would recommend the training courses to others, and 82%
had greater course-specific skills confidence after taking a
course.
Conclusions The Network has a broad user base, from individ-
ual frontline research staff through to large collaborative groups
who make use of the platform to disseminate their activities, and
is viewed as a high-quality, cost-effective and trustworthy commu-
nity. However, more needs to be done to ensure that the capacity
development initiatives of key groups, like EDCTP, make greater
and more effective use of this free and impactful resource.
PA-112 INTRODUCTION OF A NEW VACCINE INTO NATIONAL
IMMUNISATION PROGRAMMES IN AFRICA: THE ROLE
OF CAPACITY BUILDING
Carine Dochez,1 Rosemary Burnett,2 M. Jeffrey Mphahlele3. 1NESI, Antwerp,
Belgium; 2SAVIC, South Africa; 3MRC, South Africa
10.1136/bmjgh-2016-000260.141
Background Members of National Immunisation Technical
Advisory Groups, policy-makers, EPI managers and vaccinators are
tasked with making evidence-based recommendations and decisions
on whether a new vaccine merits introduction into national
immunisation programmes; implementation of new vaccine intro-
duction; and efficient management of immunisation programmes.
Therefore it is paramount that they are equipped with the latest
state-of-the-art information on vaccines and immunisation.
Methods Capacity building activities – such as high-level
in-service vaccinology courses, other interactive courses and
workshops (mid-level management training and experience
exchange workshops) – address all steps required for decision-
making on new vaccine introduction into national immunisation
programmes. These include establishing: 1) burden of disease to
be prevented; 2) existence of a good intervention (i.e. is the
vaccine efficacious, safe and acceptable for the target popula-
tion); 3) the cost of the new vaccine, its implementation and the
comparative effectiveness with other vaccines/interventions in
terms of health gains; 4) whether finances to pay for the new
vaccine are available; and 5) programmatic implications.
Interested parties are trained on this rational decision-making
process to be followed before embarking on new vaccine intro-
duction, on key implementation steps, and efficient management
of immunisation programmes.
Results Several inter-country vaccinology courses and inter-
active workshops, which were organised during the last years in
the African region (e.g. Kenya and South Africa), will be pre-
sented in detail. These capacity building activities have contribu-
ted to successful introduction of new vaccines in the African
region, key ones being rotavirus, pneumococcal and currently
human papillomavirus vaccines. This concerted effort has
contributed for example to the successful introduction of rota-
virus vaccine in 29 African countries to date.
Conclusions Capacity building efforts, like high-level in-service
courses and interactive workshops have enabled interested
parties to make evidence-based recommendations and decisions
on the introduction of any new vaccine, and to successfully
implement new vaccine introduction.
PA-113 ACHIEVEMENTS AND PRIMED PROSPECTS OF
INCREASING CAPABILITIES FOR MULTISITE CLINICAL
TRIALS IN THE EASTERN AFRICA NETWORK OF
EXCELLENCE
George Miiro,1,† Edward Mbidde,1 Norbert Peshu,2 Esther Kivaya,2
Godfrey Mfinanga,3 Bernard Ngowi,3 Reginald Kavishe,4 Mukhtar Maowia,5
Trudie Lang,6 Eric Sandstrom,7 Elizabeth Ayuo,8 Annet Nanvubya,1
Blandina Mmbaga,4 Pontiano Kaleebu9. 1UVRI, Uganda; 2KEMRI-Wellcome Trust
Research Program, Kenya; 3NIMR Muhimbili, Tanzania; 5IEND, University of
Khartoum, Sudan; 6TGHN, University of Oxford, United Kingdom; 7KI, Sweden;
8KEMRI-CDC, Kenya; 9MRC-UVRI AIDS, Uganda
10.1136/bmjgh-2016-000260.142
Background In May 2009, EDCTP supported the establish-
ment of the East African Consortium for Clinical Research
(EACCR) involving 35 regional institutions and 6 northern part-
ners to promote capacity development for collaborative multi-
site clinical trials and research. EACCR aims to contribute to
overcoming a situation of: under-funded, fragmented and unco-
ordinated regional health research; too few African scientists;
inadequate infrastructure; insufficient networking and
knowledge-sharing. We present updates on achievements and
lessons learnt on increased preparedness to conduct globally-
competitive research and clinical trials on poverty-related,
neglected and emerging infectious diseases.
Methods Retrospectively, we conducted a quasi-purposive sum-
mative evaluation through document review, participatory
appraisal, direct observation and case studies of the EACCR
work packages for governance, research, training and mentor-
ing, infrastructure, and networking between November 2015
and February 2016.
Results In the past five years, the Eastern Africa-led consensus-
driven consortium has contributed to the following results (at
least): 15 new research and capacity-strengthening grants; 150
peer-reviewed publications; 15 trials monitored; 531 scientists
and associates mentored; 12 electronic training modules on
research and bio-ethics; 2 newly ISO-accredited laboratories; 24
research sites upgraded; 20 partnerships harnessed; 2
knowledge-sharing platforms of the East African Health
Research Commission; an interactive website (www. eaccr.org);
and an additional 2 million euros leveraged.
Conclusions EACCR has increased its capacity and partner-
ships for on-going and planned multisite clinical trials; we can
sustain coordinated collaborative GCP-compliant multisite
trials and health research. We can intensify high-level advocacy
and resource mobilisation in Eastern Africa in partnership
with policy makers, other consortia and development part-
ners. We stand firm on the shoulders of current and promising
giants of EACCR, other consortia, EDCTP and other like-
minded partners and are thus prepared to conduct and dissem-
inate more African-led health research and capacity-
strengthening initiatives on poverty-related, neglected and
emerging infectious diseases in Africa during the second pro-
gramme of EDCTP.
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PA-114 BLENDED-LEARNING USING THE GLOBAL HEALTH
NETWORK ONLINE RESOURCES: A PILOT STUDY
Elizabeth Allen,1 Cordelia Leisegang,1 Tamzin Furtado,2 François Van Loggerenberg,2
Trudie Lang2. 1TGHN, University of Cape Town, South Africa; 2TGHN, University of
Oxford, United Kingdom
10.1136/bmjgh-2016-000260.143
Background Enhancing The Global Health Network’s online
offerings (TGHN eLearning, www.theglobalhealthnetwork. org)
through local facilitation of its outputs may enable its uptake by
clinical research staff. To explore this issue, we aimed to design
and pilot a blended-learning programme in collaboration with
South African research team members.
Methods A participatory research design was used, with
purposively-selected support staff and their line managers.
Formative semi-structured interviews with the former and focus
group discussions with the latter sought reflection on current
learning opportunities and career development experiences and
needs. Staff then helped design and pilot a practical, feasible
blended-learning programme over an approximately 6-month
period. The pilot was assessed on reflections of its value that
were elicited in follow-up discussions with participants.
Results Forty-five clinical research field workers, nurses,
co-ordinators, data managers and laboratory personnel (and
their respective line managers) took part. Formative discussions
suggested staff generally had the necessary skills for their jobs,
however they often lacked time and finances to develop a career
path. The blended-learning menu of options for staff that they
then co-designed and piloted included: facilitated one-to-one or
group TGHN eLearning sessions followed by a discussion
forum hosted by a volunteer content-expert; job shadows; guid-
ance in accessing training opportunities/ resources; twinning
with other research groups or staff; and a skills-sharing work-
shop. Feedback on their experience of the programme was very
positive from those who got ‘hooked’, particularly as regards
the non-threatening learning environment, building of IT com-
petence and networking opportunities. However, staff ’s per-
sonal time constraints, and our challenges in supporting remote
teams, were evident for some despite the pragmatic design.
Conclusions This flexible, practical and feasible
blended-learning program catalysed the self-development of
many research staff in the pilot, and supported their busy line
managers. As some challenges remain, the programme may
require further modification when implemented in different
contexts.
PA-115 FUNCTIONAL COMMUNICATION IN MULTISITE,
MULTILINGUAL CONSORTIUMS: EVALUATION OF THE
COMMUNICATION TOOLS USED IN THE WANETAM
NETWORK
Marie Thorpe,1 Elizabeth Batchilly,1 Jean-Pierre N’Guessan,2
Dembo Kanteh1. 1MRC, The Gambia; 2University Hospital Centre Le Dantec,
Senegal
10.1136/bmjgh-2016-000260.144
Background Effective communication is a key challenge in
managing multi-disciplinary teams (Bruce et al. 1995). This
challenge is intensified when teams are dispersed in a multi-
lingual consortium. Created in EDCTP’s capacity building call,
the ‘West African Network against TB, AIDS and Malaria’’
(WANETAM/WANETAM Plus) network partnered 19 research
institutions from 10 West African countries. WANETAM’s objec-
tives are i) Capacity building and technology transfer to prepare
West African sites for the successful conduct of clinical trials, ii)
Creation of a network for subregional scientific collaborations.
Whilst WANETAM successfully integrated capacity-building
training, it is important to evaluate the effectiveness of the con-
sortium’s communication methods. This evaluation aims to i)
Evaluate information sharing across a trilingual network; ii)
Identify key successes, gaps in communications, iii) Identify
tools that enable effective communication in multisite consor-
tiums.
Methods Project documentation was reviewed to understand
communication methods. An adapted Organizational
Communication Audit questionnaire measured how communica-
tion systems aided desired project outputs/outcomes
(Greenbaum et al 1988). Questions specifically evaluated the
effectiveness of Basecamp, IP phones and email. This question-
naire was sent to WANETAM sites to gauge user perspectives.
Results Basecamp, the online collaboration project management
software, enabled communications and document distribution in
a single system. Despite efforts, usage was low. As predicted,
technical difficulties with IP phones affected user acceptability.
Email was the central communication method used to manage
project milestones and deadlines. As the average person receives
121 emails daily over-reliance on email for primary communica-
tion poses challenges (Kane 2015).
Conclusions The role of e-collaboration is crucial in multi-site
consortiums. Despite low usage, cloud computing networks
remove the need for infrastructure (IP phones), lower costs and
allow for accessibility regardless of location. When employed
correctly, it achieves efficient, effective communication to
achieve desired consortium objectives.
PA-116 DEVELOPING A GLOBAL CORE COMPETENCY
FRAMEWORK FOR CLINICAL RESEARCH
Amélie Julé, Tamzin Furtado, Liam Boggs, François Van Loggerenberg, Trudie Lang.
Centre for Tropical Medicine and Global Health, University of Oxford, United
Kingdom
10.1136/bmjgh-2016-000260.145
Background Lack of recognition for working in clinical
research is widely cited as an impediment to its conduct. There
is a lack of career structure for the many roles involved (investi-
gators, trial managers, nurses, etc.), and a lack of understanding
of who does what. Competency frameworks exist for some indi-
vidual job roles, but these are infrequent; thus the need for a
global framework describing roles and responsibilities in a
research team. This would facilitate appraisal of staff, promote
career development by highlighting acquired skills, and illumin-
ate areas where training opportunities are lacking.
Methods In this project, we combine 28 frameworks created by
external groups, with information from 116 job descriptions
obtained from partners in clinical trial units worldwide, includ-
ing input from the EDCTP Networks of Excellence, and from
the web, to create a widely-encompassing framework derived
from 11 different roles. Using qualitative analysis software, we
systematically assess the activities performed by the clinical
research team to categorise them and define underlying
knowledge-, skill- or task-based competencies.
Results The resulting framework counts 50 competencies
required throughout the research life cycle, from assessment of
scientific literature to results dissemination via project
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management, public engagement or grant application. It is
applicable to studies that may differ in design, geographical
location, disease, etc., and can be adapted to the particular
needs of specific projects or roles. The framework was subject
to an initial validation through consultations with over 30
global health research experts in collaboration with WHO-TDR
in September 2015, resulting in enhancements and its subse-
quent beta release.
Conclusions The adaptable ‘Global Core Competency
Framework for Clinical Research’ is now accessible via The
Global Health Network, alongside a protocol for individuals
who may wish to pilot test it in their work. The framework may
be further refined before being finally approved and launched in
collaboration with WHO-TDR.
PA-117 NEW E-LEARNING TOOL FOR FEMALE GENITAL
SCHISTOSOMIASIS: A SUPPLEMENT TO THE WHO
POCKET ATLAS OF FGS
Solrun Søfteland,1 Motshedisi Sebitloane,2 Bellington Vwalika,3 Myra Taylor,2
Hashini Galappaththi-Arachchige,1 Sigve Holmen,1 Svein Gunnar Gundersen,5
Patricia Ndhlovu,5 Eyrun Floerecke Kjetland1. 1Oslo University Hospital, Norway;
2UKZN, South Africa; 3UTH, Lusaka, Zambia; 4University of Adger, Norway; 5Imperial
College London, United Kingdom
10.1136/bmjgh-2016-000260.146
Background Schistosomiasis affects 261 million people
worldwide, most of them in Africa. Female genital schisto-
somiasis (FGS) may cause abnormal vaginal discharge,
contact bleeding, genital tumours, infertility, ectopic preg-
nancies and increased susceptibility to HIV. Visualisation of
lesions is the key to diagnosis but there is little knowledge
about FGS among health professionals. In order to facilitate
the use of the WHO pocket atlas for FSG, we present an e-
learning module for medical students in endemic areas. The
e-learning material is usable on smartphones, and in areas
with low internet speed.
Methods Two FGS atlases form the platform for the e-
learning: The First Colposcopic Atlas of Schistosomiasis in
the Lower Female Genital Tract (Norseth et al. 2014) and
The WHO Pocket Atlas for FGS (WHO, 2015). Actors were
recruited for demonstration of the examination techniques.
Medical students were approached to explore their current e-
learning platforms. Website creators of two existing e-
learning modules were invited to collaborate. The project is
part of a larger project that was granted permissions by the
Biomedical Research Ethics Administration, University of
KwaZulu-Natal (KZN), South Africa.
Results A new e-learning tool is presented: all lesions,
history taking and the examination techniques for identifica-
tion of FGS are shown. There is a post-learning quiz for self-
evaluation. Medical students in an endemic area were asked
to give a qualitative evaluation on the learning outcome.
Conclusions There is a need to raise the index of suspicion
for FGS as a differential diagnosis among health care profes-
sionals. This e-learning may contribute to the dissemination
of knowledge of FGS to all health care professionals who can
access the internet when furthering knowledge in clinical
practice. Furthermore, there is a need to disseminate knowl-
edge to professionals who may not be using the internet.
PA-118 RESEARCH ETHICS CAPACITY BUILDING FOR THE NEXT
DECADE – ‘BEYOND TRAINING’ – RHINNO ETHICS AS
MODEL TO IMPROVE AND ACCELERATE ETHICS REVIEW
OF HEALTH RESEARCH
Francis Kombe,1 Jacintha Toohey,1 Carel Ijsselmuiden2. 1COHRED, South Africa;
2COHRED, Switzerland
10.1136/bmjgh-2016-000260.147
Background Wide social disparities and weak health care
systems in Africa make timely development of essential medi-
cines, vaccines, medical technologies in and for Africa a desper-
ate need, given the burden of diseases facing the continent. We
estimate that it takes, on average, 1.5 years to get research ethics
clearance in many African institutions for complex research pro-
posals needed to deal with disease and solutions. Such delay
comes with potentially high human costs. The need for
Research Ethics Committees (RECs) to promptly and compe-
tently review protocols is therefore critical. Competent and effi-
ciently RECs can save human lives, reduce costs and ultimately
contribute to scientific development.
Methods Research for Health and Innovation Organiser
(RHInnO Ethics) is both an information management system
and an expert-decision support system for individual RECs that
is currently installed in 29 RECs in 8 African countries. It
enables online, better quality, efficient and standardised reviews
that can reduce review time in complex, multicentre trials by 12
months or more.
Results What progress has been achieved in the process of
implementing RHInnO Ethics since its inception in 2013?
While training courses (long and short) have been considered as
the mainstay of research ethics capacity building for decades,
the development of this software-as-a-service platform has led
to a more substantial understanding of how we can both acceler-
ate and enhance the quality of ethics review of health research.
We present experiences of our end users on how RHInnO
Ethics contributes in enhancing the quality and efficiency of
ethics review process.
Conclusions Health research ethics review needs to go beyond
training. We also present new functionalities in RHInnO Ethics
version 2.0, including EthiCALL-(RECs connecting with other
RECs worldwide), EthiXPERT (RECs updates on research ethics
developments) as well as Invoicing, REC accreditation and
pharmacovigilance functionalities that promise to revolutionise
the research ethics review process in Africa and beyond.
PA-119 EBOLA AND CLINICAL TRIAL ACTIVITY ON THE
AFRICAN CONTINENT
Elizabeth Pienaar, Tamara Kredo. SACC, South Africa
10.1136/bmjgh-2016-000260.148
Background Ebola virus disease (EVD) results in an often fatal
acute, serious illness. There are no effective EVD treatments,
however, there is ongoing research into potential interventions
in affected African countries. Since 2005, in efforts to enhance
transparency researchers must register trials on one of World
Health Organization’s clinical trials registries. WHO’s
International Clinical Trial Registry Platform (ICTRP) collates
this data providing information about planned, ongoing or
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completed trials for researchers, funders and the public. This
study mapped African EVD trial activity as found on WHO’s
ICTRP and identified available evidence from trial publications.
Methods We conducted a cross-sectional analysis of EVD
studies registered on ICTRP. Data extraction included trial loca-
tion, intervention, participant age, and funders. We used registry
identifiers to search PubMed for publications. Descriptive ana-
lysis was conducted in MS Excel™.
Results ICTRP was searched (20 June 2016) identifying 83 EVD
studies. Of these 45 are Africa-based. Studies were registered
from 2009–2016. Recruitment status indicates 6 completed, 2
withdrawn, 1 not started, 2 unknown status and 34 ongoing.
Forty-one studies evaluate an intervention, 4 are observational.
Interventions include vaccines (25), therapeutics (17), health ser-
vices/care (1) and diagnostics (2). Children were included in 24
studies. Funding sources include local and international univer-
sities and governments, non-governmental organisations, and
pharmaceutical industry. Of the 45 registered African studies, 11
records were found on PubMed, seven of which included results
of EVD studies.
Conclusions Mapping EVD clinical trial activity on ICTRP and
searching for completed studies on PubMed can provide data on
planned, ongoing or completed trials. The current research focus
is on identifying safe and efficacious vaccines to prevent EVD
including in children. The low number of trial reports indicates
that evidence is not yet publicly accessible which may impact on
evidence-informed policy development for the region.
PA-120 THE UTILITY OF FINGERPRINT-BASED PARTICIPANT
IDENTIFICATION AND CONSENTING IN CLINICAL
TRIALS IN DEVELOPING COUNTRY SETTINGS
Joseph Okebe, Pa Modou Cham, Ismaela Abubakar, Bai Lamin Dondeh,
Umberto D’Alessandro. MRC, The Gambia
10.1136/bmjgh-2016-000260.149
Background Involvement in clinical research requires evidence
of informed participant consent, and in many low-income coun-
tries with high illiteracy rates, this is done by a fingerprint
impression on paper. Due to poor quality of the impression, the
individual is often untraceable and this reduces the quality of
the process. The study assesses the potential usefulness of finger-
prints for consenting and automated participant identification.
Methods As part of a survey in villages in the North Bank West
region of The Gambia, individuals of all ages were invited to
provide a fingerprint scan to update the pre-trial census records.
Using commercial software, scanned impressions were stored on
encrypted templates and linked to a unique identifier. A scan is
successful if any of the five fingers on the left hand is captured
but documented as a failure if none of the five fingers on the
left hand records an impression on the scanner. We determined
the proportion of successful attempts, and the effect of age and
gender on the successful scan using a logistic regression model.
Results A total of 5204 persons were scanned with 74.7% suc-
cesses for any finger; 70.3% (1550/2206) in males and 78.0%
(2339/2998) in females and gender was strongly associated with
success rate (Chi2 <0.001). The success rate in children <5
years was 70.6% (726/1029) but lowest in adult males ≥40
years; 29.7% (96/323). The odds of a successful scan were
lower in males (adjusted OR 0.53; 95% CI: 0.46–0.61; p
>0.001) and highest between ages 5–25 years (OR 8.32; 95%
CI: 6.96–9.95; p<0.001) compared to adults ≥40 years.
Conclusions The use of fingerprint-based identification is
promising. However, recognition rates are lowest in adult males,
perhaps due to occupational practice. Potential for improving
sensitivity and application in data retrieval and documenting
consent is being explored.
PA-121 IMPROVING EFFICIENCY AND QUALITY IN CLINICAL
TRIALS IN SUB-SAHARAN AFRICA
Nerina Vischer, Constanze Pfeiffer, Christian Burri. Swiss TPH, Switzerland
10.1136/bmjgh-2016-000260.150
Background Conduct of clinical trials is significantly regulated
and requires substantial infrastructure and human resource
investments and efforts. Clinical research centres in sub-Saharan
Africa face particular challenges from the increasing trial-related
workload and administration, paired with capacity limitations.
We investigated the challenges in clinical trial conduct in
sub-Saharan Africa to optimising efficiency of processes while
maintaining quality. Our working hypothesis was that existing
regulations, not adapted to these particular situations, and their
possibly overly strict interpretation were the main challenge.
Methods We used an exploratory mixed methods design. Firstly,
key informant interviews with questions about quality, guidelines,
challenges, and inefficiencies in clinical trials were conducted with
60 clinical trial staff of different professional levels in two
English- and two French-speaking African countries. Content ana-
lysis was performed to identify themes across settings and posi-
tions, respectively. Secondly, we developed an online survey to
investigate trial protocol suitability based on the main interview
themes and targeting trial staff working in sub-Saharan Africa.
Results According to the interviewees, constraints to trial effi-
ciency arose from two themes: ‘planning’ (mainly poor planning
and missing context-adaptation), and ‘site organisation’ (mainly
staff turnover and workload). The two themes are of particular
relevance since they relate only to sponsors and sites and are
therefore independent of external conditions (e.g. lengthy
approval processes and population issues). Unexpectedly, the
administrative burden resulting from the guidelines was not per-
ceived as a difficulty; rather, researchers were grateful for having
guidance in their daily work. The online survey corroborated that
trial protocols need to be adapted to local contexts by early
involvement of the sites and careful consideration of local cap-
acity, systems and conditions.
Conclusions Our data suggest that careful site assessment, appro-
priate and coherent planning, clear task allocation and manage-
ment capacity strengthening may increase trial efficiency.
Involvement of study sites in protocol development was perceived
to be beneficial.
PA-123 FIELD PERFORMANCE OF POINT-OF-CARE TO
DETERMINE HBSAG TEST FOR DIAGNOSIS OF ACTIVE
HEPATITIS B VIRUS INFECTION IN ZAMBIA
Caroline Chisenga,1 Kalo Musukwa,1 Roma Chilengi,1 Samuel Zürcher,1
Virginia Munamunungu,2 Alice Siyunda,1 Temwani Mwandu,1 Sophie Bauer,1
Gilles Wandeler,3 Michael Vinikoor1. 1CIDRZ, Zambia; 3University of Bern,
Switzerland
10.1136/bmjgh-2016-000260.151
Background In Zambia, we evaluated the field performance of
a rapid point-of-care test for hepatitis B surface antigen (HBsAg)
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which could support decentralisation and scale-up of care and
treatment of chronic hepatitis B virus (HBV) infection in
sub-Saharan Africa.
Methods At two urban public health facilities in Zambia’s
capital Lusaka, we screened a cohort of HIV-infected adults for
HBsAg per national guidelines. A subset was tested with both
Determine HBsAg (Alere, USA), using finger prick in the clinic,
and HBsAg serology (Access2Analyser, Beckman Coulter), using
serum sent to a reference laboratory. If either test was reactive,
we measured HBV viral load (VL) and determined HBV geno-
type with Sanger sequencing. We described patient demographic
and clinical characteristics (including liver fibrosis biomarkers)
and assessed the sensitivity, specificity, positive and negative pre-
dictive values (PPV and NPV) of the Determine test. In second-
ary analyses, we assessed sensitivity among patients with
replicating HBV (VL >20 IU/mL) and with high HBV VL
(>20,000 IU/mL).
Results Among 412 participants with both HBsAg tests, median
age was 34 years, 51% were women, and median CD4 was 208
cells/mm3. By serology, 66 (16%) were HBsAg-positive. HBV
genotypes were A1 (n=21; 52.5%) and E (n=19; 47.5%)
among successfully sequenced samples. Overall, the Determine
test had 87.9% sensitivity (95% CI: 84.7–91.0%), 99.7% speci-
ficity, 98.3% PPV, and 97.7% NPV. The majority of patients (6/
8) with false negative results had undetectable HBV VL and no
evidence of significant liver fibrosis. Test sensitivity increased to
95.9% among the 51 with replicating HBV and to 100% among
the 28 with high HBV VL.
Conclusions The Determine HBsAg test accurately diagnosed
HBsAg-emia in the majority of field-tested HIV patients, par-
ticularly those with higher HBV VL. False negatives tended to
have inactive HBV infection further supporting the use of this
low-cost test in public health settings in sub-Saharan Africa.
PA-125 EVALUATION OF CIRCULATING CATHODIC ANTIGEN
(CCA) URINE-CASSETTE ASSAY AS A SURVEY TOOL FOR
SCHISTOSOMA MANSONI IN DIFFERENT
TRANSMISSION SETTINGS WITHIN BUGIRI DISTRICT,
UGANDA
Moses Adriko. Vector Control Division, Ministry of Health, Uganda
10.1136/bmjgh-2016-000260.152
Background Diagnosis of schistosomiasis at the point-of-care is
a growing topic in neglected tropical disease research. There is a
need for diagnostic tests which are affordable, sensitive, specific,
user-friendly, rapid, equipment-free and delivered to those who
need it, and point-of-care is an important tool for disease
mapping and guiding mass deworming.
Methods Our study was conducted among 500 school children
randomly selected across 5 schools within Bugiri district, adja-
cent to Lake Victoria in Uganda. Duplicate Kato-Katz thick
smears were prepared in the field upon receipt of the faecal
samples and were read under a microscope within 60 minutes
of slide preparation to determine hookworm status. The slides
were again read 24 hours later for Ascaris lumbricoides,
Trichuris trichiura and S. mansoni and this was repeated for all
subsequent stool samples.
Results Of the 469 pupils who provided three stool samples for
the six Kato-Katz smears, 293 (76%) children had no infection,
109 (23%) were in the light intensity category, while 42 (9%)
and 25 (5%) were in the moderate and heavy intensity categor-
ies, respectively. Following performance analysis of CCA tests in
terms of sensitivity, specificity, negative and positive predictive
values, the overall performance of the commercially available
CCA test was more informative than single Kato-Katz faecal
smear microscopy, the current operational field standard for
disease mapping.
Conclusions The current CCA assay is a satisfactory method
for surveillance of S. mansoni in an area where disease endem-
icity is declining due to control interventions. The urine
point-of-care CCA test is an attractive tool to augment and
perhaps replace the Kato-Katz sampling within ongoing control
programmes.
PA-126 COMMUNITY KNOWLEDGE, ATTITUDES AND
PRACTICES (KAP) DURING MDA INTEGRATED MALARIA
ELIMINATION AND SCHISTOSOMIASIS AND
SOIL-TRANSMITTED HELMINTHS CONTROL STUDY IN
NGODHE ISLAND, LAKE VICTORIA, KENYA
Peter Mwaura,1 James Kongere,2 Kevin Omolloh,3 Jesse Gitaka1. 1Mount Kenya
University, Kenya; 2NUITM, Kenya; 3KEMRI, Kenya
10.1136/bmjgh-2016-000260.153
Background Knowledge, attitudes and practices (KAP) of com-
munities where mass drug administration based integrated
malaria elimination and control of schistosomiasis and soil
transmitted helminths (STH) is targeted will be critical in adher-
ing to intervention strategies. KAP surveys have the potential to
reveal lessons that will inform implementation in similar set-
tings. This study sought to assess knowledge, attitudes and prac-
tices of Ngodhe islanders in Lake Victoria Kenya during mass
drug administration (MDA) with artemisinin-piperaquine and
low dose primaquine for malaria; albendazole for STH and
praziquantel for schistosomiasis.
Methods The KAP study used a pre-tested interviewer ques-
tionnaire that was administered to 239 randomly selected
adults. Additionally, 4 focus group discussions (each consisting
of between 8–12 participants) was done with the elders,
women, youth, and mixed group. Another 6 key informant
interviews were also done.
Results All respondents (239) had heard about malaria and they
acknowledged that it is preventable; 89.1% of respondents had
heard about schistosomiasis; and another 87.4% had heard about
STH. A high percentage of 96.2 had heard about the mass drug
administration while 87% were aware of the integrated malaria,
schistosomiasis, and STH strategy. 78.2% of participants favoured
stopping MDA in case side effects were perceived to be common.
Sanitation was a major challenge with only 41.3% of the respon-
dents using latrines with the rest using bushes.
Conclusions This study revealed huge awareness of the inte-
grated strategy for malaria elimination and schistosomiasis and
STH control using mass drug administration. Nonetheless, con-
cerns on MDA drugs side effects and poor sanitation practices
will require greater engagement with the community.
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PA-127 INTERRUPTED BANCROFTIAN FILARIASIS EXPOSURE
RATES IN CHILDREN AFTER TWELVE ROUNDS OF MASS
DRUG ADMINISTRATION AND USE OF LONG-LASTING
INSECTICIDAL NETS IN RUFIJI DISTRICT, TANZANIA
Clarer Jones,1 Billy Ngasala,1 Mwelecele Malecela2. 1MUHAS, Tanzania; 2NIMR,
Tanzania
10.1136/bmjgh-2016-000260.154
Background Tanzania started implementing the WHO strategy
of mass drug administration (MDA) with ivermectin and alben-
dazole to eliminate lymphatic filariasis (LF) in Rufiji District,
which had a baseline prevalence of 49% in 2000. This study
was conducted in April 2015, six months after the latest MDA
to establish the impact of MDA and utilisation of long-lasting
insecticidal nets on the exposure rates of LF among
standard-one children born within the implementation period
of the LF elimination programme after 12 rounds.
Methods A cross-sectional study for LF circulating filarial
antigen (CFA) was performed in 5 primary schools from 5 dif-
ferent villages. A total of 659 standard-one pupils aged 6–9
years were recruited and screened for CFA using immunochro-
matographic test cards (ICT). Prior to blood sample collection,
children were interviewed on their participation in the MDA. A
finger prick whole blood sample (100 ml) drawn from each
child was applied to ICT. Results were read after ten minutes
for the presence of CFA. Also, the study involved 868 heads of
household who were interviewed on their participation in MDA
and utilisation of long-lasting insecticidal nets (LLINs).
Results The ICT results were negative for CFA and suggest that
there has been an interruption of exposure of children to LF
transmission in the study area. More than half of the screened
children (54.3%) participated in 2014 MDA round. Household
surveyed MDA coverage was 57.4% for the 2014 MDA, below
the minimum effective coverage recommended by WHO.
Majority (92.5%) of households possessed and utilised LLINs.
Of those who did not take the drugs in the last round, 88.7%
possessed and utilised LLINs suggesting its synergistic effect
with ivermectin and albendazole on LF transmission.
Conclusions Additional MDA rounds and utilisation of LLINs
in areas of high-baseline prevalence may result in considerable
decreased lymphatic filariasis infection transmission.
PA-128 THE EFFICACY OF ALBENDAZOLE AGAINST
SOIL-TRANSMITTED HELMINTHS AND THE IMPACT OF
MASS DRUG ADMINISTRATION OF ALBENDAZOLE AND
IVERMECTIN ON HEALTH STATUS
Buhari Adamu Hamidu,1 Tettevi Edward Jenner,1 Larbi John Asiedu,2
Mike Osei-Atweneboana1. 1CSIR Water Research Institute, Ghana; 2KNUST, Ghana
10.1136/bmjgh-2016-000260.155
Background The lymphatic filariasis (LF) control programme
has been on-going in Ghana since 2000 with mass drug admin-
istration (MDA) of ivermectin (IVM) and albendazole (ALB).
Soil-transmitted helminth (STH) infections control is augmented
within this programme. Therefore this study aimed to determine
the efficacy of ALB against STH infections and impact of MDA
on study participants.
Methods This was a twelve months longitudinal study. A total
of 412 subjects including school children (between the ages of
2–17 years) and pregnant women were randomly selected from
four endemic communities in Kpandai district of the Northern
region. Coprological assessment for parasites was based on the
Kato–Katz technique in both dry and rainy seasons at baseline,
21 days and 3 months post treatment. Single dose albendazole
treatment was administered to all patients at baseline.
Results Of all the parasites found (hookworm, Trichuris tri-
chiura, Hymenolepis nana, and Taenia sp.), hookworm was the
most prevalent. In the dry season, the overall STHs prevalence at
pre-treatment was 29%, while 9% and 13% prevalence was
recorded at 21 days, and three months after treatment, respect-
ively. However, in the rainy season, the overall STHs prevalence
was 8%, while 4% and 12% was recorded at 21 days and three
months respectively after ALB treatment. In general, ALB treat-
ment resulted in an overall hookworm egg count reduction rate
of 89% in the dry season and 93% in the rainy season, while the
T. trichiura egg count reduction rate was 100% in both seasons.
Conclusions STH infections still remain a significant public
health burden in Ghana. Hookworm infection seems to respond
poorly or suboptimally to ALB, raising concerns of possible
emergence of resistance which may lead to a major setback for
the control and elimination of STH infections, especially hook-
worm infections.
PA-129 CULTIVATION OF TWO IS2404 POSITIVE
MYCOBACTERIUM SPP. FROM THE ENVIRONMENT OF
ASANTE AKIM DISTRICT OF GHANA
Innocent Afeke,1 Phyllis Addo,2 Mercy Newman,3 Lies Durnez,4 Miriam Eddyani,4
Nana Ammisah,2 Mona Abas,2 Maxwell Quartey,2 Anthony Ablordey2. 1UHAS,
Ghana; 2NMIMR, Ghana; 3University of Ghana Medical School, Ghana; 4ITM
Antwerp, Belgium
10.1136/bmjgh-2016-000260.156
Background Buruli ulcer (BU) is one of the neglected tropical
diseases. Mycobacterium ulcerans is the aetiologic agent of
Buruli ulcer. Many extensive studies have failed to isolate M.
ulcerans in pure culture from the environment, even in highly
endemic areas of BU. We investigated the role of macro-
invertebrates as possible hosts or vectors for M. ulcerans by
attempting to cultivate M. ulcerans from these organisms.
Methods The study was conducted in 5 villages in the Asante
Akim District of Ghana for 10 months. Primary detection of M.
ulcerans was done by real-time PCR targeting insertion
sequence IS2404 coupled with the detection of IS2606 and
Ketone reductase genes for increased sensitivity and specificity.
Primary cultures were done using routine bacteriological media
for culturing mycobacteria, L-J and special enrichment liquid
broth, BACTEC®.
Results The overall rate of detection of IS2404 in the general
macro-invertebrate population was 12.8%. Cluster of CT-values
was observed around a mean value of 35.88 and range values of
28.35–38.61. Statistically, there were no significant differences
between the various CT-values obtained, p>0.05. The differ-
ence in ΔCT values (IS2606-IS2404) for homogenate sample
obtained from Naucoridae which was positive for the three
targets on M. ulcerans genome was estimated to be 1.77. The
present study reports the cultivation of two IS2404 positive
Mycobacteria spp. from two aquatic macro-invertebrates of the
families Belostomidae and Notonectidae both of the order
Hemiptera. The isolate from Belostomidae was identified as
either M. ulcerans or M. marinum with 98% identities that from
Notonectidae was 98% identical to M. neoaurum. The organ-
isms are yet to be passaged through mice footpad and fully
characterised.
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Conclusions For the first time M. neoaurum species was
reported to have harboured IS2404 element. Aquatic Hemiptera
are highly suspected to be vectors or hosts for M. ulcerans and
they may transmit the pathogen to humans through biting.
PA-130 MODIFIABLE RISK FACTORS OF BURULI ULCER IN
COMMUNITIES OF TWO ENDEMIC LOCAL
GOVERNMENT AREAS OF OGUN STATE, NIGERIA
Olaoluwa Akinwale, Adeniyi Adeneye, Sylvanus Ezeugwu, Yetunde Olukosi,
Babatunde Adewale, Medinat Sulyman, Margaret Mafe, Jane Okwuzu, Pam Gyang,
Timothy Nwafor, Uzoma Henry, Bilkisu Musa, Innocent Ujah. NIMR, Nigeria
10.1136/bmjgh-2016-000260.157
Background Buruli ulcer (BU) remains a neglected tropical
disease globally including in Nigeria despite its severe health
and socio-economic consequences. This study was conducted as
there is a paucity of data on community knowledge and risk
factors of BU in Nigeria.
Methods The study was conducted in the BU-endemic Yewa
North and Yewa South local government areas (LGAs) of Ogun
State, Nigeria. Study population included community members
selected using multi-stage sampling techniques. Household
survey using a semi-structured questionnaire was used for data
collection. Data were analysed using SPSS (version 20) software.
Results A total of 236 consented respondents were interviewed
(Yewa North 76.7% vs Yewa South 23.3%; males 48.7% vs
females 51.3%) with an average age of 33.1 years. Only 39.0%
had a minimum of secondary education. A little over half (128;
54.2%) reported having knowledge of BU in their communities.
However, only 35.6% adjudged BU a common disease in their
communities while 56.0% perceived it as a serious health chal-
lenge. Few (14.0%) respondents had an average of one house-
hold member who had or have BU. Most (64.8%) did not know
the cause of BU while 9.7% attributed it to witchcraft/Olobutu,
bacteria (4.2%), water contact (3.0%) and poor hygiene (3.0%).
53.4% visit riverbanks for activities that were predominantly:
washing (37.3%); swimming (35.7%); fetching water (19.8%);
and agricultural activities (4.0%). Gender and age had no sig-
nificant influence on respondents’ knowledge of the cause of BU
(p>0.05). Swimming and other activities on the riverbanks
associated with BU had significant correlation with report of BU
cases in the household (p< 0.05).
Conclusions Pervasive knowledge of BU cases and high-
perceived seriousness of the disease in the study communities
exist. Nonetheless, there is need for more public health educa-
tion emphasising common modifiable risk factors and actual
cause of BU. Overall, these results provide insights for BU pro-
gramme planning and optimisation.
PA-132 EFFECT OF SCHISTOSOMA HAEMATOBIUM INFECTION
ON PLASMODIUM FALCIPARUM MALARIA BURDEN IN
LAMBARÉNÉ, GABON
Jean Claude Dejon Agobé,1 Frejus Jeannot Zinsou,1 J Honkpehedji,1 Ulysse
Ateba Ngoa,1 Peter Kremsner,2 Ayola Adegnika1. 1CERMEL, Gabon; 2ITM Tübingen,
Germany
10.1136/bmjgh-2016-000260.158
Background Malaria remains the first cause of death in Africa.
In endemic area, it overlaps with other infections including
helminths infections. It has been shown that there are interac-
tions between the two parasites infection. Lambarene is the
endemic area for urogenital schistosomiasis, which co-exist with
P. falciparum malaria. Therefore, we decide to assess for the
first time the effect of schistosomiasis infection on malaria infec-
tion burden.
Methods In order to assess the effect of S. haematobium on
malaria infection burden, a cross-sectional study was conducted
in school children aged 6–16 years old. One blood smear was
performed and 3 urine samples were obtained to assess the pres-
ence of infections. Chi-square test and generalised linear model
were used to compare the risk to be infected by P. falciparum
parasite and Mann-Whitney-Wilcoxon test to compare the para-
sitaemia of P. falciparum. Demographic data was also collected.
Results A total of 741 children were included. The overall
prevalence was 20% and 31% for P. falciparum microscopic car-
riage and S. haematobium infection, respectively. Co-infection
of both was found in 65 (9%) participants. S. haematobium and
P. falciparum are highly prevalent in PK compared to Bindo and
Makouké areas. At univariable analysis, schistosomiasis-infected
subjects have an odd of 2.11 [1.46–3.07] to be infected by P. fal-
ciparum parasite compared to non-infected subjects. Locality
was found to confound the association which remains significant
after adjustment for age, gender and locality (aOR=1.69, [1.13–
2.59]). The effect of S. haematobium on the P. falciparum para-
sitaemia outcome was also assessed. There is no effect of
Schistosoma infection on malaria parasite density
(p-value=0.92).
Conclusions S. haematobium infection increases the risk of
being infected with P. falciparum but doesn’t affect the parasit-
aemia density of P. falciparum malaria in our study population.
PA-133 WATER SUPPLY AND SANITATION CONDITIONS IN
RURAL SOUTHERN MOZAMBIQUE AND ITS
ASSOCIATION WITH MORBIDITY AND MORTALITY
INDICATORS, 2012–2015
Berta Grau-Pujol,1,2 Charfudin Sacoor,1 Augusto Nhabomba,1 Aina Casellas,2
Llorenç Quintó,2 Carme Subirà,2 Ricard Giné,3 Antònia Valentín,2
Jose Muñoz1. 1CISM, Mozambique; 2ISGlobal Barcelona, Spain; 3Polytechnic
University of Catalonia, Spain
10.1136/bmjgh-2016-000260.159
Background Water, sanitation and hygiene (WASH) are major
health determinants, responsible for an estimated world-wide
disease burden of 5.7%. However, the debate about the effect
of water quality, hygiene and sanitation in preventing diarrhoea
is still ongoing. The aim of this study is to describe access to
improved water supply and sanitation infrastructure, as defined
by the Joint Monitoring Programme, in the Manhiça Health
Research Centre (CISM) study area and evaluate its association
with morbidity and mortality indicators.
Methods We conducted a retrospective cohort study. All
children under 15 living in the study area during the period
2012–2015 were included (N=61900). Children were fol-
lowed up until they moved from the study area, turned 15
or until 2015. Water and sanitation household data were
obtained from the CISM demographic surveillance system
(DSS) in the Manhiça district, an area of around 2380 km2.
Clinical data were obtained from CISM’s round-the-clock
morbidity surveillance system covering outpatient and hos-
pital admissions at the Manhiça District Hospital (MDH)
and rural health posts. A negative binomial regression model
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using Wald test was performed to assess the minimum
community-based incidence rates (MCBIR) for every
morbidity-mortality indicator.
Results Preliminary data showed that 86% of the children lived
at least once in a household with unimproved sanitation facilities,
27% with an unimproved water source. Spatial distribution of
unimproved water and sanitation facilities showed to be clustered.
Access to unimproved sanitation and water facilities was asso-
ciated to higher rates of diarrhoea, a significant 30% of diarrhoea
rate increase was observed for rivers, lakes and ponds as water
sources. Other morbidity indicators (malnutrition, parasitaemia,
anaemia) also showed a rate increase with the use of unimproved
water and sanitation facilities.
Conclusions Obtained results are useful to inform sector-related
decision-making processes and ultimately improve access to safe
drinking water and sanitation in rural southern Mozambique.
PA-134 NONTYPHOIDAL SALMONELLA IN THE FOODSTUFFS
AND THE HUMAN DIARRHOEAL STOOLS IN
OUAGADOUGOU, BURKINA FASO
Marguerite Nikiema,1 Absatou Ky-Ba,2 Kiswendsida Abdou Muller Comapore,2
Alfred Traore,3 Lassana Sangare1. 1CHUYO, Burkina Faso; 2Laboratoire National de
Santé Publique, Burkina Faso; 3UFR-SVT, University of Ouagadougou, Burkina Faso
10.1136/bmjgh-2016-000260.160
Background The sanitary quality of food is a global concern.
Salmonella infections are a major health problem in developing
countries. Each year, food poisoning is affecting thousands of
consumers. The objective of this study was to isolate strains of
nontyphoidal Salmonella in food and in human diarrhoeal
stools in Ouagadougou.
Methods Sixty-one samples of sandwiches bought in
Ouagadougou and 177 diarrhoeic stools specimen collected
at the University Hospital Yaldao Ouedraogo and the
Medical Centre Schiphra from May to October 2015 to
detect Salmonella. The antibiotic susceptibility testing of
Salmonella strains was done by the disk diffusion method
using 14 antibiotics. Statistical analysis of data was done with
Epi Info 7.3.
Results From the overall samples analysed, 23 strains of
Salmonella were identified including14/177 (7.9%) clinical
strains, 9/61 (14.75% ) food strains. After antigenic identifi-
cation 15 isolates (6 from foods, 9 from stools) belonged to
known serotypes including 9 typhoidal and 6 nontyphoidal
stains. Eight strains (3 from foods, 5 from stools) could not
be serotyped by the reagents available. All the serotypes iden-
tified were found in stools (2 S. typhi, 1 S. paratyphi B, 1 S.
paratyphi C, 1 S. enteritidis, 3 S. typhimurium and 1 S.
dublin) while S. paratyphi B (4), S. paratyphi C (1) and S.
enteritidis (1) only were identified in foods. Eleven (47.83%)
strains were resistant to cotrimoxazole (2/11), tetracycline (8/
11), nalidixic acid (##) and ciprofloxacine (2/11).
Conclusions The overall frequency of Salmonella is higher in
the foods than in the diarrhoeic stools. However, the sero-
type diversity of the clinical strains is more important than
that of the food strains. The street sandwiches would not be
the main sources of contamination by Salmonella. The high
rate of the Salmonella resistance to antibiotics requires a
more steady surveillance of the use of these antimicrobials.
PA-135 URGENT NEED TO EDUCATE NIGERIANS ABOUT THE
EBOLA VACCINE TRIAL PROGRAM
Adeolu Oluremi, Oluyinka Opaleye. LAUTECH, Nigeria
10.1136/bmjgh-2016-000260.161
Background With the effort of the World Health Organization
to start distributing an experimental Ebola vaccine in West
Africa, there is need to assess knowledge and willingness to par-
ticipate in Ebola virus vaccine trials (EBVT) and possible bar-
riers to participation.
Methods From June to November 2015, a structured question-
naire was used to measure the participants’ knowledge and atti-
tudes about Ebola virus vaccine in Nigeria. Data were analysed
with packages within SPSS software and p< 0.05 considered
significant.
Results A total of 5000 participants aged 18–49 years were
involved; mean age was 37 years; 3218 (64.4%) were female and
1782 (35.6%) male. Willingness to participate in Ebola virus
vaccine trials was found in 803 (16.1%) in this population. It was
higher in men than women (p=0.001), increased with education
levels (p=0.003), higher among employed than unemployed
(p=0.005) and higher among single than married (p=0.01).
Those who wanted to participate were primarily youth and
reasons for readiness to participate include: free health care,
monetary gain, international connection and employment oppor-
tunity. Decreased willingness was associated with concerns
about: fear of reverting back, side effect, refusal of spouses, phys-
ical harm, use of parenteral route for vaccine administration,
multiple doses of vaccines and societal stigmatisation.
Conclusions This study showed reduced willingness to partici-
pate in EBVT. It also revealed limited knowledge about EBVT in
Nigeria. Therefore, there is a need for proper education on the
potential role of preventive Ebola virus vaccines in the control of
epidemics and the importance of vaccination among the popu-
lace of Nigeria. Incentives for would-be subjects should also be
part of the planning to encourage greater participation in these
trials.
PA-136 EFFECT OF ONCHOCERCIASIS TREATMENT ON THE
FREQUENCY OF SEIZURES IN PATIENTS WITH EPILEPSY
AND ONCHOCERCIASIS
Mandro Michel. Provincial Division of Health of Ituri, Republic of Congo
10.1136/bmjgh-2016-000260.162
Background A high prevalence of epilepsy is mainly observed
in Onchocerca volvulus (OV) hyperendemic areas with no or
low ivermectin coverage. There is anecdotal evidence that iver-
mectin may reduce seizure frequency in patients with onchocer-
ciasis associated epilepsy (OAE).
Methods Between 2008 and 2012, Rethy in Ituri Province,
Democratic Republic of Congo, was a study site for a phase III
trial comparing moxidectin versus ivermectin as treatment for
subjects infested with OV. Participants received a single oral dose
of OV drug and were followed for 18 months. Parasitological
efficacy was assessed by skin snip exams. In July 2016, the ran-
domisation code has not been broken yet. In 2015 we traced 7
families of patients with epilepsy who had been enrolled in the
trial. We interviewed them and reviewed the trial case report
forms.
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Results Of 472 trial participants, 13(2.7%) had a medical
history of active convulsive epilepsy. After OV treatment, 6
(80%) of 7 male patients with epilepsy became seizure free
during the following 18 months. Seizures continued in this
period in only 1 person with a decrease in frequency; in the
latter microfilariae remained detectable in the skin. In all sub-
jects who became seizure free, the skin snips too became
microfilaria free for at least 6 months. None of the patients
received any anti-epileptic drug nor an additional dose of mox-
idectin or ivermectin during or after the trial. In all subjects
the frequency of seizures increased again after the 18 months
and 2 patients died in 2015, because of drowning in the river
during seizures.
Conclusions This study suggests that moxidectin and/or iver-
mectin may be able to decrease the frequency of seizures in
OV-infested people with epilepsy. A clinical trial will be needed
to support this hypothesis.
PA-137 ASSESSMENT OF THE ENDEMICITY STATUS OF
SCHISTOSOMIASIS AND SOIL-TRANSMITTED
HELMINTHIASIS IN THE GAMBIA
Yaya Camara, Bakary Sanneh. Ministry of Health and Social Welfare, The Gambia
10.1136/bmjgh-2016-000260.163
Background The Ministry of Health and Social Welfare,
The Gambia with support from WHO and Task Force for
Global Health (TFGH), conducted a national endemicity
mapping survey for schistosomiasis (SCH) and soil-
transmitted helminths (STH) to establish their endemicity
status. The survey was meant to provide baseline informa-
tion on endemicity in order to plan and implement strategic
interventions. This is a critical step towards NTD elimin-
ation by 2020.
Methods A cross-section of fifty school-aged children (SAC,
25 boys and 25 girls) per school was sampled in 209 schools
countrywide. Eligible SAC of 7 to 14 years old were randomly
selected using formula (n/50) where n=total eligible pupils per
school. Stool, urine and finger prick samples provided, were
examined for SCH and STH using Kato-Katz, urine filtration,
dip-stick and CCA techniques.
Results National prevalence of schistosomiasis and soil-
transmitted helminthiasis were 4.3% and 2.5%, respectively. At
district level, Niani had the highest prevalence of SCH, record-
ing 22%. Whereas for STH, Banjul, the capital city, had the
highest prevalence, recording 55%, followed by 22% preva-
lence in Kombo South. Schistosoma haematobium is the most
dominant parasitic infection in The Gambia. Fourteen (38%)
districts in the country are co-endemic for both STH and
SCH. Generally, male pupils are more infected with urinary
schistosomiasis than females.
Conclusions It was established that 19 (45%) of districts
mapped are endemic for schistosomiasis; thus the need for
treatment with praziquantel. Twenty (47%) of districts
mapped are endemic for soil-transmitted helminthiasis at
varying rates. However, only two STH endemic districts,
Banjul (55%), and Kombo South (22%), within the high and
very high prevalence rates of endemicity, are eligible for treat-
ment with albendazole.
PA-138 PREVALENCE OF GASTROINTESTINAL PARASITES
IN SOUTHERN MOZAMBIQUE USING A NOVEL
MULTIPARALLEL QUANTITATIVE REAL-TIME PCR
Inocencia Cuamba,1 Berta Grau-Pujol,2 Augusto Nhabomba,1 Jose Gutiérrez,2
Carlota Lázaro,2 Rojelio Mejia3. 1CISM, Mozambique; 2ISGlobal Barcelona, Spain;
3Baylor College of Medicine, United States of America
10.1136/bmjgh-2016-000260.164
Background Intestinal parasitic infections are distributed
worldwide presenting high prevalence in low-income countries.
Gastrointestinal parasites in children are associated to inhibition
of normal growth, low intellectual development, vitamin defi-
ciency by malabsorption, chronic diarrhoea and dysentery.
Available data point to global prevalence in Mozambique
(2005–2007) of 65.8% for soil-transmitted helminthiasis.
Diagnosis of gastrointestinal parasites relies on stool microscopy
which has a lower sensitivity and specificity than molecular
biology methods. Consequently, researchers have developed a
novel multi-parallel quantitative real-time PCR to detect proto-
zoa and helminths in stool. This technique was used in the
current study to determine the prevalence of gastrointestinal
parasites in the Manhiça district.
Methods Stool samples (10 g) for the detection of gastrointes-
tinal parasites were collected from 175 children, aged 2 to 10
years, recruited at the Manhiça District Hospital. Clinical and
laboratory data were obtained for all participants. Helminths
and protozoa were detected through microscopy, the gold stand-
ard method, and through multi-parallel quantitative real-time
PCR.
Results High prevalence was found for Giardia lamblia (61%).
Other prevalent parasites were Ascaris lumbricoides (10.2%),
Strongyloides stercoralis (8.6%), Cryptosporidium (4%) and
Necator americanus (2.8%). Ancylostoma duodenale and
Entamoeba histolytica were not detected in any samples
studied. More than 60% of children with A. lumbricoides pre-
sented high egg burden that was correlated with increased
Giardia burden co-infection (p=0.01).
Conclusions The preliminary results point to a high prevalence
of G. lamblia. In our sample, a high Giardia burden was asso-
ciated with higher A. lumbricoides egg count. Further analysis
will allow us to correlate findings with clinical data and to
evaluate the effect of the presence of gastrointestinal parasites
on the immunological response to malaria.
PA-139 SOIL-TRANSMITTED HELMINTH INFECTIONS AND RISK
FACTORS AMONG PRIMARY SCHOOL PUPILS IN LAGOS,
NIGERIA
Babatunde Adewale,1 Abimbola Adedeji,1 Sola Folorunsho,2 Pelumi Demehin,2
Bamidele Akinsanya2. 1NIMR, Nigeria; 2University of Lagos, Nigeria
10.1136/bmjgh-2016-000260.165
Background A survey of prevalence of soil-transmitted hel-
minth infections and associated risk factors among pupils of
primary schools carried out between June and July 2015.
Methods Four primary schools were purposely selected for the
survey (2 public and 2 private). All the pupils that consented to
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participate were given sterile universal containers for the collec-
tion of stool samples which were processed for examination
using Kato Katz technique. Structured questionnaires were
administered to the pupils to obtain demographic and risk
factors information.
Results A total of 243 pupils aged 5–15 years were recruited
for the study while 207 (85.2%) complied and returned stool
samples suitable for examination. The overall prevalence of
infection was 34.8% (males 36.8%; females 33%). There was
no significant difference between the male and female infection
rate (p=0.6) and there was also no significant difference among
the different age groups (p=0.7). About a quarter (24.2%) of
the population studied had single infection of Ascaris lumbri-
coides and 1% had hookworm infection while 4.3% had mul-
tiple infections of Ascaris lumbricoides and Trichuris trichiura.
Multiple infections of Ascaris lumbricoides, Trichuris trichiura,
and Taenia spp. occurred in 0.5%. Large proportion of pupils
engaged in risk factors such as cutting of finger nails with teeth
(58.5%), unhygienic eating habits (41.4%), and irregular hand
washing (28.5%). Majority (71.5%) of the pupils were not
aware of school deworming programme among which 35.8% of
them were positive for infection. Also 39.3% of the total
number of pupils (56) who engage in open defaecation and use
of pit latrines were positive for infection.
Conclusions This showed that unhygienic habits practiced by
pupils predisposed them to infection and the need to combine
the school deworming programme with health education to
reduce the burden of infection among pupils.
PA-140 IS TRACHOMA ON TRACK FOR ELIMINATION BY 2020?
MONITORING AND SURVEILLANCE AFTER MASS DRUG
ADMINISTRATION WITH AZITHROMYCIN FOR ACTIVE
TRACHOMA IN GUINEA BISSAU
Giovanna Cowley, Eunice Teixeira Da Silva, Meno Nabicassa, Pedrozinho Duarte
Pereira De Barros, Milena Mbote Blif, Robin Bailey, Anna Last. LSHTM, United
Kingdom
10.1136/bmjgh-2016-000260.166
Background Guinea Bissau is a trachoma-endemic country that
has pledged to eliminate blinding trachoma by 2020 by imple-
mentation of the SAFE strategy. Evidence for elimination is to
be presented in a dossier to WHO. Mass drug administration
(MDA) with azithromycin for active trachoma has been carried
out in the Bijagos and Cacheu regions. Through collaboration
with government and non-government agencies, we conducted
coverage and impact surveys to evaluate success of MDA and
build capacity in monitoring and surveillance activities within
the Programa Nacional de Saude de Bissau. Our surveys demon-
strate the feasibility of compiling the elimination dossier and
show promising results.
Methods (1) Coverage survey (Bijagos): Seven households were
randomly selected from 17 villages on five islands which had
received MDA 1 month previously. Household members
reported whether they had taken azithromycin and population
coverage was calculated. (2) Impact survey (Cacheu): 15 house-
holds were randomly selected from 20 clusters. Trained ophthal-
mic nurses recorded cases of follicular trachoma (TF) amongst
1–9 year-olds and of trachomatous trichiasis (TT) amongst
people aged 15 and above. Prevalence estimates of TF and TT
were calculated.
Results (1) MDA Coverage (Bijagos): Estimated MDA coverage
was 90.9% overall (n=518) and 94.4% amongst children aged
1–9. (2) Impact survey (Cacheu): 701 1–9 year-olds and 1557
>14 year-olds were examined. The estimated prevalence of
TF1–9 was 0.3% and that of unoperated TT>14 was between
0.1 and 0.4%.
Conclusions These surveys provide evidence that MDA can
achieve very high levels of coverage in remote and poorly
accessible areas and can reduce TF to below the WHO elimin-
ation threshold. Successful TF elimination can allow focus to
shift to operating TT, which remains a significant public health
problem after MDA. These surveys demonstrate how sound epi-
demiological methods can be used in programmatic settings to
evaluate elimination campaigns, guide future programme activ-
ities and contribute to global data collection.
PA-141 THE INTERNATIONAL GOOD CLINICAL PRACTICES
GUIDELINES: TIME FOR A REVISION?
Raffaella Ravinetto,1 Halidou Tinto,2 Ermias Diro,3 Joseph Okebe,4
Yodi Mahendradhata,5 Suman Rijal,6 Eduardo Gotuzzo,7 Pascal Lutumba,8
Alain Nahum,9 Kateljine De Nys,10 Minnes Casteels,10 Marleen Boelaert1. 1ITM
Antwerp, Belgium; 2CRUN, Burkina Faso; 3University of Gondar, Ethiopia; 4MRC,
The Gambia; 5Gadiaj Madah University, Indonesia; 6BPKIHS, Nepal; 7Humboldt
Tropical Medicine Institute, Peru; 8University of Kinshasa, Republic of Congo; 9CREC,
Benin; 10KU Leuven, Belgium
10.1136/bmjgh-2016-000260.167
Background The Good Clinical Practices (GCP) codes of the
World Health Organization and the International Conference of
Harmonization set international standards for clinical research.
But critics argue that they were written without considering the
challenges faced by clinical researchers in low- and
middle-income countries (LMIC).
Methods We analysed the challenges met when conducting
clinical trials in LMIC, including in several locations in
sub-Saharan Africa and in EDCTP-funded trials. We compared
these challenges to GCP guidance, in order to (a) verify if there
are gaps between the international GCP codes and the field
reality in LMIC, and (b) formulate recommendations for GCP
improvement if needed.
Results We identified shortcomings in the GCP guidance con-
cerning three broad domains: ethical, legal and operational. We
identified also eleven specific issues: the double ethical review of
‘externally sponsored’ trials; the informed consent in children;
the informed consent in illiterate people; the informed consent
comprehension; the definition of vulnerability; the post-trial
access to communities; the role of communities as key stake-
holders in research; the definition of sponsor; the guidance for
contractual agreements; the clinical monitoring; the laboratory
quality management systems; and the quality assurance of inves-
tigational products. For each specific issue, we formulated a rec-
ommendation for the improvement of GCP.
Conclusions Clinical trials are increasingly conducted in
LMICs, thus a comprehensive revision of GCP guidelines is
needed, to ensure adequate guidance for researchers operating
in these contexts, and to maximise protection of research parti-
cipants. The revised GCP code should be strongly rooted in
ethics, sensitive to different socio-cultural perspectives, and
allow consideration of trial- and context-specific challenges.
This can be only achieved if researchers, sponsors, regulators
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and ethical reviewers from LMIC are transparently involved in
the revision process, as well as non-commercial researchers and
sponsors, and major agencies that fund international collabora-
tive clinical research.
PA-142 ESTABLISHMENT OF A SUB-REGIONAL ETHICS
COMMITTEE IN CENTRAL AFRICA TO ADDRESS THE
NEEDS OF MULTICOUNTRY PROJECTS: AN OCEAC
INITIATIVE
Sylvie Kwedi Nona. OCEAC, Cameroon
10.1136/bmjgh-2016-000260.168
Background The Universal Declaration on Bioethics and
Human Rights, adopted by UNESCO, requires that governments
establish National Ethics Committees (NECs) capable of review-
ing ethical and scientific aspects on research involving human
beings. These NECs are government gatekeepers tasked with
ensuring that research conducted in their territories is in compli-
ance with national and international ethics requirements. In
Central Africa, NECs are lacking in some countries, barely func-
tional in others either crippled by lack of expertise, scarce
opportunities for training or by an environment not conducive
to quality and ethical research. To remedy this shortcoming,
OCEAC was awarded an EDCTP grant to put in place a
common Ethics Committee for Central Africa.
Methods Six designated representatives of Ministries of Health,
with appropriate background and skills, from Cameroon, Chad,
Equatorial Guinea, Gabon, Republic of Congo, and the Central
African Republic were selected to be members of the sub-
regional Ethics Commitee. In order to ensure the proper com-
position of this committee, ethics experts originating from
central Africa were selected through a call for candidates widely
published in various ethics and research networks in the sub-
region.
Results CERSAC (Comité d’Ethique de la Recherche et de la
Santé en Afrique Centrale) is the designation of the resulting
sub-regional Ethics Committee, assembling fifteen members
from the six CEMAC countries and the Democratic Republic of
Congo. Since 2014, CERSAC has provided streamlined reviews
of health research projects conducted in more than one Central
Africa country. A total of 37 local emerging-career researchers
and ethics committee members were trained.
Conclusions CERSAC enhances the ethical conduct and social
value of research and optimises the protection of human
research participants for communities in dire need. The commit-
tee also provides a harmonised platform to address ethical chal-
lenges related to the conduct and output of health research in
Central Africa.
PA-143 INVOLVEMENT OF STAKEHOLDERS IN THE REPORTING
PROCESS OF SERIOUS ADVERSE EVENTS DURING
CLINICAL TRIALS IN A SUB-SAHARAN RESEARCH
CENTER, LAMBARÉNÉ, GABON
Kabwende Lumeka,1 Agnandji Todagbe2. 1CERMEL, Gabon; 2ITM Tübingen,
Germany
10.1136/bmjgh-2016-000260.169
Background The pharmacovigilance of medical products for
human use should start during the clinical development and
continues after licensure. In developed countries, regulatory
agencies are actively involved in all steps of pharmacovigilance.
In sub-Saharan African countries, the lack and weaknesses of
national regulatory authorities are being addressed through
regional regulatory authorities like AVAREF 2 which aims to
oversee pharmacovigilance duties across countries. Informing
such initiative about the current practices for the reporting of
serious adverse events is needed.
Methods We reviewed the reporting of clinical trials performed
in CERMEL from 2006–2016. The methods of serious adverse
events (SAE) reporting and handling was the main objective of
the review.
Results The most frequent methods used to reporting SAE for
the clinical trials reviewed in Lambarene were: 31% (5/16)
paper Case Report Forms (CRF) only, 25% (4/16) electronic
case report form (eCRF) without alert, 13% ( 2/16) paper CRF
+phone call and 13% (2/16) phone +email or fax+ paper CRF
and 6% (1/16) electronic SAE reporting system with alert.
Generally, all studies reported SAEs directly to the sponsors
who reacted according to their guidelines. Only 2 of 16 studies
could involve the Institutional Review Board (IRB), Ethics
Committees, and the Data Safety Monitoring Committee
(DSMC) and eventually reported to the Regulatory Authorities
in the country. The Local Safety Monitoring was involved only
in one study which used the eCRF with alert.
Conclusions It appears that in the current practices, the report-
ing and handling of SAEs are mainly done by investigators and
sponsors. Although both are the key stakeholders to do so,
more active involvement of regulatory authorities is an essential
step towards establishment of a pharmacovigilance system and
would improve the community engagement towards clinical
trials. Electronic reporting with alert system could be one of the
methods suitable to involve all partners.
PA-144 ACTIVE PHARMACOVIGILANCE IN CôTE D’IVOIRE
Mariam Mama Djima. Institut Pasteur, Côte d’Ivoire
10.1136/bmjgh-2016-000260.170
Background In Africa, pharmacovigilance (PV) is a relatively
new science. Yet the African context is favourable to the
irrational use of medicines, the circulation of counterfeit drugs,
and a high consumption of traditional medicine. This should
make PV in African countries a critical and crucial issue to
ensure the safe use of treatments available. The collection
system used in pharmacovigilance in Africa is predominantly
passive. This passive system suffers from significant underreport-
ing because it detects only 1–10% of adverse events. The limit
in the passive detection and the growing concerns about security
in the long term of drugs widely used in health programs, have
stimulated in many countries the implementation of active
systems such as actively seeking to improve the development of
PV in their countries. In Côte d’Ivoire, pharmacovigilance at the
regulatory level started in 1988. What is actually the state of
pharmacovigilance and the impact of active research in the
development of pharmacovigilance?
Methods This is an observational descriptive study using a
qualitative analysis of interviews in order to provide answers to
these questions. The interview guides are constructed from a
questionnaire already used in the monitoring of pharmacovigi-
lance activities by the Uppsala Monitoring Center in countries
with limited resources.
Results Active surveillance has several sources. A well-known
source is the pharmaceutical industry in the conduct of clinical
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trials and the risk management plans. The pharmaceutical indus-
try accounts for over 80% of reports of adverse effects at
national level. The second data source are research centres, but
the reporting of adverse effects is not made at national level.
The last source of data comes from active operational research
studies which as a source are weak and this should be strength-
ened.
Conclusions Active pharmacovigilance is to be encouraged in
Côte d’Ivoire because it will collect data to improve the safety
of medicines consumed by the population.
PA-145 ETHICAL AND SCIENTIFIC CONSIDERATIONS FOR THE
DESIGN AND IMPLEMENTATION OF THE PREP
DEMONSTRATION PROJECT IN NIGERIA
Morenike Ukpong,1,2 Atiene Sagay,3 Hadiza Khamofu,3 Kwasi Torpey,3
Evaristus Afiadigwe,3 James Anenih,3 Oliver Ezechi,3 Chidi Nweneka,3
John Idoko3. 1Obafemi Awolowo University, Nigeria; 2NHVMAS, Nigeria; 3Nigeria
PrEP Demonstration Study, Nigeria
10.1136/bmjgh-2016-000260.171
Background This abstract highlights the ethical and scientific
considerations that informed the development and review of the
Nigeria PrEP demonstration study protocol.
Methods A desk review was conducted on all the meeting
reports that led to the choice of the study design and the deci-
sions made to modify the protocol for the PrEP demonstration
project in Nigeria. The study focused on the ethical and scien-
tific rationales for modifying the Partners’ PrEP Sero-discordant
protocol for this study as well as for the first and second proto-
col amendments of this study.
Results The decision to conduct a PrEP study was based on the
outcome of a modelling study that suggested that sero-
discordant couples will benefit from access to condom, TasP, and
PrEP. Next, the decisions on the target population for the PrEP
demonstration study, the models for evaluation at specific
project site, and the design of the community engagement pro-
gramme were reached through a formative research which
engaged 611 individuals using multiple media. The study did
not exclude study participants based on Hepatitis status and
HIV risk profile since Truvada was an effective hepatitis treat-
ment and the prevalence of hepatitis infection is high in
Nigeria. Participants’ interest in PrEP use was considered
enough reason to prescribe PrEP in a country where uptake of
ARV is slow and stigma associated with ARV use is high. Also,
HIV-negative partners could assess when the viral load of the
HIV-positive partner was 400 copies/ml. Since adherence was a
challenge for PrEP use, adherence was enhanced through the
use of the MEMS Cap.
Conclusions A PrEP demonstration study that mimics real life
scenarios for PrEP provision within public health care institu-
tions and is designed on the basis of community consultations,
ethical and scientific considerations, will enhance the success of
PrEP roll-out in resource-limited settings like Nigeria.
PA-146 SCHISTOSOMIASIS, PRAZIQUANTEL AND FOOD: THE
CONTROL OF A MALADY AMONG SCHOOL-AGE
CHILDREN IN UGANDA
Simon Muhumuza,1 Anne Katahoire,1 Fred Nuwaha,1 Annette Olsen2. 1Makerere
University School of Public Health, Uganda; 2University of Copenhagen, Denmark
10.1136/bmjgh-2016-000260.172
Background Annual school-based mass treatment with prazi-
quantel is the cornerstone for schistosomiasis control among
school-age children in Uganda. However, uptake of treatment is
low. We evaluated strategies for improved uptake of mass treat-
ment and the effects on the prevalence and mean intensity of S.
mansoni infection
Methods Through serial cross-sectional surveys conducted in
2011 and 2012 in 12 primary schools in Jinja district and a
cluster randomised trial conducted in 2013, the levels of uptake
of praziquantel and the prevalence and mean intensity of S.
mansoni infection among school children were determined.
Additionally, in 2012, the effect of increased teacher motivation
to distribute treatment was assessed. In 2013, the effectiveness
of provision of a pre-treatment snack in improving uptake was
evaluated.
Results A total of 1010, 1020 and 1284 randomly selected chil-
dren were enrolled in 2011, 2012 and 2013, respectively.
Uptake of praziquantel was 28.2% (95% CI: 22.9%–33.6%) in
2011. Prevalence and intensity of S. mansoni infection was
35.0% (95% CI: 25.4%–37.9%) and 116.1 eggs per gram of
stool (epg) (95% CI 98.3–137.1), respectively. With increased
teacher motivation in 2012, uptake increased to 48.9% (95%
CI: 45.8%–52.0%). The prevalence and intensity of S. mansoni
infection was 32.6% (95% CI: 29.6%–35.5%) and 133.1 epg
(95% CI: 99.0%–167.2%), respectively. Provision of a pre-
treatment snack in 2013 increased uptake to 85.5% (95% CI:
82.5%–91.7%) and reduced the prevalence and intensity of S.
mansoni infection to 8.2% (5.6%–12.2%) and 15.9 epg (95%
CI: 12.3%–19.2%), respectively.
Conclusions Although teacher motivation increased uptake of
mass treatment, the realised uptake was too low to affect the
prevalence and intensity of schistosomiasis among school chil-
dren. Conversely, provision of a pre-treatment snack achieved a
high uptake. The increased uptake significantly reduced the
prevalence and intensity of S. mansoni infection in this age
group.
PA-147 PILOTING DHIS2 SYSTEM IN VISCERAL LEISHMANIASIS
SURVEILLANCE
Seth Okeyo, Raymond Omollo, Robert Kimutai, Michael Ochieng,
Thaddaeus Egondi. DNDi, Kenya
10.1136/bmjgh-2016-000260.173
Background The District Health Information System 2
(DHIS2) is a tool for collection, validation, analysis and presen-
tation of both individual (tracker) and aggregated data tailored
to integrated health information management activities. DHIS2,
developed by the Health Information Systems Programme
(HISP) in collaboration with University of Oslo, is a modular
web-based software package built with open source Java frame-
works. Visceral leishmaniasis (VL) is not captured in the DHIS2
regional database, and therefore coming up with the modalities
of aggregating available data from clinical trials and general
patient records into the DHIS2 national database is crucial for
surveillance.
Methods DHIS2 runs on Tomcat Server and PostgreSQL. We
set up the VL surveillance program with different stages: enrol-
ment and demographics, initial treatment outcome and
follow-up visits. In this system, a patient is enrolled into the
system and data is collected in individual data elements; data
Indicators are built to help aggregate the data and thereafter
used for report generation. It is programmed to visualise data
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and display reports in the system dashboard which can then be
used to present data.
Results Piloting DHIS2 has enabled us to set up a system that
uses the set indicators programmed to aggregate data, thus able
to produce reports on the data and the user is also able to select
the type of report in the form of pivot tables, charts and graphs
and also in GIS mapped data.
Conclusions DHIS2 system is an open source that can be custo-
mised and expanded to capture detailed individual surveillance
data and shared in reports. This data is useful for tracking
neglected tropical diseases such as VL. Data can be handled in
the following modalities: i) use of off-line data synchronisation.
ii) remote data collection using mobile devices iii) data aggrega-
tion and organisation iv) data visualisation and presentation
through charts, graphs and pivot tables.
PA-148 STRENGTHENING PRISON HEALTH SYSTEMS:
FEASIBILITY AND CHALLENGES OF INTRODUCING
PRISON HEALTH COMMITTEES (PRHCS) IN ZAMBIAN
CORRECTIONAL FACILITIES
Clement Moonga,1 Chisele Chileshe,2 George Magwende,2 German Henostroza,3
Stephanie Topp1. 1CIDRZ, Zambia; 2Zambia Correctional Services, Zambia;
3University of Alabama at Birmingham, United States of America
10.1136/bmjgh-2016-000260.174
Background In Zambia, prison health and health services are in
a state of ‘chronic emergency’. Since 2013, the Zambian
Corrections Service (ZCS) partnered with Centre for Infectious
Disease Research in Zambia (CIDRZ) to understand and
strengthen prisoner health and access to healthcare. A key com-
ponent of this work was the establishment of 11 facility-level
Prison Healthcare Committees (PrHCs) comprising officer and
inmate members, with a specific remit to deliver health education
and provide monitoring for facility level service access. Findings
presented are from operations research evaluating the feasibility
of these PrHCs.
Methods Mixed qualitative methods included, in-depth inter-
views (11 Ministry and ZCS officials; 6 facility managers) and
focus group discussions (FGDs) with members of 6 PrHCs, and 6
groups of non-PrHC-inmates in the same facilities. Memos were
generated from participant observation in workshops and meet-
ings preceding and after implementation. All activities were
subject to verbal informed consent and interviews and FGDs
were audio-recorded with permission.
Results Key informants were strongly supportive of PrHCs,
noting potential for improved health information dissemination,
strengthened preventive service-coverage, routine service monitor-
ing and facility-level accountability. PrHC members confirmed
ZCS-led training had taken place and that they had been given
authority to deliver information-based health interventions and
facilitate quicker referrals to primary care. The early phase of
implementation (3–6 months at data collection) produced mixed
accounts regarding PrHCs’ capacity to fulfil other preventive ser-
vices or conduct data collection. Departure of PrHC members due
to transfer and/or release was the most frequently listed challenge.
Conclusions These data suggest the feasibility of establishing a
committee comprising both officers and inmates to address a fun-
damental gap in facility-level mechanisms for health information
delivery and service accountability. Findings nonetheless suggest
PrHCs will require iterative adjustments and ongoing
problem-solving by local officials. Context-sensitive application of
these principles to other settings may yield positive outcomes.
PA-149 DETERMINING THE ENVIRONMENTAL, SOCIAL AND
CULTURAL CONTEXTS OF A PROPOSED
SCHISTOSOMIASIS HEALTH EDUCATION INTERVENTION
IN EGGUA, YEWA NORTH LOCAL GOVERNMENT AREA,
OGUN STATE NIGERIA
Chiaka Anumudu, Olugbenga Onile, Victoria Oladele, Adewale Adebayo,
Henrietta Awobode. University of Ibadan, Nigeria
10.1136/bmjgh-2016-000260.175
Background The role of health education in the control of
schistosomiasis cannot be over-emphasised. Central to its utility
is an understanding of the way a community perceives, under-
stands and can explain how schistosomiasis occurs among them.
Methods In order to study the environmental, social and cul-
tural determinants of continued schistosomiasis prevalence in
Eggua, we administered a semi-structured questionnaire to 371
adults and 265 children between November 2012 and
December 2015. We asked questions about their occupation,
present and previous water contact pattern, knowledge of schis-
tosomiasis, sanitation, smoking and alcohol behaviour and
length of residence in the village.
Results The respondents ranged in age from 35 to above 60
years; 45% had no schooling and 30% had a least a primary
education. Most were farmers (48%) and traders (30%) with a
small number (2%) of fisher-folk and had been at this work for
more than 15 years. The majority (93%) were Christian, of a
denomination in which members spend long periods in the river
praying. The rivers are the main source of water for a large
number of respondents (63%). Water contact is frequent: 90%
go at least daily to the rivers. All the respondents worked at
non-itinerant jobs. Despite the research surveys were taking
place in Yewa since 2009, 90% of respondents did not know the
cause of blood in urine and self-reported haematuria was low
(4.6%). Many homes did not have a latrine. Children respon-
dents also didn’t have knowledge of the cause of schistosomiasis
(60%); those who had heard about it were not well educated on
ways to avoid being infected; and 83% did not know they could
be re-infected after treatment.
Conclusions Formal health education initiatives for the control
of schistosomiasis in Eggua are imperative and these findings
should be taken into account in designing them.
PA-150 MATERNAL UROGENITAL SCHISTOSOMIASIS,
MONITORING DISEASE MORBIDITY BY SIMPLE
REAGENT STRIPS
Oyetunde Oyeyemi,1 Alexander Odaibo2. 1Babcock University, Nigeria; 2University of
Ibadan, Nigeria
10.1136/bmjgh-2016-000260.176
Background Urine analysis is one of the recommended antenatal
guidelines for early diagnosis of pregnancy-associated complica-
tions. While urine analysis by dipstick had been used in practice
to provide useful information on other urinary tract infections,
its application for early detection of urogenital schistosomiasis in
pregnant women is often downplayed in most endemic areas.
Our study therefore assessed the performance of some common
urinalysis parameters in the diagnosis of maternal urogenital
schistosomiasis in endemic rural communities of Nigeria.
Methods The cross-sectional epidemiological survey of urogeni-
tal schistosomiasis was conducted among pregnant women in
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Yewa North Local Government, Ogun State, Nigeria. The
women were examined for infection with Schistosoma haemato-
bium microscopically and screened for macrohaematuria, micro-
haematuria and proteinuria using standard urine chemical
reagent strips.
Results Of 261 volunteer participants, 19.9% tested positive for
S. haematobium infection. The proportion of microhaematuria
(23.8%) was significantly higher than that of macrohaematuria
(3.8%) and proteinuria (16.8%) (p<0.05). Microhaematuria
with sensitivity (82.7%) and specificity (89.0%) was the best
diagnostic indicator of urogenital schistosomiasis.
Macrohaematuria with the least sensitivity (11.8%) was
however the most specific (98.1%) for diagnosing urogenital
schistosomiasis in pregnant women. Maximum microhaematuria
sensitivity (100.0%) was observed in women between 15–19
years but sensitivity was consistently low in other older age
groups. Maximum sensitivity, specificity and predictive values
(100.0%) were recorded for microhaematuria in first trimester
women. Diagnostic efficiency of proteinuria and macrohaema-
turia was also better in first trimester women except the 25.0%
specificity recorded for proteinuria. The overall diagnostic per-
formance of microhaematuria and proteinuria was best in secun-
digravidae.
Conclusions Microhaematuria can be used for early detection of
urogenital schistosomiasis in endemic areas especially in younger
and first trimester women. Treatment with praziquantel is recom-
mended for the women in their late trimester in order to avert
associated adverse pregnancy outcomes.
PA-151 FROM LABORATORY RESEARCH TO THE PUBLIC:
SCIENCE COMMUNICATION FOR POLICY, RESEARCH
COMMUNITY AND PUBLIC
Emily Kabuye, Tom Lutalo, Pontiano Kaleebu, Edward Mbidde. UVRI, Uganda
10.1136/bmjgh-2016-000260.177
Background The Government of Uganda uses empirical evi-
dence for policy formulation. The Uganda Virus Research
Institute (UVRI) and the International Association of National
Public Health Institutions (IANPHI) trained journalists and
scientists to communicate research processes and findings to the
public. This improved the capacity to communicate important
information during outbreaks and to disseminate research find-
ings as part of policy formulation.
Methods Through training workshops, 30 research scientists
including study coordinators, research officers and principal
investigators interacted with 12 health reporters from various
media houses. Training covered writing policy briefs and press
releases. Attendees were taken through the ‘dos and don’ts’
when being interviewed by television/radio journalist while jour-
nalists were trained in basic epidemiology terms and research
processes. They analysed research papers to find different story
angles. They conducted mock media talk shows for television
and radio and these sessions were reviewed by all those in
attendance, identifying areas for improvement.
Results Key findings revealed that journalists do not ably write
about research findings because they do not understand the sci-
entific research procedure. Training journalists on health
research communication, ethical issues and research procedure
enabled them to appreciate the scientific research process.
Continued interaction was found to be of help to articulate
research findings for health journalist before they are presented
in print and audio media for the wider audience/public. This
method built capacity of participating scientists to communicate
to the lay audiences. It also helped the scientists plan for the
media and policy makers during future dissemination of their
research findings.
Conclusions Meaningful engagement of journalists and the
public by scientists results in proper understanding of the ethical
and scientific research procedure. This calls for systematic
investment by research organisations and, during proposal
development, budgeting for communication and knowledge
translation of research findings to benefit policy makers and the
wider research community.
PA-152 THE EFFECT OF HELMINTH CO-INFECTION ON
MALARIA-SPECIFIC IMMUNOGLOBULIN G RESPONSES
Clarisse Njua-Yafi,1 Theresa Nkuo-Akenji,2 Judith Anchang-Kimbi,2 Tobias Apinjoh,2
Regina Mugri,2 Hanesh Chi,2 Rolland Tata,2 Charles Njumkeng,2 Daniel Dodoo,3
Michael Theisen,4 Eric Achidi2. 1University of Yaoundé I, Cameroon; 2University of
Buea, Cameroon; 3NMIMR, Ghana; 4SSI, Denmark
10.1136/bmjgh-2016-000260.178
Background Malaria and helminthiases overlap extensively in
their epidemiological distributions, and co-infections are
common. Helminth infection has a profound effect on the
immune system such as the induction of immuno-regulatory
mechanisms such as potent regulatory T cell responses known to
suppress cellular effector mechanisms.
Methods The prevalence of malaria parasitaemia, intestinal hel-
minths, co-infection and anaemia was determined in a cross-
sectional study (March 2011) of 372 children aged 6 months to
10 years resident in Mutengene in south-western Cameroon.
Plasma total IgG and IgG1–4 subclass antibody levels to P. falcip-
arum apical membrane antigen 1 (AMA1), the N-terminal non-
repeat region (GLURP R0) and the C-terminal repeat region of
glutamate rich protein (GLURP R2) and merozoite surface
protein 3 (MSP3) were measured by standardised ELISA.
Results Prevalence was as follows: malaria parasitaemia (mp)
18%, pyrexia 25.4%, helminths 19.7%, and anaemia 71.5%.
Amongst those who were mp-positive, 25.4% were symptomatic
(4.5% overall). Almost all helminth infections were the soil-
transmitted helminths Ascaris, Trichuris and hookworm (96.4%)
with a few cases of Hymenolepis and Enterobius. Haemoglobin
concentration (g/dl) correlated positively with age and negatively
with mp density (p≤0.001). The mean haemoglobin (g/dl) level
of participants co-infected with both parasites (3.4%) was higher
compared to participants infected with either Plasmodium
(15.8%) or helminths (16.1%) alone (p< 0.01). IgG and IgG1–4
subclass antibody levels to all recombinant antigens correlated
positively with age (p< 0.01). Total IgG, IgG1, 2 & 3 levels to
all the antigens tested were significantly (except MSP3 IgG2,
p=0.08) higher in participants infected with Plasmodium alone,
compared to the co-infection, helminths only and no infection
groups. Decreased levels of AMA1 IgG associated significantly
with co-infection (OR=0.27, 95% CI:0.11–0.68). Increased
MSP3 IgG and IgG1–4 levels were significantly associated with
children infected with Plasmodium alone compared to children
co-infected with both parasites.
Conclusions Infection with intestinal helminths stifles protective
anti-plasmodial antibody responses.
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PA-153 SAFETY OF RVSV EBOLA VACCINE, AFTER 6 MONTHS
FOLLOW-UP, IN ADULTS: A PHASE 1 TRIAL CONDUCTED
IN LAMBARÉNÉ, GABON
José Fernandes,1,2,3 Emmanuel B. Bache,1 Régis M Obiang Mba,1 Anita
L. Kabwende,1 Benjamin Mordmüller,1,2 Sanjeev Krishna,1,2,4 Peter G. Kremsner,1,2
Martin P. Grobusch,1,2,3 Agnandji Selidji Todagbe1,2. 1Centre de Recherches
Médicales de Lambaréné (CERMEL), Albert Schweitzer Hospital, Lambaréné, Gabon;
2Institute for Tropical Medicine, University of Tübingen (Germany); 3Centre of
Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Division
of Internal Medicine, Academic Medical Centre, Amsterdam, The Netherlands;
4Institute for Infection and Immunity, St. George’s, University of London, UK
10.1136/bmjgh-2016-000260.179
Introduction The Centre de Recherches Médicales de Lambaréné
(CERMEL) in Gabon, member of the ‘VSV-EBola CONsortium’
(VEBCON), evaluated safety and immunogenicity of the
rVSVΔG-ZEBOV-GP vaccine in African volunteers from an area
with previous Ebola outbreaks before its use during the last out-
break in West Africa.
Methods From November 2014 to April 2015 we performed an
open-label, dose escalation phase 1 trial to assess safety, side-effect
profile, and immunogenicity of rVSV-ZEBOV. A total of 115
healthy adults both male and non-pregnant or lactating female
volunteers aged 18–50 years old living in Lambaréné (Gabon)
were included. Participants were allocated to five vaccine dose
groups: 3×103 PFU (n=20), 3×104 PFU (n=20), 3×105 PFU
(n=20), 3×106 PFU (n=39) and 2×107 PFU (n=16). Here, we
present data on adverse events (AE) and serious adverse events
(SAE) between days 180 and 365 after vaccine injection (Day 0).
Results From Month six to Month 12, the proportion of volun-
teers with AE as well as number and grade of AEs per volunteer
were similar in the five groups. A higher total number of events
occurred in the cohort 3×106 PFU, the largest group. Most symp-
toms were mild to moderate. No clinically significant laboratory
changes were observed. Three events - two episodes of P. falcip-
arum malaria and one snake bite - were graded as serious, because
they required hospitalizations. Both SAE were judged as non-
related to the vaccine and resolved without sequelae. None of the
adverse events was related to rVSV-ZEBOV vaccine.
Conclusions Our results confirmed an acceptable profile of safety
and tolerability of rVSV-ZEBOVup to 12 months of follow-up. In
order to investigate possible late-stage safety signals follow-up
period of the study was extended to five years. Integrating data
(assessment until 60 months) from all the VEBCON study sites is
the next key step allowing a final conclusion about safety
of rVSV-ZEBOV. The trial was registered on the Pan African
Clinical Trials Network website with the number
PACTR201411000919191
PA-154 RUBELLA SEROPREVALENCE AMONG HIV-INFECTED
AND UNINFECTED ZAMBIAN CHILDREN AND
ADOLESCENTS
Kalumbu Matakala,1 Catherine Sutcliffe,2 Kelly Searle,2 Michelle Greenman,2
Kaitlin Rainwater-Lovett,2 Philip Thuma,1 William Moss2. 1Macha Research Trust;
2JHSPH, United States of America
10.1136/bmjgh-2016-000260.180
Background Congenital rubella syndrome remains a significant
cause of morbidity and mortality among children in sub-Saharan
Africa. A safe and effective vaccine is available and many coun-
tries, including Zambia, plan to introduce the measles-rubella
vaccine by 2020. HIV-infected youths may be an important
group to consider as they may remain susceptible to rubella
virus due to waning immunity. More information is needed in
this age group to guide policy on catch-up rubella vaccination
campaigns after introduction.
Methods This cross-sectional study was nested within ongoing
studies of HIV and malaria in Southern Province, Zambia. Dried
blood spot cards from children and youths 5–15 years of age
enrolled in these studies from 2009–2013 were selected and
tested for IgG antibodies to rubella virus. Antibody levels
among HIV-uninfected youth, HIV-infected treatment-naïve
youth, and HIV-infected youth receiving antiretroviral therapy
(ART) were compared.
Results 617 HIV-uninfected, 144 HIV-infected treatment-naïve,
and 128 HIV-infected youth receiving ARTwere included in the
study. The proportion seropositive for rubella virus was signifi-
cantly higher among HIV-uninfected youth (54.7%) compared
to HIV-infected treatment-naïve youth (41.7%) and
HIV-infected youth receiving ART (49.6%). The proportion of
youth with equivocal results was significantly higher for the two
groups of HIV-infected youth (treatment-naïve=11.8%; receiv-
ing ART=7.9%) compared to HIV-uninfected youth (1.1%).
Within groups, the proportion seropositive increased with age.
Other than age, no demographic or clinical characteristics were
associated with susceptibility among HIV-infected youth.
Conclusions Our results suggest that HIV-infected youth would
benefit from vaccination against rubella virus. Half of all youth in
rural Zambia were susceptible to Rubella virus. When rubella
vaccine is introduced, failure to target older girls in immunisation
campaigns could lead to an increase in congenital rubella cases.
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